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Abstract 
CD4 T cell lineage choice epitomises the ability of the immune system to 
become  tailored  to  a  specific  threat  and  provides  a  framework  for 
understanding  the  mechanisms  behind  cell  specification.  The 
differentiation of T effectors from naïve cells gives rise to pro-inflammatory 
lineages  including  T  helper  1  (Th1)  and  Th2  and  anti-inflammatory 
regulatory  T  cells  (Treg).  An  additional  lineage  of  Treg  also  exits  the 
thymus in parallel to naïve T cells and together these Treg are required for 
prevention of autoimmunity. These T cell lineages are distinct in terms of 
their  cytokine  production  and  functional  effects  but  also  through  their 
differences in gene expression and its regulation, which are orchestrated 
by the presence of lineage-specifying transcription factors specific for each 
lineage. In addition, post-translational modification of histones also provide 
insights into this transcriptional regulation and more recently the pervasive 
and tissue-specific transcription of multiple classes of RNA species without 
protein coding capacity, non-coding RNA (ncRNA), has been found to play 
a role in cell differentiation and function. 
 
In this thesis I identify several ncRNAs with differential expression different 
T cell lineages. This includes ncRNAs upregulated Treg compared to T 
responders. The characterization of these, including their expression in the 
autoimmune context of systemic lupus erythematosus (SLE), is presented 
and  their  possible  biological  functions  are  examined.  The  relevance  of 
histone  modifications  for  influencing  Treg  identity  in  SLE  is  also 
investigated.  An  additional  class  of  ncRNAs  that  originate  from  gene 
enhancer regions, eRNA, is also investigated in the context of Th1 versus   4 
Th2 lineage choice. This enhancer transcription is increased genome-wide 
in Th1 cells at enhancers with high density T-bet binding in, termed ‘super-
enhancers’.  The  functional  relevance  of  these  eRNAs,  including  at  the 
super-enhancer  upstream  of  the  Th1  signature  cytokine  gene,  IFNG,  is 
also investigated in knockdown experiments. 
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1  Introduction 
1.1  CD4 T cell lineages 
CD4  T  cell  lineage  choice  epitomises  the  ability  of  the  immune  system  to 
become tailored to a specific threat and additionally provides a framework for 
understanding the mechanisms behind cell specification. The identification of 
distinct  subtypes  of  CD4+  T  cells  began  with  the  observation  that  this 
population appeared heterogeneous in activity, particularly regarding B cell help 
[1]. The first two identified lineages, termed T helper 1 (Th1) and T helper 2 
(Th2), were further defined by differences in cytokine production, with Th1 cells 
producing IFNγ and Th2 cells producing IL-4 [2], IL-5 [3] and IL-13 [4, 5] (Figure 
1.1). The concept of distinct lineages was reinforced by the finding that these 
differences were stable during passage [2], demonstrating this specialisation to 
be  heritable.  The  production  of  these  signature  cytokines  underpins  the 
functional importance of these specialised T cell lineages within the immune 
system.  IFNγ  secreted  from  Th1  cells  activates  macrophages  [6]  allowing 
clearance of intracellular pathogens, such as viruses and intracellular bacteria 
in what is termed a Type I response, while Th2 cytokines IL-4 and IL-5 support 
expansion of B cells and subsequent antibody production by plasma cells in the 
humoral immune response [7], leading to clearance of extracellular pathogens, 
such as extracellular bacteria and helminths [8] in a Type II response. This is 
the basis of the Th1/2 paradigm and is illustrated in Figure 1.1. 
     18 
 
Figure 1.1: T cell differentiation 
CD4  T  cell  lineage  differentiation  allows  a  response  from  the  immune  system  to  be 
tailored to the pathogenic setting and also provides a framework for understanding the 
mechanisms  behind  cell  specification.  Naïve  CD4  T  cells  exit  the  thymus  and  upon 
stimulation  differentiate  into  specialised  subsets  under  the  influence  of  cytokines  that 
reflect the particular pathogenic threat. Signalling downstream of these cytokines leads to 
activation of STAT transcription factors which prepare the chromatin landscape for the 
expression of lineage-specifying transcription factors. In addition, naturally occurring Treg 
exit the thymus as a distinct lineage in parallel with naïve T responder cells. Each subset 
is  characterised  by  the  production  of  signature  cytokines.  There  is  some  plasticity 
between these subsets, as illustrated by the grey arrows. Dysregulation of differentiation 
leads to immune pathology. STAT: signal transducer and activator of transcription; iTreg: 
induced regulatory T cell; nTreg: naturally occurring regulatory T cell. 
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1.1.1  The Th1 versus Th2 paradigm  
The  differentiation  of  naïve  T  cells  into  specialised  effector  helper  cells 
takes  place  in  the  peripheral  lymphatic  system  after  exiting  the  thymus 
(Figure 1.1). This differentiation requires stimulation of the T cell receptor 
(TCR)  by  presentation  of  cognate  antigen  in  the  context  of  the  major 
histocompatibility  complex  (MHC)  II  [9].  The  direction  of  polarisation  is 
determined by the cytokine environment of the T cell, which results from 
the earlier response of the innate immune system to the pathogen present 
and reflects the signature cytokines it later produces. The presence of an 
intracellular pathogen leads to production of IL-12 by antigen presenting 
macrophages  and  dendritic  cells  (DCs)  [10],  which  induces  Th1 
differentiation [11]. Subsequent production of IFNγ from Th1 cells also has 
an autocrine effect in promoting Th1 differentiation [12]. The presence of 
an  extracellular  pathogen  leads  to  production  of  IL-4,  possibly  from 
basophils [13], and the induction of Th2 differentiation. In addition, the T 
cell growth factor, IL-2, supports the proliferation all T cells [14] and the 
use of these cytokines has been harnessed for in vitro differentiation of 
Th1 and Th2 cells. The Th1/2 paradigm has been further extended with the 
discovery of peripherally induced Th17 cells that are characterised by their 
production of IL-17 [15] and differentiate in response to fungal infection in 
the  presence  of  TGF-β a n d  I L -6  [16].  An  immune  suppressive  subset, 
induced  regulatory  T  cells  (iTreg),  differentiate  in  the  presence  of  IL-2, 
upon which they are heavily dependent, and TGF-β [17]. These cells also 
have a physiologically occurring counterpart termed natural regulatory T 
cells (nTegs), which exit the thymus as a distinct cell lineage in parallel 
with naïve T cells [18]. Pathologies are associated with the dysregulation   20 
of  each  of  these  subsets,  with  allergies  associated  with  increased  Th2 
cytokine  production  and  a  Type  II  response  [19]  and  autoimmune 
syndromes being associated with increased Th1 [20] and Th17 [21, 22] 
activity and decreased Treg function [23-26]. 
1.1.2  Regulatory T cells 
The inflammatory response, while often effective at fighting an invading 
pathogen,  is  also  harmful  to  host  tissues  through  the  production  of 
inflammatory  mediators  that  may  enzymatically  and  chemically  degrade 
tissues.  In  healthy  individuals,  these  processes  are  controlled  through 
mechanisms of regulation and tolerance. These mechanisms are required 
in  the  resolution  phase,  when  an  infection  has  been  cleared  and 
inflammatory  processes  need  to  be  dampened  down,  and  also  to  limit 
immune  responses  to  non-pathogenic  foreign  antigens  (such  as  food 
antigens) and self-antigens. Mechanisms of tolerance are categorised as 
central (occurring in the central lymphatic system) or peripheral (occurring 
after  immune  cells  reach  the  peripheral  lymphatic  system).  Central 
tolerance takes place in the primary lymphoid organs (thymus and bone 
marrow)  during  immune  cell  development.  For  example,  in  the  thymus, 
self-reactive T lymphocytes are recognised by the strong affinity of their T 
cell  receptor  (TCR)  complex  for  self-antigens  presented  in  the  MHC 
context. These self-reactive T cells are either deleted through apoptosis or 
are stimulated to replace their TCR by receptor editing [27]. A proportion of 
self-reactive  T  cells  escape  the  thymus  into  the  periphery.  Here,  their 
activity must be restrained by peripheral tolerance mechanisms. Peripheral 
tolerance mechanisms include the induction of anergy, which occurs when 
a self-reactive T cell meets its cognate self antigen in the absence of co-  21 
stimulation. Co-stimulatory signals are produced by ligation of CD28 on the 
T cell with CD80 and CD86 on an APC. These APC surface molecules are 
upregulated  when  the  immune  system  is  activated,  for  example  in  the 
presence of an infection or acute inflammation. When inflammatory signals 
are not present and this co-stimulation is suboptimal, the T cell becomes 
functionally inactivated.  
 
In  an  inflammatory  environment,  when  co-stimulation  is  provided,  other 
mechanisms exist to damped down the immune response. This includes 
the  activity  of  cells  with  a  specialised  function  for  suppressing  immune 
responses.  This  is  termed  ‘dominant’  tolerance  and  has  been 
demonstrated by the adoptive transfer of T cells [28]. Of these suppressor 
cells, regulatory T cells are the archetype.  
 
The concept of a specialised cell subset capable of dominant peripheral 
tolerance arose in the 1970s [29, 30] and was originally highly contentious 
[31]. Then in 1985, Sakaguchi and colleagues demonstrated that depletion 
of splenocytes expressing the T cell marker, CD5, resulted in multiorgan 
autoimmunity, implying that a T cell subset must be actively involved in 
preventing  activation  of  the  immune  system  against  self-antigens  [32]. 
Publications in the 1990s and since have cemented a role for a subset of T 
lymphocytes with a suppressive specialty [33, 34]. This suppressive subset 
was further defined in mice by the presence of the T cell co-receptor CD4 
and the IL-2 receptor alpha subunit, CD25 [33]. Later work in humans also 
demonstrated  that  the  CD4+CD25+  T  lymphocyte  compartment  confers 
dominant peripheral tolerance [35, 36].   22 
 
In 2003, the molecular control of Treg identity began to be revealed. Work 
simultaneously published by three independent laboratories demonstrated 
this  regulatory  function  to  be  dependent  on  the  forkhead  transcription 
factor, FOXP3 [37-39]. The cell surface phenotype of regulatory T cells 
(Tregs) has since been further defined with absence of the IL-7 receptor, 
CD127, enriching for FOXP3-expressors among CD4+CD25+ T cells [40, 
41]. 
1.1.2.1  Suppressive mechanisms of Treg 
Tregs limit the activity of a variety of immune effector cells. This includes 
CD4
+ and CD8
+ effector T cells, natural killer (NK) cells, natural killer T 
cells (NKT) [42, 43], antigen presenting cells (APCs) such as dendritic cells 
(DCs)  B  cells  and  monocytes  [44],  macrophages,  mast  cells  and 
osteoblasts [45]. Although there is evidence that antigen-specific Treg are 
more  potent  [46],  Treg  have  been  shown  to  suppress  independently  of 
antigen  specificity  [47]  and  through  the  phenomenon  of  ‘linked 
suppression’,  may  be  activated  by  their  cognate  antigen  before 
suppressing  responses  to  other  antigens  [48].  In  addition,  ‘infectious 
tolerance’  describes  the  phenomenon  by  which  activated  Treg  promote 
suppressive activity in other cells.  
 
There is not a single unified mechanism for Treg suppressive function but 
instead  Tregs  appear  to  exert  their  suppressive  effect  in  various  ways, 
mediated  by  both  cell  contact  and  soluble  factors.  Some  of  these  are 
illustrated in Figure 1.2 and are described in the following paragraphs. I 
have  used  the  term  T  responder  (Tresp)  throughout  this  thesis  to   23 
distinguish Treg from other effector T cells with possible pro-inflammatory 
activities.     24 
 
Figure 1.2: Suppressive mechanisms of CD4 FOXP3+ Treg.  
The suppressive mechanisms employed by Tregs are diverse and affect several effector 
cells.  A:  Surface  expression  of  cytokine  receptors,  such  as  the  IL-2  receptor  alpha 
subunit, CD25, sequesters pro-inflammatory molecules. B: CTLA-4 in its surface bound 
and  soluble  form  competes  with  CD28  on  Tresp  to  bind  the  co-stimulatory  molecules 
CD80 and CD86 from antigen presenting cells (APCs) such as DCs. Ligation with these 
receptors also results in their down regulation and the promotion of apoptosis in APCs. C: 
Adhesion molecules such as lymphocyte function associated antigen 1 (LFA-1) promote 
the aggregation of Tregs around APCs and their spatial competition with Tresp. D: CD39 
and  CD73  catalyse  the  breakdown  of  pro-inflammatory  ATP  to  anti-inflammatory 
adenosine.  E:  Secretion  of  cytokines  such  as  TGF-β a n d  I L -10  provide  ‘infectious 
tolerance’  by  promoting  suppressive  function  in  other  cells,  for  example  through  the 
induction of naïve cells into induced Treg. F: The cytolytic pore-forming enzymes perforin 
and granzyme allow Treg to induce apoptosis in target cells. Tresp: T responder; DCs: 
dendritic cell; iTreg: induced Treg. 
   
Tresp 
CD25 
IL-2 
CTLA-4 
Treg 
CD28 
DC 
CD86 
LFA-1 
ICAM-1 
A
CD39 
CD73 
ATP 
AMP 
Adenosine 
iTreg  Naïve 
T 
TGF-β 
IL-10 
B 
B
C
D
E
F  25 
1.1.2.1.1  Cell-contact mediated mechanisms 
Cytotoxic T-Lymphocytes Antigen-4 (CTLA-4) is a T cell surface molecule 
analogous to the co-stimulatory molecule CD28 in that it ligates with CD80 
and CD86 on APCs. However, in contrast to CD28, CTLA-4 ligation results 
in the transduction of inhibitory rather than stimulatory signals. This leads 
to reduced activation of the T cell itself but its expression on Treg has also 
been shown to have a role in Treg suppression of other cells. Our lab has 
shown that reduced surface CTLA-4 on Treg leads to reduced suppression 
of IFN-γ production by T responders [49]. In addition, competition of Treg 
with Tresp for ligation of CD80 and CD86 on APCs leads to a reduced 
likelihood  of  Tresp  activation.  Similarly,  the  Treg-APC  interaction  may 
result in capture of CD80 and CD86 and a reduced ability for APCs to 
further interact with other T cells [50]. This interaction may also have APC-
intrinsic effects with signal transduction downstream of CD80 and CD86 
leading to downregulation of these molecules and even apoptosis [51].  
 
Extracellular  adenosine  metabolism  by  the  Treg  derived  CD39 
(ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1) and CD73 
(ecto-5'-nucleotidase)  also  reduces  Tresp  activity.  These  cell  surface 
molecules catalyse the conversion of ATP to AMP and AMP to adenosine, 
respectively.  The  resulting  adenosine  acts  as  an  anti-inflammatory 
mediator, signalling through adenosine receptors located on the surface of 
Tresp [52, 53]. Ligation with the adenosine receptor results in increased 
intracellular cAMP in Tresp and a concomitant reduction in their function 
[54]. This pericellular production of adenosine by Tregs has been shown to 
suppress the proliferation of activated T effector cells [55].   26 
 
By promoting the aggregation of Treg around APCs, adhesion molecules 
may also be important in reducing inflammation by spatial competition with 
Tresp  for  interaction  with  APCs  [51].  For  example,  lymphocyte  function 
associated antigen 1 (LFA-1) is an integrin found on several immune cell 
lineages  and  is  involved  in  recruitment  to  sites  of  inflammation  through 
affinity to ICAM-1. Treg lacking LFA-1 have been shown to have a reduced 
function in vivo [56]. 
 
Other extracellular Treg molecules with roles in suppression include the 
lymphocyte activation gene 3 (LAG-3) and glucocorticoid induced tumour 
necrosis factor receptor (GITR), which are both increased upon activation. 
The  mechanistic  role  of  LAG-3  in  Treg  function  is  not  known  but 
expression is increased upon culture with Tresp and blocking of LAG-3 
inhibits  Treg  suppression  while  ectopic  expression  confers  suppressive 
activity [57]. GITR is found at a high level on Treg. However, elucidation of 
its role and function is complicated by the fact that it is expressed on other 
immune system components and is upregulated on Tresp upon activation. 
While its role in the suppressive function of Treg is unknown, signalling via 
GITR  has  been  shown  to  expand  the  Treg  population  while  retaining 
function [58]. 
1.1.2.1.2  Soluble factor mediated mechanisms 
The inhibitory effects of CTLA-4 described above may also be produced by 
secretion of soluble CTLA-4 from Treg [51]. Other soluble factors include 
perforin and granzyme, components of cytoplasmic granules also used by 
cytotoxic T cells and NK cells. Perforin triggers result in pore formation in   27 
target cells, allowing the induction of apoptosis through caspase activation 
as granzyme is released into the cell through these pores [59-61].  
 
Being defined by high expression of the IL-2 receptor alpha subunit, CD25, 
Tregs are thought to limit inflammation by sequestering this T cell growth 
factor  away  from  Tresp,  thus  limiting  their  growth  [60].  This  same 
mechanism  of  sequestration  may  also  apply  to  other  pro-inflammatory 
cytokines such as IL-1 and TNF-α [62, 63].  
 
Tregs also contribute to the cytokine milieu through the secretion of anti-
inflammatory cytokines including transforming growth factor-beta (TGF-β), 
IL-10  and  IL-35.  TGF-β  influences  activation,  proliferation  and 
differentiation of target cells, for example it has been shown to inhibit Th1 
differentiation and to suppress CD8+ cytotoxic T lymphocytes [64, 65] and 
NK cells [43]. IL-10 is predominantly secreted from non-FOXP3 expressing 
suppressor cells i.e. Tr1 cells [66]. However, increased production of IL-10 
by FOXP3+ Tregs has also been thought to protect against the mouse 
model  of  multiple  sclerosis,  experimental  autoimmune  encephalomyelitis 
(EAE) [67-69]. Treg IL-10 production may have effects on APC and NK 
function  [70].  IL-35  production  from  FOXP3+  Tregs  has  been  shown  to 
suppress Tresp proliferation and to limit mucosal inflammation in vivo [68, 
71, 72]. 
 
In  addition  to  inhibiting  the  action  of  immune  effectors,  these  anti-
inflammatory  cytokines  also  promote  suppressive  function  in  other  cells 
and so amplify their suppressive effects through infectious tolerance. This   28 
includes through the differentiation of naive T cells into FOXP3 expressing 
and  suppressive  iTregs  in  the  presence  of  TGF-β [ 6 3 ,  7 3 ] .  I n  a d d i t i o n ,  
TGF-β has been shown to skew Tresp to a suppressive Tr1 phenotype 
[74]. 
 
This collection of mechanisms employed by Treg may reflect the presence 
of different physiological subsets of Tregs, some of which are discussed in 
more detail below. 
1.1.2.2  Subsets of CD4+FOXP3+ Tregs 
The expression of molecules associated with Treg function varies under 
different activation conditions or environmental and physiological contexts. 
In addition there are no cell surface markers that are limited to Treg only. 
Even CD25 and FOXP3 are increased in Tresp upon activation, which can 
be  problematic  for  identifying  and  isolating  Treg.  This  lack  of  unifying 
features hints at heterogeneity in the CD4+FOXP3+ population. 
1.1.2.2.1  Naturally  occurring  and  peripherally  induced 
Tregs 
‘Naturally occurring’ Tregs (nTregs) represent a specialised subset of T 
cells that is developmentally determined in the thymus before activation in 
the periphery through the encounter of antigen [75]. These nTreg exit the 
thymus expressing FOXP3 alongside undifferentiated naïve CD4 T cells. In 
the appropriate cytokine context, IL-2 and TGF-β, activation of naïve CD4 
T cells induces expression of FOXP3 and suppressive activity as these 
cells differentiate into iTreg [76-79]. In addition, human in vivo evidence 
shows some regulatory CD4+FOXP3+ cells may arise from CD4+FOXP3-   29 
memory,  as  opposed  to  naïve,  cells  [80].  nTregs  and  iTregs  may  have 
separate and synergistic roles in vivo [81, 82]. iTreg differentiation may be 
particularly  relevant  at  sites  of  inflammation  where  they  are  required  to 
curtail the potentially harmful effects of an immune response [68, 83]. This 
includes  in  gut-associated  lymphoid  tissue  (GALT),  where  induction  of 
tolerance  is  necessary  in  the  presence  of  foreign  materials  such  as 
commensal bacteria and food antigens [84]. There is mechanistic support 
for the in vivo generation of iTreg from studies in mouse [17, 76, 85]. In 
vitro generation of iTreg has therapeutic possibilities through the induction 
of  Treg  from  naïve  T  cells  with  the  subsequent  return  to  the  body. 
However, while in vitro culture has lead to successful Treg induction from 
mouse  cells,  FOXP3  expression  in  human  cells  in  this  context  is  not 
synonymous  with  suppressive  ability.  These  FOXP3-expressors  even 
secrete the T cell growth factor, IL-2, implying they are pro-inflammatory, 
and it has been suggested that FOXP3 in this context may reflect general 
T cell activation rather than a lineage with suppressive function [86]. This 
implies there may be another signal required for human iTreg generation. 
Several  groups  have  shown  that  alternative  protocols  involving  all-trans 
retinoic acid (atRA) [87] and stimulation of the aryl hydrocarbon receptor 
(AhR)  through  dioxin-like  ligands  such  as  TCDD  (2,  3,  7,  8- 
Tetrachlorodibenzodioxin) [88] produce functionally suppressive Treg. The 
differences  between  Treg  of  mice  and  humans  may  reflect  different 
requirements to support stability and reduce plasticity of Tregs and might 
also suggest the phenotype orchestrated by FOXP3 may differ between 
the two species.  
   30 
The  transcription  factor  Helios  has  been  suggested  as  a  marker  to 
distinguish  nTreg  from  iTreg,  with  its  expression  being  restricted  to  the 
former [89]. As both mouse and human in vitro induced Treg lack Helios 
expression, it was suggested that Helios is not affected by TCR stimulation 
and therefore is not a marker of activation, in the way that FOXP3 is [89]. 
However, since this assertion was made, other evidence has shown Helios 
expression to reflect the context of stimulation [90, 91]. In addition, Helios 
has been associated with Tresp lineages [92]. Work in T cell lines has 
shown Helios may have a potential role in Treg function through binding of 
the FOXP3 promoter, as identified by ChIP-Seq, with knockdown of Helios 
leading to downregulation of FOXP3 expression [93]. 
1.1.2.2.2  Naïve and memory Tregs 
CD4 T cells exit the thymus in a naive state being unactivated and not 
terminally differentiated. When the TCR of a naive T cell ligates with its 
cognate antigen in the context of MHCII in the peripheral lymphoid organs, 
it becomes activated and proliferates. This results in clonal expansion of 
effector T cells with specificity to the activating antigen. These antigen-
stimulated lymphocytes then patrol the periphery to enact this response 
where it is required when re-encountering the same antigen. After clearing 
an infection and inflammation is resolved, the number of T cells specific to 
the  antigen  decreases  until  only  a  residual  population  remains.  These 
memory  cells  reside  in  the  bone  marrow  until  promoted  to  expand  and 
respond  once  again  upon  recognition  of  the  same  epitope,  allowing  a 
faster response to the secondary infection therefore conferring immunity. 
 
Naïve  CD4  T  cells  exiting  the  thymus  express  the  cell  surface  protein   31 
tyrosine phosphatase receptor CD45RA. This is the largest isoform of the 
gene  PTPRC,  the  alternative  splicing  of  which  is  linked  to  activation  of 
naive T cells. When the TCR is stimulated by ligation with antigen, the T 
cell  undergoes  alternative  splicing  of  the  PTPRC  gene,  with  differential 
expression  of  isoforms  delineating  maturational  status.  Eventual 
maturation to a memory phenotype is denoted by expression of the RO 
isoform.  Therefore,  these  isoforms  can  be  used  to  distinguish  between 
naïve and memory CD4 T cells. 
 
Within  the  Treg  population,  expression  of  CD45RA  has  demonstrated 
phenotypic  and  functional  heterogeneity  within  the  Treg  population.  For 
example,  CD45RA-negative  Tregs  show  decreased  CpG  methylation  at 
the RORC locus, which encodes the Th17 lineage specifying transcription 
factor,  RORγ,  implying  more  plasticity  at  the  level  of  transcriptional 
regulation  in  memory  compared  to  naïve  Treg  [94,  95].  Miyara  and 
colleagues  [96] performed a phenotypic comparison of Treg varying in 
CD45RA  and  FOXP3  expression,  delineating  several  subsets.  They 
concluded  that  FoxP3
loCD45RA+  cells  represent  resting  Tregs.  Upon  in 
vivo activation these expand and become FoxP3
hiCD45RA-. Both of these 
populations are potently suppressive but this expansion appears to result 
in rapid death of these Tregs after exerting their suppressive function. In 
addition FoxP3
loCD45RA- cells lack suppressive function, express RORC 
and secrete the pro-inflammatory cytokines IL-2 and IFNγ, so these may 
represent recently activated effector T cells transiently expressing FOXP3. 
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1.1.3  The  relevance  of  Treg  lineage  dysregulation  for 
autoimmunity 
Treg are necessary for peripheral tolerance of the immune system to self-
antigens.  Mutations  disrupting  the  Treg-specifying  transcription  factor 
FOXP3,  occur  in  the  IPEX  (immunodysregulation  polyendocrinopathy 
enteropathy  X-linked)  syndrome  and  its  murine  counterpart  the  Scurfy 
phenotype, lead to an absolute lack of Treg and systemic autoimmunity 
[25]. Ablation of Treg in in vivo models leads to autoimmune pathology 
involving  multiple  organ  systems  including  gastritis,  thyroiditis,  diabetes 
and  inflammatory  bowel  disease  [23,  25],  and  is  fatal  [26].  Disease  is 
ameliorated by adoptive transfer of Tregs to Treg-depleted mice [24] and 
to mouse models of autoimmune diseases, such as non-obese diabetic 
(NOD) mice (a type I diabetes model) [97] and experimental autoimmune 
encephalomyelitis (EAE, a multiple sclerosis [MS] model) [98]. Co-culture 
experiments  have  demonstrated  a  reduced  ability  of  Tregs  from  MS 
patients to suppress the proliferation of T effectors from healthy individuals 
[99]. Tregs from individuals with T1D have also demonstrated a reduced 
responsiveness to IL-2, which correlates with loss of FOXP3 expression 
[100].  Post-mortem  histological  analysis  has  shown  that  FOXP3+  Tregs 
are  rare  in  the  pancreatic  islets  of  patients  with  type  1  diabetes  (T1D) 
implying that inadequate numbers of Tregs at the site of inflammation are 
in part responsible for the disease [101]. In MS, Treg numbers appear to 
be increased in both cerebrospinal fluid [102]
 and peripheral blood [102-
104] and therapy normalises this increase [105]. This could indicate that in 
the  context  of  autoimmunity,  not  all  FOXP3-expressing  CD4  cells  are 
suppressive [106].   33 
1.1.3.1  The  clinical  presentation  of  systemic  lupus 
erythematosus (SLE) 
Systemic  Lupus  Erythematosus  (SLE)  is  the  archetypal  systemic 
autoimmune disease. It is distinguished from other systemic autoimmune 
diseases  by  the  presence  of  auto-antibodies  to  nuclear  components  in 
over  95%  of  patients  [107].  These  nuclear  components  include  double-
stranded DNA and nucleosomes but also antigens with unknown biological 
roles, such as ‘Ro’ and ‘Sm’, the nomenclature of which has been based 
on the lupus patients in which they were first described [107].  
 
Patients present with diverse clinical manifestations and so it is has been 
debated  whether  SLE  should  be  considered  a  single  disease  or  a 
collection  of  diseases.  Auto-antibody  repertoire  reflects  clinical 
presentation  with  reactivity  being  relevant  to  the  organs  and  tissues 
involved in pathology [108]. The diversity of organ involvement and tissue 
destruction,  as  illustrated  in  Figure  1.3,  can  include  arthritis,  nephritis, 
dermatological  lesions,  haematological  abnormalities  (eg.  anaemia  and 
thrombocytopenia),  cardiovascular  problems  and  neurological 
complications (ranging from seizures to psychosis). Chronic and extreme 
fatigue  is  also  a  common  and  debilitating  symptom.  In  addition,  the 
classical physical defining feature of lupus is the ‘butterfly rash’ across the 
face, which was considered to resemble the bite of a wolf when it heals 
[109]. It was this distinctive mark that lead to recognition of lupus in the 
18
th Century and gave the disease its name from the Latin for wolf [109].  
 
Patients  also  vary  with  respect  to  disease  severity,  control  of  disease   34 
through treatment and in their pattern of disease flares. Disease activity is 
measured by anti-DNA antibody titre, a value of 50 IU (International Units) 
being considered normal and an increase seen with disease activity, and 
complement C3 level, 0.9 g/L being considered normal and a decrease 
being seen with disease activity. In addition, classification systems have 
been designed to aid standardisation of descriptions of disease severity. 
This includes the British Isles Lupus Assessment Group (BILAG) index, 
through which disease progression is assessed by comparison of clinical 
features  and  organ  involvement  with  previous  observations.  Scores  are 
based on whether the clinical feature was present in the previous visit or is 
new and whether the feature has improved or worsened. The Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) is a similar system 
but clinical features are scored without reference to clinical history. 
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Figure 1.3: The Diverse Clinical Presentations of Systemic Lupus Erythematosus 
SLE  patients  exhibit  heterogeneous  clinical  presentations.  A:  Organ  involvement  and 
tissue destruction can result in arthritis, nephritis, dermatological lesions, haematological 
abnormalities, cardiovascular problems and neurological complications. B: The classical 
‘butterfly rash’, which was considered to resemble the bite of a wolf as it heals. Images 
adapted from the image gallery of National Institute of Arthritis and Musculoskeletal and 
Skin Diseases (NIAMS) [110].     36 
1.1.3.2  The epidemiology of SLE 
As is common for autoimmune diseases, there is no cure for SLE and its 
cause in not fully understood. Reported prevalence is 20 to 150 cases per 
100,000 people (0.02-0.15%) [111], however SLE is 9 times more common 
in  women  than  men  and  the  incidence  rate  amongst  women  is  164 
(Caucasian) to 406 (African American) per 100,000 women (0.16-0.41%) 
[111]. Onset of disease typically occurs between 16 and 55 years of age 
(65% of patients) [111], but is not limited to this age bracket [111, 112]. 
Survival rate in the 1950s was estimated to be 4 years for 50% of patients 
[108]. Worldwide, death as a direct result of disease activity (for example 
through organ failure) has declined [113] but mortality continues to arise 
from complications. These complications include infections associated with 
non-specific  immunosuppressive  treatments  [114],  increased 
cardiovascular risks [113, 114] and cancer (often non-Hodgkin’s lymphoma 
and lung cancer) [113, 114]. The survival rate has improved to 80% at 15 
years. However, this more favourable statistic still however implies that a 
lupus patient diagnosed at the age of 20 has a 1 in 6 chance of dying by 
the  age  of  35  [108].  These  statistics  also  highlight  the  longevity  of  this 
disease that requires decades of medical intervention. 
 
The gender difference indicates potential aetiological roles for hormonal 
and genetic factors. Hormonal involvement is supported by the common 
age of onset being during reproductive years and reported associations 
with oral contraceptives, post-menopausal hormone replacement therapy, 
pregnancy  and  breastfeeding  [111].  X  chromosome  involvement  is 
suggested by the presence of SLE associated variants (including in the   37 
genes IRAK1, MECP2 and TLR7) [111], an increased prevalence in men 
with Klinefelter’s syndrome (XXY) and a decreased prevalence in women 
with Turner’s syndrome (XO) [111]. Clearly gender is not the only influence 
as not all women are affected and men are not resistant. However, there 
are interesting parallels between the higher prevalence of autoimmunity in 
women in general [115], the female specific need for foetal tolerance, an 
evolutionary  association  of  peripheral  Treg  induction  with  placental 
mammals  [116]  and  the  encoding  of  the  Treg  lineage-specifying 
transcription factor FOXP3 on the X chromosome. 
 
Further support for the role of genetics is supported by ethnic and familial 
associations  [111],  including  a  high  concordance  rate  (14  to  57%)  of 
monozygotic twins [117, 118]. Risk alleles exist in immunologically relevant 
genes, including those for complement and innate immunity components, 
lymphocyte  signalling  proteins  and  the  major  histocompatibility  locus 
(MHC). However, genetic associations account for only 18 percent of SLE 
incidence  [111]  and  so  environmental  and  epigenetic  factors  also 
contribute. 
 
Environmental  associations  have  included  factors  thought  to  reflect 
immune  system  disturbance,  such  as  pollutants,  including  silica,  and 
allergies to medications [111]. There are links with exposure to ultraviolet 
(UV) light and this has particular relevance for patients with dermatological 
involvement [111]. Viral infections have also been associated with SLE. 
This includes higher antibody titres and viral loads relating to Epstein-Barr 
virus (EBV) [111] and also suggestions that viral infection or mimicry by   38 
endogenous retroviruses may represent triggering events. Interestingly, a 
viral response signature, including interferon production is associated not 
only with SLE but with other fatigue related syndromes [119-121]. 
1.1.3.3  Treatment of SLE 
Standard  treatment  for  SLE  begins  with  non-specific  anti-inflammatory 
agents including disease-modifying anti-rheumatic drugs (DMARDS), such 
as  hydroxychloroquine,  azathioprine,  leflunomide,  methotrexate, 
mycophenolate mofetil, cyclophosphamide and cyclosporine [122]. This is 
accompanied  by  administration  of  non-steroidal  anti-inflammatory  drugs 
(NSAIDs) and corticosteroids [122]. The broad action of these therapies 
results in long-term toxicity and immune-compromisation that manifest as 
side  effects  including  osteoporosis  and  increased  risk  of  opportunistic 
infection [122]. The use of these non-specific therapies is far from ideal 
and is limited if possible [122-124]. 
 
Patients with greater disease activity and those not responsive to the first 
line therapies described above may progress to treatments with greater 
associated costs. This includes monoclonal antibody therapies aimed at 
depleting abnormal or overactive immune components such as rituximab 
and belimumab, which have been licensed for use in other clinical contexts 
and are directed at limiting the activity of B cells [125]. Rituximab, which is 
directed  against  the  mature  B  cell  marker  CD20  and  results  in  B  cell 
depletion, has been approved for use in other autoimmune diseases and 
also  shows  clinical  success  in  SLE    [124,  126,  127].  However,  two 
randomised  controlled  trials  have  not  been  successful  [128,  129]. 
Belimumab  is  a  monoclonal  antibody  against  B-cell  activating  factor   39 
(BAFF) and leads to inhibition of B-cell survival and differentiation. This 
results  in  reduction  of  autoantibodies,  which  correlates  with  reduced 
disease  activity  in  SLE  [130].  In  March  2011,  the  Food  and  Drug 
Administration (FDA) approved the use of anti-BAFF monoclonal antibody, 
belimumab,  for  treatment  of  SLE  in  the  United  States  [124]  and  the 
European  Medicines  Agency  (EMA)  has  recommended  the  granting  of 
marketing  authorisation  [131].  In  the  United  Kingdom  however,  the 
National Institute for Health and Clinical Excellence (NICE) has rejected 
the use of belimumab as the perceived health benefits are outweighed by 
costs [122].  
 
Hematopoietic  stem  cell  transplantation  (HSCT)  has  been  used  for  re-
education of the immune system in SLE. Transplant-mediated mortality is 
however a concern and so HSCT remains a possibility only in cases of 
aggressive disease where other possibilities are exhausted, rather than as 
a routine treatment [132, 133]. 
1.1.3.4  The immune pathology of SLE 
The  pathogenesis  of  SLE  is  multifactorial  but  culminates  in  the  loss  of 
tolerance to self-antigens, followed by activation and expansion of auto-
reactive lymphocytes with the concomitant production of pro-inflammatory 
mediators  and  autoantibodies.  This  eventually  leads  to  systemic 
inflammation and tissue damage. 
 
The  autoantibody  repertoire  of  SLE  patients  is  diverse  as  it  reflects 
heterogeneous organ involvement but reactivity against nuclear antigens is 
a  defining  feature  of  SLE  that  is  shared  among  95%  of  patients.  This   40 
characterisation  of  SLE  on  the  basis  of  autoantibody  production  has 
strongly implicated a role for B cells in SLE pathogenesis. In support of the 
central role of B cells in SLE, patients show differences in B cell maturation 
and  class  switching,  in  addition  to  repertoire  [134].  These  B  cell 
abnormalities  may  potentially  be  secondary  to  inflammation  rather  than 
intrinsic  defects  but,  in  spite  of  this,  B  cell  targeting  therapies,  such  as 
rituximab  and  Belimumab  (described  in  Section  1.1.3.3),  are  attractive 
options. 
 
A  theory  for  the  abundance  of  anti-nuclear  antigen  antibodies  is  that 
inefficient  clearance  of  apoptotic  cellular  debris  leads  to  exposure  of 
nuclear epitopes and the production of immune complexes against these. 
In support of this, increased apoptosis is seen in lymphocytes from SLE 
patients, possibly due to their increased activation [135] and accumulation 
of post-apoptotic debris is seen in B cell germinal centres of lymph nodes 
of SLE patients [136]. Classical complement components (C1q, C2, C4) 
aid the clearance of immune complexes and autoantigens and, consistent 
with this, deficiencies in these early complement components predispose 
towards  SLE  [137].  Activity  of  later  components  of  the  complement 
cascade,  however,  contributes  towards  pathogenesis  with  hydrolysis  of 
alternative complement pathway component, C3, leading to downstream 
promotion of inflammation and tissue injury [137]. The serum level of C3 is 
therefore  associated  with  immune  activation  and  is  indicative  of  active 
disease in SLE patients. 
 
In  addition  to  complement,  further  dysregulation  of  the  innate  immune   41 
response is seen in SLE, with increased signalling downstream of the Toll-
like  receptors  (TLRs)  4  [138],  7  [139]  and  9  [140]  associated  with  the 
initiation  and  perpetuation  of  SLE  [141].  These  TLRs  recognise 
lipopolysaccharide,  single-stranded  RNA  and  unmethylated  CpG 
sequences, respectively, the latter two again reflecting the involvement of 
nuclear epitopes. The activity of anti-viral-response associated receptors is 
echoed in the cytokine signature seen in SLE patients. 
 
SLE patients  demonstrate  a  unique  inflammatory  cytokine  environment, 
particularly  regarding  high  levels  of  the  anti-viral  response  associated 
cytokine, interferon-alpha (IFN-α) [142], and IFN-α inducible genes [143-
146]. The primary producer of IFN-α appears to be plasmacytoid dendritic 
cells  (pDCs)  [137,  147].  This  IFN-α  production  drives  autoimmunity  by 
promoting  the  maturation  and  pro-inflammatory  role  of  DCs  [148],  the 
differentiation of plasma cells [149] and also B and T cell signalling [148]. 
The  serum  from  SLE  patients  is  also  high  in  the  pro-inflammatory 
cytokines IL-6 (from monocytes, fibroblasts and endothelial cells in addition 
to  lymphocytes)  [150,  151]  and  IL-17  (from  neutrophils,  NK  cells,  CD4, 
CD8, double negative and γδ T cells) [151, 152] and also the pleiotropic 
cytokine TNF-alpha [150], the role of which is poorly understood although 
levels correlate with disease activity [153]. 
 
The  Th17  CD4  T  helper  cell  lineage  has  been  implicated  in  SLE 
pathogenesis  through  the  increased  production  of  the  pro-inflammatory 
cytokine IL-17 [154] and reduced IL-2, which inhibits Th17 differentiation 
[155].  In  addition,  the  role  of  T-lymphocyte  help  for  autoantibody   42 
production by B cells is critical to the pathogenesis of SLE. This includes in 
class-switching  and  costimulation  by  T  follicular  helper  cells  [156].  In 
addition, signalling through the T cell immunological synapse is aided by 
an abnormal membrane lipid aggregation and profile in SLE [157]. 
1.1.3.5  CD4 T cell transcriptional abnormalities in SLE 
Gene expression profiling of PBMCs and whole CD4 T cells reflects the 
IFN-α signature that is characteristic of SLE [158, 159]. Acetylation level of 
global H3 and H4 is reduced in SLE CD4 T cells, as is the global H3K9 
methylation level, while global H3K4 methylation is not different to healthy 
individuals  [160].  In  correlation  with  this,  mRNA  levels  of  the  histone 
acetyltransferases CBP and P300, the histone deacetylases HDAC2 and 
HDAC7,  and  histone  methyltransferases  SUV39H2  and  EZH2  are 
decreased  [160].  However,  activity  of  these  histone  modifiers  and  the 
specific genomic sites that exhibit differences in post-translational histone 
modifications are unknown [161]. Increased H3K27me3 at the promoter of 
hematopoietic progenitor kinase 1 (HPK1) has been observed in CD4 T 
cells, which correlated with an expected decrease in mRNA and protein. 
[162]. In terms of T cell relevant transcription factors, STAT1 has been 
implicated in SLE pathogenesis by its role in interferon signalling, however 
total and phosphorylated levels do not correlate with SLE [163, 164]. In 
whole  T  cells  (pan-CD3),  phosphorylated  STAT5  levels  are  increased 
above healthy controls and rheumatoid arthritis patients [163]. 
1.1.3.6  Treg in SLE pathogenesis 
As described above, the immune pathogenesis of SLE is multifactorial and 
is underpinned by a general dysregulation of inflammatory mediators. As   43 
Treg  are  essential  for  limiting  deleterious  autoimmune  reactions  in  the 
periphery,  they  have  been  investigated  for  their  relevance  to  SLE 
pathogenesis. This has uncovered some evidence of both quantitative and 
functional  differences  in  the  Treg  of  SLE  patients  compared  to  healthy 
individuals and other disease controls. 
1.1.3.6.1  Quantitative differences 
Accounts  of  numerical  differences  in  Treg  vary  according  to  phenotypic 
description [165]. When identifying Treg using the basic criteria of CD4+ 
and CD25+, several studies find that Treg are depleted in SLE patients 
[166,  167],  both  with  [168]  and  without  [169]  correlation  with  disease 
severity.  Another  study  showed  a  non-significant  trend  for  increase  of 
CD4+CD25+  T  cells,  with  numbers  significantly  correlating  with  disease 
severity but also with corticosteroid treatment, suggesting that evaluating 
numbers of Treg is confounded by treatment rather than directly related to 
disease [170]. When Treg are defined as CD25 high or ‘bright’, the majority 
of studies see that they are decreased in patients [171-176] but a minority 
still observe that numbers compare with healthy individuals [177, 178] or 
even  that  they  are  increased  [179].  More  recent  studies  that  exclude 
CD25+ cells expressing CD127, a population that is enriched for FOXP3+ 
‘true’  Treg  [40],  find  a  decrease  in  Treg  that  correlates  with  increased 
numbers  of  Th17  cells  [180,  181].  When  FOXP3  expression  is  used  to 
define  Treg,  regardless  of  CD25  or  CD127  expression,  the  majority  of 
studies, including data from our lab [182], show an increase [174, 183, 
184], with some still showing normal numbers [167, 185]. When FOXP3 is 
assessed in the CD25+ compartment, increased numbers are seen [186]. 
However,  when  analysis  is  confined  to  the  CD25  high  population  and   44 
numbers of FOXP3 expressing cells examined, the converse is found and 
decreased  numbers  are  observed  [187,  188],  but  again  there  are 
exceptions [189]. CD127- Treg and CD25 high FOXP3+ Treg, which are 
likely to represent the same population, show a general consensus of a 
decrease in numbers in SLE. The comparisons with CD25- Treg indicate 
that in SLE patients FOXP3 expression is more frequent in CD25- CD4 T 
cells compared to a healthy setting, while in CD25+ cells it is decreased. 
This  suggests  instability  to  the  Treg  phenotype.  As  Treg  are  highly 
dependent upon IL-2 for survival and FOXP3 expression [190, 191], the 
impaired  production  of  IL-2  seen  in  SLE  patients  [192]  supports  the 
possibility of Treg defects that relate to the expression of the IL-2 receptor, 
CD25. 
 
Decrease  in  numbers  of  Treg  may  be  due  to  deficient  production, 
maintenance, stability or survival of Treg and potentially may arise prior to 
disease onset but also in response to the inflammatory environment of the 
disease itself or to treatment. Increases in Treg numbers may reflect the 
expected physiological response of an attempt to limit reactivity against 
self-antigens.  This  could  be  interpreted  as  Treg  being  functionally 
equivalent  to  those  from  healthy  individuals,  but  with  the  extent  of 
inflammation,  and/or  the  presence  of  defects  outside  of  the  Treg 
compartment,  being  too  extreme  for  Treg  to  restrain.  Alternatively, 
increased  numbers  may  reflect  Treg  expansion  in  response  to 
inflammation, even though the cells exhibit defective suppressive capacity. 
1.1.3.6.2  Functional differences 
As  with  investigations  into  numerical  differences,  there  is  conflicting   45 
evidence on functional defects in Treg in SLE. As assessed by the in vitro 
suppression assay, the CD25-high population has been shown by some to 
be normal in terms of suppression of Tresp proliferation [172, 185, 188] 
and  cytokine  production  [172],  with  some  evidence  showing  a  defect 
resides  within  the  Tresp  rather  than  Treg  population  [185].  However, 
defects in this population have also been observed in the suppression of 
proliferation [176], but not in all patients [177] and these defects correlate 
with disease activity [193]. Defective suppression is also seen in the total 
CD25 population regardless of therapy [166]. In addition, functional Treg 
from both healthy individuals and SLE patients have been shown to be 
rendered defective following culture with APCs from SLE patients [186]. 
 
Identifying functional defects in Tregs in SLE is complicated by their low 
frequency in peripheral blood (1% of PBMCs), which is decreased further 
under the lymphopenic condition of active disease. This is compounded by 
the heterogeneous nature of SLE, because any defects found may not be 
applicable  to  all  patients,  and  the  likelihood  that  examining  peripheral 
blood Tregs will not fully reflect those situated in inflamed sites. In addition, 
the heterogeneity of Treg themselves, and the possibility of Treg subsets 
with  differences  in  phenotype  and  suppressive  mechanisms,  further 
complicates  functional  assessment.  There  is  no  accepted  Treg-specific 
marker that can be used for identification or isolation; FOXP3 and CD25 
are  also  expressed,  at  least  temporarily,  in  activated  responder  T  cells 
without conferring suppressive function [194]. 
 
In  support  of  defective  Treg  activity  in  SLE,  the  inflammatory  cytokine   46 
environment has been shown to impact on Treg function. For example, 
IFN-a  production  from  APCs  rendered  Treg  dysfunctional  [186].  Serum 
from SLE patients is characterised by high levels of IL-6 [150] and TNF-a 
[150, 153], both of which may interfere with Treg function; IL-6 promotes 
the conversion of Tregs to an inflammatory Th17 phenotype [195], which 
has been implicated in other autoimmune diseases [196]. Correspondingly, 
levels of the Th17 cytokine IL-17 have also been found to be increased 
in SLE patients  [152];  TNF-alpha,  through  TNF receptor  II  mediated 
signalling,  can  down-regulate Foxp3 expression  in  Treg and  hence 
potentially  diminish  suppressive  capacity  [197].  Additional  support  for 
potential  Treg  defects  comes  from  a  recent  SNP  association  study 
between sub-phenotypes of the disease and overactive variants of known 
FOXP3 target genes [198]. 
1.1.4  Development and differentiation of T cells 
Below I describe the intracellular events downstream of developmental and 
environmental stimuli that facilitate T cell differentiation. These signalling 
events  lead  to  the  activation  of  transcription  factors  that  have  common 
roles  among  all  T  cell  subsets  but  also  those  that  promote  lineage 
specification. 
1.1.4.1  TCR signalling 
Signalling events downstream of antigen presentation lead to activation of 
the T cell through several pathways. Engagement of the CD4 co-receptor 
with  MHCII  from  an  APC  leads  to  lymphocyte-specific  tyrosine  kinase 
(LCK) binding to the intracellular domain of CD4 (reviewed in [199]). This 
brings LCK into close vicinity with the CD3 intracellular chains leading to   47 
phosphorylation  of  intracellular  tyrosine-based  activation  motifs  (ITAMs) 
enabling  the  recruitment  and  activation  of  Zeta-chain-associated  protein 
kinase 70 ZAP70 [199]. This is followed by phosphorylation of the linker for 
activation  of  T  cells  (LAT)  and  the  formation  of  a  complex  of  multiple 
signalling proteins. Events downstream of this LAT ‘signalsome’ lead to 
electrochemical signalling, via the release of calcium ions (Ca
2+) from the 
endoplasmic  reticulum,  and  activation  of  the  mitogen-activated  protein 
kinase  (MAPK)  kinase  and  nuclear  factor  kappa-light-chain-enhancer  of 
activated B cells (NF-κB) signalling pathways [199].  
 
Concomitant  signalling  through  CD28,  as  well  as  CD3,  by  the  co-
stimulatory molecules CD80 and CD86 is required to avoid T cell anergy. 
Phosphorylation of intracellular motifs of CD28 recruits phosphatidylinositol 
3-kinase (PI3K), which targets AKT and leads to activation of transcription 
factors  including  NF-κB,  NFAT  and  mammalian  target  of  rapamycin 
(mTOR) [200]. CD28 signalling also leads to protein kinase C theta (PKC-
θ)  phosphorylation  followed  by  activation  of  c-Jun  N-terminal  kinases 
(JNK)  and  extracellular  signal-regulated  kinases  (ERK)  1  and  2  [200]. 
There are differential requirements for CD3 and CD28 signalling between 
Treg  and  Tresp  development.  For  example,  signalling  molecules 
downstream of mTOR, specifically p70S6 kinase (p70S6K) and 4E binding 
protein 1 (4E-BP1), show reduced phosphorylation in Treg compared to 
Tresp [201]. This is consistent with the use of rapamycin, which inhibits the 
mTORC1 subunit of mTOR, as an immunosuppressant in clinical use and 
also for the preferential expansion of Treg over Tresp in vitro [202]. 
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1.1.4.2  Treg specific development 
Treg develop in the thymus as a lineage distinct to naïve Tresp and are 
also induced in the periphery from naïve T cells. In the thymus T cells go 
through a selection process to eliminate those with a self-reactive TCR, the 
result of the somatic gene rearrangement that is necessary for the diverse 
TCR repertoire that allows us to acquire immunity to limitlessly evolving 
pathogens. T cells with self-reactivity are stimulated to undergo receptor 
editing or programmed cell death in the process of negative selection. This 
process is not completely efficient and self-reactive T cells do escape the 
thymus including in healthy individuals. The presentation of self-antigen by 
thymic epithelial cells has been proposed to also positively select for, or 
promote the development of, Treg. There is evidence of TCR reactivity to 
self-antigen in the Treg population [203, 204] and it has been suggested 
that  this  self-reactivity  among  immuno-suppressive  nTreg  leads  to  their 
activation  in  the  periphery,  guarding  against  autoimmunity.  Escape  of 
these self-reactive nTreg from the thymus may be reliant on a lower avidity 
for  self-antigen  below  the  threshold  for  negative  selection  [205,  206]. 
Signalling  downstream  of  this  TCR  engagement  may  also  promote  the 
development  of  Treg  function  in  thymocytes  [207].  The  downstream 
consequences  of  TCR  signalling  are  discussed  in  the  following 
paragraphs. High expression of CD25 suggests Treg are dependent on its 
ligand,  IL-2,  and  this  is  shown  by  the  development  of  spontaneous 
autoimmunity  in  IL-2  deficient  mice  [208].  In  the  periphery,  de  novo 
generation of iTreg from naïve T cells also involves TGF- β [17]. 
 
Treg  are  dependent  upon  IL-2  binding  CD25,  the  alpha  subunit  of  the   49 
receptor, which is highly expressed and is used to define and isolate Treg. 
This  alpha  chain  of  the  receptor  is  not  thought  to  transduce  signalling 
directly but dimerises with the beta (CD122) and gamma (CD132) chains 
to  form  the  IL-2  receptor  complex.  The  beta  and  gamma  chains  are 
phosphorylated  by  Janus  kinases  (JAK)  1  and  3,  respectively  [209], 
leading  to  recruitment  and  activation  of  the  transcription  factor  signal 
transduce and activator of transcription (STAT) 5 [210].  
 
TGF-β signalling promotes the differentiation of Treg over pro-inflammatory 
lineages. Upon TGF-β binding to TGF-β receptor II (TGF-βRII), receptor 
dimerization with TGF-βRI leads to recruitment and activation of receptor-
regulated  SMADs  (R-SMADs)  2  and  3  [211,  212].  These  have  been 
suggested  to  complex  with  common-mediator  SMAD  (co-SMAD)  4 
followed by translocation of this transcription factor tripartite complex to the 
nucleus [213, 214]. Activation of SMAD independent signalling pathways 
may  also  occur  downstream  of  the  TGF-β  receptors.  This  is  poorly 
characterised but may lead to activation of JNK, p38 MAPK and NF-κB 
downstream  of  MAPK  kinase  kinases  (MAPKKKs)  [215,  216].  These 
events  may  converge  on  SMAD  pathways  to  regulate  SMAD  signalling 
[216].  
 
Paradoxically,  signalling  through  receptors  for  the  pro-inflammatory 
cytokine  TNF-α  promotes  Treg  activity.  The  stabilisation  of  Treg 
phenotype,  function  and  expansion  [217,  218]  in  response  to  TNF 
production by pathogenic Tresp may allow for a negative feedback loop 
that  limits  Tresp  activity  [219].  This  has  been  shown  to  be  mediated   50 
through TNFR2 [217, 219, 220] and other members of the TNF receptor 
superfamily, including OX40 and 4-1BB [221]. 
 
Ultimately, these signalling cascades link the cells external environment to 
rearrangement  of  the  chromatin  landscape  and  changes  in  gene 
expression,  allowing  adaptation  of  the  T  cell  phenotype  to  an 
environmental stimulus [199]. 
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1.2  Transcriptional control of T cell differentiation  
Despite the nearly identical DNA sequence present in the genes of each 
cell  of  an  organism,  distinct  cellular  identities  are  formed  from  the 
increased  activity  of  cell  specific  genes  and  the  repression  of  genes 
relevant  to  alternative  cell  fates.  For  example,  in  Th1  cells  IFNG  is 
upregulated while IL4 is downregulated and vice versa for Th2 cells. The 
maintenance of this cell specific gene expression over cell divisions allows 
the  inheritance  of  cell  identity  and  the  establishment  of  cell  lineages. 
Control  of  gene  expression  at  the  level  of  transcription  provides  a 
mechanism for this epigenetic inheritance and influences cell identity. This 
level  of  regulation  therefore  has  consequences  for  normal  cellular 
processes, such as fighting invading pathogens, and for disease when this 
differentiation becomes dysregulated, for example in autoimmunity. 
1.2.1  Transcription factors controlling T cell differentiation  
1.2.1.1  Lineage-specifying transcription factors 
The concept of distinct lineages has been reinforced by the discovery of 
lineage-specifying transcription factors for each subset, the expression of 
which  is  both  necessary  and  sufficient  for  functional  activity.  These  are 
known to bind and regulate key functional genes specific to their respective 
lineage. GATA-3, a member of the GATA family of zinc finger transcription 
factors, was found to be preferentially expressed in Th2 compared to Th1 
cells  [222]  and  GATA  binding  sites  are  present  upstream  of  the 
IL4/IL5/IL13 gene cluster [223]. Knockdown showed GATA-3 was required 
for the expression of these Th2 cytokines [222], while ectopic expression 
of GATA-3, alongside stimulation, induces their expression [222]. A few   52 
years after this discovery, a member of the T box family of transcription 
factors,  T-bet  (T  box  expressed  in  T  cells,  Tbx21)  was  found  to  be 
expressed  in  Th1  but  not  Th2  cells  [224].  Other  members  of  the  Tbox 
family of transcription factors have roles in development. Members of this 
transcription  factor  family  recognise  a  common  sequence  through  a 
conserved DNA binding domain, the Tbox [225], and are recognised as 
both transcriptional activators and repressors [225]. Ectopic expression of 
T-bet activates IFNG [224] which contains a Tbox consensus binding site 
[224].  In  addition,  the  loss  of  T-bet  results  in  susceptibility  to  Type  I 
infections [226]. Both GATA-3 and T-bet can re-polarise cells towards their 
respective lineages when expression is enforced in the alternative lineage 
[222, 224]. T-bet interacts with the H3K4 methyltransferase subunit RbBp5 
and  the  H3K27  demethylase  JMJD3  [227]  and  T-bet  binding  correlates 
with  permissive  histone  modifications,  including  H3K9  acetylation  [228] 
and H3K4 methylation [229], at Th1 upregulated genes. However as T-bet 
is also found at locations lacking these modifications and at loci that are 
not upregulated, it is unlikely these histone marks are a direct result of 
binding  of  the  transcription  factor  [229].  While  T-bet  is  known  to  be 
required  for  binding  of  the  chromatin  insulator  CTCF  (CCCTC-binding 
factor) [230], the biochemical mechanism of T-bet and T-box function in 
general is not fully understood. 
 
In 2003, the publication of three studies demonstrated the requirement for 
the  transcription  factor  FOXP3  for  Treg  function.  This  was  elucidated 
through  mapping  the  genetic  cause  of  the  murine  autoimmune  scurfy 
phenotype [37-39] and its human equivalent, IPEX syndrome [38] to the   53 
FOXP3 locus. Supporting this, ectopic expression of FOXP3 conferred a 
Treg  like  suppressive  activity  to  T  responder  cells  [38]  and  limited 
autoimmune disease [39]. The equivalent transcription factor governing the 
Th17  lineage  has  since  been  identified  as  RORγt  [231].  These 
transcription  factors  have  historically  been  considered  to  be  ‘master 
regulators’,  a  term  that  indicates  omnipotence  over  cell  phenotype. 
However,  their  co-expression  has  been  frequently  observed  and  fluidity 
between these lineages in now appreciated, leading to the more modest 
term ‘lineage-specifying factors’. This is expanded upon in Section 1.2.2. 
1.2.1.2  Lineage-plasticity and co-expression of lineage-
specifying transcription factors 
Although T cell lineages have distinct phenotypes, there is some plasticity 
between subsets. For example, Th17 cells can produce the Th1 cytokine 
IFNγ  [232]  while  Treg  may  acquire  a  Th17  phenotype,  which  is  pro-
inflammatory rather than suppressive. This instability in Treg contributes 
to,  rather  than  contains,  inflammation  and  has  been  implicated  in  the 
pathogenesis of autoimmunity [233, 234]. Genetic lineage tracing has been 
used to track the fate of mouse Treg in vivo. This showed that ex-Treg, 
which had downregulated Foxp3, were increased in inflamed tissues and 
their  adoptive  transfer  promoted  autoimmune  diabetes  [235].  Such 
instabilities in T cell lineages also have functional rather than pathogenic 
consequences. For example, fully differentiated Th2 cells can repolarise in 
vivo to a Th1 functionality when confronted with a Type I infection [236]. 
Expression  of  the  lineage-specifying  transcription  factors  reflects  this 
diffusion of T cell identity. For example, Foxp3 is seen in activated but non-
suppressive  T  effectors  and  may  reflect  chromatin  remodelling  of  the   54 
Foxp3 locus downstream of TCR signalling and may be expressed without 
the associated Treg phenotype [235]. In addition, the expression of these 
transcription  factors  is  not  mutually  exclusive  as  once  thought  and  co-
expression can be seen in the same cells [237]. This co-expression may 
have functional importance. The expression of T-bet [238-241] or Gata3 
[242] alongside Foxp3 in Treg may allow Treg to co-opt a partial Th1 or 
Th2 phenotype, respectively, for more targeted regulation. Supporting this 
theory, T-bet expression in FOXP3-expressing Treg occurs in response to 
Th1 cytokines IFNγ [239] and IL-27 [241] and leads to expression of Th1 
associated chemokine receptor CXCR3 [239], with accumulation of T-bet 
positive  Treg  being  seen  during  type  1  inflammation  [239].  In  addition, 
Gata3  complexes  with  Foxp3  and  its  deficiency  leads  to  Th2  mediated 
inflammatory disease [242].  
 
Beyond  Treg,  the  repolarisation  of  Th2  cells  to  functional  Th1  cells, 
mentioned above, is reflected in transcription factor expression [236]. Work 
from our lab and others [243, 244] has shown that Gata3 is also expressed 
in Th1 cells [236, 243-246] but that expression of T-bet has a dominant 
effect [245, 246]. The presence of Gata3 in Th1 cells may be functional in 
controlling  expression  of  pan-T  cell  active  genes,  such  as  TCR  genes 
[243]. In addition, expression of T-bet and GATA-3 has been observed in 
RORγt  expressing  Th17  memory  cells,  with  a  suggestion  that  this  may 
allow  potential  for  repolarisation  [247],  which  has  been  demonstrated 
through  priming  of  Th1  cells  with  the  Th17  type  pathogen,  Candida 
albicans  [248].  Co-expression  has  also  been  observed  in  several 
immunopathologies such as experimental allergic encephalomyelitis [249],   55 
juvenile  idiopathic  arthritis  [250]  and  allergic  asthma  [251]  and  may 
contribute to pathology.  
 
Our lab has explored the interplay between T-bet and GATA3 with ChIP-
Seq demonstrating that GATA3 binding transitions from Th2-specific sites 
in Th2 cells to T-bet Th1-specific sites in Th1 cells [246], suggesting that T-
bet acts dominantly in the relocation of other transcription factors. This is 
consistent with suggestions that T-bet’s primary function is to repress the 
alternative  Th2  transcriptional  program  [252,  253].  A  similar  relationship 
has been seen between TBX5 and GATA4 during cardiac development 
[254],  suggesting  a  common  mechanism  for  T-box  family  member 
transcription factors. Furthermore, T-bet binds the Bcl6 transcription factor 
DNA  binding  domain  thereby  occluding  its  function  [255,  256].  These 
observations  show  that  lineage-specifying  transcription  factors  are  not 
omnipotent and that defining T cell subsets on the basis of their expression 
alone is limited. Therefore it is important to understand the additional levels 
of regulation involved not only at lineage specific genes but genome wide. 
1.2.1.3  STATs and other pioneer factors 
As described above, TCR signalling initiates activation of activator protein 
(AP)  -1,  NFAT  and  NF-κB.  These  transcription  factors  are  not  lineage-
specific  [257]  but  their  binding  precedes  and  theoretically  enables 
recruitment of lineage-specifying transcription factors [258]. For example, 
FOXP3  appears  to  primarily  bind  sites  targeted  by  these  transcription 
factors as they are already accessible in Treg precursor cells [258]. Such 
precursor transcription factors that allow the activity of lineage-specifying 
factors have been termed ‘pioneers’ [258]. NFAT [259, 260] and NF-κB   56 
[259] have been shown to cooperate with FOXP3. Similarly, cofactors have 
been postulated to pre-bind DNA, facilitating open chromatin conformation 
prior to FOXP3 binding [258]. In addition, transcription factors of the same 
structural family may act as placeholders, for example FOXO1 through its 
similarity in binding specificity to FOXP3 [258]. 
 
The STAT transcription factors are also considered to be pioneers and are 
activated  in  a  lineage-specific  manner  [261].  STAT  activation  occurs 
downstream of cytokine signalling. When IL-12 binds its receptor, STAT4, 
sequestered at the membrane is phosphorylated and enters the nucleus, 
where it binds and activates expression of the Th1 signature cytokine IFNγ 
[262-265]. This in turn has an autocrine effect by activating STAT1 [266]. 
IL-4 meanwhile, activates STAT6 [267], culminating in expression of the 
Th2  lineage-specifying  transcription  factor  GATA-3  [268].  STAT3  is 
activated  by  IL-6  [269]  leading  to  Th17  differentiation  [270]  and  IL-2 
activates STAT5 for Treg differentiation [271]. Binding site motifs for these 
STATs are present in the regulatory regions of the genes encoding the 
lineage-specifying transcription factors. For example, STAT4 and STAT1 
bind  the  gamma-interferon-activation-site-with-three-base-pair-spacer 
(GAS-3) motif upstream of IFNG [261] and STAT6 binds GAS-4 upstream 
of  IL4  [261].  Genome-wide  profiling  shows  that  STATs  are  extensively 
associated with regulatory regions, even to a greater extent than lineage-
specifying  factors  [261]  and  deficiency  of  STATs  leads  to  disruption  of 
these  regulatory  regions,  which  cannot  be  rescued  by  expression  of 
lineage-specifying transcription factors [261]. 
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1.2.1.4  Cofactors 
The  biochemical  mechanisms  of  how  the  T  cell  transcription  factors 
regulate gene expression are not well understood but given their binding is 
associated with both up and downregulation of gene expression [272, 273], 
their specific modes of activity are likely influenced by binding partners. In 
addition to augmenting the activity of transcription factors, cofactors have 
potential  to  act  as  placeholders  at  regulatory  regions  thereby  directing 
transcription factor binding. 
 
T-bet cofactors include ETS1 [274] and RUNX3 [275]. Interaction of T-bet 
with RUNX3 competes with Gata3 and is necessary for repression of Il4 
through  this  mechanism  [276,  277].  The  presence  of  ETS1  binding 
upstream of Ifng is necessary for T-bet mediated induction of Ifng and type 
1 inflammation in vivo [274]. A mass spectrometric analysis identified over 
300 proteins associated with FOXP3 that may act to regulate its activity 
[242]. This included transcription factors that were already known to have 
roles  in  Treg  such  as  FOXP1,  RUNX1  and  IKZF1  (Eos),  as  well  as 
components of several chromatin-modifying complexes [242]. While these 
cofactors  are  not  Treg  specific,  synergy  with  FOXP3  may  target  their 
activity to Treg relevant genes. The Th2 lineage-specifying GATA3 was 
also found in this FOXP3 ‘interactome’ complex [242] and is also known to 
bind the FOXP3 promoter [278], and vice versa [242]. In Foxp3
CreGata3
fl/fl 
mice, although the number of Treg was similar to littermate controls, the 
Treg-specific loss of Gata3 was shown to increase Th2 mediated intestinal 
inflammation  and  dermatitis  [242],  demonstrating  that  this  interaction  is 
immunologically  relevant.  This  co-expression  of  FOXP3  and  an   58 
inflammatory  lineage-specifying  transcription  factor  may  allow  Treg  to 
adapt their phenotype to the immunological setting, for example through 
the expression of Th1 or Th2 homing receptors, allowing their targeting to 
relevant anatomical sites [239]. 
1.2.2  Enhancers and regulatory regions 
Enhancer regions are DNA elements that increase expression of a gene 
above the level seen with the minimal promoter region [279], can exert 
their influence over various distances [280], regardless of orientation [279] 
and can recruit RNA polymerase II (RNAPII) in the absence of a promoter 
[280]. These characteristics, first described in reference to the enhancing 
effect  of  enforced  expression  of  the  SV40  promoter  on  the  beta-globin 
gene, have come to form the basic definition of the enhancer element in 
metazoans [281]. Following this, the first intrinsic eukaryotic enhancer to 
be described was at the immunoglobulin heavy chain (IgH) locus, where 
chromosomal rearrangements outside of the promoter-proximal region are 
required for high level expression of the recombined immunoglobulin gene 
[282-284]. These properties ultimately lead to a communication between 
enhancers and promoters that regulates the expression of a gene. This 
communication  can  be  enhanced  with  increasing  proximity  between  the 
enhancer  and  promoter  [279]  but  can  also  occur  over  large  genomic 
distances [285]. 
1.2.2.1  Features of enhancers 
In  addition  to  the  properties  described  above,  additional  features  of 
enhancers  include  an  association  with  DNaseI  hypersensitivity  sites 
(DHS),  the  binding  of  transcription  factors  and  coactivators  and  the   59 
presence of signature histone modifications. DHS are identifiable through 
nuclease treatment followed by DNA sequencing and represent genomic 
regions with enhanced accessibility, as indicated by increased cleavage 
[286]. This accessibility is directly related to transcriptional activity through 
an increased capability to bind regulatory complexes. Supporting this, DHS 
loci are associated with functionally relevant and cell type specific genes 
[287]. The profiling of genome wide DHSs has been used to identify de 
novo regulatory regions, including putative enhancers [258, 288]. However, 
DHS are also found associated with genes of closely related alternative 
cell fates and so, for example, naïve T cells and Treg share 99% of DHS 
sites [258]. In addition, not all genes associated with DHSs are transcribed 
[289].  These  observations  have  lead  to  a  distinction  between  active 
enhancers,  which  are  currently  operating  within  a  cell  to  activate  gene 
expression, and inactive but poised enhancers, the accessibility of which 
allows a response to the cellular environment should an alternative cell 
fate or transcriptional program be required [290]. Both active and poised 
enhancers  are  marked  by  mono-methylation  of  histone  H3  at  lysine  4 
(H3K4me1,  Section  1.2.3,  Table  1.1,  [289]),  a  permissive  histone 
modification that is associated with accessible areas of chromatin and is 
lost  as  enhancers  are  decommissioned  during  differentiation  [291]. 
However, only active enhancers are marked by acetylation of H3K27 [290], 
a mark that is gained at lineage-specific loci as differentiation progresses 
[290]. It is not fully understood if these histone modifications are a cause or 
consequence of enhancer formation and activity, however their deposition 
has electrostatic effects on chromatin conformation and provides binding 
sites  for  regulatory  proteins  (Section  1.2.3,  Table  1.1).  In  addition,  the   60 
binding  of  transcription  factors,  coactivators  and  chromatin-modifying 
complexes with known activities is informative of enhancer formation. For 
example,  the  coactivator  CREB  binding  protein  (CBP)  and  its  family 
member  P300  have  histone  acetyltransferase  activity  [292]    and  their 
genomic occupancy corresponds with DHS sites and has been used to 
identify active enhancers [293-295]. The transcriptional coactivator BRD4 
(Bromo-domain containing 4) [296] recognises acetylated histones, such 
as H3K27ac [297], is required at active genes for processive elongation of 
transcription  (Section  1.2.2)  and  has  been  associated  with  active 
enhancers [296, 298]. The co-assembly of multiple complexes and their 
cooperation at enhancers is recognised and termed ‘The Enhanceosome’ 
[299]  and  binding  site  motifs  for  transcription  factors  are  also  found  at 
enhancers.  
 
Supporting  the  fundamental  importance  of  enhancers,  several  diseases 
are  associated  with  disruptions  of  enhancer  relevant  complexes.  This 
includes  general  developmental  abnormalities  seen  in  Rubinstein-Taybi 
syndrome caused by CBP or P300 mutations [300, 301] and in Cornelia de 
Lange syndrome, which is associated with mutations in components of the 
Cohesin complex [302, 303]. Additionally, mutation of enhancer sequences 
but  not  coding  sequences  are  involved  in  several  diseases  including 
Burkitt’s  lymphoma,  in  which  chromosomal  translocations  have  been 
observed  in  close  proximity  to  the  oncogenic  MYC  gene  [304],  and  a 
subset  of  β-thalassemias  that  show  disruption  of  an  upstream  DNaseI 
hypersensitive region [305]. 
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1.2.2.2  Mechanisms of enhancer function 
The communication between enhancer and promoter for the influence of 
gene  expression  is  exemplified  in  Drosophila  by  insertion  of  gypsy 
retrotransposon  element,  which  blocks  enhancer-promoter  interaction 
through recruitment of the chromatin insulator protein, Hairy wing [306]. In 
mammalian  cells  this  formation  of  chromatin  boundaries  between 
enhancers and promoters is mediated by CTCF (CCCTC-binding factor) 
[307].  Potential  mechanisms  for  enhancer-promoter  communication 
include:  tracking  of  transcriptional  machinery  from  an  enhancer  to  a 
promoter,  looping  of  DNA  to  bring  enhancer  and  promoter  into  close 
proximity independently of the intervening DNA, and cooperation of both 
mechanisms [281]. Theories of tracking suggest complexes are recruited 
to  an  enhancer,  they  may  migrate  along  the  DNA  until  reaching  the 
promoter [308]. Looping of DNA to allow interaction between an enhancer 
and  promoter  without  interaction  with  the  intervening  DNA  sequence  is 
supported  by  the  chromosome  conformation  capture  technique,  which 
identifies physical interactions between genomic regions. This looping has 
been demonstrated at the beta-globin locus with mediation through CTCF 
[309]. The conserved non-coding sequences that CTCF binds have also 
been  shown  to  interact  with  Cohesin  complexes  [310],  which  have  a 
canonical  role  in  sister-chromatid  cohesion  [311]  but  have  also  been 
shown  to  influence  gene  expression  [312].  Mediator,  a  macromolecular 
coactivator complex that binds transcription factors at regulatory regions 
and promoters, also influences gene expression through DNA looping in 
cooperation  with  Cohesin  [313,  314].  Complications  in  predicting  the 
communication between enhancers and promoters arise from the ability of   62 
enhancers  to  communicate  with  multiple  promoters  [315]  and  multiple 
promoters to contact a single enhancer [316]. In addition, while a shorter 
distance between an enhancer and promoter can increase the effect on 
gene  expression  [279],  long  range  communications  are  also  efficient  in 
other circumstances [285] and so relative position alone does not predict 
interaction [317]. 
1.2.2.3  Super-enhancers 
Locus control regions (LCRs) are defined by their ability to enhance the 
expression of linked genes to physiological levels in a tissue-specific and 
copy number dependent manner at ectopic chromatin sites [318]. Genomic 
methodology  has  allowed  similar  regulatory  elements  to  be  identified 
across the genome, as highly occupied target (HOT) regions, transcription 
initiation platforms (TIPs, [319]) or ‘super-enhancers’ [320, 321]. HOT loci 
have been defined in Drosophila as regions that exhibit enriched binding 
for multiple transcription factors [322, 323] with this increased transcription 
factor binding complexity correlating with nucleosome displacement [324], 
a  feature  of  active  chromatin.  Compared  to  classical  enhancers,  this 
accumulation  of  multiple  transcription  factors  with  modest  individual 
influence may provide critical mass allowing a synergistic effect on gene 
expression [322]. These binding patterns can be used as a predictor of the 
in vivo functional effect of transcription factors for which there is limited 
understanding [325]. In mouse similar regions with high transcription factor 
occupancy have been referred to as transcription initiation platforms (TIPs) 
[319]. This transcription factor density has been shown In ESCs through 
binding  of  the  pluripotency  master  regulator  transcription  factors  Oct4, 
Sox2 and Nanog [321] and interpreted as clustering of enhancers to form   63 
stretched regions of ‘super-enhancers’ [320, 321]. These super-enhancers 
exhibit preferential binding of the transcriptional coactivator BRD4 and are 
associated  with  oncogene  transcription  [320].  Following  this, 
pharmacological  inhibition  of  BRD4  leads  to  disruption  of  binding 
preferentially at super-enhancers with a decrease in transcription from the 
associated  oncogenes  [320].  Supporting  a  role  in  disease,  super-
enhancers are enriched for disease associated DNA sequence variants in 
disease relevant cell types [326]. Compared to normal enhancers these 
clusters exhibit increased levels of the active enhancer marks of H3K27Ac 
and DNaseI hypersensitivity and correlate with greater transcription from 
associated genes with binding of transcription factors being necessary for 
this. This transcription from associated genes is also cell type specific in 
differentiated cells of the haematopoietic system [321].     64 
1.2.2.4  T cell enhancers and regulatory regions 
Demonstrating the importance of transcription factor binding at enhancers, 
T cell enhancers are enriched for lineage relevant STAT binding sites with 
the  STAT1  and  STAT4  motifs  corresponding  to  Th1-specific  enhancers 
and the STAT6 motif corresponding to Th2-specific enhancers [261], while 
general T cell transcription factor motifs such as AP-1 and NFAT, which 
are activated following TCR signalling, are found at both [261, 319]. Such 
transcription factors are activated downstream of signalling pathways and 
so this enrichment of binding demonstrates the link between environmental 
stimulus and enhancer activity through the priming of enhancers through 
chromatin  remodelling  [258,  261].  Furthermore  the  binding  of  P300  is 
dependent upon these lineage-associated transcription factors [261, 327]. 
A  recent  profile  of  the  histone  and  transcriptional  landscape  in  human 
Tresp  and  functional  expanded  Treg  identified  differential  enrichment  of 
transcription  factor  binding  motifs  at  enhancers.  This  included  greater 
enrichment of KLF (Krüppel-like factor), FOX (forkhead) and STAT5 motifs 
at  Treg  enhancers  and  greater  enrichment  of  RUNX  motifs  at  Tresp 
enhancers,  with  ChIP-Seq  binding  data  reflecting  this  motif  enrichment 
[328]. Co-factors of lineage-specifying transcription factors and structural 
family  members  have  been  shown  to  have  a  role  at  poised  enhancers 
[258].  For  example,  enhancers  that  are  bound  by  the  Treg  lineage-
specifying transcription factor FOXP3 in Treg are accessible and bound by 
FOXP3  cofactors,  including  ETS  and  RUNX,  in  Treg  precursors,  which 
may facilitate FOXP3 recruitment [258]. FOXO1 (forkhead box protein O1), 
which  does  not  show  Treg  specific  expression  but  is  structurally 
homologous to FOXP3 and is essential for Treg development [329, 330],   65 
may  act  as  a  pioneer,  binding  the  forkhead  motif  at  enhancers  in  Treg 
precursors  and  being  displaced  by  FOXP3  upon  Treg  differentiation, 
demonstrating  another  mechanism  for  maintaining  accessibility  of 
enhancers prior to their activation [258]. 
1.2.2.5  IFNG  –  a  paradigm  for  lineage-specific  gene 
regulation 
The IFNG regulatory region is relatively well characterised and as such 
represents  a  paradigm  for  the  study  of  gene  regulation  and  enhancer 
function.  The  characterisation  of  this  regulatory  region  began  with  the 
identification  of  several  DHS  sites  in  Th1  cells  [331]  with  transgenic 
luciferase reporter assays [332-334] and deletion experiments [335, 336] 
allowing  identification  of  the  minimal  region  required  for  optimal  IFNG 
expression.  Nomenclature  of  the  individual  enhancer  regions  has  been 
based on the location relative to IFNG of several conserved non-coding 
sequences  (CNSs),  to  which  DHS  sites  map  [335,  337-340].  The 
occupancy of transcription factors including GATA3, several STATs [264, 
341-343] and of course T-bet [335] have now been profiled as have the 
presence of permissive and repressive histone modifications [344-346]. In 
addition, the influence of 3D chromatin architecture has also been explored 
at  IFNG  through  binding  of  the  chromatin  insulator  CTCF  [230]  and 
cohesin [347].  
1.2.3  Post-translation histone modifications 
Histone proteins are the basis for physical organisation of DNA within the 
nucleus and thus are closely related to the accessibility of DNA and gene 
expression. Four families of histone protein, H2A, H2B, H3 and H4, exist   66 
as  homodimers  in  an  octomeric  complex  which  together  with  the  linker 
histone H1 forms the nucleosome around which 146 base pairs of DNA is 
wrapped. The basic nature of histone proteins facilitates their interaction 
with the negatively charged DNA phosphate backbone and modification of 
this electrochemical interaction directly impacts upon accessibility of DNA 
to other nuclear regulatory components. These modifications are covalent 
and chemically varied, and include the deposition of small chemical groups 
through acetylation (COCH3), methylation (CH3) and phosphorylation (P). 
Larger moieties can also be added through ubiquitinylation (addition of a 
ubiquitin polypeptide), SUMOylation (small-ubiquitin-like-modifier proteins) 
and  ADP-ribosylation  (ADP-linked  ribose  sugar).  These  modifications 
frequently  occur  on  the  tails  of  histone,  which  protrude  out  of  the 
nucleosome.  Nomenclature  for  histone  modifications  (eg.  H3K4me3)  is 
based upon the histone protein (eg. H3), the residue of this protein (eg. 
K4) and the modification (eg. trimethylation – me3).  
 
As well as influencing DNA accessibility through electrochemical alteration, 
these chemical modifications create binding sites for additional chromatin 
modifiers and regulatory molecules with more specific activities. As histone 
modifications occur in various combinations and within the context of other 
chromatin modifications, their direct biological causes and consequences 
are not fully understood. This understanding is further complicated by the 
general  topology  of  chromatin  and  potential  for  positional  or  sequence 
context  effects.  However  some  have  clear  associations  with  open  and 
active  chromatin  while  others  are  found  at  repressed  chromatin.  Those 
relevant to this work are described in Table 1.1. Molecules involved in the   67 
deposition  (writers)  and  recognition  (readers)  of  these  modifications  are 
also detailed. 
1.2.3.1.1  Acetylation 
With the addition of a negatively charged acetyl group, the positive charge 
of histones is neutralised leading to a reduced affinity of the histone to the 
negatively charged DNA, resulting in greater conformational flexibility and 
accessibility. Acetylation of histones is therefore broadly associated with 
transcriptionally  active  regions  of  chromatin.  Histone  acetyl  transferases 
include the P300 and CREB binding protein (CBP) family of co-activators 
[292]. In addition to their electrostatic influence, acetylated lysines, such as 
H3K27Ac, are recognised by bromodomains [348] including that in BRD4 
(Bromo-domain  containing  4)  [297],  a  complex  that  positively  regulates 
transcription  [349].  Due  to  their  functional  relevance,  the  occupancy  of 
CBP/P300 [295] and BRD4 [281, 350] has been used to identify active, as 
opposed to poised, enhancers [290]. 
1.2.3.1.2  Methylation 
Methylation  of  histones  is  associated  with  activation  and  repression, 
depending  upon  context,  with  deposition  being  catalysed  by  histone 
methyltransferases, of which several can target the same residue [351]. 
For example H3K4 is modified by several MLL and SET complexes [351]. 
Tri-methylation of histone H3 at lysine 4 (H3K4me3) is found at the 5’ end 
of actively transcribed genes in association with the transcription initiating 
form  of  RNAPII  [351-353],  which  is  phosphorylated  at  Ser5  of  the  C-
terminal domain. In contrast H3K36me3, catalysed by the histone methyl 
transferase Set2 [354], occurs along the gene body, accumulating towards   68 
the  3’  end,  and  is  associated  with  the  transcription  elongating  form  of 
RNAPII  (phosphorylated  at  Ser2  of  the  C-terminal  domain)  [351,  355]. 
H3K4me1  can  be  found  flanking  H3K4me3  at  active  and  poised  genes 
[356] and, in addition, is associated with enhancer regions, although there 
is debate over the whether in this context it occurs in the presence [344] or 
absence [293] of H3K4me3. H3K27me3, meanwhile, is a feature of the 5’ 
end of silent genes residing in open chromatin and is deposited by the 
histone methyltransferase (HMT) EZH2, a subunit of polycomb repressive 
complex 2 (PRC2) [357]. H3K27me3 is present at IFNG and TBX21 and 
other Th1 genes in Th2 cells and is also present at IL4/5/13 and GATA3 in 
Th1  cells  [340,  358].  In  addition,  PRC2  is  necessary  for  Th1-cell 
specification  as  demonstrated  in  Ezh2  deficient  mice  in  which  the 
repression  of  alternative  lineage  genes  including  Tbx21  and  Gata3  is 
dysregulated leading to a Th2-mediated asthma like pathology [359]. 
 
H3K9me3 has been found in large areas of repressed chromatin where its 
deposition  is  catalysed  by  the  Suv39  class  of  HMTs  [360]  and  it  is 
associated  with  transcriptional  repression  of  potentially  deleterious 
transposons and repeats at pericentromeres [361, 362]. In addition, it has 
also been reported along the body of elongated genes [363]. 
 
Histones  are  methylated  during  transcriptional  processes  and  create 
binding sites for complexes that function in later stages of transcription. 
Methylation is recognised by highly conserved chromodomains, which are 
present  in  several  chromatin-modifying  complexes  with  varying 
specificities.  For  example,  chromodomain  containing  HP1  recognises   69 
H3K9  methylation  [364]  and  CBX  subunits  of  PRC1  recognise  H3K27 
methylation  [365].  Both  of  these  recognition  events  are  related  to 
subsequent  transcriptional  repression.  H3K36me3  is  recognised  by 
chromodomain  containing  Eaf3,  part  of  an  HDAC-containing  complex, 
which  functions  in  transcriptional  elongation  through  the  repression  of 
cryptic start sites in the gene body post-expression [355]. Aside from this, 
H3K4me3 is recognised by the NURF complex [351] which catalyses ATP-
dependent  chromosome  remodelling  [366]  allowing  transcriptional 
activation [367]. H3K4me1 is recognised by the WDR5 subunit of the MLL1 
complex [351, 368] although the functionally significant events downstream 
of this recognition are not fully understood [351]. 
 
Combinatorial  modifications  include  the  active  mark  H3K4me3  and  the 
repressive  mark  H3K27me3,  which  are  paradoxically  found  together  in 
bivalency  [369].  This  is  seen  at  tissue  specific  genes  of  alternative  cell 
fates  in  embryonic  stem  cells,  which  become  de-repressed  upon 
differentiation  [369].  This  has  been  suggested  to  allow  the  poising  of 
lineage-specific genes for their rapid activation in future cell states. The 
same phenomenon also occurs during adult T cell differentiation where in 
naïve cell precursors both histone marks are found at Tbx21 and Gata3 
but H3K27me3 is lost at Tbx21 in Th1 cells and at Gata3 in Th2 cells [358]. 
This demonstrates that genes corresponding to alterative fates are not fully 
switched off but instead remain poised for activation in the future, should 
they  be  required,  which  may  be  important  for  lineage  plasticity  as 
described in Section 1.2.1.2     70 
Table 1.1: Example histone modifications and their associated transcriptional 
status 
The  post-translational  modification  of  histones  is  associated  with  both  activation  and 
repression  of  transcription.  These  modifications  are  deposited  by  histone  modifying 
complexes  (writers)  and  recognised  by  adapter  molecules  and  chromatin-modifying 
complexes (readers). Brackets detail complexes in which these enzymatic subunits are 
found. The details of histone modifications and associated readers and writers given here 
are limited to those with relevance to this thesis. 
 
Histone  Residue  Modification  Writers  Readers  Transcriptional 
association 
H3 
K4 
Mono-
methylation 
(me1) 
MLL1-5,  
SET1A, B [351] 
WDR5 (MLL1) 
[368] 
Found at enhancers [293]. 
Also seen at active 
promoters in combination 
with H3K4me3 [356]. 
Tri-methylation 
(me3) 
MLL1-5,  
SET1A,B [351] 
BPTF (NURF) 
[351, 367] 
Associates with the 
initiating form of RNAPII 
and found at start sites of 
active and poised genes 
in yeast [352] and higher 
eukaryotes [353]. 
K27 
Tri-methylation 
(me3) 
EZH2 (PRC2) 
[357] 
CBX7 (PRC1) 
[370] 
At inactive genes and (in 
association with K4me3) 
at developmentally 
regulated genes poised 
for activation [357, 369] 
Acetylation 
(ac) 
P300-CBP 
family [292] 
Bromodomains 
[348] including 
BRD4 [297] 
Presence in combination 
with H3K4me1 marks 
active, as opposed to 
inactive or poised, 
enhancers [290]. 
K36  Tri-methylation 
(me3)  SET2 [354]  Eaf3 [355] 
Transcriptional elongation. 
Presence along the gene 
body, in conjunction with 
H3K4me3 at the promoter 
region, indicates active 
and processive 
transcription [355]. 
K9  Tri-methylation 
(me3) 
Suv39h HMTs in 
heterochromatin 
[360], EHNT 
HMTs in actively 
transcribed 
genes [371] 
HP1 [364] 
Found in repressed 
heterochromatin but also 
associated with 
transcriptional elongation 
in actively transcribed 
genes [363] and at active 
promoters [372]. 
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1.2.3.2  Transcriptional elongation by P-TEFb  
Effective regulation of transcriptional elongation in addition to initiation is 
necessary for gene expression. As described in above, at lineage specific 
genes  of  alternative  cell  fates  the  presence  of  histone  modifications 
associated with transcriptional initiation in bivalency with those associated 
with repression demonstrates the importance of transcriptional elongation 
for lineage choice. 
 
RNAPII recruitment to the core promoter results from the assembly of a 
cascade  of  basal  transcription  factors  following  the  initial  binding  of  the 
TATA binding protein (TBP), which commonly recognises the TATA box 
sequence  motif  [373].  This  RNAPII  recruitment  is  stochastic  and 
dependent upon accessibility of the core promoter, which is influenced by 
chromatin  conformation.  Therefore  RNAPII  recruitment  may  occur  at 
promoters that are accessible but not relevant to the cell’s current state. 
Regulation at the point of elongation therefore enforces cell type specific 
gene expression. Initial RNAPII binding leads to the production of short 
transcripts of 20-60nt due to pausing adjacent to the promoter [374, 375]. 
For progression of RNAPII out of the promoter-proximal region, and for 
productive elongation of transcription through the gene body to occur, the 
carboxyl terminal domain (CTD) of RNAPII must be phosphorylated at the 
serine  2  position.  Conversely,  paused  RNAPII  is  phosphorylated  at  the 
serine  5  position.  This  phosphorylation  is  catalysed  by  the  positive 
transcription  elongation  factor  (P-TEFb).  P-TEFb  is  a  heterodimeric 
complex including CyclinT1 (or T2) and the cyclin dependent kinase CDK9 
[376]. P-TEFb activity is negatively regulated through sequestration by the   72 
scaffolding  RNA  7SK  [377,  378]  and  is  recruited  in  its  active  form  to 
promoters by BRD4 [349], which recognises acetylated histones, or as part 
of the super-elongation complex [379]. Both the inhibition of CDK9 kinase 
activity  by  Flavopiridol  [380]  and  the  blocking  of  the  acetyl-recognising 
bromo  and  extra-terminal  (BET)  domain  of  BRD4  by  JQ1  [381]  lead  to 
genome-wide inhibition of transcription. In addition, BRD4 occupancy has 
been  identified  at  enhancers  [296,  298,  320,  326,  382-384]  but  the 
importance  of  P-TEFb  here  is  not  well  understood.  Some  reports  have 
demonstrated  that  P-TEFb  activity  is  required  for  downstream  gene 
expression [385] while others challenge its role at enhancers [386, 387]. 
So far, P-TEFb occupancy at super-enhancers has not been observed. 
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1.3  Non-coding RNA 
1.3.1  Refining the central dogma of molecular biology 
The  understanding  of  the  basis  of  molecular  biology  has  traditionally 
placed  RNA  in  the  role  of  regulating  translation  of  DNA-encoded 
instructions  into  proteins,  the  effectors  of  cell  phenotype.  In  addition  to 
messenger RNAs (mRNA), this includes ribosomal RNA (rRNA), transfer 
RNA  (tRNA),  small  nuclear  RNA  (snRNA),  which  are  denoted  by  a  U- 
prefix  descriptive  of  their  high  uridine  content,  have  a  central  role  co-
transcriptional  RNA  splicing  (reviewed  in  [388]),  and  small  nucleolar 
(snoRNA), which are located in the nucleolus where they have a canonical 
role in ribosome synthesis and the post-transcriptional modification of RNA 
[389].  Supplementary  to  these  roles,  microRNAs  (miRNA)  regulate 
translation through the targeting of complementary mRNA transcripts for 
destruction  or  by  inhibiting  their  translation  [390].  Hinting  at  translation-
independent  roles  for  small  RNAs,  piwi-interacting  RNA  (piRNA),  so 
named  for  their  processing  by  piwi  proteins,  which  are  gamete  specific 
members miRNA biogenesis machinery, were identified as having a role in 
transcriptional  silencing  of  repetitive  regions  such  as  transposon 
sequences  during  spermatogenesis  thereby  promoting  genomic  fidelity 
[391].  In  2001,  the  sequencing  of  the  human  genome  unexpectedly 
uncovered that the number of protein-coding genes does not increase with 
species  complexity,  with  our  genome  committing  less  than  2%  of  its 
sequence  to  this  task  [392].  The  advent  of  whole  genome  sequencing 
techniques has demonstrated that the majority of the genome, while not 
coding for protein, is transcribed into RNA [393]. Suggestive of functional 
importance, this pervasive transcription has been shown to be at least in   74 
part  tissue  specific  and  developmentally  regulated  [394]  and  subject  to 
RNA processing mechanisms including polyadenylation and splicing [395]. 
The role of non-coding DNA and the non-coding (ncRNA) produced from it 
has been debated with the assertion that transcriptional activity of ‘junk 
DNA’ does not equate to function [396, 397]. Transcription of ncRNA could 
be  a  stochastic  by-product  of  unregulated  accessibility  of  DNA  to 
transcriptional machinery. In addition, functional consequences can lie in 
the act rather than the product of transcription and, where the production of 
RNA  is  functional,  the  sequence  identity  of  the  RNA  itself  may  be 
irrelevant.  However  some  ncRNAs  have  been  demonstrated  to  be 
functional. This is exemplified through the requirement of the ncRNA XIST 
for  X-chromosome  inactivation  [398].  Several  other  ncRNAs  have 
annotated  functions,  some  related  to  lineage  specification,  and  are 
described below. 
1.3.2  Genomic classification of non-coding RNA 
The  classification  of  these  newly  identified  transcripts  on  the  basis  of 
location of genomic origin and size of transcript has been fundamental to 
understanding the consequences of the transcription of ncRNAs [399] and 
has been facilitated by current sequencing technologies. On the basis of 
purification techniques, ncRNAs have been crudely divided into short and 
long, 200 nucleotides being the cut-off length [400, 401]. Nether of these 
fractions  are  homogenous  in  identity,  containing  transcripts  that  are 
diverse  in  properties  and  function.  These  properties  influence  their 
regulation,  activity  and  function,  which  lead  to  further  classification  of 
transcripts. Mechanistic details have been delineated for several members 
of these classes and are discussed in Section 1.3.3. These mechanisms   75 
are not common to all transcripts with the same genomic classification and 
may  be  shared  with  transcripts  with  dissimilar  genomic  origins.  Also 
important to note is that some presumed ncRNAs may be found to code for 
short  peptides  and  so  the  ultimate  proof  of  non-coding  function  is  in 
demonstrating mechanistic importance of the transcript itself [402]. 
 
Figure 1.4 illustrates how the genomic location and structure of ncRNAs 
influences their identity and how several classes have been defined on this 
basis  and  have  potential  roles  in  transcriptional  regulation  of  lineage 
specific gene expression. These classes, as described in Sections 1.3.2.1 
to 1.3.2.4, include long intergenic ncRNAs (lincRNAs), natural antisense 
transcripts (NATs), promoter associated short RNAs and enhancer RNAs 
(eRNAs).     76 
 
Figure 1.4: Classes of ncRNA in relation to genomic origin 
The  genomic  location  and  structure  of  ncRNAs  influences  their  identity  and  ultimately 
function. A: lincRNAs are transcribed, spliced and polyadenylated similar to mRNAs. B: 
Natural antisense transcripts are transcribed antisense to protein coding genes. C: Short 
non-coding  transcripts  are  transcribed  from  transcription  start  sites.  D:  NcRNAs 
transcribed from enhancer regions may mediate the long range effects of enhancers.   
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1.3.2.1  Long intergenic non-coding RNAs 
Many long ncRNAs are encoded in a genic structure similar to protein-
coding  genes  in  that  they  have  distinct  introns  and  exons,  can  be 
alternatively  spliced  under  canonical  splice  site  signals  [403]  and  are 
processed in a similar manner through capping and polyadenylation [404]. 
These  have  been  termed  long  intergenic  ncRNAs  (lincRNAs),  reflecting 
their position in intergenic regions, as shown in Figure 1.4.A. LincRNA loci 
are  now  recognised  as  genes  themselves,  just  lacking  open  reading 
frames  longer  than  100  codons  [402],  and  they  are  catalogued  by 
annotation consortia such as RefSeq and Gencode [403]. LincRNA genes 
are marked by the same histone modifications as protein-coding genes, 
which  are  reflective  of  transcription  status,  including  H3K4me3  and 
H3K36me3 at the TSS and gene body of transcriptionally active genes, 
respectively  [405].  Unlike  protein-coding  genes,  lincRNA  genes  show 
preference for comprising two exons [403], although some are single exon 
(eg. Malat1 and Neat1) [404] and their exons and introns are longer [403]. 
LincRNA genes also show enrichment of sequences derived from common 
repeats, including LINES, SINES and LTRs [403, 406, 407]. These repeat 
sequences  may  be  key  to  influencing  secondary  structure,  for  example 
through  self  annealing  to  form  stem-loop  structures,  which  may  form 
binding sites for regulatory protein complexes. However, not all lincRNAs 
contain  repeats  [403].  A  key  distinction  between  protein-coding  and 
lincRNA genes is in sequence conservation; non-coding sequences show 
less evolutionary conservation than protein coding sequences as they are 
under  different  selective  pressures  and  evolutionary  constraints  as  they 
are not restricted by codon choice required to maintain protein structure   78 
and  function.  However,  lincRNAs  exhibit  more  selection  pressure  than 
neutrally  evolving  sequences  [403-406]  and  exons  and  promoters  are 
more conversed than introns [403, 405]. Interestingly, although expressed 
at a lower level [408], lincRNAs show more tissue specific expression than 
protein coding genes [403]. The importance of some lincRNAs has been 
challenged through observations that loss of transcript experiments often 
have no functional consequences, for example HOTAIR [409]. This may 
reflect a specificity of function for these transcripts, which perhaps is only 
exhibited under certain conditions and organismal or cellular pressures or 
at  specific  temporal  points  of  differentiation.  However,  in  support  of 
lincRNA function, a recently developed cohort of lincRNA knockout mice 
has  demonstrated  the  functional  importance  of  several  lincRNAs  [410]. 
LincRNAs for which knockout produced extreme effects included Peril, for 
which  knockout  resulted  in  perinatal  lethality  (although  with  only  50% 
penetrance for the homozygote), possibly due to associated changes in 
gene expression within the brain, Fendrr, the loss of which also resulted in 
death soon after birth, which was associated with respiratory failure and 
oesophageal and gut abnormalities, and Mdgt, the loss of which leads to 
stunted growth [410]. 
1.3.2.2  Natural antisense transcripts 
Natural  antisense  transcripts  (Figure  1.4.B)  by  definition  are  encoded 
antisense  to  other  genes.  They  may  or  may  not  share  the  genomic 
features of lincRNA such as canonical start and stop sites, splice sites and 
polyadenylation signals. Their genomic orientation is often relevant to a 
biological role through influencing transcription of the sense-strand gene. 
This  influence  can  be  positive  through  recruitment  of  transcriptional   79 
machinery  or  negative  through  transcriptional  interference.  These 
mechanisms are elaborated on in Section 1.3.3.1. 
1.3.2.3  Promoter-associated RNAs 
Transcripts of heterogeneous lengths, are produced from transcription start 
sites  (TSS)  of  genes  in  addition  to  the  production  of  full  length, 
polyadenylated  RNA  (Figure  1.4.C)  [411-415].  Transcripts  of  50-200nt 
have  been  termed  promoter-associated  short  RNAs  (PASRs)  [411]  or 
TSS-associated RNAs (TSSa RNA) [412], while smaller transcripts with a 
similar  distribution  around  the  TSS  have  been  termed  tiny  RNAs  [415]. 
These  transcripts  are  produced  bidirectionally,  transcribed  in  both  the 
same and divergent orientations to the host gene [412, 413, 415], and are 
associated with paused RNAPII [416]. Our lab has shown that RNA of 50-
200nt are transcribed from the TSS of polycomb target genes in primary 
human T cells with their presence being independent of polycomb activity 
[416]. These RNAs interact with PRC2 and are lost from polycomb target 
genes that are activated upon cell differentiation, indicating their presence 
may  support  the  interaction  of  polycomb  complexes  with  chromatin  at 
these  genes  [416].  Transcripts  described  elsewhere  have  been  termed 
promoter  upstream  transcripts  (PROMPTs).  PROMPTs  have  been 
characterised  as  short,  polyadenylated  and  capped  transcripts  that  are 
ubiquitously transcribed bidirectionally from 0.5 to 2.5kb upstream of active 
TSSs [417]. These transcripts have been suggested to arise from stalling 
of transcriptional machinery [418]. The transcription of promoter associated 
short  RNAs  may  promote  the  maintenance  of  chromatin  in  an  open 
conformation  at  a  TSS  and  may  provide  a  reservoir  of  transcriptional 
machinery in close vicinity for rapid induction of gene expression [419].   80 
1.3.2.4  Enhancer RNAs 
RNAPII binding has historically been observed at active enhancers [280] 
and  has  more  recently  been  shown  to  be  functional  through  the 
transcription of RNA at these sites [386, 420]. The transcripts produced 
from  enhancers  can  be  polyadenylated  or  not  [420,  421],  may  be 
bidirectionally transcribed [420-423] and are predominantly unspliced and 
unstable  [386].  These  eRNAs  are  low  abundance  compared  to  mRNAs 
and lincRNAs, an observation that is explained by their low stability [386] 
and rapid degradation by the exosome, the macromolecular complex that 
catalyses RNA decay. It has been suggested that this degradation may 
lead to the production of potentially functional shorter transcripts. 
 
In  neuronal  cells,  Kim  et  al  (2010)  showed  that  transcriptionally  active 
enhancers, identified by binding of the transcriptional coactivator CBP, are 
marked  by  H3K27ac  and  H3K4me1  [420].  Compared  to  RNA  produced 
from  promoters,  these  transcribed  regions  showed  a  lower  ratio  of 
H3K4me3 to H3K4me1. Also in contrast to promoters, which can exhibit 
bidirectional transcription but with preference for sense strand production, 
these enhancers RNAs showed no bias in directionality.  
 
Theories  for  a  transcription  independent  role  for  RNAPII  processivity  at 
enhancers  include  tracking  of  the  transcriptional  machinery  towards  a 
promoter  (Section  1.2.2.2  [308]).  It  has  also  been  suggested  that  the 
transcriptional  activity  that  produces  eRNAs  may  function  to  keep  an 
enhancer  region  in  an  open  chromatin  confirmation  by  steric  force  or 
through  maintaining  separation  of  DNA  strands  thereby  enforcing   81 
accessibility [424]. In addition, the process of transcription is required for 
histone acetylation at extra-genic loci, as shown by the effect of inhibition 
of  transcription  with  actinomycinD,  which  is  not  seen  with  inhibition  of 
protein synthesis with cyclohexamide treatment [386], and may allow for 
enhancer functionality. 
 
Suggesting a function for this transcription, the level of eRNA frequently 
correlates  with  mRNA  transcription  from  nearby  genes  [420].  In 
macrophages,  70%  of  genome  wide  RNAPII  binding  is  associated  with 
enhancers  and  results  in  transcription  in  response  to  stimulation  by 
endotoxin which is temporally coordinated with proximally located protein-
coding  genes  [386],  suggesting  a  role  in  environmental  response.  The 
production  and  dispersal  of  eRNA  (Figure  1.4.D)  may  provide  a 
mechanism for the long range effects of enhancers, which can be distantly 
located to the genes they regulate. These transcripts may aid maintenance 
of  enhancer-promoter  interaction  through  looping  [425-427]  or  allow  the 
targeted recruitment of chromatin-modifying complexes and transcriptional 
machinery,  explaining  how  these  complexes  are  targeting  to  specific 
genes.  Functional  experiments  have  demonstrated  that  the  presence  of 
eRNA transcripts themselves are required for optimal expression of their 
associated  genes  [420,  421,  427-429].  Mousavi  et  al  (2013)  examined 
eRNAs transcribed from muscle cell enhancers bound by the myogenic 
transcription  factors  MyoD  and  MyoG.  Knockdown  with  siRNA  of 
transcripts  from  a  core  enhancer  marked  by  H3K4me1  upstream  of 
MYOD1  lead  to  reduced  MYOD1  expression  at  both  the  transcript  and 
protein level. In addition, knockdown and overexpression of a transcript   82 
from  a  distal  regulatory  region  affected  MYOG  expression  [428].  In 
macrophages,  Lam  et  al  (2013)  showed  that  the  repressive  nuclear 
receptor  Rev-Erbs  inhibits  gene  expression  by  targeting  enhancers  that 
are suppressed in a macrophage specific manner [429]. The function of 
Rev-Erbs in this context was associated with inhibition of transcription from 
these  enhancers  [429].  Again,  assays  for  knockdown  of  eRNAs 
demonstrated a corresponding effect on nearby mRNA production [429]. 
During  LPS-induced  monocyte  activation,  Ilott  et  al  (2014)  catalogued 
several classes of non-coding transcripts including over 70 eRNAs [421]. 
Knockdown of an NF-κB regulated eRNA upstream of the IL1B gene in a 
monocytic  cell  line  led  to  reduced  expression  of  IL1B  [421].  Functional 
effects  for  eRNAs  have  recently  been  demonstrated  in  neurons  by 
Schaukowitch  et  al  (2014),  with  knockdown  of  transcripts  from  one 
enhancer  being  shown  to  decrease  downstream  transcription  of  mRNA 
from  the  Arc  (Activity  regulated  cytoskeletal  protein)  gene,  which  is 
functional  during  activation  of  neuronal  synapses  by  neurotransmitters 
[427].  While  these  reports  of  eRNA  function  at  the  transcript  level  are 
encouraging, the effects of these knockdown experiments are often small, 
both  in  terms  of  target  knockdown  and  effects  on  downstream  gene 
expression, and it is mechanistically unclear why such experiments should 
have  an  effect  given  that  eRNAs  are  restricted  to  the  nucleus  and  are 
already unstable. 
1.3.3  Mechanisms of RNA function 
Mechanisms  for  possible  ncRNA  functions  are  still  uncertain,  but  their 
effects could conceivably include acting as decoys, scaffolds or guides for 
regulatory complexes [430] and additionally there is some evidence they   83 
may  influence  the  activity  of  such  complexes  through  allosteric  effects 
[431]. As guides, ncRNAs may form binding sites to recruit proteins such 
as  chromatin-modifying  complexes  to  specific  genomic  regions.  As 
scaffolds,  binding  of  an  ncRNA  to  multiple  complexes  may  allow 
orchestration  and  co-localisation  of  the  independent  activities  of  such 
complexes.  As  decoys,  ncRNAs  may  sequester  complexes  away  from 
alternative targets such as regulatory DNA sequences. The mechanistic 
and functional consequences of ncRNA transcription are in part influenced 
by their genomic origin but also by their structure and cellular localisation. 
Effects on gene expression and cellular identity can be mediated through 
both cis-  and  trans-regulatory  mechanisms.  This  distinction  between cis 
and trans regulation is related to the proximity of a non-coding locus to a 
gene with cis-acting ncRNAs being transcribed from the same locus as 
their target while trans-acting RNAs may have effects at a distant site with 
this interaction possible being mediated by looping of DNA to bring such 
sites into close proximity [432, 433] or by RNA diffusion. 
1.3.3.1  Cis-regulation of gene expression 
Promoter-associated non-coding transcripts (Section 1.3.2.3) are likely to 
act  through  cis-regulatory  mechanisms  and  include  the  short  ncRNAs 
described by our lab [416] and others [412, 413, 415] and also promoter 
upstream transcripts (PROMPTs) [417, 418, 434]. Those described by our 
lab, which are enriched at repressed polycomb target genes, precipitate 
with the PRC2 polycomb complex [416] and are predicted to form stem-
loop  secondary  structures.  The  formation  of  secondary  structure  of 
ncRNAs  has  frequently  been  suggested  to  provide  potential  for  specific 
protein-RNA interactions [435]. These structures may explain the targeted   84 
recruitment  of  PRC2  to  specific  genes.  Supporting  this  theory,  many 
chromatin-modifying complexes are known to contain subunits capable of 
binding RNA in vitro [436, 437]. 
 
While direct evidence of functionality is still missing, the transcription of 
PROMPTs has been suggested to have an activatory effect on counterpart 
gene expression. It is been postulated that the presence of polyA sites 
upstream of TSSs limits transcription to the production of short, unstable 
transcripts  upon  bidirectional  transcription  at  these  promoters.  This 
transcription  may  maintain  the  promoter  in  an  accessible  conformation, 
which is supported by an observation that transcription in the PROMPT 
window (0.5kb-2.5kb) upstream of the Sphk1 gene is anti-correlated with 
repressive CpG methylation [438]. PROMPTs are preferentially degraded 
by the exosome, compared to their gene counterparts [417, 434] and this 
degradation  is  thought  to  enforce  directionality  of  transcription  and 
expression from the gene in cis [418]. In addition, PROMPTs may provide 
reservoirs of RNAPII activity in close proximity, ready to be harnessed for 
gene transcription. 
 
Interactions with chromatin-modifying complexes have been suggested as 
possible  mechanisms  for  several  classes  of  ncRNAs.  For  example 
lincRNAs have also been reported to associate with histone modifiers and 
the  chromatin  insulator  CTCF  [439,  440].  The  chromatin  modifying 
complexes  PRC2  and  CoREST  coimmunoprecipitate  in  native  RNA 
immunoprecipitation  assays  with  several  lincRNAs,  which  has  been 
suggested to support the existence of a physical association [441, 442].   85 
Such  associations  have  led  to  suggestions  that  an  interaction  between 
XIST and the repressive complex PRC2 is the basis for X chromosome 
inactivation [398]. In mammals, X chromosome inactivation in the cells of 
the homeogametic sex is required for dosage compensation. XIST RNA is 
upregulated on the future inactive X with a 5’ internal transcript of XIST, 
repA (repeat A), reported to recruit PRC2 through the formation of stem-
loop structures, leading to silencing of the chromosome [398]. The basis 
for  this  interpretation  is  that  native  RNA  immunoprecipitation  and 
electrophoretic mobility shift assays (EMSAs) show an in vitro association 
between repA and PRC2 and that in some circumstances knockdown of 
repA containing transcripts leads to a decrease in H3K27me3, which is 
deposited  by  PRC2  [398].  The  extent  to  which  interactions  between 
ncRNAs  and  chromatin  modifying  complexes  is  specific  is  however 
controversial [443]. The in vitro assays, such as EMSAs, upon which these 
interactions are based may not effectively discriminate between specific 
and  non-specific  interactions  but  may  rather  reflect  general  structural 
properties  of  RNAs.  Lack  of  crosslinking,  in  order  to  prevent  RNA 
degradation,  during  native  RNA  immunoprecipitation  may  lead  to  non-
specific in vitro associations that do not reflect the in vivo state. In addition 
the use of isotype controls reflects assay specificity rather than that of the 
protein  itself.  The  more  recently  developed  PAR-CLIP  and  iCLIP 
techniques combine UV crosslinking of RNA to protein with radiolabelling 
[444] and RNase protection assays and sequencing to better characterise 
interactions.  Through  such  techniques,  support  for  interactions  between 
RNA and the PRC2 component JARID2 has been found [445]. Despite 
controversy surrounding the nature of its interaction with PRC2, support for   86 
a cis-regulatory role for XIST itself in X chromosome inactivation is strong 
and is demonstrated by ectopic expression of an inducible XIST transgene 
leading to chromosomal condensation, even when inserted into autosomes 
[446]. 
 
While the inactive X condenses, expression of XIST from the future active 
X is downregulated in cis by its natural antisense transcript TSIX. There is 
some evidence that this downregulation may occur through recruitment of 
the DNA methyltransferase DNMT3a by TSIX leading to DNA methylation 
and  repression  of  the  XIST  promoter  [447].  Another  natural  antisense 
transcript, the Zeb2 NAT, has been shown to have cis-regulatory effects 
with consequences for epithelial to mesechymal (EMT) transition [448], a 
hallmark  of  metastatic  initiation  for  cancer  progression.  Zeb2  is  a 
transcriptional repressor of E-cadherin, which is upregulated during EMT. 
Interestingly Zeb2 mRNA positively correlates with its target, E-cadherin. 
This paradox is explained by an observed reduction in Zeb2 translation, 
which is determined by alternative splicing of Zeb2 leading to the exclusion 
of  an  internal  ribosome  entry  site  (IRES)  sequence.  This  alternative 
splicing is dependent upon the antisense NAT [448]. 
 
LincRNAs with a positive effect on gene expression have been termed in 
some  literature  as  ‘activating  ncRNAs’  (ncRNA-a)  [449],  some  of  which 
have been shown to operate in cis. This is exemplified by ncRNA-7 (now 
annotated by Gencode as TRERNA1), which is required for activation of 
SNAI1 (Snail family zinc finger 1), a regulator of EMT. Depletion of ncRNA-
7 using siRNA has been shown in functional assays to mirror the migratory   87 
effects  of  loss  of  SNAI1  [449].  This  RNA  was  shown  to  interact  with 
components of the Mediator complex, a large multisubunit complex that 
associates  with  transcriptional  machinery  to  regulate  gene  expression 
[450].  This  interaction  influences  localisation  and  activity  of  Mediator, 
resulting in the transcriptional activation of SNAI1 [426]. Chromatin capture 
demonstrated an association between ncRNA-7 and the SNAI1 promoter, 
showing a physical interaction of these two loci despite their separation by 
kilobases  of  DNA.  This  interaction  is  explained  by  DNA  looping,  which 
allows  the  long  range  transcriptional  activation  effects  of  this  ncRNA-a 
through  a  cis-regulatory  mechanism  [426].  Another  ncRNA-a  with  cis-
regulatory  effects  is  HOTTIP.  RNA  immunoprecipitation  and  GST  pull 
down indicates that HOTTIP may interact with the WDR5 subunit of the 
H3K4me3  histone  methyltransferase  complex  MLL  and  has  been 
hypothesised to recruit this complex to the HOX genes locus [451]. 
 
Cis-regulatory  mechanisms  suggested  for  eRNAs  include  increased 
RNAPII occupancy at the downstream target gene, as demonstrated by 
Mousavi  et  al  (2013)  [428].  In  these  experiments,  siRNA  was  targeted 
against eRNAs transcribed in muscle cells and though RNAPII occupancy 
at the enhancer locus was not affected, it was reduced at the downstream 
gene [428]. The Arc eRNA described in neurons by Schaukowitch et al 
(2014) has been shown to support upregulation of the downstream Arc 
gene by acting as a decoy for the repressive complex negative elongation 
factor  (NELF)  [427].  This  was  demonstrated  by  knockdown  of  eRNAs 
using antisense locked nucleic acids (LNAs) (Section 5.2.8), which led to 
retention of NELF at the downstream gene in association with a reduction   88 
in elongation RNAPII and mRNA synthesis. 
1.3.3.2  Trans-regulation of gene expression 
Trans-regulatory  mechanisms  are  relevant  to  cytoplasmic  ncRNAs  but 
have also been demonstrated for nuclear localised ncRNAs with roles in 
transcriptional regulation. 
 
The overexpression of an eRNA transcribed from a myogenic regulatory 
region  leads  to  activation  of  expression  of  MYOG,  which  encodes  a 
regulatory  factor  for  myogenesis  [428].  This  effect  observed  by  ncRNA 
overexpression  demonstrates  the  functional  activity  of  the  ncRNA  is 
independent of its genomic location and the act of transcription, while the 
association of this transcript with increased genomic accessibility suggests 
its  activity  is  located  within  the  nucleus  [428].  In  another  example, 
transcription of the long ncRNA HOTAIR is thought to orchestrate HOX loci 
expression in trans by acting as a guide. The coordinated temporal and 
spatial expression of the HOX loci is fundamental to metazoan body plan 
organisation  [452],  with  silent  regions  being  repressed  through  PRC2 
[453]. HOTAIR (HOX antisense intergenic RNA) is transcribed antisense to 
the HOXC chromosomal locus and has been suggested on the basis of 
native RNA immunoprecipitation to interact with PRC2 to target it in trans 
towards the HOXD locus. Consistent with this, siRNA depletion of HOTAIR 
leads to loss of H3K27me3 and increased transcription at the HOXD locus 
[454].  In  addition,  support  for  an  interaction  with  the  LSD1-CoREST 
histone  demethylation  complex,  which  removes  H3K4me3,  has  been 
interpreted as evidence for a scaffolding role for HOTAIR in linking LSD1-
CoREST  and  PRC2,  allowing  coordination  of  repressive  chromatin   89 
features [455]. The upregulation of HOTAIR has clinical relevance through 
an  association  with  metastatic  breast  cancer  that  has  prognostic  value 
[456]. MALAT1, (metastasis associated lung adenocarcinoma transcript 1, 
also  called  NEAT2  (non-coding  nuclear-enriched  abundant  transcript  2) 
has been suggested to perform a scaffolding role through an interaction 
with  splicing  factors  and,  through  this,  influences  their  localisation  to 
nuclear paraspeckles with effects on alternative splicing [457]. Again, this 
assertion  is  controversial  because  subsequent  work  with  a  MALAT1 
knockout mouse has revealed no obvious phenotype [458]. The lincRNA 
GAS5 (growth arrest specific 5) has a stem-loop structure that resembles 
the glucocorticoid response element upstream of glucocorticoid responsive 
genes. Through this mimicry, GAS5 acts as a decoy by interacting with the 
DNA binding site of the glucocorticoid receptor and in line with a functional 
role in sequestering the protein, GAS5 is upregulated in growth arrested 
cells [459]. Another example of a decoy RNA is PANDA (p21 associated 
ncRNA  DNA  damage  activated),  which  binds  the  pro-apoptotic  NF-YA 
transcription  factor  thus  titrating  it  away  from  target  genes  [460].  The 
potential  for  allosteric  influence  of  RNA  on  enzyme  catalysis  is 
demonstrated by the inhibition of CBP and P300 acetyltransferase activity 
by the TLS (translocated in liposoma) protein being promoted by binding of 
RNA to TLS [431]. 
1.3.4  Non-coding RNAs in T cells 
Several ncRNAs have been identified as having roles in T cells, including 
during  lineage  specification.  Recently,  a  profile  of  lincRNA  expression 
across T cell differentiation in mice was performed identifying LincR-Ccr2-
5’AS as being upregulated in Th2 cells and regulated by Stat6 and Gata3   90 
[461].  Depletion  of  LincR-Ccr2-5’AS  using  shRNA  resulted  in  reduced 
migration of Th2 cells to the lungs in vivo as well as a decrease in Th2 
upregulated genes, although this effect was demonstrated as a genome-
wide average rather than at specific genes. These data therefore suggest 
that  LincR-Ccr2-5’AS  acts  as  an  activating  lncRNA  (ncRNA-a)  [461]. 
Another lincRNA, NRON (noncoding repressor of NFAT) has been shown 
to  augment  the  activity  of  the  T  cell  transcription  factor  NFAT,  as 
demonstrated  through  luciferase  assays.  NRON  associates  with  several 
proteins in the cytoplasm including members of the importin-beta family, 
which mediate cytoplasmic to nuclear transport. Through this association, 
NRON  regulates  the  cellular  localisation  of  NFAT  thus  repressing  its 
transcriptional activity [462]. A lncRNA downstream and antisense to the 
Th1 cytokine gene Ifng has been shown to be Th1-specific and positively 
correlate  with  Ifng  transcription,  although  its  expression  is  decreased 
rather than increased upon stimulation [463]. Tmevpg1 (Theiler’s murine 
encephalitis  virus  persistence  gene  1,  also  called  NeST:  nettoie 
Salmonella pas Theiler's [in French] or cleanup Salmonella not Theiler's [in 
English]) was first characterised through the influence of its polymorphisms 
on  susceptibility  of  mice  to  Theiler’s  virus  [463]  but  its  expression  also 
leads  to  decreased  Salmonella  pathogenesis  through  increased  Ifng 
production  in  CD8  T  cells  [436].  It  has  been  suggested  to  act  as  an 
enhancer-like lncRNA (analogous to an ncRNA-a) and in humans (called 
IFNG-AS1), its position relative to IFNG is conserved and its expression is 
regulated  by  Stat4  and  T-bet  [464,  465].  Tmevpg1  is  localised  to  the 
nucleus [436] and evidence supports a physical association of the RNA 
with  the  histone  methyltransferase  WDR5  and  a  correlation  is  seen   91 
between  Tmevpg1  expression  and  H3K4me3  at  Ifng  [436].  Ectopic 
expression  of  Tmevpg1  also  increases  Ifng  expression  showing  that 
regulation is independent of genomic location and therefore occurs in trans 
[464]. 
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1.4  The scope of this thesis 
Through  the  experiments  I  present  here,  I  have  investigated  the 
transcriptional regulation of T cell lineages, beginning with differential gene 
expression  analysis  to  identify  lineage-specific  transcription.  I  start  by 
focusing on Treg specific transcription (Chapter 3) and identify a set of 
ncRNAs that are preferentially expressed in Treg compared to Tresp and 
may exert control over Treg phenotype and function. I also investigate the 
dysregulation of these in the systemic autoimmune disease SLE, for which 
there  is  some  evidence  of  Treg  defects,  particularly  when  naïve  and 
memory  subsets  have  been  investigated.  I  have  explored  the 
transcriptional regulation of the Treg state further by identifying differences 
in transcription factor expression and histone modifications that relate to 
differences observed in SLE patents. In addition, I have explored the role 
of  T-bet  in  Th1-specific  transcription  by  investigating  regions  of  high 
density  binding,  super-enhancers,  through  their  production  of  eRNAs 
(Chapter 4). I have interrogated the functional roles of these Treg lincRNAs 
on Treg biology and of T-bet super-enhancer eRNAs on downstream gene 
expression using the IFNG gene and its counterpart super-enhancer as a 
model (Chapter 5). Finally, I present an overall discussion of this work in 
Chapter 6. 
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2  Materials and Methods 
2.1  Solutions and buffers 
Table 2.1: Solutions and buffers 
Solution or buffer  Constituent  Final concentration 
Complete media  Roswell Park Memorial Institute-1640 (RPMI, Sigma-
Aldrich) 
 
Foetal Calf Serum (FCS, Invitrogen)  10% 
Penicillin-streptomycin (Invitrogen)  100U/ml 
Freezing media  FCS   
Dimethylsulphoxide (DMSO, Sigma-Aldrich)  10% 
Magnetic cell sorting 
(MACS) buffer 
PBS (Invitrogen)  1x 
FCS  0.5% 
Ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich)  2mM 
Xylene cyanol loading dye  Bromophenol blue  0.2% 
Xylene Cyanol  0.2% 
Glycerol (Sigma)  30% 
H2O   
Tris acetic acid EDTA (TAE) 
buffer 
Tris (Sigma)  40mM 
Glacial acetic acid (Sigma)  0.1% 
EDTA, pH8 (Sigma)  1mM 
 
2.2  Cell methods 
2.2.1  Sample collection and PBMC isolation 
Healthy donors and SLE patients were recruited in accordance with ethical 
approval obtained from University College London (ethics approval number 
02/0241).  Fifty  millilitres  of  heparinised  blood  were  collected  from  SLE 
patients (University College Hospital, London, UCLH) or healthy controls 
using  butterfly  needles  (Therumo)  into  50ml  syringes  (BD  Biosciences). 
Peripheral  blood  mononuclear  cells  (PBMCs)  were  isolated  by  Ficoll-
Hypaque  (GE  Healthcare)  density  centrifugation  as  follows.  Blood  was 
diluted  (25ml  blood  to  15ml  RPMI/5%  FCS)  in  50ml  Falcon  tubes  (BD 
Biosciences)  and  10ml  Ficoll  slowly  layered  underneath  using  a  10ml 
stripette  (Fisher  Scientific).  Layered  blood  was  centrifuged  at  800g  for 
30min at 21°C with the break off during both acceleration and deceleration. 
The  PBMC  layer  (situated  between  the  Ficoll  and  plasma  layers  after 
centrifugation) was extracted using a pastette (Sarstedt), with care not to   94 
disturb other layers, and deposited into a new 50ml Falcon tube containing 
10ml RPMI (5% FCS). The isolated PBMC suspension was washed twice 
with RPMI (5% FCS) with centrifugation at 450g for 10min at 4°C.  
2.2.2  Freezing of PBMC  
Isolated PBMCs were resuspended in 10ml RPMI (5% FCS) and counted 
with a haemocytometer (Hycor). Cells were pelleted at 450g for 10min at 
4°C  and  resuspended  in  freezing  media  (4°C)  at  10x10
6  cells/ml.  Cell 
suspension was aliquoted into cyrovials (Nunc) at 1.5ml per 2ml vial and 
gradually  cooled  to  -80°C  in  an  isopropanol-containing  cryo-container 
(Nalgene) before being transferred to liquid nitrogen.  
2.2.3  Thawing of frozen cells 
When required, cells were rapidly thawed by incubation in a water bath at 
37°C until liquid and resuspended in 15ml of complete media (37°C). Cells 
were washed twice in complete media with pelleting at 450g for 10min at 
4°C. 
2.2.4  Flow cytometry staining and analysis 
For intracellular cytokine staining, cells were incubated for 5 hr at 37°C in 
complete  media  with  stimulation  provided  by  phorbol  myristate  acetate 
(PMA, 40ng/ml, eBioscience) and ionomycin (2µg/ml, Sigma) and inhibition 
of Golgi export of protein provided by addition of monensin (1 in 1000, BD 
Biosciences). Cells for staining were washed twice with PBS and pelleted 
at 450g for 10min at 4°C. For the exclusion of dead cells an intracellular 
membrane amine reactive viability stain was used (Live/Dead ® Fixable 
Dead Cell Stain Kit, Life Invitrogen) as per the manufacturers instructions. 
Flow  cytometry  antibodies  to  extracellular  antigens  were  added  at  their   95 
titrated concentration in MACS buffer and incubated in the dark at 4°C for 
20min. For staining of less than 1x10
6 cells this was performed in 20µl in a 
96-well U-bottom plate. For staining of greater numbers of cells (eg. for 
sorting)  staining  volumes  were  scaled  up  to  100µl  per  10x10
6  cells. 
Surplus antibodies were removed by washing in MACS with cell pelleting 
at  450g  for  10min  at  4°C.  Cells  were  fixed  with  FoxP3  fix  buffer 
(eBioscience) for 20min at 4°C. For detection of intracellular antigens, cells 
were washed in FOXP3 permeabilisation buffer (eBioscience), pelleted at 
450g for 10min at 4°C and antibodies for intracellular antigens added at 
their  titrated  concentrations.  Cells  were  incubated  in  the  dark  at  room 
temperature for 1hr and surplus antibodies removed by washing in FOXP3 
permeabilisation buffer. Cells were pelleted at 450g for 10min at 4°C and 
resuspended in MACS buffer. Flow cytometry acquisition was performed 
on  a  LSR  Fortessa  (BD  Biosciences)  or  Image  Stream  (Amnis)  and 
analysed  on  Flowjo  software  (Tree  Star). Compensation  was  performed 
using  anti-mouse  Igk  and  negative  compensation  particles  (BD 
Biosciences).  Gating  strategies  and  antibodies  are  detailed  in  Section 
2.2.6. 
2.2.5  Fluorescence associated cell sorting (FACS) 
Cells were washed once with MACS buffer and pelleted at 450g for 10min 
at 4°C and extracellular antigen staining performed as per section 2.2.4. 
Cells were pelleted at 450g for 10min at 4°C and resuspended in MACS 
buffer  at  40x10
6  cells/ml  and  passed  through  a  35µm  filter  to  remove 
aggregates.  For  the  exclusion  of  dead  cells,  1µl  of  DAPI  (1mg/ml)  was 
added 10 min prior to sorting. Cells were sorted on a FACS Aria II (BD 
Biosciences) and isolated populations collected in MACS (50% FCS).    96 
2.2.6  Flow cytometry gating strategies and antibodies 
Figure 2.1 illustrates gating strategies for flow cytometry analysis and cell 
sorting and Table 2.2 gives details of antibodies.     97 
 
 
Figure 2.1: Gating strategies for flow cytometry analysis and cell sorting 
Gating  strategies  for  T  cell  subsets.  A:  Total  Treg  and  total  Tresp  based  on  surface 
antigens. B. Total Treg and total Tresp based on the Treg lineage-specifying transcription 
factor FOXP3. C. Total Treg and CD25+ Tresp and CD25- Tresp. D. Naïve and memory 
subsets of Treg based on CD45RA expression. 
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Table 2.2: Flow cytometry antibodies 
Antibodies were diluted to their titrated concentration in MACS buffer for fluorescence activated cell sorting or in FACS buffer for ex vivo and in 
vitro flow cytometry staining. 
Corresponding plot in 
Figure 2.1 
Antigen  Fluorophore  Clone  Isotype  Concentration  Manufacturer  Catalogue number 
A.   CD4  AF700  RPA-T4  Ms IgG1, κ  1/80  BDBioscience  557922 
CD25  PE  M-A251  Ms IgG1, κ  1/5  BDBioscience  555432 
CD127  PerCP.Cy5.5  eBioRDR5  Ms IgG1, κ  1/10  eBioscience  45-1278-42 
B.  CD4  AF700  RPA-T4  Ms IgG1, κ  1/80  BDBioscience  557922 
CD25  PE  M-A251  Ms IgG1, κ  1/5  BDBioscience  555432 
CD127  PerCP.Cy5.5  eBioRDR5  Ms IgG1, κ  1/10  eBioscience  45-1278-42 
CD45RA  FITC  HI100  Mouse IgG2b, k  1/40  BDBioscience  555488 
C.   CD4  AF700  RPA-T4  Ms IgG1, κ  1/80  BDBioscience  557922 
CD25  PE  M-A251  Ms IgG1, κ  1/5  BDBioscience  555432 
CD127  PerCP.Cy5.5  eBioRDR5  Ms IgG1, κ  1/10  eBioscience  45-1278-42 
D.  CD4  AF700  RPA-T4  Ms IgG1, κ  1/80  BDBioscience  557922 
FoxP3  AF647  236A/E7  Ms IgG1  1/50  eBioscience  51-4777-42 
Used alone and also in combination with antibodies described in A, B and C. 
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2.2.7  In vitro Treg induction 
TCDD    (2,  3,  7,  8-Tetrachlorodibenzo-ρ-diooxin)  inductions  were 
performed  as  described  by  Gandhi  et  al.  (2010)  [88].  Naïve  CD4  T 
lymphocytes were isolated as described in Section 2.2.5 and cultured in 96 
well flat-bottom plates at 300x10
3 cells per well in 200µl complete media 
with  plate  bound  anti-CD3  (1µg/ml,  UCHT1,  eBioscience),  soluble  anti-
CD28  (1µg/ml,  CD28.2,  eBioscience),  IL-2  (50U/ml,  Peprotech),  human 
recombinant  TGF-β  (10ng/ml,  R&D)  and  TCDD  (100nM,  Cambridge 
Isotype Laboratories).  After 6 days, cells were analysed by flow cytometry 
as described in Section 2.2.4. 
2.2.8  In vitro Treg expansion 
Treg were isolated as described (Section 2.2.5) and cultured in a 96-well 
flat-bottom plate at 2x10
5 per well with 100nM rapamycin, 1000IU/ml IL-2 
and at a 1:1 ratio with Human T cell activator CD3/28 Dynabeads ® (Life 
Technologies).  IL-2  was  replenished  at  day  2  and  cultures  split  1in2 
whenever media appeared visibly exhausted. Cells were harvested after 8 
days. 
2.2.9  In vitro Th1 polarisation 
Naïve cells were obtained as per Sections 2.2.1, 2.2.5 and 2.2.6. Naïve 
CD4  T  cells  exit  the  thymus  expressing  long  ‘RA’  isoform  of  the  cell 
surface  receptor,  CD45.  After  TCR  stimulation,  the  gene  encoding  the 
receptor, PTPRC, is alternatively spliced eventually leading to expression 
of the ‘RO’ isoform on memory T cells. Repeated restimulation in vitro has 
shown  re-expression  of  CD45RA  can  occur  in  non-naïve  cells  [466]. 
Therefore additional markers are required to isolate naïve T-lymphocytes.   100 
This  includes  a  lack  of  CD25  expression,  which  is  upregulated  after 
antigen encounter, and the chemokine receptor CCR7, hence naïve CD4 T 
cells  can  be  identified  as  CD45RA+CD45RO-CD25-CCR7+.  Cells  were 
cultured  at  37°C,  5%  CO2  in  complete  media  supplemented  with  IL-12 
(10ng/ml),  anti-IL-4  (10µg/ml)  and  IL-2  (100IU/ml).  Stimulation  was 
provided with CD3/28 activation beads at a 1:1 ratio with cells. At day 2 or 
3 (whenever media was visibly exhausted) media was replaced. At further 
time points cells were split 1 in 2 as needed. Cultures were harvested at 
various  time  points  up  to  13  days.  For  cultures  longer  than  7  days, 
activation  beads  were  replaced  to  provide  an  additional  round  of 
stimulation.  Cells  were  harvested  as  ‘unstimulated’  or  restimulated  with 
either PMA (40ng/ml) and ionomycin (2µg/ml) or CD3/28 activation beads 
(1:1 ratio with cells).  
2.2.10 Transfection for siRNA-mediated knockdown 
siRNA were designed using Dharmacon’s proprietary online siRNA design 
algorithm  [467].  siSTABLE  modifications  (proprietary  knowledge)  were 
added  to  enhance  efficiency  of  siRNA  knockdown,  a  requirement  for  T 
cells [468]. siRNA were resuspended in PBS as per the manufacturer’s 
instructions. A FITC-tagged non-targeting transfection indicator (siGLO ™, 
Dharmacon) was included at a 1:1 ratio with the targeting siRNA to assess 
siRNA uptake by flow cytometry at 24hr post transfection. Knockdown was 
assessed relative to a non-targeting control. siRNA sequences are detailed 
in  Table  2.3.  In  order  to  transfect  siRNA  into  cells,  two  electroporation 
devices were used (Sections 2.2.10.1 and 2.2.10.2). 
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Table 2.3: siRNA sequences 
Target  ID  Sense (5’ to 3’)  Antisense (5’ to 3’) 
FOXP3    TCGAAGAGCCAGAGGACTT  AAGTCCTCTGGCTCTTCGA 
SMARTpool 
(pool of 4) 
Proprietary knowledge, Dharmacon.  Proprietary knowledge, Dharmacon. 
ncRNA30  1  CCTCTGAAATTGTGAGACA  TGTCTCACAATTTCAGAGG 
2  GATGGGAATTGTTGGATAA  TTATCCAACAATTCCCATC 
miR-146a    GGTGAAATCTCAACCGACA  TGTCGGTTGAGATTTCACC 
 
 
2.2.10.1  Nucleofector ™ 2b Device, Lonza 
Cells  were  washed  in  PBS  and  supernatant  removed.  Cells  were 
resuspended in 100µl room temperature Nucleofection solution ® (Human 
T cell Nucleofection kit, VPA-1002, Lonza) with the addition of siRNA and 
transferred to an electroporation cuvette. For ex vivo unstimulated cells, 
5x10
6,  or  as  many  as  possible,  were  used  per  condition  and 
electroporation program U-014 used, as per the manufacturer’s instruction 
[469].  This  program  was  recommended  for  increased  viability.  For 
expanded, stimulated T cells, 1-5x10
6 cells were used per condition and 
electroporation program T-023 or T-020 used, as per the manufacturer’s 
instructions  [469].  Complete  media  (500µl,  37°C)  was  added  and  cells 
transferred to a well of a 12 well plate containing 1.5ml 37°C complete 
media. Media was replaced 5hr post-transfection. 
2.2.10.2  Agile Pulse Electroporation System, BTX 
Cells  were  activated  through  a  protocol  optimised  by  Laurie  Menger 
(Sergio Quezada, Karl Peggs) as follows: cells were cultured in a 12 well 
plate at 1x10
6 per ml with activation beads (1:1 ratio with cells) in X-Vivo™ 
15 media (Lonza), 10% FCS and 300IU/ml IL-2. After 3 days cells were 
washed in cytoporation media (BTX) and resuspended at 5x10
6 per 200µl 
for each condition with addition of siRNA for electroporation.   102 
2.2.11 Culture  for  Locked  Nucleic  Acid  (LNA)-mediated 
knockdown 
LNA were designed using Exiqon’s proprietary online antisense inhibition 
design  algorithm  [470].  LNA  were  resuspended  in  H2O  as  per 
manufacturers  instructions.  A  FAM-tagged  non-targeting  control  was 
included at a 1:1 ratio with the targeting LNA to assess uptake by flow 
cytometry. Knockdown was assessed relative to the non-targeting control. 
LNA  sequences  are  detailed  in  Table  2.4.  Cells  were  activated  with 
aCD3/28 beads (1:1 ratio) in complete media with the addition of LNA the 
media at various concentrations and cells harvested at the required time 
point. 
Table 2.4: LNA sequences 
Target  ID  Sense (5’ to 3’)  Antisense (5’ to 3’) 
GAPDH    TTGTCATACCAGGAA  TTCCTGGTATGACAA 
MALAT1    GGCATATGCAGATAATGTTC  GAACATTATCTGCATATGCC 
CRNDE  1  CAATCCAATAAAGAC  GTCTTTATTGGATTG 
2  AAGTCAACCTATAC  GTATAGGTTGACTT 
3  AAACTGGCAATCAA  TTGATTGCCAGTTT 
4  AATAGCCAGTACAG  CTGTACTGGCTATT 
5  GCCGCAAGAGGCGG  CCGCCTCTTGCGGC 
TBX21 eRNA 2 plus  1  CCTGCTAATCGAAC  GTTCGATTAGCAGG 
2  AGAGGTGACACAATT  AATTGTGTCACCTCT 
IFNG eRNA 3 minus  1  CCACAAGCCATTTTAA  TTAAAATGGCTTGTGG 
2  TACTTCTGTATGCTGA  TCAGCATACAGAAGTA 
IFNG eRNA 1 minus  1  ATAGTAAGACTGCAAG  CTTGCAGTCTTACTAT 
2  CAGGGATTTGGGTCAG  CTGACCCAAATCCCTG 
IFNG eRNA 2 plus  1  ACATGAGGATAACTTG  CAAGTTATCCTCATGT 
2  TTGACAGCTCACTTCT  AGAAGTGAGCTGTCAA 
IFNG eRNA 7 plus  1  TGAGTGCCTTTAAGAA  TTCTTAAAGGCACTCA 
2  GTTACAGGTTGGAGAA  TTCTCCAACCTGTAAC 
 
2.3  RNA methods 
2.3.1  RNA extraction 
Cells  intended  for  RNA  extraction  were  pelleted  at  450g  for  10min, 
supernatant removed and cells resuspended in 1ml Trizol® (Invitrogen) for 
up to 10x10
6. Alternatively, for small cell numbers, cells were resuspended 
in  250l  Trizol  LS  ®  (Invitrogen)  and  cells  and  stored  at  -80°C  until 
extraction. Upon thawing, 200µl of chloroform was added per 1ml Trizol®   103 
and  samples  shaken  by  hand  for  15s.  Phases  were  separated  by 
centrifugation at 12,000g for 15min at 4°C. The aqueous phase, containing 
RNA,  was  transferred  to  a  new  RNase-free  1.5ml  tube  (Eppendorf). 
Organic  phases,  containing  DNA  and  protein,  were  returned  to  -80°C. 
Isopropanol (500µl, Sigma) and 20µg of glycogen (Roche) were added to 
the  aqueous  phase  and  incubated  at  room  temperature  for  10min. 
Precipitated RNA was pelleted by centrifugation at 10,000g for 10min at 
4°C.  Supernatant  was  discarded  and  pellet  washed  with  1ml  room 
temperature  75%  ethanol  (Sigma).  RNA  was  pelleted  again  with 
centrifugation at 6000g for 5min at 4°C, supernatant discarded and pellet 
air-dried at room temperature for 5min. RNA pellets were resuspended in 
25µl RNase-free H2O and concentration determined by spectrophotometry 
(Nanodrop 2000, Thermo Scientific). 
2.3.2  DNaseI treatment of RNA 
DNaseI reactions were performed in 50µl with 10x DNase TURBO™ buffer 
(Ambion) and 50x DNaseI TURBO™ enzyme (Ambion) with incubation at 
37°C  for  30min.  DNase  inactivation  reagent  (5µl,  Ambion)  was  added, 
incubated for 2min at room temperature and inactivation reagent pelleted 
by centrifugation at 10,000g for 1.5min. Supernatant (45µl) was transferred 
to a new tube and 150µl of 100% ethanol, 5µl sodium acetate (Sigma) and 
20µg glycogen added. RNA was precipitated at -20°C for 1hr and pelleted 
by centrifugation at 18,000g for 30min at 4°C. Supernatant was discarded 
and RNA washed with 1ml 80% ethanol (-20°C) and pelleted at 10,000g 
for 10min at 4°C and supernatant discarded. RNA pellets were air-dried at 
room temperature for 5 min and resuspended in 25µl RNase-free ddH2O 
and  concentration  determined  by  spectrophotometry  (Nanodrop  2000,   104 
Thermo Scientific). 
2.3.3  Assessment of RNA quality 
Extracted  and  DNaseI  treated  RNA  was  assessed  for  the  presence  of 
contaminants by spectrophotometry (Nanodrop 2000, Thermo Scientific). 
Absorbance ratios of 260nm to 280nm or 230nm of greater than 1.8 were 
presumed to be indicative of high purity. RNA degradation was assessed 
on  an  Agilent  2100  Bioanalyzer  using  an  Agilent  RNA  6000  Picochip 
according  to  the  manufacturers  instructions  [471].  An  RNA  Integrity 
Number  (RIN)  greater  than  7,  or  comparable  electropherogram,  was 
considered to indicate sufficient quality for microarray or RNA-Seq gene 
expression analysis. 
2.3.4  Reverse transcription 
Up to 5µg of DNaseI treated RNA was made up to a volume of 11µl with 
H2O  and  were  incubated  with  1µl  primers  (either  oligo(dT)20,  50µM, 
Invitrogen  P/N58063,  or  random  hexamers,  0.2µg/µl,  Thermo  Scientific, 
♯50142)  and  1µl  dNTP  mix  (10mM  each  dATP,  dGTP,  dCTP,  dTTP, 
Promega) at 65°C for 5min followed by 1min on ice to anneal primers. Four 
microliters  of  First  Strand  Buffer  (5x,  Invitrogen),  1µl  DTT  (0.1M, 
Invitrogen), 1µl RNaseOUT™ Recombinant RNase Inhibitor (40 units/µl, 
Invitrogen)  and  1µl  reverse  transcriptase  (SuperScript®  III,  200  units/µl, 
Invitrogen) were added (final volume 20µl). The reaction was incubated at 
for 10min at 25°C followed by 50min at 50°C and finally 15min at 85°C to 
inactivate the reverse transcriptase enzyme. 
2.3.5  Labeling and amplification of RNA for microarrays 
RNA was labelled with Agilent Low Input Quick Amp 2 Colour Labelling kits   105 
according to the manufacturers instructions [472]. The reagents detailed 
below were provided with this kit unless otherwise stated. Sample RNA 
(i.e. RNA from SLE patients or healthy donors) was mixed with spike-in 
control  (Agilent,  #  5188-5279)  A  and  labelled  with  Cy3-CTP.  Reference 
RNA (Stratagene Universal Human Reference RNA, Agilent) was mixed 
with  spike-in  control  B  and  labelled  with  Cy5-CTP.  RNA  template  was 
annealed with T7 promoter primer and first strand cDNA synthesised with 
First  Strand  Buffer,  0.02M  DTT,  1mM  dNTP  and  Affinity  Script  RNase 
Block  Mix  with  incubation  at  40C  for  2hr.  Affinity  Script  enzyme  was 
inactivated  by  incubation  at  70C  for  15min.  Complementary  RNA  was 
transcribed  with  Transcription  Buffer,  0.01M  DTT,  1x  NTP  mix  (which 
included fluorescently labelled CTP) and T7 RNA Polymerase Blend with 
incubation at 40C for 2hr. Labelled RNA was purified using the Qiagen 
RNeasy mini kit and spin columns according to manufacturers instructions 
[472].  Labelled  RNA  was  hybridised  at  60C  for  17hr  to  Sureprint  G3 
Human  Gene  Expression  microarrays  with  8x60K  format  (Agilent 
#G4851A).  Incorporated  fluorescence  was  read  on  an  Agilent  High 
Resolution C scanner.  
2.3.6  RNA-Seq library preparation 
Prior to RNA-Seq library preparation all RNA was DNaseI treated (Section 
2.3.2)  and  quality  assessed  (Section  2.3.4).  A  RIN  of  7  or  above,  or 
comparable  electropherogram  was  considered  of  sufficient  quality  for 
RNA-Seq. All libraries were prepared with 1µg of DNaseI treated total RNA 
as starting material. Preparation of RNA for polyadenylated RNA libraries 
required purification of polyadenylated RNA (Oligotex™, Qiagen) as per 
the  manufacturer’s  instructions.  Total  RNA  library  preparation  required   106 
removal  of  ribosomal  RNA  (Ribo-zero™  Gold,  epicentre)  followed  by 
removal  of  5’  cap  structure  (Section  2.3.6.1).  All  libraries  required 
fragmentation  and  repair  (Section  2.3.6.2)  prior  to  library  generation 
(NEBNext  ®  Multiplex  Small  RNA  Library  Prep  Set  for  Illumina,  NEB 
#E7300S/L) and gel purification (Section 2.3.6.3).  
2.3.6.1  Removal of 5’ cap structure 
RNA,  in  7µl,  was  incubated  with  tobacco  acid  pyrophosphatase  (TAP) 
buffer (Ambion) and 2µl TAP enzyme (Ambion, 2380G) at 37
 oC for 1 hour. 
To re-purify RNA the reaction was made up to 115µl with H2O and 15µl 
ammonium  acetate  and  150µl  acid  phenol  chloroform  added.  After 
vortexing and centrifugation at 13,000g for 5 mins, the aqueous phase was 
removed to a new eppendorf containing 150µl chloroform. Centrifugation 
was  repeated  and  RNA  from  the  aqueous  phase  was  precipitated  with 
150µl isopropanol. After a 10-minute incubation at room temperature, RNA 
was  pelleted  by  centrifugation  and  pellet  washed  with  80%  ethanol, 
supernatant  removed  and  pellet  air  dried  for  5  min  before  being 
resuspended in H2O. 
2.3.6.2  Fragmentation and repair 
RNA was made up to a volume of 182µl with H2O and incubated with Tris 
(pH8,  40mM  final  concentration),  magnesium  acetate  (30mM  final 
concentration)  and  potassium  acetate  (100mM  final  concentration)  in  a 
total volume of 200µl at 94°C for 4min. Reactions were placed immediately 
on ice and 20µl 0.5M EDTA added. Fragmented RNA was precipitated with 
20µl sodium acetate, 500µl ethanol and 20µg glycogen at -20°C for 1hr. 
RNA  was  pelleted  by  centrifugation  at  13000g  for  30min  and  pellets   107 
washed with 500µl 75% ethanol (-20°C) with centrifugation at 13000g for 
5min. Pellets were air-dried for 5min and resuspended in 16µl H2O. Two 
microliters of 10x phosphatase buffer (NEB), 1µl of Antarctic phosphatase 
(NEB) and 1µl RNaseOUT (Invitrogen) were added (final volume 20µl) and 
reactions  incubated  for  at  37°C  for  30min  followed  by  5min  at  65°C. 
Reactions were made up to 50µl with 17µl DDW, 5µl 10x PNK buffer, 5µl 
ATP (10mM), 1µl RNaseOUT and 2µl PNK and incubated at 37°C for 1hr.  
RNA was purified using RNeasy kit reagents (Qiagen) according to the 
following protocol: Fragmented RNA was made up to 100µl with H2O and 
350µl RLT buffer added and sample vortexed. Six hundred and seventy 
five microliters of ethanol were added and the sample mixed by inverting 
the  tube.  Sample  was  applied  to  an  RNeasy  MinElute  column  in  a 
collection  tube,  centrifuged  and  flow-through  discarded.  Five  hundred 
microliters of RPE buffer was applied to the column, centrifuged and flow 
through  discarded.  The  same  process  was  performed  with  750µl  80% 
ethanol. The column was then centrifuged with the lid open for 5min and 
residual  liquid  removed  from  the  rim  of  the  column  with  a  pipette.  The 
column was transferred to a clean 1.5ml eppendorf tube and 15µl H2O 
applied to the centre of the membrane and RNA eluted by centrifugation. 
2.3.6.3  Gel purification of RNA-Seq library 
Ten microliters of Xylene Cyanol loading dye were added to each PCR 
library before loading onto a 2% agarose TAE gel with SYBRsafe nucleic 
acid stain. Gels were electrophoresed at 100V for 40min or until primer 
dimer  bands  were  resolved  from  library  product  bands.  DNA  was 
visualised on a dark reader and bands between 130bp and 350bp (relative 
to  Hyperladder  V,  Bioline)  excised  with  a  sterile  scalpel.  DNA  was   108 
extracted  from  the  gel  using  the  Qiagen  MinElute  kit  according  to 
manufacturer’s instructions but without heating gel in QG buffer and with 
an extra PE buffer wash. DNA was eluted in 15µl EB buffer, preheated to 
50
oC.  
2.3.6.4  Library sequencing 
Libraries  were  quantitated  by  qPCR  (Library  quantification  kit, 
KAPABIOSYSTEMS) and average fragment size analysed by Bioanalyzer 
(DNA HS assay, Agilent). Libraries were sequenced on an Illumina HiSeq 
with 50bp paired end sequencing. 
2.4  DNA methods 
2.4.1  Primer design 
Primers were designed using the Roche Universal Probe Library Assay 
Design Centre [473, 474] or Primer3 [475]. Suggested primer pairs were 
tested by in silico PCR (UCSC genome browser) to ensure specificity for 
producing a single amplicon. 
For QPCR validation of microarray data, primers were designed as close 
as  possible  to  the  microarray  probe  target  sequence.  Primers  were 
synthesised (Sigma-Aldrich) and tested by QPCR (Section 2.4.2) on cDNA 
using a four-stage 1 in 5 serial dilution. Primer pairs with an efficiency rate 
of 90-105% and sequence specific amplification (melting curve analysis) 
were considered admissible. All primer sequences are given in Table 2.5.  109 
Table 2.5: Primer sequences 
Presence of a probe sequence indicates use of TaqMan™ chemistry. All other primers were used with SYBR® Green. Hs: Human; Ms: Mouse. 
Target  Species  ID  Forward (5' To 3')  Reverse (5' To 3')  Probe (5' to 3') 
ACTB 
Hs 
  
AGCACAGAGCCTCGCCTTT  TCATCCATGGTGAGCTGGC    
Mm  TCTTTGCAGCTCCTTCGTTG  ACGATGGAGGGGAATACAG    
HPRT 
Hs  AGTCTGGCTTATATCCAACACTTG  GACTTTGCTTTCCTTGGTCAGG  6FAM-TTTCACCAGCAAGCTTGCGACCTTGA -TAMRA 
Mm  TCAGTCAACGGGGGACATAAA  GGGGCTGTACTGCTTAACCAG    
GAPDH 
Hs  GGCTGAGAACGGGAAGCTT  AGGGATCTCGCTCCTGGAA  6FAM-TCATCAATGGAAATCCCATCA-TAMRA 
Mm  ATGATGCGCAAAGGTATGCA  CCCCATCTCCCCCTTCCT    
ncRNA30 
Hs 
A  GGCTCCATGCCAGTCCTAT  TTTGTGAGCATTGGCACAG    
B  ATGGCAGAAGGTCTAGTGGG  GGCACTTGAACCTCACAACA    
C  CATTGTATGGAGGGGTTCTGC  ACTTGAACCTCACAACAGAACT    
D  CAAATGGGATGCAGTGGACC  GGCACTTGAACCTCACAACA    
miR146a     ATGAAAGAGTAACCTGTCCCAGA  AGAATGAGCATGCTGTGGAGT    
CRNDE 
A  CAGCCGTTGGTCTTTGAAAT  AAACCACTCGAGCACTTTGA    
B  GGCGCTAACGGTCGGTAA  ACCAGCCTTGGGATGAATTT    
C  TGAACTAAGGGGTTCCTCCA  TTTGGTACCCATGACTGGAA    
D  GATCGCGCTATTGTCATGGAG  CTTCAGAATCTCCTCCTTCCA    
FOXP3 
Hs 
  
GAAACAGCACATTCCCAGAGTTC  ATGGCCCAGCGGATGAG    
IRX5  TGGCTAAAGACCCGAAAATG  GGGAGAGTCTTTGCACAGGT    
NR4A3  GTGTCTCAGTGTTGGAATGGT  TTTGGTTTGGAAGGCAGACG    
MALAT1  GACGGAGGTTGAGATGAAGC  ATTCGGGGCTCTGTAGTCCT    
MKI67  ACGAGACGCCTGGTTACTA  GCTCATCAATAACAGACC CATTTAC    
CB144112  AGTAACCTGTGATCTTCCCCT  GGGGTTGCCTACTCTTCTGT    
GPR15  TGTTGAGCATTGTGACCTGC  CCTGATTGCTGGTAATGGGC    
IFNG 
Hs  AAACGAGATGACTTCGAAAAG  ACAGTTCAGCCATCACTTGG    
Mm     GCCAAGTTTGAGGTGAGACG  GTGGACCACTCGGATGAGC    
IFNG eRNAs  Hs 
A2  CAGAGAAATGCCAGCAAAAAC  ACCCTCGTTGTGCTAGTTCG    
A3  CTGGAATGTCTCCACTGAGC  CTCAGGAAGGGTTTGTGAGC    
B1  ACCTGAGCCAGCTCCTATCC  CGGTAGAGGGGAAAAACAGC      110 
Target  Species  ID  Forward (5' To 3')  Reverse (5' To 3')  Probe (5' to 3') 
B2  TCGCTTTCCTTTCTCCAGTT  TGACAAACCCTCTTACAACCA    
C1  GGATGTGCTGTTTTTCACACC  CTGGAGCAATCCTATCACAGC    
D1  AGCATGCTGGAAAATGAACC   AAGATGCTTGGGTGTGTGC    
D2  TTCAAGGTCCCTGTTTCTGC   GCAGAAGATGCTTCCTCCAG    
E1  GGCCAAGTCTTTCTCAGAGC  TTCCCTGGACTGTTGTAGGC    
E2  GCCTGAAGTCCCTATGTTGC  TGATTTGCACACTGCTCACC    
F1  GCCCACACTTGGTTTAATGC  GTGGAAACAAGTGCAAAACG    
F2  CTTTGTTGGTTTGGCCAGTT  GTCACACCTTGGCTCCTGAT    
G1  ATGTCCTTCCTGTGGGTCAC  CTGGGCTGAAGAGAGGAATG    
G2  CCTCATGTGCTTTTCTTCCTC  ACTCAGCCAGGCACTTTGAG    
G3  TAGTGCCCAAGCCACATAGG  TGAGATTGGCAGTAACACAGC    
H1  GGAGCATGAACAGATGTGAGG  GTGTGCAGGGCTCCTATGC    
H2  TCTAGCCACCCTAAGCATCC  GGTTTCCTCTCAGGGTACTGG    
I1  ATGACCCCAAGACTGAAACG  AGGTGGGACTTCACCAAGG    
I2  CAGGGGCACAATGAAAGC  GCTATTGGCATACAGCATGG    
J2  TTGAATAAGCCGATTGTTTGC  GAGCATAGGACTCCCTGTGG    
J3  CTCTTCAGGGGTGTTCATGG  ATGCAGGGTCTGATCTGAAGG    
S  CAGTCACAGGCAGAGGGTAA  TACTACCTGCCTTGCCAACA    
T  TGATACCCAACTAACATGCCAA  TCAGGAGTGCTTTTCAACTCT    
R  CGAACATGCACAGTGACCTC  AGCAGGACCAGGATCCTTTC    
Mm 
Aii1  CTTCATGCTTGGTCCTTTGG  CAGGGCTACACAGGAAAACC    
Aii2  TGCAGACAGGGAAATAAAAGC  AAGTCACCCCACCATAGAGC    
Bi1  CCAAGATGAGTCAGCACAAGG  CACGCGCCAGAATAAATAAG    
Bi2  TATTTGCCCGCTGTTGACC  GTAAGGCATGTTCTTGACTGC    
Bii1  AAGGCCCTGACTTCATTAGC  GGCTCTCCTCTGCAGAATCC    
Bii2  AATTGTGGTCGTTGTGTCTCC  GCCTGGGTTTCTGATACAGC    
Ci1  GTCGCTAGGAGCACTATACCG  CTTGCAACTTAAAGCCAAAGC    
Ci2  CAAATTAACCTCAGCCATGC  TGGCCATTTAAAGCTTCTCC    
Cii1  CAACTGAGGCATTAGCAGAGC  TCGTACAGAAAGGACTTCACG    
Cii2  CTCAGCTGCAAAAGAAAAGG  TGTAACCCTGCTTCTGACTCC      111 
Target  Species  ID  Forward (5' To 3')  Reverse (5' To 3')  Probe (5' to 3') 
Cii3  GTCGTTAACTTTCCCGATCC  AGCCCACACAGGAATCTGAG    
Cii4  GATGGCTTGCTCACATACTCC  AACCATGGAAACTTGTCAGG    
Cii5  TTAGCTTGCCCTGTTCTTGC  TGGATCGTGCAGCTAAGAGG    
Cii6  AGCTTGACTTTCATGCTTCC  GCTACCCATTTCCCAGAGG    
Ciii1  CGAAGGGGGAAAGATGTACC  AGCATCTCCTCCTTTTCTTCC    
Ciii2  AGTGCCCACTGCAATACAGG  AAGGGCCTCAACTCTTTGC    
Di1  CTTCCTTTCTAGGCCTGTCC  CATGCCATGTATCAGTGTTCC    
Di2  GACAGAGGAAGAGGGTGTGG  AACTCAGGGGACTGGTTTCC    
Ei1  TTTGATTGTTTGCACAAGACC  AGTTAGAAGTGGGGCTCTGG    
Ei2  TCATGCTGTTGAAAGAAATGG  TTTGTGCTTTCCTGATTCACC    
Fi1  TTCTGCAGGCTCACTATTGG  GTGCGCTGCCTGTAAAGC    
Fi2  GCGCAACCAGGATGTAGG  CTGGTGGTGGATGTAACAGG    
Gi1  TCCGTGTGACATGTCGTTTAG  AACAGAAGCCCTGCATTTTG    
Gi2  CAGCTAAAGCCCCAAGAATG  TGGGAACTGGATTGTGTTTG    
Hi1  TCTGGAGTAGGGATGGAAGG  GACCCAGATGACCAAATTAGC    
Hi2  TCTTGTGCTTTCATCTTTTGC  CCCAAACTTGGTGCTACCTG    
Hii1  AAAAGCCCAGAGTGTCAACC  GCTCTTCTCTTTCCAAGAAGC    
Hii2  AGCTCCCATTAATGACACACC  GTGGTAACACACACACACACC    
Ji1  CACACACACATGGATGCAC  AGCCAGAACAGACAGACAGAC    
Ji2  CACTTGGGAGGTAGAGACAGG  TATACCCTTGGCTGTTCTGG    
S  CAAGGGTTGAGAATGGGTGC  GCCATCACTCTCTTGGGGAT    
S  TGAGGGCTAGATGGAATGGT  TTGAAGATCACTCCTGCAAGT    
R  GTGCTGTGACTGTAAGGTGC  ACAGGCTCACTTTCCTCTCC    
TBX21 eRNAs 
Hs 
1 
CGAAGGAAGCCGTTTAGAGC  AGAAACCGCACAGTGTTCAC    
Mm  CTGAGACACGGCTCTGTCA  AATGGTCTGAGGGTGAGGC    
Hs 
2 
TGTGTCACCTCTCTGAGCAC  AGAGGACACTATCGTTCCCA    
Mm  AGGGTGGTAGTACAGGCTTG  CCATCCTCCAGCCTCAGG    
   112 
2.4.2  qPCR 
Q-PCR was performed using QuantiTect SYBR green PCR kit (Qiagen) 
chemistry  if  possible  or  QuantiFast  Probe  RT-PCR  Plus  kit  (Qiagen) 
alternatively. Reactions were performed in 10µl with 5ng cDNA template, 
300nM  primers  and  250nM  probe  (when  relevant).  Cycling  conditions 
were: 95°C (10min) followed by 40 cycles of 95°C (15s) and 60°C (1min). 
All reactions were performed in triplicate in an Applied Biosystems® 7500 
Fast Real-time PCR system with no reverse transcriptase and no template 
(water) negative controls. If the standard deviation of number of cycles to 
threshold (ct) exceeded 0.5ct, outlying replicates were excluded. 
2.5  Bioinformatics methods 
2.5.1  Analysis of microarray data 
RNA  was  labelled,  amplified  and  hybridised  to  slides  as  described  in 
Section  2.3.5.  Microarray  slides  were  scanned  with  an  Agilent  High 
Resolution  C  Scanner.  Fluorescence  intensities  were  converted  into  log 
base 10 expression ratio of Cy5 to Cy3 using Feature Extraction software 
(Agilent, v10.7). Data was extracted and converted into inverse log base 2 
expression  ratios  of  Cy3  (sample)  to  Cy5  (reference)  signal  in  Excel 
(Microsoft).  For  normalisation,  expression  ratios  were  iteratively  median 
centred ten times across both genes and arrays and filtered to remove 
genes with less than one value across all arrays (performed in Cluster 3.0 
[476]).   
2.5.2  Hierarchical clustering 
Hierarchical clustering was performed using Cluster 3.0 [476] on median 
centred log2 expression ratios. Pairwise Pearson correlation coefficients   113 
were calculated using Cluster 3.0 and unsupervised hierarchical clustering 
performed by average linkage analysis. Heatmaps and dendrograms were 
viewed with Java Treeview [477]. 
2.5.3  Principle component analysis 
Log2 expression ratios of sample to reference were uploaded to Cluster 
3.0 in a text file. Expression ratios were iteratively mean centred ten times 
across both genes and arrays (performed in Cluster 3.0).  Eigenvectors of 
the covariance of the matrix of the data were calculated by Cluster 3.0 and 
principle  components  exported  as  a  text  file  for  analysis  in  Microsoft® 
Excel®. 
2.5.4  Ranksum and rankproduct analysis 
Ranksum  and  rankproduct  analysis  were  performed  using  RankProdIt 
[478-481]. Log2 expression ratios of sample to reference (log base 2) were 
iteratively median centred ten times across both genes and arrays filtered 
to remove genes with less than one value across all arrays (performed in 
Cluster 3.0). Text files containing the data were uploaded to RankProdIt 
[481],  allowing  comparison  of  two  conditions  (cell  subsets)  at  a  time  to 
identify  significantly  up  and  down  regulated  transcripts.  To  identify 
differential expression unique to each T cell population, the population in 
question was treated as ‘condition 1’ and all other populations treated as 
‘condition 2’. To interrogate Treg or Tresp as a whole population, rather 
than individual naïve and memory subpopulations, naïve Treg and memory 
Treg were grouped as ‘condition 1’ and compared with naïve Tresp and 
memory Tresp as ‘condition 2’.  RankProdIt calculates the ‘rank product’ 
for each gene being upregulated in an array and its combined probability of   114 
upregulation over replicate arrays, as shown in Equation 2.1. 
Equation 2.1: Calculation of rank product 
RP: Rank product; g: gene; up: upregulated; k: number of replicates; i: replicate; r: rank; n: 
number of genes; Π = cumulative product. 
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Rank sums were calculated similarly (Equation 2.2): 
Equation 2.2: Calculation of rank sum 
RS: Rank sum; g: gene; up: upregulated; k: number of replicates; i: replicate; r: rank; n: 
number of genes; Σ = cumulative sum. 
!" !
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!!!
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Rank  products  and  sums  for  downregulated  genes  were  similarly 
calculated. Genes were sorted by pfp value (proportion of false positives, 
analogous to a false discovery rate), a lower pfp value corresponding to 
greater statistical significance. A cut-off pfp value of 0.05 was taken. 
2.5.5  Identification of non-coding transcripts 
Non-coding  transcripts  were  identified  using  publically  available  gene 
annotations  accessed  through  the  UCSC  Genome  Browser  [482]. 
Evidence  came  from  several  international  consortia.  Details  of  their 
annotation process and curation are detailed in Table 2.6. 
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Table 2.6: Evidence for gene predictions and non-coding annotations 
These tracks are publically available from the UCSC genome browser. 
UCSC Genes 
Gene predictions are based on RefSeq (see below), Genbank [483], CCDS [484], UniProt [485] and Rfam [486]. The 
Kozak consensus sequence (start-codon) and orthologous predicted proteins from other species are used as evidence 
of protein-coding capacity. It also considers nonsense-mediated-decay and start-codons in any frame upstream of the 
predicted start codon as evidence of lack of coding potential. [487]. 
 
ENCODE/GENCODE v12 
The GENCODE project aims to annotate with high accuracy based on computational, manual and experimental 
approaches.  Manual annotations (HAVANA) are merged with automated annotations (Ensembl) with priority being 
given to the former. Non-coding transcripts are characterised as ‘antisense’, ‘lincRNA’, ‘miRNA’, ‘mT_rRNA’, 
‘mT_tRNA’, ‘rRNA’, ‘snoRNA’ or ‘snRNA’ if well characterised or ‘non_coding’, ‘processed transcript’, ‘retrotransposed’ 
or ‘misc_RNA’ if poorly characterised. Annotations do not include MHC and immunoglobulin genes or single-exon 
genes. Annotations are categorised 1 to 5 (1 having the best support) or ‘not analysed’. Confidence of annotation is 
based on mRNA and EST alignments from UCSC (see above) and Ensembl (see below). Support is also gained from 
the International Nucleotide Sequence Database Collaboration (GenBank, EMBL, DDBJ). Suspected erroneous 
transcripts, as identified by Ensembl, UCSC, HAVANA and RefSeq are flagged [488, 489]. 
 
NCBI RNA Reference Sequence Collection (RefSeq) 
Comprehensive gene annotations are based on GenBank, NCBI computational analysis, user feedback and manual 
curation. Uncurated annotations are supported by WGS, inference by genome sequence analysis eg. Homology, 
computational predictions and protein homology support. Curated annotations have functional descriptive information 
added [490-492]. 
 
Vertebrate Genome Annotation (Vega) database 
Long ncRNA (lncRNA) are defined as annotated genes with no ORF. These are subdivided: lncRNA non-coding: gene 
is known from published literature to not code for a protein; lncRNA 3prime_overlapping_ncrna: ditag and/or published 
experimental data supports the existence of short non-coding transcripts. lncRNA ambiguous ORF: transcripts are 
believed to be protein coding (take this into account in judging annotation evidence!!) with more than one possible ORF. 
lncRNA antisense: gene overlaps a coding exon on the opposite DNA strand or is known in the literature to regulate an 
antisense coding gene. lncRNA long interspersed ncRNA (lincRNA): Gene is intergenic to protein coding genes and is 
>200bp. lncRNA ncRNA_host: Gene has a separate transcript that hosts other ncRNAs such as microRNAs. lncRNA 
retained_intron: gene has alternatively spliced transcripts that contain intronic sequence relative to other coding 
transcripts. lncRNA sense_intronic: Gene has a long non-coding transcript in introns of a coding gene, which does not 
overlap coding exons. lncRNA sense_overlapping: On the same strand as a coding transcript that resides within an 
intron of the non-coding transcript. lncRNA processed_transcript: Doesn’t contain an ORF but is miscellaneous to other 
lncRNA biotypes [493]. 
 
Ensembl Gene Predictions – Ensembl 68 
Includes automatic and manual curation (by HAVANA) of confirmed and predicted non-coding and protein coding 
genes. LincRNA annotation is supported by presence of H3K4me3-K36me3 domains, limited ORF (<35%), lack of 
protein domain evidence (PFAM, InterPro) [494, 495]. 
 
lincRNA and Transcripts of Uncertain Coding Potential (TUCP) 
Includes de novo annotations not covered by RefSeq, UCSC and GENCODE identified by RNA-Seq of 24 human cell 
subsets. Annotations have been filtered to remove transcripts with any evidence of protein domain or coding potential 
and non-lincRNA annotations. Transcripts of lower confidence are termed ‘TUCPs’ (Transcripts of uncertain coding 
potential) [496]. 
 
C/D and H/ACA Box SnoRNAs, ScaRNAs and MicroRNAs Identified with SnoRNABase and MiRBase 
Covers annotations of pre-miRNA from miRBase [497] and snRNA and scaRNA from snoRNABase [498]. Presence of 
C/D and H/ACA are sequences indicating rRNA and snRNA modification activity. 
 
Human expressed sequence tags (ESTs), spliced and unspliced 
ESTs from Genbank ® [483]. Spliced ESTs have evidence of at least one intron of 32bp to 750kb and GT/AG ends. 
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A scoring system was developed to assess the priority of each transcript 
for future analysis Table 2.7. 
Table 2.7: Scoring system for transcript prioritization 
Score  Criteria  Outcome 
0  At least one exonic protein-coding, miRNA, snRNA rRNA or tRNA annotation  Transcript dismissed 
1  No annotation and no EST evidence or unspliced ESTs only 
2  No annotation and evidence of spliced EST  Transcript considered 
for future analysis 
3  Annotated as non-coding by at least one consortia but with low confidence 
3  Annotated as non-coding by more than one consortia and with high 
confidence 
Transcript retained for 
future analysis 
5  Annotated as long ncRNA by all consortia with high confidence 
6  Annotated as long ncRNA by all consortia, with high confidence and has some 
background literature 
Transcript prioritised 
for future analysis 
 
2.5.6  Gene ontology 
Gene ontology was performed using DAVID GO [499, 500] using Agilent 
Oligo  IDs  as  identifiers.  Unless  otherwise  specified,  the  background 
reference was all probes on the array.   
2.5.7  Identification of disease associations with non-coding 
genes of interest 
Information on published disease associations was taken from publically 
accessible databases: Genetic Association Studies of Complex Diseases 
and Disorders (GAD, [501], OMIM [502], ClinVar [503], the International 
Standards for Cytogenomic Arrays Consortium (ISCA, [504], the Catalogue 
Of  Somatic  Mutations  In  Cancer  (COSMIC,  [505],  the  Rat  Genome 
Database (RGD, [506]), Human Gene Mutation Database Public Variants 
[507], Gene reviews [508], NHGRI catalog of published GWAS [509], and 
publications. These databases encompassed dbSNP entries.  
2.5.8  Identification of transcription factors 
Genes encoding transcription factors were identified by comparison with 
the  most  recently  published  peer-reviewed  catalogue  of  human   117 
transcription  factors  [510].  This  catalogue  is  based  on  evidence  for 
sequence  specific  DNA  binding  activity,  excluding  basal  transcription 
factors that form the core transcriptional machinery. This evidence includes 
the presence of a known DNA binding domain and published experimental 
evidence  for  high  confidence  entries.  Lower  confidence  transcription 
factors,  for  which  no  functional  evidence  exists  for  their  activity,  were 
included  due  to  the  presence  of  domains  never  observed  in  proteins 
without transcription factor activity. 
2.5.9  RNA-Seq analysis 
Sequencing  data  was  received  in  FASTQ  format.  Adaptors  and  PCR 
duplicates  were  removed  and  paired-end  unique  reads  above  20bp  in 
length were aligned to reference genome hg19 with TopHat2 using default 
parameters  (performed  by  John  Ambrose).  Bam  and  bigwig  files  were 
created with Samtools [511] and Bamtools [512].Cuffdiff2 [513] was used 
for  differential  expression  analysis  (John  Ambrose,  Alessandro 
Riccombeni). Read coverages were calculated using ngsplot and feature 
count  (Bamtools,  [512].  For  statistical  comparisons  of  RPKM  the 
Kolmogorov-Smirnov  Test  was  used  [514].  This  is  non-parametric  and 
distribution  free.  Data  visualisation  was  performed  in  UCSC  Genome 
Browser [482] and Microsoft Excel ®. 
2.5.10 ChIP-Seq analysis 
Sequencing  data  was  analysed  by  Aditi  Kanhere,  Richard  Jenner, 
Alessandro  Riccombeni.  Peak  calling  was  performed  with  MACS 
(Parameters?)  (Richard  Jenner,  [515]).  T-bet  stitched  enhancers  and 
super-enhancers were defined by Richard Jenner using the Rank Ordering   118 
of  Super-enhancers  (ROSE)  algorithm  [320,  321].  Briefly,  the  ROSE 
algorithm  scans  12kb  windows  across  the  genome,  stitching  together 
transcription  factor  peaks  within  these  windows  as  a  single  enhancer. 
Enhancers are then ranked by RPKM of transcription factor reads. The cut-
off for super-enhancer versus enhancer is taken at the point of inflection 
with  normal  enhancers  having  a  linear  relationship  between  rank  and 
RPKM  and  super-enhancers  having  an  exponential  relationship. 
Enhancers  within  2kb  of  a  transcription  start  site  are  removed  from 
analysis. H3K4me3 ChIP-Seq data were provided by Paul Lavender and 
P-TEFb and RNAPII ChIP-Seq experiments were performed by Richard 
Jenner and Arnulf Hertweck. 
2.5.11 Publically available genomic data used in this work 
Publically available genomic data used in this work is catalogued in Table 
2.8. Quality and fidelity of data was assessed with FastQC [516]. 
Table 2.8: Publically available genomic data used in this work 
Publically available RNA-Seq and ChIP-Seq data was used in some analyses presented 
here. These can be identified using the accession numbers provided here. WCE: Whole 
Cell Extract. 
Species  Cells  Data  Accession numbers and 
references 
Human 
 
 
 
Treg  Ex vivo 
CD4+CD25+CD127- 
ChIP-Seq  H3K4me3  GSM772944 
H3K4me1  GSM772973 
H3K27me3  GSM772946 
H3K9me3  GSM772943 
H3K36me3  GSM772945 
WCE  GSM772914 
Activated (CD3/28) 
CD4+CD25+ 
FOXP3  SRX060160 [517] 
RNA-Seq  PolyA+  SRX060156 [517] 
Ex vivo CD4+CD25+  SRX060154 [517] 
Tresp  Ex vivo CD4+CD25-  ChIP-Seq  H3K4me3  GSM772867 
H3K4me1  GSM772849 
H3K27me3  GSM772868 
H3K9me3  GSM772850 
H3K36me3  GSM772866 
WCE  GSM772915 
Activated (CD3/28) 
CD4+CD25- 
FOXP3  SRX060163 [517] 
RNA-Seq  PolyA+  SRX060159 [517] 
Ex vivo CD4+CD25-  SRX060158 [517] 
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3  Identification  and  characterization  of  ncRNAs 
upregulated in Treg   
3.1  Introduction 
3.1.1  T cell lineage plasticity 
CD4 T cell lineages play specialised roles within the immune system with 
Th1 versus Th2 phenotypes, which are tailored towards type I and type II 
infections,  respectively,  epitomising  this.  While  there  are  distinct 
characteristics to each lineage (Section 1.1), for example the production of 
lineage-specific  cytokines,  there  is  inherent  flexibility.  This  plasticity  is 
shown  through  the  co-expression  of  lineage-specifying  transcription 
factors, which were once thought of as master regulators (Section 1.2.1), 
and  the  bivalent  presence  of  permissive  and  repressive  histone 
modifications at lineage-specific genes, which allows repressed genes to 
be maintained in a poised-to-be-active state (Section 1.2.3). This plasticity 
has functional relevance in facilitating the immune response to a changing 
environment but there are deleterious consequences when lineage choice 
becomes dysregulated. In the systemic autoimmune disease SLE there is 
some evidence of Treg abnormalities, particularly when naïve and memory 
subsets,  defined  by  differential  expression  of  CD45RA,  are  observed. 
These defects could relate to disease aetiology or could be the result of 
the  disease  environment.  Understanding  the  perturbation  of  Treg 
phenotype in SLE at a transcriptional level will inform models of Treg and T 
cell plasticity and may give insight into disease pathogenesis. 
3.1.2  ncRNAs show lineage-specific expression 
Multiple classes of ncRNAs have been reported to exhibit cell type specific 
expression (Section 1.3.2). Several mechanisms have been suggested for   120 
how these ncRNAs may influence cell identity (Section 1.3.3) including the 
possibility that they may influence the expression of other lineage-specific 
genes  at  the  level  of  transcription  through  the  recruitment  of  chromatin 
modifying complexes. The functional importance of several ncRNAs has 
been  demonstrated.  However,  to  date  no  non-coding  RNAs  have  been 
characterised in Treg. 
3.1.3  Aims 
1.  Define a specific set of lincRNAs upregulated in Treg compared to 
Tresp. 
2.  Characterise these Treg-specific lincRNAs. 
3.  Examine differential expression of mRNAs and incRNAs between 
healthy individuals and SLE patients. 
4.  Identify  differences  in  gene  expression  and  histone  modification 
between naïve and memory subsets of Treg and between SLE patients 
and healthy controls.      121 
3.2  Results 
3.2.1  Identification  of  differentially  expressed  transcripts 
between Treg and Tresp 
I  began  investigating  the  transcriptional  differences  between  Treg  and 
Tresp  by  examining  gene  expression  differences  between  these 
populations, focusing on naïve and memory subsets as these have been 
demonstrated to exhibit differing phenotypes with Treg, which are not fully 
understood.  To  achieve  this,  naïve  and  memory  Treg  and  Tresp  were 
isolated as described in Sections 2.2.1 to 2.2.6 with donors ranging in age 
from 23 to 54 years (median: 30; standard deviation: 12) and being female. 
RNA was prepared according to Sections 2.3.1 to 2.3.3 and microarrays 
performed as per Section 2.3.5.. Array data were extracted and normalised 
as  per  Section  2.5.1.  To  gain  an  overview  of  the  data  I  performed 
hierarchical clustering and visualised correlations in gene expression using 
Treeview,  as  described  in  Section  2.5.2.  This  showed  trends  in  gene 
expression seen in previously published research (Figure 3.1), including 
expression  of  the  genes  associated  with  Treg  function  such  as  those 
encoding for the lineage-specifying transcription factor, FOXP3 [37-39], the 
IL-2  cell  surface  receptor,  IL2RA  (CD25)  [33],  the  CTLA4  cell  surface 
receptor,  which  is  constitutively  expressed  on  Treg  and  mediates 
suppressive  function  [518]  and  the  transcription  factor,  IKZF2  (Helios) 
which has been identified as being upregulated in Treg but whose function 
is not yet well understood [93]. The gene for the cell adhesion molecule 
PECAM1  (CD31),  which  is  known  to  be  expressed  upon  recent  thymic 
emigrants [519], was upregulated in naïve cells compared to memory for 
both  Treg  and  Tresp,  as  expected.  Published  data  on  differential   122 
expression of AHR and RORC between naïve and memory Treg [96] were 
also  recapitulated.  These  reflections  of  previously  published  data  gave 
confidence that this microarray data can be used to  detect changes in 
gene  expression  relevant  to  Treg  biology.  To  identify  genes  with 
statistically different expression between Treg and Tresp and naïve and 
memory  subsets  I  used  rank  product  analysis  as  described  in  Section 
2.5.4.  Figure  3.2  illustrates  the  numbers  of  significantly  up-  and 
downregulated  genes  unique  to  each  population.  The  identity  of  these 
transcripts is detailed in Section 7.1 of the appendix. Figure 3.2.A shows 
that 527 transcripts in total were differentially regulated between all Treg 
and all Tresp with 320 (61%) being upregulated in Treg. Fewer differences 
in gene expression were identified between naive and memory subsets of 
Treg  and  Tresp  (Figure  3.2.B).  For  naïve  Treg  no  transcripts  were 
identified as uniquely downregulated, for naïve Tresp only 2 were identified 
as  upregulated  and  for  Tresp  memory,  6  (2%)  were  identified  as 
downregulated. More transcripts were uniquely upregulated in naïve Treg 
than to naïve Tresp (70 versus 2, respectively). This could reflect a more 
specialised role for naïve Treg, which exit the thymus as a distinct lineage, 
than  naïve  Tresp,  which  are  undifferentiated  and  may  be  relatively 
transcriptionally inactive. 
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Figure 3.1: Gene expression patterns reflect published literature. 
Correlations in gene expression between naïve and memory subsets of Treg and Tresp 
from healthy individuals were examined. These patterns are visualised here as a heatmap 
with reference to genes that demonstrated previously published gene expression trends. 
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Figure 3.2: Numbers of differentially expressed transcripts from CD4 T cell 
populations from healthy individuals 
Transcripts with statistically significant differential expression were identified by Ranksum. 
A: Comparison of all Treg compared to all Tresp. B: Transcripts uniquely differentially 
regulated  in  each  naïve  and  memory  subset.  The  percentage  of  the  total  number  of 
differentially expressed transcripts is given while bracketed numbers indicate the absolute 
number of transcripts.  
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3.2.2  Identification  and  validation  of  non-coding  RNAs 
upregulated in Treg 
The  process  of  distinguishing  non-coding  from  coding  transcripts  relied 
upon  publically  available  gene  annotation  evidence,  as  described  in 
Section 2.5.5. Of the 320 transcripts upregulated in Treg, 22 (6.9%) were 
categorised  as  non-coding.  This  proportion  does  not  represent  relative 
biological  ratios  of  protein  coding  to  non-coding  transcripts  but  instead 
reflects  array  design  bias  and  the  stringency  of  non-coding 
characterisation,  as  described  in  Section  2.5.5.  The  identities  of  these 
transcripts  are  given  in  Table  7.25  of  the  appendix  and  their  relative 
expression levels are illustrated in Figure 3.3.  
 
I next sought to validate the differential expression of these ncRNAs in an 
independent set of donors. Of these non-coding transcripts upregulated in 
Treg compared to Tresp, differential expression of 7 (29%) was validated 
by qPCR in three additional donors (Figure 3.4): MIR146A (fold difference: 
21.8; p=0.177), CRNDE (fold difference: 7.2; p=0.0178), LINC00312 (fold 
difference:  20.8;  p=0.0183),  PTTG3P  (fold  difference:  2.12;  p=0.006), 
LOC286442  (fold  difference:  7.0;  p=0.011),  ENST00000444919  (fold 
difference:  1.4;  p=0.0508),  ENST00000415387  (fold  difference:  43.8; 
p=0.0137). The array probe and qPCR primers detect the pri-miRNA form 
of miR146a, which has been previously identified as upregulated in Treg 
before [520] and has functional relevance for Treg biology [521]. Published 
work on miR-146a in Treg has been limited to differential expression of the 
mature form of the miRNA, so detection of the pre-processed form shown 
here  indicates  that  miR-146a  expression  is  regulated  prior  to  activity  of   126 
miRNA processing machinery such as Dicer and Drosha. In addition, the 
ability to identify a Treg relevant miRNA supported the approach used here 
for finding additional ncRNAs.      127 
 
Figure 3.3: Heatmap illustrating statistically significant upregulation of ncRNAs in 
Treg compared to Tresp 
Twenty-two Treg upregulated transcripts were identified as ncRNAs. They are shown here 
in order of fold difference between Treg and Tresp. The predicted false positive rate (PFP, 
analogous  to  a  false  discovery  rate)  is  also  given  to  demonstrate  the  statistical 
significance  of  their  differential  expression.  The  genes  FOXP3  and  CD25,  which  are 
known  to  be  upregulated  in  Treg,  are  given  as  a  comparison,  as  is  CD127,  which  is 
downregulated in Treg,  
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Figure 3.4: QPCR validation of ncRNA expression 
Quantitative PCR in additional donors to those used to obtain microarray data. A: FOXP3 
(left), is known to be upregulated in Treg compared to Tresp while the housekeeping gene 
5S ribosomal RNA (right) should be similarly expressed between the two populations. B: 
Treg upregulated ncRNAs identified by array that were validated by qPCR. N=3; Error 
bars represent SEM, one-tailed t-test.   
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3.2.3  Histone modifications at Treg ncRNA genes 
To further validate the expression data, differential histone modifications 
between Treg and Tresp were examined using publically available ChIP-
Seq data detailed in Section 2.5.11. The presence of H3K4me3 (a mark of 
transcriptional  initiation)  at  the  TSS  and  H3K36me3  (transcriptional 
elongation) across the gene body would support the upregulation of these 
ncRNAs  at  the  transcriptional  level.  The  presence  of  H3K4me3  at  an 
ncRNA  TSS  supports  the  assumption  that  the  ncRNA  derives  from  an 
independent  gene  rather  than  being  a  product  of  RNAPII  read  through 
from a neighbouring gene. 
 
The relative enrichment of these histone modifications between Treg and 
Tresp supports the regulation of these genes at the level of transcriptional, 
rather  than  through  post-transcriptional  mechanisms,  such  as  targeted 
RNA degradation, and can also be used to determine if this regulation is 
independent  of  neighbouring  genes  or  is  a  by-product  and  possibly 
‘transcriptional noise’.  
 
Figure 3.5 shows the enrichment of each of these histone modifications at 
the  ncRNA  genes  in  primary  human  Treg  and  Tresp.  As  expected,  the 
Treg  upregulated  gene  FOXP3  shows  enrichment  of  H3K4me3  and 
H3K36me3  in  Treg  while  IL2,  which  is  not  expressed  in  Treg,  shows 
greater  enrichment  of  H3K4me3  in  Tresp  and  the  housekeeping  gene 
ACTB shows no cell type specific enrichment of either modification. Of the 
Treg upregulated ncRNAs, LOC286442 and MIR146A both show greater 
enrichment  of  H3K4me3  and  H3K36me3  in  Treg.  These  were  also  the 
most overexpressed Treg ncRNAs in the microarray data (Figure 3.3). All   130 
other Treg ncRNAs do not show obvious differential enrichment between 
Treg and Tresp but CRNDE is marked with H3K4me3 in both cell types, as 
is ENST00000444919. Several ncRNA genes do not appear, by histone 
modifications,  to  be  transcribed  independently  of  their  neighbouring 
genomic  genes.  For  example,  LINC00312  has  greater  H3K36me3 
enrichment in Treg but this may be due to regulation of the upstream gene 
LMCD1,  which  is  supported  by  the  lack  of  H3K4me3  at  LINC00312. 
Likewise,  the  slight  increase  in  H3K36me3  over  ENST00000415387  in 
Treg over Tresp and the lack of H3K4me3 may reflect expression of the 
upstream  gene  IKZF2  (Helios),  which  has  a  known  Treg  specific 
expression pattern. In addition, the ENST00000415387 gene overlaps with 
IKZF2 and so transcription from this region may be due to ‘read-through’ of 
IKZF2 rather than active regulation of  ENST00000415387. 
 
The  presence  of  monomethylated  of  H3K4  (H3K4me1)  has  been 
associated with poised and active enhancer regions [289, 344, 356] where 
it is enriched relative to H3K4me3. While both marks are often found at the 
TSS of protein coding genes and reflect how these genes are regulated, a 
variation  in  pattern  is  suggestive  of  regions  with  enhancer  activity.  In 
addition, enhancer regions have been shown to produce ncRNA, which 
may  play  a  role  in  functional  effects  on  the  transcriptional  regulation  of 
other  genes.  Therefore  examining  the  presence  of  H3K4me1  at  the 
genomic loci of Treg ncRNA can inform their potential role in transcriptional 
regulation as enhancer RNAs. As  
 
Figure  3.5  illustrates,  the  FOXP3  gene  shows  prominent  enrichment  of 
H3K4me3 at the TSS while H3K4me1 is minimal in comparison. MIR146A   131 
shows  a  similar  pattern  as  does  CRNDE,  which  suggests  these  are 
regulated  in  a  similar  way  to  protein  coding  genes  as  is  expected  for 
lincRNAs  and  pri-miRNAs.  PTTG3P  however  shows  little  enrichment  of 
neither  H3K4me3  nor  H3K4me1.  ENST00000444919  has  greater 
enrichment of H3K4me3 compared to H3K4me1 at its TSS and in addition 
has shows some H3K4me1 at its gene body, as does ENST00000415387 
however this could relate to the presence of their overlapping neighbouring 
genes,  ITGA6  and  IKZF2,  respectively.  H3K4me1  is  also  seen  along 
LOC286442, which is not overlapped by an annotated gene. LINC00312 is 
most ‘enhancer-like’ showing poor enrichment of H3K4me3 but enrichment 
of  H3K4me1  nearby.  In  addition,  LINC00312  is  monogenic,  which  is  a 
feature of enhancer RNAs.   132 
Figure 3.5: Histone modifications at ncRNA genes upregulated in Treg  
(Continued to page 134) The relative enrichment of histone modifications associated with transcriptional initiation (H3K4me3) and elongation 
(H3K36me3) and enhancer regions (H3K4me1) at Treg ncRNA genes in Treg and Tresp. WCE represents the background total DNA. FOXP3 and 
IL2 genes are given as examples of genes known to be upregulated in Treg and Tresp, respectively, while the housekeeping ACTB is present at 
similar levels in both cell types. H3K4me3: Trimethylation of lysine 4 on histone 3; H3K36me3: Trimethylation of lysine 36 on histone 3; H3K4me1: 
Monomethylation of lysine 4 on histone 3; WCE: Whole cell extract. 
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Figure 3.5: Histone modifications at ncRNA genes upregulated in Treg  
(Page  132-134)  The  relative  enrichment  of  histone  modifications  associated  with  transcriptional  initiation  (H3K4me3)  and  elongation  (H3K36me3)  and 
enhancer regions (H3K4me1) at Treg ncRNA genes in Treg and Tresp. WCE represents the background total DNA. FOXP3 and IL2 genes are given as 
examples of genes known to be upregulated in Treg and Tresp, respectively, while the housekeeping ACTB is present at similar levels in both cell types. 
H3K4me3: Trimethylation of lysine 4 on histone 3; H3K36me3: Trimethylation of lysine 36 on histone 3; H3K4me1: Monomethylation of lysine 4 on histone 3; 
WCE: Whole cell extract. 
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Figure 3.5: Histone modifications at ncRNA genes upregulated in Treg 
(Continued from page 132) The relative enrichment of histone modifications associated with transcriptional initiation (H3K4me3) and elongation (H3K36me3) 
and enhancer regions (H3K4me1) at Treg ncRNA genes in Treg and Tresp. WCE represents the background total DNA. FOXP3 and IL2 genes are given as 
examples of genes known to be upregulated in Treg and Tresp, respectively, while the housekeeping ACTB is present at similar levels in both cell types. 
H3K4me3: Trimethylation of lysine 4 on histone 3; H3K36me3: Trimethylation of lysine 36 on histone 3; H3K4me1: Monomethylation of lysine 4 on histone 3; 
WCE: Whole cell extract.
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3.2.4  FOXP3 binding at Treg ncRNA genes 
Lineage-specifying  transcription  factors  orchestrate  the  transcriptional 
program of each T cell lineage. The corresponding transcription factor for 
Treg,  FOXP3,  has  been  associated  with  both  up  and  down  regulated 
genes in Treg. For example, it is seen at the IL-2 gene, which encodes a 
major  T  cell  growth  factor  and  is  therefore  not  expressed  by  anti-
inflammatory Treg, and at the FOXP3 gene itself, implying it enforces its 
own expression through positive feedback. FOXP3 has therefore been 
suggested to act as either a repressor or activator, depending on context. 
Using publically available ChIP-Seq data from human Treg (detailed in 
Section  2.5.11),  I  investigated  whether  the  genes  encoding  the  Treg 
upregulated ncRNAs were bound by FOXP3. If so, this would support the 
Treg specific biological relevance of these ncRNAs. As Figure 3.6 shows, 
FOXP3 bound its own gene at the promoter and first intron, as previously 
shown in mouse [258] and the miR-146a gene which has a known role in 
Treg  biology  is  also  bound,  which  has  not  be  published.  Of  the  Treg 
ncRNAs, CRNDE and ENST00000444919 exhibit FOXP3 binding at their 
promoters,  which  they  share  with  other  genes  and  may  indicate  the 
ncRNA genes are not specifically targeted by this FOXP3 recruitment. 
LINC00312  does  not  appear  to  be  bound  by  FOXP3  although  the 
upstream gene LMCD1 is, which supports the possibility that LINC00312 
is transcribed as a byproduct of LMCD1 activation. ENST00000415387, 
also has FOXP3 binding in its 3’ region, which overlaps IKZF2, but this 
binding  also  extends  further  along  the  gene  in  an  intronic  region.  The 
FOXP3 binding seen near PTTG3P this could be targeting the intron of 
the gene antisense to PTTG3P. LOC286442, which is relatively distant to   136 
other annotated genes, has FOXP3 binding at both its promoter and in an 
intronic region.      137 
 
Figure 3.6: FOXP3 binding at Treg ncRNA genes  
FOXP3 occupancy at Treg ncRNA genes. Rep: replicate. ChIP-Seq was obtained from a 
publically available resource detailed in Section 2.5.11.    
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3.2.5  Genomic structure of Treg ncRNA genes 
Being  defined  by  a  lack  of  protein  coding  capacity  in  their  primary 
sequence,  the  identity  and  role  of  ncRNAs  is  underpinned  by  their 
genomic evolution. Understanding the biological function of ncRNAs can 
therefore be informed by knowledge of their genomic structure. Figure 3.7 
illustrates  the  genomic  location  of  each  validated  Treg  ncRNA  and 
displays  intron-exon  structure,  alternative  isoforms  and  repetitive 
elements. 
 
CRNDE is notable for its many (10) alternative isoforms compared to the 
other ncRNAs that have at most 2 (LOC286442) but commonly only one 
isoform.  In  terms  on  intron-exon  structure,  LINC00312  and  PTTG3P 
consist  of  one  exon  without  any  intronic  sequence  while  LOC286442, 
MIR146A,  ENST00000444919  and  ENST00000415387  contain  large 
intronic regions.  
 
Repetitive  elements  are  more  associated  with  non-coding  genes  than 
protein  coding  genes  [404],  possibly  because  their  mechanisms  of 
function are more tolerant to transposon insertion i.e. there are no open 
reading  frames  or  stop  or  start  codons  to  disrupt.  It  has  also  been 
suggested that repeats may contribute to ncRNA function [404] as they 
would allow base pairing for self-annealing, leading to the formation of 
potentially  functional  secondary  structures,  and  annealing  with  other 
ncRNAs.  These  functional  repeat-sequence  domains  are  seen  in 
Kcnq1ot1 [522] and Xist [523]. The repeats seen in CRNDE correspond 
with exonic sequences (Figure 3.7), which would be consistent with them   139 
having a role in the transcribed product. LINC00312 and PTTG3P are 
notable  by  their  lack  of  repeats.  This  is  consistent  with  PTTG3P,  a 
pseudogene,  diverging  from  a  protein-coding  gene  and  might  suggest 
LINC00312  has  a  similar  evolutionary  origin.  The  other  ncRNA  genes 
(LOC286442,  MIR146A,  ENST00000444919  and  ENST00000415387) 
contain several repetitive elements of various classes. The presence of 
repeats  in  lincRNAs  has  been  associated  with  expression  in  other 
contexts,  for  example  human  endogenous  retrovirus  subfamily  H 
(HERVH)  containing  lincRNAs  appear  to  transcribed  in  a  stem  cell 
specific manner [407].      140 
 
Figure 3.7: Genomic identities of ncRNA genes upregulated in Treg 
The  genomic  structure,  location  and  repetitive  character  of  each  Treg  ncRNA  gene. 
Ensembl annotations are shown here, as these were most comprehensive. Alternative 
isoforms are shown as well as any intronic, same strand transcripts annotated as other 
genes. For simplicity, antisense annotations have been removed from the view. SINE: 
short interspersed nuclear elements; LINES: long interspersed nuclear elements; LTR: 
long terminal repeats.   
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3.2.6  Correlations  between  Treg  ncRNA  expression  and 
genomic neighbours 
Several  mechanisms  have  been  suggested  for  how  ncRNAs  may 
influence  cell  phenotype.  This  includes  at  the  level  of  transcriptional 
regulation of other genes with known biological functions. This influence 
of ncRNAs in transcriptional regulation has been seen in cis at genes 
encoded  in  close  proximity  to  ncRNA  genes  (Section  1.3.3.1,  [403]). 
Therefore  Treg  ncRNAs  encoded  near  genes  with  known  biological 
functions  in  Treg,  T  cells  or  with  relevant  biological  processes  are  of 
particular  interest.  I  examined  the  nearest  gene  annotations  upstream 
and  downstream  of  each  validated  ncRNA  genes  (Figure  3.8).  Their 
orientation relative to the ncRNA gene was also noted as this impacts on 
the  mechanism  of  cis-regulatory  ncRNAs  (Section  1.3.3.1).  I  also 
correlated  the  expression  of  each  ncRNA  and  its  neighbouring  genes 
(Figure 3.9).  
 
CRNDE is encoded 2kb from the TSS of IRX5 in a divergent antisense 
orientation (Figure 3.8). This orientation suggests that the two genes may 
share promoters or other regulatory regions and published research on 
promoter  characteristics  in  this  area,  which  includes  a  CpG  island, 
supports this [524]. Concordant expression between the two genes has 
been previously noted [525, 526] although expression of CRNDE without 
IRX5 has also been seen [526]. IRX5 encodes an Iroquois homeobox 
transcription factor with roles in development of several tissues [527, 528] 
however  there  is  no  literature  relating  to  the  role  of  IRX5  in  T  cells. 
Examining CRNDE and IRX5 across naïve and memory Treg and Tresp   142 
shows a relatively poor correlation in expression between the two genes 
(Pearson  correlation  coefficient:  0.49;  Figure  3.9).  The  nearest  gene 
encoded  downstream  of  CRNDE  is  another  ncRNA  (RP11-1136G4.1). 
The  product  of  this  gene  is  poorly  characterised  and  so  correlation  in 
expression would not inform the function of CRNDE. Co-expression data 
is also limited as no probes to this gene were incorporated into the array 
design.  
 
LINC00312 is overlapped by another ncRNA gene, AC034187.2, which is 
poorly characterised and is not included in the array data. Also nearby 
are LMCD1 and another ncRNA that is antisense to LMCD1, LMCD1-
AS1. LINC00312 shows a relatively strong correlation in expression with 
LMCD1 (Pearson correlation coefficient of 0.69, Figure 3.9) and both are 
preferentially upregulated in memory Treg above other subsets (Figure 
3.9). No published data could be found on the LMCD1 (LIM and Cysteine 
rich  domains  1)  protein  in  T  cells  but  in  cardiac  myocytes  LMCD1 
expression  correlates  with  increased  activity  of  calcineurin  and  NFAT 
[529],  two  signaling  proteins  that  are  relevant  to  T  cell  activation 
downstream of TCR signalling. 
 
PTTG3P  is  antisense  to  SGK3  (serum/glucocorticoid  regulated  kinase 
family,  member  3),  which  is  associated  with  non-T  cell  specific  cell 
metabolism, proliferation and survival [530]. VCPIP1 (valosin containing 
protein  complex  interacting  protein  1)  is  located  100kb  downstream  of 
PTTG3P  on  the  same  strand  and  although  abnormal  CpG  island 
methylation has apparently been seen in breast cancer [531] its biological   143 
function is not well understood. MCMDC2 (minichromosome maintenance 
domain containing 2) is encoded ~100kb upstream on the same strand as 
PTTG3P and again its function is poorly characterised and no probes for 
this  gene  are  found  on  the  array.  Correlations  in  expression  between 
PTTG3P  and  both  SGK3  and  VCPIP1  are  weak  (-0.33  and  0.34, 
respectively, Figure 3.9).  
 
The gene encoding LOC286442 is located in a large region (hundreds of 
kbs)  with  no  protein  coding  genes.  As  Figure  3.8  shows,  there  are 
however  non-coding  genes  relatively  nearby  but  the  role  of  these  is 
unknown and probes for these are not present on the arrays. 
 
MIR146A  shows  a  relatively  strong  co-expression  (Pearson  correlation 
coefficient of 0.78, Figure 3.9) with PTTG1 (pituitary tumor-transforming 
1) that is oncogenic in several cellular contexts, including in T cells [532]. 
PTTG1 is encoded upstream of MIR146A on the same strand. PTTG1 
might  also  be  implicated  in  T  cells  by  its  association  with  the  Treg 
inducing cytokine TGF-β [533,], which has been observed in the context 
of  breast  cancer.  ATP10B  (ATPase,  class  V,  type  10B)  is  encoded 
downstream of miR-146a but expression between the two is not strongly 
correlated and the role of this protein is not well understood. 
 
ENST00000415387 is encoded near several other ncRNAs (Figure 3.8) 
but probes to these are not available on the array. Data on the protein 
coding genes ERBB4 and IKZF2 are available and of these the latter is 
strongly correlated with ENST00000415387 (correlation coefficient: 0.73).   144 
IKZF2 encodes the Treg specific transcription factor, Helios [93]. Helios 
has  been  suggested  to  distinguish  nTregs  from  iTregs  [89],  but  this 
assertion is controversial and the contribution of Helios to Treg function is 
still not understood. The relative orientation of the two genes, with the 5’ 
end of ENST00000415387 overlapping the 3’ end of IKZF2, (Figure 3.8), 
is consistent with transcription read through from IKZF2.  
 
Finally, ENST00000444919 and PDK1 are in an divergent orientation with 
their theoretical promoter regions occupying the same region (Figure 3.8), 
which would indicate their expression may be positively correlated. Unlike 
CRNDE  and  IRX5,  which  are  in  a  similar  orientation  (see  above), 
ENST00000444919 and PDK1 (pyruvate dehydrogenase kinase, isozyme 
1), the mitochondrial enzyme that catalyses oxidative decarboxylation of 
pyruvate  to  acetyl  coenzyme-A  for  entry  into  the  Krebs  cycle,  are  not 
strongly  correlated  (Pearson  correlation  coefficient:  0.49,  Figure  3.9). 
ITGA6,  an  integrin  that  is  expressed  on  T  cells  [534],  is  also  on  the 
opposite  strand  to  ENST00000444919  but  in  a  convergent  orientation 
(Figure  3.8)  and  also  does  not  show  a  correlated  expression  pattern 
(Figure 3.9).      145 
 
Figure 3.8: Genomic relationships of Treg ncRNA to other genes 
The orientations of Treg ncRNA genes relative to neighbouring genes. Numbers indicate 
the distance (kb) between genes. A negative number indicates an overlap of genes. 
Black: ncRNAs; Blue: protein coding genes; Yellow: miRNAs; Green: other ncRNAs.    
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Figure 3.9: Correlation in expression of Treg ncRNA and genomic neighbours 
Correlations in expression patterns between Treg ncRNAs and their neighbouring genes 
identified in Figure 3.8. Only neighbouring genes for which there were array probes are 
shown.  Genes  detected  by  several  microarray  probes  have  data  for  each  probe 
presented separately. Co-expression was assessed by Pearson correlation coefficient 
with  a  cut-off  for  strong  positive  correlation  taken  at  0.7  and  for  a  strong  negative 
correlation  at  -0.7.  The  correlation  between  FOXP3  and  IL2RA  (CD25)  is  shown  as 
positive control...   
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3.2.7  Disease associations of ncRNA loci 
Association of genomic variants in ncRNA loci with disease may reveal 
roles  for  these  ncRNA  in  the  biological  processes  underpinning  these 
diseases. Although sequence variation in ncRNA does not have the same 
functional consequences as its does in protein coding genes, many trait 
associated variants lie outside of protein-coding regions [509], supporting 
the biological relevance of non-coding regions. At the DNA level, these 
non-coding  regions  may  represent  regulatory  elements,  such  as 
enhancers and promoters, the mutation of which could influence disease 
through disrupted binding of regulatory proteins with deleterious effects 
on gene expression. At the RNA level, variation in non-coding regions 
may influence the activity of enhancers, which may mediate their long-
range effects through RNA. In lincRNAs, these sequence variations could 
be  deleterious  through  effects  on  the  formation  of  RNA  secondary 
structures and on the binding of proteins whose activity they influence. I 
used publically available data on the association of several classes of 
sequence variation with disease (Section 2.5.7) to inform the biological 
activity of these Treg ncRNAs. Accession numbers for relevant variants 
found and details on their disease associations are given in Table 3.1. 
 
As  Table  3.1  shows,  every  Treg  ncRNA  locus  included  an  annotated 
disease-associated  variation.  The  majority  of  these  were  copy  number 
variations (CNVs, denoted by the ‘nsv-’ prefix to the accession number in 
Table 3.1) and several quantitative trait loci (QTLs) were also identified 
(‘RGD-’  prefix).  All  copy  number  variations  and  QTLs  extended  for 
several Mbp and included multiple gene annotations. As these disease   148 
associations are not gene specific it is not likely that these ncRNA are 
involved in the processes underlying these diseases and therefore these 
categories of variants are not particularly informative of ncRNA function. 
In  addition,  these  CNVs  and  QTLs  are  associated  with  non-specific 
descriptions  of  traits  such  as  ‘Developmental  delay  and/or  other 
significant  developmental  or  morphological  phenotypes’.  Single 
nucleotide polymorphisms (SNPs, denoted by the ‘rs-‘ prefix in Table 3.1) 
however only span a single nucleotide, as the phrase implies, and so are 
localised to the ncRNA gene of interest. SNPS were seen in two Treg 
ncRNA  genes:  MIR146A  and  ENST00000415387.  The  MIR146A 
genomic sequence contains six SNPs in total, which are associated with 
several  cancers  and  the  autoimmune  disease  systemic  lupus 
erythematosus  (Table  3.1).  Meanwhile,  ENST00000415387  contains  a 
SNP associated with age-related cognitive decline. No disease causing 
(as opposed to disease associated) mutations were found at any of these 
non-coding loci. 
 
Of  the  diseases  associated  with  Treg  ncRNA  loci,  listed  in  Table  3.1, 
those with an immunological basis and potential Treg involvement include 
the autoimmune rheumatoid diseases rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE) and cancer. The relationship between these 
ncRNA loci and these diseases may inform understanding of the activity 
of these ncRNA within Treg. Additional detail on these variants, including 
the statistical significance of disease variation and relevant literature are 
given  in  Table  3.2.  The  QTL  covering  LINC00312  is  significantly 
associated with is one study of familial RA in North American probands   149 
(p=0.0139, [535]). Defects in Treg have been shown to contribute to RA 
pathogenesis  [49,  536].  MIR146A  is  associated  with  several  disease 
related variants including a QTL relating to allergic asthma (P=1.30E-6, 
[537]) and several cancers including prostate (P=0.01, [538]) and thyroid 
(P=7.00E-6,  [539]  cancers.  In  addition  several  SNPs  have  been 
described  in  MIR146A  with  varying  degrees  of  association  with  SLE 
[540]. 
     150 
Table 3.1: Diseases and disorders associated with ncRNA gene loci 
Genomic variants in Treg ncRNA loci that have disease associations. The ‘nsv-’ prefix in 
accession numbers refer to dbVar entries and are copy number variations covering large 
regions of several Mbp. An ‘RGD-’ prefix refers to quantitative trait loci (QTL) from the 
Rat Genome Database. The 'rs-’ prefix relates to single nucleotide polymorphism (SNP) 
entries in dbSNP. More specific details on relevant variants are given in Table 3.2. 
ncRNA  Variant accession numbers  Associated diseases and disorders 
CRNDE  nsv532013  Developmental delay and/or additional 
significant and other morphological 
phenotypes 
LINC00312  nsv530211, nsv529969, 
nsv530239, nsv529645, 
nsv529996, nsv530240, 
nsv529998, nsv530001, 
nsv529957, nsv529958, 
RGD:1298511 
Developmental delay and/or other significant 
developmental or morphological phenotypes, 
rheumatoid arthritis 
PTTG3P  nsv529749, nsv532267, 
nsv532269, nsv532316, 
nsv532317, nsv53291, 
RGD:1331637 
 Seizure, developmental delay and/or other 
significant developmental or morphological 
phenotypes, cleft palate, periauricular pit , 
chronic obstructive pulmonary disease 
LOC286442  nsv532481, nsv529062, 
nsv529062, nsv529317, 
nsv531694, nsv529586, 
nsv531684, RGD:1300008 
Learning difficulties, global developmental 
delay, developmental delay and/or other 
significant developmental or morphological 
phenotypes, decreased liver function, 
delayed speech and language development, 
ventricular septal defect 
MIR146A  rs2910164, rs2961920, 
rs73318382, rs13157399, 
rs57095329, rs6864584 
Several cancers, asthma, systemic lupus 
erythematosus 
ENST00000444919  nsv532791, nsv529744, 
nsv532796, nsv531267, 
RGD:1300023 
Developmental delay and/or other significant 
developmental or morphological phenotypes, 
seizure, global developmental delay, blood 
pressure 
ENST00000415387  nsv531671, nsv531672, 
nsv531673, nsv529667, 
nsv531321, nsv531677, 
rs10497985, RGD:1300023 
Developmental delay and/or other significant 
developmental or morphological phenotypes, 
blood pressure, age-related cognitive decline 
 
 
Table 3.2: Variants with disease associations with Treg relevance at Treg ncRNA 
loci 
Additional details of ncRNA variants associated with Treg implicated diseases. 
Treg ncRNA  Variant  Disease association  P-value  References 
LINC00312  RGD:1298511  Rheumatoid arthritis QTL3 (familial 
rheumatoid arthritis). QTL locus is over 
3Mbp. 
0.0139  [535] 
MIR146A  rs57095329 
 
Systemic lupus erythematosus  2.74E-8  [540] 
rs2961920, 
rs2910164 
Several cancers including prostate and 
thyroid 
0.01; 7.00E-
06 
[538, 539] 
RGD:1331665  Allergic/atopic asthma related QTL 2  0.0000013  [537] 
 
.     151 
3.2.8  Differential  gene  expression  between  SLE  patients 
and healthy controls 
To  further  characterise  the  relevance  of  these  Treg  ncRNA  to  Treg 
biology, their expression was compared between healthy individuals and 
patients  with  SLE,  the  archetypal  systemic  autoimmune  disease.  As  a 
major  role  of  Treg  is  the  maintenance  of  peripheral  tolerance  and  the 
prevention of autoimmunity, defects in Treg have been suggested as a 
possible etiological cause of SLE. Some differences in Treg identity have 
been  observed  and  include  numerical  and  phenotypic  differences, 
including between naïve and memory populations, and some evidence of 
functional  defects  in  in  vitro  suppression  assays,  but  observations  are 
often  contradictory.  Although  understanding  of  the  contribution  of  Treg 
behaviour to SLE is not fully understood, the disease allows an in vivo 
examination of Treg in an inflammatory setting that is relevant to their 
function.  In  addition,  examining  the  expression  of  novel  and  possibly 
functional Treg upregulated transcripts may inform understanding of Treg 
identity in an autoimmune context. 
 
Naïve and memory Treg and Tresp were isolated from healthy individuals 
and  SLE  patients  as  described  in  Sections  2.2.1  to  2.2.6.  RNA  was 
prepared according to Sections 2.3.1 to 2.3.3 and microarrays performed 
as per Section 2.3.5. The age range of healthy individuals was 23 to 54 
years (median: 30; standard deviation: 12) and of SLE patients was 21 to 
37 years (median: 35; standard deviation: 7). All donors were female and 
Caucasian. The SLE patients were selected to reflect general SLE rather 
than  subtypes  of  the  disease,  based  on  clinical  features,  and  had  not   152 
received biological therapy. Patients with active disease were chosen if 
possible, however the exaggerated lymphopenia in these patients often 
impeded  the  preparation  of  these  low  frequency  T  cell  subsets  for 
microarray analysis.  Details of each donor and clinical details of SLE 
patients  are  given  in  Table  7.26  and  Table  7.27.  Array  data  were 
extracted and normalised as per Section 2.5.1. Hierarchically clustering, 
as described in Section 2.5.2, showed trends in gene expression seen in 
previously  published  research  (Figure  3.10).  This  included  interferon 
alpha inducible genes, IFI27, IFI44 and IFI44L and viral response related 
genes, including TRIM22, which are relevant to the immune signatures 
seen  in  SLE,  as  described  in  Section  1.1.3.4.  This  recapitulation  of 
published data relevant to SLE immune pathogenesis gives confidence in 
the data. 
 
Transcripts  exhibiting  significantly  different  expression  between  SLE 
patients  and  healthy  controls  were  identified  as  described  in  Section 
2.5.4. A comparison of all CD4 T cell subsets between SLE patients and 
healthy individuals identified 317 transcripts as upregulated in SLE and 
504 as downregulated. The identities of these are given in Table 7.11 and 
Table  7.12,  respectively.  The  number  of  significantly  differentially 
expressed  transcripts  between  SLE  patients  and  healthy  controls,  and 
their distribution between in Treg and Tresp subsets are represented in 
Figure 3.11   153 
Figure 3.10: Hierarchical clustering of CD4 T cell subsets from SLE patients and healthy controls reflects previously published work 
Relative expression levels in naïve and memory Treg and Tresp from SLE patients and healthy controls of genes with previous associations with 
SLE. HC: Healthy control; SLE: Systemic lupus erythematosus. EPSTI1: epithelial stromal interaction 1  [158]; IFI27: interferon, alpha-inducible 
protein   [158,  541]  IFI44:  interferon-induced  protein  44  [158,  542];  IFI44L:  interferon-induced  protein  44-like  [543];  IFIT3:  interferon-induced 
protein with tetratricopeptide repeats 3 [158]; LAP3: leucine aminopeptidase 3 [158] ; MX1: MX dynamin-like GTPase 1 [158]; MX2: MX dynamin-
like GTPase 2 [158]; OAS1: 2'-5'-oligoadenylate synthetase 1 [158]; TRIM22: tripartite motif containing 22; USP18: ubiquitin specific peptidase 18; 
OAS3: 2'-5'-oligoadenylate synthetase 3 [158]; MMP9: matrix metallopeptidase 9 [544]; NAB2: NGFI-A binding protein 2 [158].  154 
 
Figure 3.11: Numbers of differentially expressed transcripts in CD4 T cell subsets 
between healthy individuals and SLE patients 
Transcripts with statistically significant differential expression between SLE patients and 
healthy  individuals  were  identified  by  Ranksum.  A:  Comparison  of  naïve  and  memory 
Treg and Tresp subsets. B: Transcripts uniquely differentially regulated in each naïve and 
memory subset. The percentage of the total number of differentially expressed transcripts 
is given while bracketed numbers indicate the absolute number of transcripts.     155 
As  Figure  3.11  shows,  when  comparing  naïve  and  memory  subsets  of 
Treg  and  Tresp  between  SLE  patients  and  healthy  individuals,  few 
statistically  significant  gene  expression  differences  were  found.  Only  16 
genes were differentially regulated in total with 1 being seen in the naïve 
Treg  comparison  (Table  7.15  and  Table  7.16),  7  in  the  memory  Treg 
comparison (Table 7.17 and Table 7.18), 3 in the naïve Tresp comparison 
(Table 7.21 and Table 7.22) and 5 in the memory Tresp comparison (Table 
7.23 and Table 7.24). The identities of these genes are detailed in Section 
7.1.2. When comparing total Treg, 52 transcripts were upregulated and 32 
were downregulated in SLE (Table 7.13 and Table 7.14) while in Tresp 50 
genes  were  upregulated  and  92  downregulated  (Table  7.19  and  Table 
7.20). The identities of these genes are detailed in Section 7.1.2. 
 
To interrogate gene expression differences relating to global changes in 
transcriptional regulation, transcription factors were identified according to 
Section  2.5.8.  The  differential  expression  of  these  in  Treg  subsets  is 
shown in Figure 3.12. Of the 92 transcripts that were differential expressed 
between  the  Treg  of  SLE  patients  and  healthy  individuals,  9  were 
transcription factors. Three were upregulated in SLE in total Treg (MAFB, 
FOSL2  and  NR4A3)  while  5  were  downregulated  (HOMEZ,  ZFP14, 
ZNF175,  ZNF232,  ZN404).  MAFB  (V-maf  musculoaponeurotic 
fibrosarcoma oncogene homolog B) was also upregulated in the memory 
subset of Treg. Although expression of MAFB has been reported in T cells 
before  [545],  literature  on  its  expression  is  predominantly  restricted  to 
macrophage  differentiation  where  its  role  is  not  comprehensively 
understood but has been observed to increase upon stimulation [546]. Of   156 
these transcription factors, one has a known role in Treg function: NR4A3 
(nuclear receptor subfamily 4, group A, member 3), also known as NOR1. 
NR4A3, along with NR4A1 and NR4A2, has recently been shown to have 
an  essential  role  in  Treg  development  [547].  NR4A  family  transcription 
factor  knockout  mice  have  fewer  Treg  and  develop  autoimmunity  and 
ChIP-Seq shows all members of the family bind the FOXP3 [547].     157 
 
Figure 3.12: Differential expression of transcription factors in Treg between SLE 
patients and healthy individuals 
Differentially expressed transcription factors in Treg and Tresp between SLE patients and 
healthy individuals were identified. Their relative expression levels are shown here across 
5  biological  replicates  with  corresponding  fold  difference  between  SLE  and  healthy 
controls (HC) and the significance level. PFP: predicted false positive.   
     158 
3.2.9  Differential expression of Treg ncRNAs between SLE 
patients and healthy individuals 
I considered whether the ncRNAs preferentially expressed in Treg were 
deregulated in SLE patients. Figure 3.13 compares their expression levels 
and  gives  fold  differences  between  SLE  and  healthy  controls  alongside 
level of significance. 
 
None  of  the  7  Treg  ncRNAs  were  statistically  differentially  expressed 
between SLE patients and healthy individuals when comparing each T cell 
subset  individually.  As  an  alternative  approach  to  examining  their 
deregulation, I compared SLE patients and healthy individuals in terms of 
fold differences in expression between Treg and Tresp (Figure 3.14.A) and 
naïve and memory Treg (Figure 3.14.B). This allowed me to highlight any 
trends that may tend towards significance but fall below the statistical cut-
off. As expected, the known Treg relevant genes FOXP3, CTLA4, IKZF2 
(Helios)  and  IL2RA  (CD25)  were  more  highly  expressed  in  total  Treg 
compared  to  Tresp  for  both  SLE  patients  and  healthy  controls  (Figure 
3.14.A). The fold difference of these genes between Treg and Tresp in 
SLE was directly proportional to that in healthy individuals. This lack of 
difference between SLE patients and healthy controls is reflective of the 
published body of research that has not consistently seen differences in 
SLE  in  such  Treg  specific  genes  in  the  total  Treg  population  (Section 
1.1.3.6). When examining these genes between naïve and memory Treg 
subsets, Figure 3.14.B shows that expression levels are similar between 
subsets in both SLE and HC. Genes that are known to be differentially 
expressed between these subsets (AHR, RORC, PECAM1, Figure 3.14.A)   159 
show their expected trends and these are similar between SLE and HC. 
Regarding  Treg  upregulated  ncRNAs,  subtle  differences  were  however 
seen: LOC286442 and PTTG3P had a higher fold difference between total 
Treg and Tresp in healthy individuals compared to SLE patients, implying 
they are decreased in SLE Treg and/or increased in SLE Tresp (Figure 
3.14.A).  In  addition,  CRNDE  showed  the  greatest  difference  in  fold 
difference of expression in naïve Treg compared to memory Treg between 
SLE patients (median log2 ratio: 0.6) and healthy individuals (median log2 
ratio: -1.6) (Figure 3.14.B)     160 
 
Figure 3.13: Comparison of Treg ncRNA expression between SLE patients and 
healthy  individuals. 
Left: Heatmap showing the expression of Treg ncRNAs in naïve and memory Treg and 
Tresp from SLE patients and healthy controls. Right: Fold difference and predicted false 
positive rate (PFP) between SLE patients and healthy controls. HC: healthy control.   
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Figure 3.14: Comparison between healthy individuals and SLE patients of 
expression of Treg ncRNA between T cell subsets 
Scatter plots of log2 fold difference in expression between T cell subsets in SLE patients 
and healthy controls. A: Treg compared to Tresp. B: Naïve Treg compared to memory 
Treg. Treg ncRNAs are highlighted in red. Genes known to be upregulated in Treg are in 
grey  and  those  known  to  be  upregulated  in  naïve  T  cells  are  in  green.  Global  gene 
expression (i.e. all genes on the array) is shown in black.   
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3.2.10 Differences  in  histone  modifications  at  autoimmune 
responsive genes 
To further identify differences in Treg between SLE patients and healthy 
individuals  at  the  level  of  transcription  regulation,  histone  modification 
patterns  were  compared.  Differences  at  this  level  would  highlight 
mechanisms  that  influence  the  Treg  transcriptional  program  in  a 
physiologically relevant autoimmune setting. 
 
The  number  of  cells  required  for  ChIP-Seq  precluded  the  use  of  this 
technique  for  identifying  histone  modifications  in  SLE  patients.  SLE 
patients are lymphopenic and, due to the heterogeneity of the disease as 
well  as  biological  variation  in  general,  pooling  of  patient  samples  to 
increase material available would significantly reduce the power to identify 
SLE versus healthy differences. To adapt to this challenge I investigated 
histone  modifications  in  healthy  donors  at  genes  that  were  differentially 
regulated between healthy donors and SLE patients. I hypothesised that 
genes that change in expression in an inflammatory autoimmune context 
would exhibit differences in histone modifications compared to genes with 
unchanged expression and that these differences in histone modification 
may relate to their responsiveness to autoimmune inflammation.  
 
As  detailed  in  Section  3.2.8,  differential  gene  expression  between  SLE 
patients  and  healthy  controls  was  determined  through  microarrays  and 
Ranksum analysis. Histone modification ChIP-Seq data was obtained from 
a  publically  available  source  (Table  2.8).  The  lists  of  genes  up-  and 
downregulated in SLE Treg were compared to a background control list (all   163 
genes  on  the  array)  for  differences  in  profiles  of  histone  modifications: 
H3K4me3  (a  mark  of  transcriptional  initiation),  H3K36me3  (elongation), 
H3K27me3 (poised repression), H3K4me1 (enhancer function), H3K9me3 
(heterochromatic  repression)  and  whole  cell  extract  (background 
enrichment). Figure 3.15 illustrates the average enrichment profile of each 
histone modification across differentially expressed genes.     164 
 
Figure 3.15: Average enrichment profile of histone modifications at genes 
differentially regulated in SLE Treg 
Average  enrichment  profiles  for  several  histone  modifications  showing  the  average 
number  of  reads  mapping  across  the  length  of  genes  from  2kb  upstream  to  2kb 
downstream. WCE: whole cell extract. TSS: transcription start site; TES: transcription end 
site.    
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The profile of H3K9me3 was notable as it differed with genes upregulated 
in HC Treg compared to the background gene list. In comparison, other 
histone modifications showed comparable enrichment in all genes similar 
to  the  background  enrichment  (WCE).  To  determine  the  statistical 
significance  of  this  enrichment,  the  cumulative  frequency  distribution  of 
H3K9me3  enrichment  was  compared  between  differentially  expressed 
genes.  In  Treg  cells  (Figure  3.16.A),  genes  upregulated  in  the  Treg  of 
healthy  individuals  (24  genes)  had  a  maximum  difference  in  cumulative 
distribution  (D)  of  0.2296  compared  to  a  random  selection  of  genes. 
Although this difference was not statistically significant (P: 0.146), it was 
larger and more significant than the same comparison in whole cell extract 
(D: 0.1939; P  0.308). In Tresp cells (Figure 3.16.B), genes upregulated in 
Tresp of healthy individuals compared to SLE patients (73 genes) had a 
maximum difference in distribution of 0.2210 (P: 0.114) while in whole cell 
extract this comparison was 0.1439 (P: 0.109). This demonstrated a trend 
towards  enrichment  of  H3K9me3  at  genes  differentially  expressed 
between SLE and HC in both Treg and Tresp. As the level of significance 
may  have  been  limited  by  the  low  numbers  of  differentially  expressed 
genes, and as this enrichment appeared in both Treg and Tresp, I also 
compared genes that were upregulated in total CD4 T cells (504 genes). 
This  comparison  is  given  with  Treg  (Figure  3.16.  C)  and  Tresp  (Figure 
3.16. D) ChIP-Seq data. In Treg, the maximum difference in distribution 
was 0.0925, which was statistically significant (P: 0.006) and larger than in 
WCE (D: 0.0; P: 1.0). In Tresp, the maximum difference in distribution also 
statistically  significant  was  (D:  0.1188,  P:  <10-3,  compared  to  WCE:  D: 
0.1142; P: <10-3), showing that genes that are upregulated in total CD4 T   166 
cells  compared  to  SLE  are  enrichment  for  H3K9me3  in  both  Treg  and 
Tresp.     167 
 
Figure 3.16: Cumulative frequency distributions of H3K9me3 enrichment at SLE 
deregulated genes 
Cumulative frequency distributions showing the difference in H3K9me3 enrichment and 
WCE at genes up and downregulated in healthy controls compared to SLE patients and at 
a control set of randomly selected genes. A: IP performed in Treg. For genes upregulated 
in Treg, H3K9me3 D=0.2296 (P=0.146) and WCE D=0.0194 (P  0.308). B: IP performed 
in  Tresp.  For  genes  upregulated  in  Tresp  H3K9me3  D=0.2210  (P:  0.114)  and  WCE 
D=0.0144  (P:  0.109).  C:  IP  performed  in  Treg.  For  genes  upregulated  in  total  CD4, 
H3K9me3 D=0.0925 (P: 0.006) and WCE D=0.0 (P=1.0). D: IP performed in Tresp. For 
genes  upregulated  in  total  CD4,  H3K9me3  D=0.1188  (P=<10
-3),  WCE  D=0.1142  (P: 
0.000). IP: Immunoprecipitation; WCE: whole cell extract. RPKM: reads per killobase per 
million mapped reads. Brackets detail the number of genes in each list. 
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3.3  Discussion 
Here  I  have  identified  for  the  first  time  ncRNAs  with  roles  potentially 
specific  to  Treg  biology.  This  identification  of  lincRNAs  differentially 
expressed between Treg and Tresp is consistent with data from other labs 
showing that this class of ncRNAs is often cell type specific. 
 
I identified 22 ncRNAs in total as being upregulated in Treg compared to 
Tresp  (Figure  3.3)  with  differential  expression  of  7  being  validated  by 
qPCR  in  3  additional  donors.  Of  the  other  15  Treg  ncRNAs  that  were 
detected by microarray but not validated by qPCR, several showed the 
expected trend of increased expression in Treg but data did not meet the 
significance  threshold  of  0.05.  This  lower  statistical  significance  was 
influenced by the number of replicates (3), the magnitude of difference in 
expression between Treg and Tresp and donor variation and so with an 
increased number of replicates the significance for differential expression 
of  these  ncRNAs  may  increase.  Others  were  problematic  to  assay  by 
qPCR  due  to  their  high  repetitive  content,  a  feature  that  has  been 
associated with lincRNAs  [403]. In Chapter 5 I have chosen to focus on 
the ncRNAs validated here as their more robust differential expression in 
Treg  supports  their  investigation  in  downstream  functional  assays.  In 
addition to qPCR validation I have used publically available ChIP-Seq data 
on enrichment of histone modifications (transcriptional initiation: H3K4me3; 
and  H3K36me3:  elongation)  and  FOXP3  to  support  their  conversely 
regulated expression in Treg and Tresp (Figure 3.5). Histone modification 
data  also  allowed  interpretation  of  their  biological  roles  (H3K4me1  is  a 
marker of enhancer RNA transcription) and FOXP3 occupancy suggested   169 
expression of these ncRNAs might be regulated by this Treg-specifying 
factor.  The  identity  of  these  transcripts  was  further  probed  through  the 
genomic  structure  of  ncRNA  genes  (Section  3.2.5),  correlation  of  their 
expression with neighbouring genomic genes with known biological roles 
(Section  3.2.6)  and  presence  of  annotated  disease–associated  genomic 
variants (Section 3.2.7). The potential relevance of these Treg ncRNAs for 
defects in Treg function was explored through their expression in SLE, in 
which Treg have been shown to have phenotypic differences including in 
naïve and memory subsets (Section 3.2.8).  
 
The identities of the qPCR validated Treg ncRNAs are now summarised 
and  discussed  in  relation  to  previously  published  data  and  the  data 
presented here: 
3.3.1  MIR146a 
The detection of upregulated miR-146a (ENST00000517927) in Treg is not 
novel but this recapitulation of previously published work  [520, 521] gives 
confidence in the microarray data. Disease associated variants are also 
well documented in MIR146A compared to the other ncRNAs (Table 3.1) 
and  include  associations  with  Treg  related  diseases  such  as  several 
cancers  [538, 539], asthma  [537] and SLE  [540] (Table 3.2). Mir-146a 
was detected here in its pri-miRNA form, which has not previously been 
shown  in  Treg  and  thus  demonstrates  that  mir-146a  abundance  is 
regulated at the level of transcription. MIR146A had a high fold difference 
in expression between Treg and Tresp by microarray (13.4 fold, Figure 
3.3)  and  qPCR  (21.8  fold,  Figure  3.4)  and  as  expected  shows  clear 
enrichment  of  H3K4me3  and  H3K36me3  in  Treg  compared  to  Tresp 
(Figure 3.5). In addition, there is clear enrichment of FOXP3 across the   170 
MIR146A  locus  (Figure  3.6).  Interestingly,  MIR146A  shows  a  strong 
positive  correlation  with  its  genomic  neighbour  PTTG1  (Pearson 
correlation coefficient: 0.78, Figure 3.9), which is encoded in an antisense 
divergent  orientation  (Figure  3.8)  and  may  therefore  share  upstream 
regulatory regions. 
3.3.2  LINC00312  
LINC00312 showed a fold enrichment of 9.4 by array (Figure 3.3) and 20.8 
by qPCR (Figure 3.4) compared to Tresp and supporting this, preferential 
enrichment of H3K36me3 can be seen in Treg (Figure 3.5). In addition it is 
the only Treg ncRNA to be more highly expressed in memory compared to 
naïve  Treg  (Figure  3.3  and  Figure  3.13.B).  There  is  little  enrichment  of 
H3K4me3 at the gene for LINC00312 however the presence of H3K4me1 
nearby (Figure 3.5) and its mono-exonic structure (Figure 3.7) suggest it 
may behave as an enhancer RNA. The LINC00312 locus is found within a 
quantitative trait locus that correlates with the Treg-relevant autoimmune 
disease  rheumatoid  arthritis  (Table  3.2)  [49,  535,  536].  However  this 
association maps to a large locus that contains multiple genes and so does 
not inform specifically about LINC00312 activity. In addition, detection of 
LINC30012 could also be a result of expression of an unnanotated long 
isoform of the upstream gene LMCD1. This could also explain the lack of 
H3K4me3 at LINC00312 as well as the strong correlation in expression 
between  LINC00312  and  LMCD1  (Figure  3.9).  The  latter  has  been 
reported to increase in expression with calcineurin and NFAT activity [529], 
signalling molecules relevant to T cell activation that are more active in 
memory T cells.   171 
3.3.3  PTTG3P  
PTTG3P is a pseudogene and therefore less likely than other non-coding 
transcripts to have evolved to mediate a function at the transcript level. 
While there is FOXP3 binding near PTTG3P (Figure 3.6), this could relate 
to the presence of the antisense gene SK3G (Figure 3.8) and the lack of 
enrichment of neither H3K4me3 nor H3K4me1 (Figure 3.5) may suggest it 
is not an actively regulated gene in Treg.  
3.3.4  ENST00000444919  
Although  significant,  the  increased  expression  of  ENST00000444919  in 
Treg compared to Tresp was low by both array (2.45 fold, Figure 3.3) and 
qPCR (1.4 fold, Figure 3.4) and in line with this enrichment of H3K4me3 is 
similar in both T cell subsets (Figure 3.5). ENST00000444919 does show 
FOXP3  binding  at  the  promoter  (Figure  3.6)  suggesting  it  is  actively 
regulated in Treg and has a large intron to exon ratio with the presence of 
several repeat elements similar to other ncRNAs (Figure 3.7). However the 
upstream region, which may harbour regulatory elements, is shared with 
that of PDK1, which is in a divergent orientation (Figure 3.8), and the low 
correlation in expression between the two (Figure 3.9) may suggest this 
FOXP3 only regulates the PDK1 gene. 
3.3.5  ENST00000415387 
ENST00000415387 is encoded at the 3’ end of IKZF2, which encodes the 
Treg transcription factor Helios (Figure 3.8  [93]), and the two are strongly 
correlated  in  expression  (Figure  3.9),  which  is  consistent  with 
ENST00000415387 having a role in Treg biology through regulating IKZF2 
expression.  However  due  to  the  orientation  of  ENST00000415387  with   172 
IKZF2 the presence of an unannotated or unspliced isoform of IKZF2 could 
also explain the increased signal by array and qPCR. Supporting this, the 
TSS  for  ENST00000415387  lacks  a  H3K4me3  peak  while  upstream  on 
can be found at the TSS of IKZF2 (Figure 3.5).  
3.3.6  CRNDE 
CRNDE has distinct H3K4me3 enrichment at the TSS while H3K4me1 is 
minimal (Figure 3.5), which is consistent with a role as a lincRNA rather 
than  enhancer  RNA.  In  addition,  there  may  be  some,  although  low, 
occupancy  of  FOXP3  at  the  promoter  (Figure  3.6),  which  supports 
regulation  of  the  gene  in  Treg.  CRNDE  has  obtained  its  name  from  its 
observed upregulation in colorectal adenomas and adenocarcinomas, an 
early  event  in  colorectal  neoplasias    [524].  CRNDE  was  classified  with 
relative high confidence as a lincRNA in an evaluation of genome-wide 
annotations  [496]. In other literature it is referred to as lincIRX5, after the 
protein-coding  gene  it  neighbours  [441],  and  linc1399  after  the  mouse 
ortholog  [405].  CRNDE  is  also  upregulated  in  hepatocarcinoma    [548], 
haematological malignancies  [524] and brain cancer  [524]. In support of a 
functional role for CRNDE in cancer, genes affected by siRNA knockdown 
of CRNDE in fibroblasts are enriched for processes relating to cancer, cell 
death and cell cycle  [441, 524]. Comparison of SLE patients and healthy 
individuals  showed  here  that  of  all  Treg  ncRNAs,  CRNDE  showed  a 
greater tendency to be decreased in memory Treg in SLE (Figure 3.14.B). 
This may reflect a lower proliferative status of memory Treg in SLE, which 
may  relate  to  the  decreased  activity  of  this  Treg  subset  that  has  been 
observed by others  [96] (Section 1.1.3.6.1). In addition to cancer cells, 
CRNDE  has  been  observed  to  be  highly  expressed  in  embryonic  stem   173 
cells    [442]  and  has  been  associated  with  pluripotency,  based  on  the 
observation  that  expression  decreases  with  specialisation    [526].  The 
exception is neurogenesis where expression increases compared to ESCs, 
although it becomes undetectable in adult neurons  [526, 549].  
 
Enforced expression of a CRNDE transcript containing a highly conserved 
intronic  region  termed  genomic  vertebrate  conserved  intron  4  (gVCIn4) 
promotes growth and suppresses apoptosis in fibroblasts  [526]. Unspliced 
transcripts  containing  intronic  regions,  including  gVCIn4,  are 
downregulated by insulin and insulin-like growth factor (IGF), an effect that 
is inhibited by blockade of the insulin signalling pathways PI3K/Akt/mTOR 
and Raf/MAPK  [550]. Knockdown of gVCIn4 containing transcripts with 
siRNA  in  fibroblasts  affects  expression  of  insulin  related  signalling 
molecules  and  downstream  processes  including  glucose  and  lipid 
metabolism  [550]. Therefore CRNDE transcripts may antagonise events 
downstream  of  insulin  signalling.  Knockdown  of  spliced  isoforms  of 
CRNDE did not have this effect and were not downregulated by insulin in 
fibroblasts  [550]. CRNDE has been detected in T cells before although at 
a low level compared to other cell types such as spermatozoa  [526] and 
consistent with a potential role in pluripotency, expression in thymic T cells 
decreases  from  the  double  positive  (CD4+CD8+)  to  single  positive 
(CD4+CD8-  and  CD4-CD8+)  states    [551].  Increased  expression  in  of 
CRNDE Treg compared to Tresp has not been previously reported. 
 
The expression of lncRNAs has been suggested as a mechanism for the 
genomic targeting of chromatin-modifying complexes for the regulation of 
transcription of specific genes through cis-regulatory mechanisms (Section   174 
1.3.3.1.  [441]).  Consistent  with  this,  the  promoters  for  CRNDE  and  its 
neighbouring gene IRX5 are adjacent, share the same CpG island and a 
comparison  across  several  tissue  types  shows  their  expression  is 
correlated  [526], suggesting that CRNDE transcription may influence IRX5 
transcription. Furthermore CRNDE has been shown to physically associate 
with  the  chromatin-modifying  complexes  PRC2  and  CoREST  by  native 
RNA  immunoprecipitation  [441]  and  knockdown  of  PRC2  and  CRNDE 
show overlap in the biological processes affected  [441]. Although CRNDE 
and IRX5 do not strongly correlate (Figure 3.9) and there is no published 
Treg-relevant role for IRX5, CRNDE may instead influence recruitment of 
these  chromatin-modifying  complexes  to  other  genes.  However,  this 
evidence  should  be  treated  cautiously  as  the  use  of  native  RNA 
immunoprecipitation  is  limited  for  demonstrating  a  direct  interaction.  In 
addition, the theory of specific interactions of lncRNAs and PRC2 has been 
recently challenged by the observation that broad range of RNAs, including 
mRNA, have a capacity to bind PRC2  [552, 553]. The repeats seen in 
CRNDE that correspond with exonic sequences (Figure 3.7) support the 
importance of secondary structure in the transcribed product, which may 
be required for interaction with chromatin modifiers.  
3.3.7  LOC286442  
LOC286442 had the highest fold difference between Treg and Tresp of 
any ncRNA by array (13.9 fold, Figure 3.3) and supporting this differential 
expression  there  was  clear  greater  enrichment  of  H3K4me3  and 
H3K36me3 at the LOC286442 gene in Treg compared to Tresp (Figure 
3.5).  In  addition  FOXP3  binds  at  the  promoter  and  in  intronic  regions 
(Figure  3.6)  supporting  the  possibility  of  Treg-specific  regulation  of  the   175 
gene.  In  addition,  this  ncRNA  is  of  interest  as  there  is  a    higher  fold 
difference between total Treg and Tresp in healthy individuals compared to 
SLE patients, implying they are decreased in SLE Treg and/or increased in 
SLE Tresp (Figure 3.14.A). 
 
Based  on  the  conclusions  above,  of  the  ncRNAs  upregulated  in  Treg 
compared to Tresp, LOC286442 and CRNDE appeared to have the most 
potential  for  functional  assays  investigating  their  biological  relevance  in 
Treg and this is the subject of Chapter 5.  
3.3.8  Transcriptional differences in SLE Treg 
In  both  Treg  and  Tresp  cells  from  a  healthy  individual  H3K9me3  was 
enriched  at  genes  that  were  increased  in  expression  in  CD4  T  cells  of 
healthy individuals compared to SLE patients (Figure 3.15, Figure 3.16). 
This  enrichment  at  differentially  expressed  genes  was  significant  when 
compared to enrichment at randomly selected genes (Figure 3.16). This 
was in comparison to other histone modifications (H3K4me3, H3K4me1, 
H3K36me3 and H3K27me3) and WCE, which did not show an obvious 
difference (Figure 3.15). This was unexpected as the majority of literature 
on H3K9me3 reports its enrichment in repressed chromatin including at 
peri-centromeres  and  at  repeats  and  transposons  [361,  362].  In  these 
regions  the  presence  of  H3K9me3  is  understood  to  repress  deleterious 
transcriptional activity in part through recruitment of HP1 [364]. However a 
minority  of  H3K9me3  related  literature  reports  its  enrichment  along  the 
gene  body  of  actively  transcribed  genes  with  Vakoc  et  al.  2005  first 
demonstrating this [363]. Vakoc et al found that tri-methylation of H3K9 
was induced during activation and lost when transcription was inhibited.   176 
This was seen in murine cell lines as well as primary T cells stimulated 
through  CD3,  including  at  the  Il2  gene  [363].  H3K9me3  was  increased 
along  the  gene  body  compared  to  the  promoter  [363],  as  is  seen  here 
(Figure 3.15), and inhibition of phosphorylation of the RNAPII CTD led to a 
reduction  in  H3K9me3  along  the  gene  body  of  active  genes  but  not  at 
microsatellites, suggesting a difference in the role of H3K9me3 in active 
compared  to  inactive  chromatin  and  a  relationship  with  transcriptional 
elongation.  Vakoc  et  al.  also  demonstrated  the  recruitment  of  the 
H3K9me3 associated chromatin-modifier HP1γ and an interaction between 
this and elongating RNAPII [363]. Others have since shown that presence 
of HP1γ may slow the processivity of RNAPII leading to inclusion of exons 
[371],  therefore  demonstrating  a  relationship  between  H3K9me3  and 
alternative splicing, which is supported by the enrichment of H3K9me3 at 
included exons of the CD44 gene [371]. This suggests that the differential 
expression between HC and SLE may relate to regulation of elongation 
and/or alternative splicing. Regulation of gene expression at this point may 
allow response to an inflammatory environment. H3K36me3, which is also 
associated  with  elongation,  did  not  appear  to  differ  at  differentially 
expressed genes, suggesting that H3K9me3 but not H3K36me3 mediated 
transcriptional  elongation  is  associated  with  the  regulation  of  this 
inflammation related set of genes. 
 
Through examining differential expression in Treg between SLE patients 
and healthy controls, I identified several transcription factors of potential 
interest that may contribute to differential gene expression. This included 
MAFB  (V-maf  musculoaponeurotic  fibrosarcoma  oncogene  homolog  B)   177 
and NR4A3 (Figure 3.12, Section 3.2.8). MAFB was upregulated in Treg in 
general  as  well  as  in  the  memory  (CD45RA-)  subset  of  Treg  in  SLE 
patients. A recent profile of differential expression of transcription factors 
between CD45RA+ and CD45RA- Treg has demonstrated that CD45RA- 
Treg express higher levels of transcription factors of other lineages [328]. 
This includes a MAF family member, c-MAF (V-maf musculoaponeurotic 
fibrosarcoma  oncogene  homolog),  which  has  a  known  role  in  T  cell 
differentiation in promoting both Th2 [554, 555] and Th17 [556] phenotypes 
and regulates transcription of targets of ETS1 transcription factor targets 
[557]. Given the structural similarity of the MAF family members, which 
bind DNA though a basic leucine zipper domain, the role of c-MAF in T cell 
differentiation may inform the relevance of MAFB upregulation in SLE. The 
transcription factor NR4A3 was also identified as being upregulated in SLE 
Treg.  NR4A3  has  been  recently  identified  as  having  a  role  in  Treg 
development [547]. This upregulation in SLE may reflect a role of NR4A3 
in supporting the response of Treg to the inflammatory environment and 
may demonstrate that SLE Treg are capable of this response.  
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4  Identification of enhancer RNAs in Th1 cells 
4.1  Introduction 
4.1.1  T-bet super-enhancers 
Our lab has reported that the majority of T-bet binding sites are located 
distally to known gene promoters [246], suggesting the regulatory action of 
T-bet is mediated through enhancers. This binding often occurs in domains 
containing five or more distinct T-bet peaks [246]. At individual gene loci, 
including the IFNG locus, [246], these extended T-bet domains correlate 
with  DHS  sites  and  the  presence  of  H3K4me1,  indicating  an  open 
chromatin conformation suggestive of functional enhancer elements [246]. 
The high density T-bet bound regions upstream of IFNG have orthologs in 
mouse [246]. In genome-wide analyses, genes distal to such domains are 
enriched for biological processes related to immune response, supporting 
a biological significance for these extended T-bet bound domains  [246]. 
Furthermore,  T-bet  binding  at  distal  elements  in  addition  to  proximal 
elements,  as  opposed  to  proximal  elements  alone,  is  more  likely  to 
correlate with lineage specific gene expression. Supporting the importance 
for  distal  binding  of  T-bet,  knockout  of  Tbx21  (T-bet)  in  mouse  has 
demonstrated that genes bound both distally and proximally by T-bet were 
four times more likely to be dependent on T-bet expression that those only 
bound  proximally.  Similar  data  were  seen  for  Gata3  suggesting  this 
phenomenon  is  representative  of  lineage-specifying  transcription  factor 
behaviour in general.  
 
The  extended  T-bet  cis-regulatory  regions  identified  by  Kanhere  and 
colleagues  resembles  recently  defined  super-enhancers  (described  in   179 
Section 1.2.2.3). To confirm this, Richard Jenner used the ROSE (rank 
ordering  of  super-enhancers)  algorithm  [320,  321],  which  stiches 
neighbouring enhancers together and ranks these by transcription factor 
binding  [321],  to  define  super-enhancers  using  in-house  human  and 
mouse T-bet ChIP-Seq data. The output of the ROSE algorithm for T-bet in 
human Th1 cells is shown in Figure 4.1 (made by Richard Jenner), which 
shows  that  rather  than  the  amount  of  T-bet  binding  having  a  linear 
relationship with rank across all T-bet enhancers, a subset of enhancers, 
super-enhancers,  exhibit  markedly  high  T-bet  enrichment.  Using  this 
approach,  our  lab  has  identified  374  super-enhancers  and  2817  typical 
enhancers in human Th1 cells (data currently in peer review). 
4.1.2  Recruitment  of  P-TEFb  to  super-enhancers  and 
lineage-specific genes 
While exploring the mechanism of super-enhancer function and lineage-
specific  gene  expression,  our  lab  has  observed  comparable  RNAPII 
binding in the promoter region of Th1-specific genes in both Th1 and Th2 
cells  (Figure  4.2.A,  Arnulf  Hertweck  and  Richard  Jenner),  implying  that 
recruitment  of  RNAPII  is  not  regulated  in  a  lineage-specific  manner. 
However,  differential  RNAPII  binding  is  observed  along  gene  bodies 
(Figure  4.2.A,  Arnulf  Hertweck  and  Richard  Jenner),  suggesting  that 
RNAPII  processivity  through  transcriptional  elongation  is  regulated  in  a 
more lineage-specific manner than transcriptional initiation. To explore the 
control of this elongation, ChIP-Seq was performed to assess the lineage 
specificity of binding of the elongation factor P-TEFb (Figure 4.2, Richard 
Jenner and Arnulf Hertweck). Upon stimulation, RNAPII and P-TEFb show 
greater  lineage-specific  enrichment  at  genes  associated  with  super-  180 
enhancers  and  compared  to  typical  enhancers.  This  showed  that 
transcriptional elongation through P-TEFb recruitment correlated with the 
increased  T-bet  binding  that  defines  super-enhancers.  Additionally, 
extensive  P-TEFb  binding  was  observed  at  the  super-enhancers 
themselves in addition to genes (Figure 4.2.B). 
 
Given that eRNAs have been identified to be transcribed from enhancers 
and that P-TEFb is bound at these sites, these data suggest that eRNAs 
are also transcribed from T-bet super-enhancers. Furthermore, knockdown 
of eRNAs transcribed from other enhancers in other cell types has been 
reported  to  repress  expression  of  neighbouring  genes  (discussed  in 
Section  1.3.2.4).  Linking  these  observations,  P-TEFb  has  also  recently 
been shown to be required for eRNA transcription [385].     181 
 
Figure 4.1: Identification of super-enhancers 
T-bet bound enhancers ranked by signal and the relationship between rank and signal 
examined to identify super-enhancers. Super-enhancers were distinguished from typical 
enhancers  by  their  markedly  increased  enrichment  of  T-bet  (performed  by  Richard 
Jenner). The closest genes to the five highest ranking super-enhancers are indicated on 
the left. The super-enhancers closest to the Th1 signature genes IFNG and TBX21 are 
also indicated.   
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Figure 4.2: T-bet occupancy at lineage-specific genes and super-enhancers 
A: Average number of ChIP-seq reads for RNA pol II and P-TEFb (reads/million, input 
subtracted) in unstimulated (US) and restimulated (RS) human Th1 and Th2 cells. All 
genes are bound by RNA pol II in at least one condition and divided into those associated 
with  a  super-enhancer  (n=231)  or  a  typical  enhancer  (n=1307).  B.  ChIP-seq  binding 
profiles (reads/million) for T-bet, RNA pol II and P-TEFb in unstimulated and restimulated 
human Th1 and Th2 cells at example Th1 genes. 
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4.1.3  Aims 
1.  To  examine  the  transcriptional  output  of  T-bet  super-enhancers 
genome-wide and at specific genes. 
2.  To  characterise  super-enhancer  transcription  in  terms  of  features 
previously  seen  at  enhancers  including  polyadenylation  and 
bidirectionality. 
3.  To examine the relationship between T-bet and P-TEFb binding with 
super-enhancer eRNA transcription. 
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4.2  Results 
4.2.1  Genome-wide  strand-specific  RNA-seq  of  Th1  and 
Th2 cells 
I  aimed  to  perform  RNA-Seq  on  human  Th1  and  Th2  cells  and  naïve 
precursors  as  this  would  allow  de  novo  identification  of  previously 
unannotated  transcripts  that  may  emanate  from  enhancer  regions.  As 
published  research  has  shown  that  enhancer  RNA  may  lack 
polyadenylation,  I  intended  to  compare  enrichment  of  RNA  from  T-bet 
super-enhancers  in  RNA-Seq  libraries  generated  from  polyadenylated 
(polyA) RNA and total cellular RNA, which would include both polyA and 
non-polyA  RNA.  Another  reported  characteristic  of  enhancer  RNA  is 
bidirectionality i.e. transcription from both DNA strands emanating from a 
common start site, and in order to detect this strand specific sequencing 
was required. As RNA sequencing had not been previously performed in 
our lab, I optimised several library generation conditions.  
 
Fragmentation  of  RNA  prior  to  library  generation  (Section  2.3.6.2)  is 
required due to current limitations of sequencing technologies, which can 
only  read  relatively  short  sequences  efficiently.  However,  over 
fragmentation leads to the generation of reads that are too short and the 
unnecessary sequencing of PCR adapters and primers at the expense of 
information  on  the  intervening  insert  of  interest.  The  optimal  library 
fragment  size  for  the  Illumina  HiSeq  is  180  to  200bp.  In  addition, 
homogeneity  of  fragment  size  reduces  sequencing  bias.  As  Figure  4.3 
shows, two incubation times for chemical fragmentation were compared. 
Four minutes was chosen because fragment size was shorter and more   185 
uniform. 
 
In addition, the number of cycles during PCR library generation required 
optimisation. Too few would result in reduced sensitivity to low abundance 
reads while too many would lead to excessive duplication and decreased 
complexity. I compared generation of PCR libraries using the minimum and 
maximum number of cycles (12 and 15, respectively). Ribosome depleted 
RNA from 1µg total RNA, a yield of around 5ng, was used for this test as 
this reflected the lower limit of RNA available for use. Therefore this also 
allowed  a  test  for  the  ability  to  prepare  sequencing  libraries  from  low 
quantities of RNA. As Figure 4.4 shows, 15 cycles produced a clear smear 
between 150 and 350 bp, which was the expected size of the library and 
demonstrated the ability to generate sequencing libraries from this limited 
amount  of  starting  material.  Twelve  cycles,  also  produced  this  smear 
although  less  distinct  as  expected.  Both  conditions  produced  a  clear 
resolution between library products and the primer dimer band at ~100bp. 
In  order  to  maximise  sensitivity  of  low  abundance  reads  from  the  low 
amount  of  starting  material,  15  cycles  was  ultimately  used  for  library 
generation from samples of interest.     186 
 
Figure 4.3: RNA fragmentation optimisation prior to RNA-Seq library generation 
Bioanalyzer  electropherograms  showing  a  comparison  of  library  size  under  different 
incubation times for chemical fragmentation of total RNA. A: Illumina directional mRNA-
Seq electropherogram showing the optimal fragment length (180-200bp) for an Illumina 
HiSeq  sequencer.  Upper  and  lower  peaks  (43  and  113  bp)  are  size  standards.  B: 
Comparison  of  incubation  time  showing  increased  uniformity  in  fragment  size  with 
increased incubation time.   
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Figure 4.4: PCR library generation test 
Due to the low amount of material available, test PCR libraries were generated from 1µg 
of ribosome depleted total RNA from CD4 T cells. A comparison was made of the lower 
(12) and upper (15) recommended cycling repetitions.   
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I performed a preliminary analysis of Th1 and Th2 polarisation in three 
donors  by  microarray  before  selecting  the  most  appropriately  skewed 
samples  for  RNA-Seq.  Assessment  of  polarisation  was  based  on 
expression  of  the  Th1-specific  genes  TBX21  and  IFNG  and  the  Th2-
specific genes GATA3, IL13, IL4 and IL5 in naïve precursors and Th1 and 
Th2  cells  harvested  at  several  time  points  during  T  cell  polarisation 
cultures (cultures performed by Ian Jackson). Cells were harvested at days 
3, 7 and 13 with a comparison of unstimulated and restimulated cells at 
day 13 As shown in Figure 4.5, for all three donors, IFNG and TBX21 were 
upregulated  in  Th1  polarising  conditions  at  all  time  points  compared  to 
naïve  precursors.  Th2  polarising  conditions  also  led  to  consistent 
upregulation of GATA3 compared to both naïve precursors and Th1 cells. 
IL4 expression in Th2 cells was greater at d13 upon restimulation but was 
comparable  to  Th1  cells.  This  less  robust  Th2  polarisation  was  also 
reflected in expression of IL13, which was not Th2 specific in any of the 
three  donors.  Donor  2  however  exhibited  the  most  lineage  appropriate 
expression of IL5 and was selected for RNA-Seq experiments. Donor 3 
was  discounted  due  to  the  increased  expression  of  IFNG  seen  in 
restimulated cells from day 13 and donor 1 taken forward as a biological 
replicate  instead.  RNA-Seq  libraries  from  total  and  polyadenylated  RNA 
from donors 1 and 2 with day 13 unstimulated and restimulated Th1 and 
Th2 cells were prepared and sequenced as described in Section 2.3.6.     189 
 
Figure 4.5: Assessment of Th1/2 polarisation for RNA sequencing by microarray.  
Naïve precursors from 3 biological replicates were sorted and cultured under Th1 and Th2 
polarising conditions (by Ian Jackson) and lineage specific gene expression assessed by 
microarray. Cells were harvested at days 3, 7 and 13. Cells were harvested with and 
without additional restimulation for donor 3 at day 7 and all donors at day 13.    
Remove memory 
IL4 
IFNG 
Th1 genes 
Th2 genes 
TBX21 
GATA3 
IL5 
IL13 
IL4 
IFNG 
Th1 
Th2 
TBX21 
GATA3 
IL5 
IL13 
IL4 
IFNG 
Th1 
Th2 
TBX21 
GATA3 
IL5 
IL13 
1  2  3  1  2  3  1  2  3  3  1  2  3  1  2  3  1  2  3  1  2  3  3  1  2  3  1  2  3  Donor 
Th2 
d3  d7  d13 
Th1 
d3  d7  d13 
u
n
s
t
i
m
u
l
a
t
e
d
 
r
e
s
t
i
m
u
l
a
t
e
d
 
Naive 
u
n
s
t
i
m
u
l
a
t
e
d
 
u
n
s
t
i
m
u
l
a
t
e
d
 
u
n
s
t
i
m
u
l
a
t
e
d
 
r
e
s
t
i
m
u
l
a
t
e
d
 
r
e
s
t
i
m
u
l
a
t
e
d
 
r
e
s
t
i
m
u
l
a
t
e
d
   190 
4.2.2  Super-enhancer RNA production is Th1 specific and 
increased upon stimulation 
T-bet super-enhancers were distinguished from typical enhancers (Richard 
Jenner)  using  T-bet  ChIP-Seq  data  from  two  replicate  ChIP-Seq 
experiments  (performed  by  Richard  Jenner  and  Arnulf  Hertweck)  as 
described  above  and  in  Section  2.5.10.  As  production  of  RNA  from 
enhancers  has  been  associated  with  lineage  specific  gene  expression 
[385,  387,  421,  425,  428,  429,  558-560],  I  first  examined  T-bet  super-
enhancer for their lineage specific transcription. Figure 4.6.A illustrates the 
average profile of RNA production at T-bet bound sites in super-enhancers 
in Th1 and Th2. Donor 1 does not exhibit differential RNA production from 
these  sites.  This  lack  of  lineage  specific  transcription  at  these  sites  is 
reflected  in  the  microarray  data,  which  showed  poorer  polarisation, 
particularly in respect to IL4 expression (Figure 4.5). Donor 2, which was 
well polarised according to transcription factor and cytokine expression as 
measure by microarray (Figure 4.5), exhibited a clear greater production of 
RNA at super-enhancers in Th1 cells. Figure 4.6.B shows the cumulative 
distribution  of  RNA  production  from  these  sites,  which  has  a  maximum 
difference between Th1 and Th2 cells of 0.2082 from donor 2, which is 
statistically significant (P<10
-3).     191 
 
Figure 4.6: T-bet super-enhancers show lineage specific RNA production 
Comparison  of  RNA  production  in  T-bet  super-enhancers  in  Th1  and  Th2  cells.  A: 
Average profile of RNA (reads/million mapped reads) in super-enhancers centered on T-
bet site locations in Th1 cells. B: Cumulative frequency distributions for the amount of 
RNA produced from these sites in Th1 and Th2 cells. KS tests on distributions showed no 
statistical difference for donor 1 (D: 0.1115; P: 0.065) but donor 2 showed a maximum 
difference of 0.2082 (P<10
-3). RPKM: reads per kilobase per million mapped reads.    
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Stimulation of CD3 and CD8 is required for T cells to become activated 
and  elicit  a  pro-inflammatory  response.  This  stimulation  leads  to 
remodelling of lineage-specific and effector loci, such as IFNG [228, 337, 
338]. To see if this stimulation affects the transcriptional activity of super-
enhancers,  I  compared  RNA  sequencing  data  from  Th1-polarised 
unstimulated and restimulated cells. Similar to Figure 4.6, donor 1 did not 
show this trend, which reflects the poor polarisation seen in this donor.  As 
Figure 4.7 shows, restimulated cells from donor 2 exhibited increased RNA 
production at super-enhancers than unstimulated cells. This is seen in the 
average  profile  around  T-bet  sites  Figure  4.7.A  and  the  maximum 
difference  in  cumulative  distribution  of  RNA  between  unstimulated  and 
restimulated  cells,  0.1190  (Figure  4.7.B),  is  statistically  significant 
(P=0.041, KS test).      193 
 
Figure 4.7: RNA production at super-enhancers increases upon stimulation 
Comparison of RNA production in T-bet super-enhancers in Th1 cells before and after 
stimulation. A: Average profile of RNA (reads/million mapped reads) centered on T-bet 
sites. B: Cumulative frequency distributions for the amount of RNA produced from these 
sites  before  and  after  stimulation.  KS  tests  on  distributions  showed  no  statistical 
difference for donor 1 (D: 0.0967; P: 0.153) but donor 2 showed a maximum difference of 
0.1190 (P: 0.041). RPKM: reads per kilobase per million mapped reads.    
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4.2.3  Characterisation of super-enhancer eRNAs at specific 
genes  
RNA-Sequencing  data  was  processed  for  visual  representation  in  the 
UCSC genome browser as described in Section 2.5.9. This allowed visual 
inspection  of  specific  super-enhancer  loci  at  Th1  relevant  genes  in 
comparison with ChIP-Seq data. Figure 4.8 shows four super-enhancers, 
which are proximal to genes expressed in Th1 cells. This includes the Th1 
specific  cytokine  IFNG  and  Th1  lineage-specifying  transcription  factor 
TBX21  (T-bet)  in  addition  to  the  cytotoxic  serine  protease  GZMB 
(Gramzyme B), which has been associated with Th1 cells  [561] and the 
pro-protein protease FURIN, which is preferentially expressed on Th1 cells  
[562]. At each super-enhancer the presence of transcripts can be seen in 
the  total  RNA  fraction  from  Th1  restimulated  cells.  In  accordance  with 
average profiles (panel A from Figure 4.6 and Figure 4.7) and cumulative 
frequency distributions (panel B from Figure 4.6 and Figure 4.7) of RNA 
production around T-bet sites, these transcripts are specific to Th1 cells 
and increase upon restimulation. As the ChIP-Seq data shows, this eRNA 
production is coincident T-bet binding with the most abundant RNA-Seq 
reads aligning with T-bet peaks. A role for T-bet in this eRNA production is 
also  suggested  by  the  presence  of  RNAPII  at  T-bet  sites.  In  addition, 
RNAPII binding at these eRNA loci increases with stimulation and P-TEFb 
binding also follows this trend. In addition, as the presence of H3K4me3 at 
enhancer RNA loci is debated  [289, 293, 344, 356], I examined ChIP-Seq 
data available from our lab, confirming that these eRNA loci are marked by 
H3K4me3 (Figure 4.8).   195 
 
Figure 4.8: Characterisation of super-enhancer eRNAs at specific genes 
(See previous page) RNA-Seq and ChIP-Seq data at super-enhancers near several Th1 relevant genes were visualised using the UCSC genome 
browser. ChIP-Seq data shows T-bet binding from two replicate experiments, P-TEFb and RNAPII binding in unstimulated and restimulated cells 
and H3K4me3 RNA-Seq tracks show positive (+) and negative (-) strand data from Th1 restimulated total RNA (red) in comparison with RNA-Seq 
from Th2 (blue) and unstimulated (grey) cells and RNA from the polyadenylated fraction (green). Red bars at the bottom and dotted lines specify 
super-enhancer locations and genes proximal to these are annotated, From left to right are super-enhancers upstream of IFNG (IFNγ), TBX21 (T-
bet. This super-enhancer also overlaps with TBKBP1 [TBK1 binding protein 1]), GZMB (granzyme B) and FURIN (furin). All data are from donor 2. 
US: unstimulated; RS: restimulated. 
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4.2.4  Super-enhancer eRNAs are not polyadenylated 
Comparison with RNA-Seq data from the polyA+ fraction shows that these 
eRNAs are enriched in the total RNA fraction (Figure 4.8) demonstrating 
that they lack polyadenylation, a feature that has been reported of other 
enhancer RNAs  [420, 421]. To examine if this was a genome-wide feature 
of super-enhancer transcripts I compared total and polyA+ RNA fractions in 
terms of the average profiles and cumulative distribution of RNA production 
around T-bet sites at super-enhancers. As Figure 4.9 shows, the total RNA 
fraction  from  donor  2  showed  clear  enrichment  of  RNA  from  enhancers 
compared  to  the  polyA+  purified  fraction.  The  maximum  difference  in 
distribution  was  0.1673  (P=0.001).  For  donor  1,  which  showed  poorer 
polarisation by microarray than donor 2 (Figure 4.5), a small enrichment 
was seen in total RNA (D:0.1041) which was not significant (P=0.102). 
     197 
 
Figure 4.9: Super-enhancer eRNAs RNA are not polyadenylated 
Comparison  of  RNA  production  in  T-bet  super-enhancers  in  Th1  cells  from  total  and 
polyA+  purified  fractions.  A:  Average  profile  of  RNA  (reads/million  mapped  reads)  in 
super-enhancers centered on T-bet site locations. B: Cumulative frequency distributions 
for the amount of RNA produced from these sites. KS tests on distributions showed no 
statistical  difference  for  donor  1  (D:  0.1041  P=0.102)  while  for  donor  2  the  maximum 
difference,  D,  was  0.1673  (P=0.001).  RPKM:  reads  per  kilobase  per  million  mapped 
reads.   
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4.2.5  T-bet  sites  at  super-enhancers  produce  more  RNA 
than those at typical enhancers 
As  transcription  at  enhancers  has  been  shown  to  be  important  for 
enhancer function [386, 421, 427] I sought to compare the amount of RNA 
produced from super-enhancers and typical enhancers. Super-enhancers 
are distinguished from typical enhancers by an increased presence of T-
bet.  This  T-bet  binding  occurs  over  extended  genomic  regions  with  the 
boundary of the enhancer being defined by an absence of further T-bet 
binding in an additional 15kb window from the last peak. Super-enhancers 
are  in  essence  more  extended  stretches  of  T-bet  bound  DNA  and  are 
therefore longer than normal enhancers. To account for this, rather than 
comparing  the  whole  length  of  the  enhancer  for  RNA  production,  I 
focussed on the region within close proximity of each T-bet binding site. To 
distinguish  eRNAs  from  other  transcripts,  I  excluded  T-bet  sites  at 
enhancers that overlapped with known protein coding and lincRNA genes 
and repeats (tRNA, rRNA, snRNA). As Figure 4.10 shows, T-bet sites at 
super-enhancers  were  associated  with  increased  production  of  RNA 
compared  to  those  at  typical  enhancers.  This  is  demonstrated  by  the 
average profile of RNA over the genomic site in Figure 4.10.A and also 
through the cumulative distribution of RNA from T-bet sites, Figure 4.10. B. 
Comparison of the cumulative distributions of super-enhancers and typical 
enhancers  showed  that  the  maximum  difference  in  distribution,  D,  was 
0.2132 (P <10
-3) for donor 1 and 0.2122 for donor 2 and that this increase 
in  RNA  production  is  statistically  significant  (P  <10
-3  for  both  donors). 
Figure 4.10.C. demonstrates that for both donors, super-enhancers were 
more  likely  to  produce  RNA  than  typical  enhancers  (65%  and  70%  for   199 
super-enhancers compared to 45% and 50% for typical enhancers) and 
had  a  higher  median  RPKM  (0.01  and  0.027  for  super-enhancers 
compared to 0 and 0.003 for typical enhancers). Therefore increased T-bet 
binding correlates with increased transcription.      200 
 
Figure 4.10: Super-enhancers produce more RNA than typical enhancers 
Comparison of amount of RNA produced from super-enhancers and typical enhancers. A: 
Average profile of RNA (reads/million mapped reads) at T-bet sites and super-enhancers 
compared to typical enhancers. Profiles are centered on T-bet sites and show a flank of 
1kb each side. B: Cumulative frequency distributions for amount of RNA measured as 
RPKM produced from super-enhancers and typical enhancers. KS tests on distributions 
showed a maximum difference of  0.2132 (P<10-3) and 0.2122 (P<10-3) for donor 1 and 2 
respectively. C: Comparison of T-bet sites at super-enhancers and typical enhancers in 
terms of the proportion that exhibit RNA production and their median RPKM. RPKM: reads 
per kilobase per million mapped reads.   
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4.2.6  Super-enhancer transcription is bidirectional 
Several publications have reported bidirectional transcription from loci with 
potential  roles  in  regulating  gene  expression.  This  includes  short  RNAs 
produced from transcription start sites  [412, 413] and promoter upstream 
transcripts (PROMPTs) which are commonly found 0.5-2.5kb upstream of 
protein coding genes  [417, 418, 434] and some descriptions of enhancer 
RNAs    [420-423].  Bidirectional  transcription  has  not  however  been 
previously  examined  at  super-enhancers.  The  super-enhancer  images 
presented in Figure 4.8 indicate that some transcript start sites exhibit this 
bidirectional  character.  Clear  examples  can  be  seen  in  the  super-
enhancers upstream of GZMB and FURIN (Figure 4.8). I therefore sought 
to quantify the bidirectional character of super-enhancer transcription using 
the same 1kb flanking regions around T-bet sites as described in Sections 
4.2.2 to 4.2.5. Bidirectional transcription was mathematically defined as a 
lower than 2-fold difference in RNA-Seq read count between the regions 
up and downstream of a T-bet site (i.e. equal transcription each side of a 
T-bet  site,  log2  ratio  of  -1  to  +1,  Figure  4.11).  Transcription  with 
directionality was defined as a greater fold difference (log2 ratio of <-1 or 
>+1). As Figure 4.11 shows, I compared transcription from T-bet sites at 
super-enhancers  with  typical-enhancers  and  with  the  transcription  start 
sites of RefSeq annotated genes, which are expected to show directional 
transcription.  As  expected,  transcription  from  annotated  genes  exhibited 
clear directionality, shown by a high proportion of TSSs with an unequal up 
versus downstream read count ratio. Only 19% of TSSs showed unbiased 
directionality in their transcription while 81% showed a read count ratio of 
more than 2. Super-enhancers and typical enhancers differed from gene   202 
TSSs  with  around  a  third  of  sites  exhibiting  equal  directionality  in 
transcription.  This  is  a  similar  proportion  of  bidirectional  transcription  as 
published  for  other  enhancers    [421].  Super-enhancers  and  typical 
enhancers  showed  comparable  proportions  of  bidirectional  transcription 
(35% and 33%, respectively). 
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Figure 4.11: Transcription from T-bet sites at super-enhancers is bidirectional 
The  directionality  of  transcription  around  T-bet  sites  in  super-enhancers  and  typical 
enhancers  was  quantitated  by  calculating  the  ratio  of  reads  upstream  (+  strand)  and 
downstream (- strand) of each site. Bidirectionality was defined as a fold difference of less 
than  2  (log2  ratio  between  -1  and  +1).  The  proportion  of  T-bet  sites  associated  with 
bidirectional transcription and with directional preference was calculated. The start sites of 
RefSeq annotated genes (genes) are given as a comparator expected to have directional 
preference. TSSs: transcription start sites. 
   
0.00 
0.15 
0.30 
0.45 
P
r
o
p
o
r
t
i
o
n
 
o
f
 
s
i
t
e
s
 
Log2 (+ strand read count / - strand read count) 
< -1  -1 to 1  > 1  < -1  -1 to 1  > 1  < -1  -1 to 1  > 1 
TSSs of genes  T-bet sites at  
super-enhancers 
T-bet sites at  
typical enhancers   204 
4.2.7  T-bet  is  required  for  IFNG  super-enhancer 
transcription 
Our lab and others have described elements around the Ifng locus that are 
highly conserved and bound by T-bet [245, 246, 337-340]. These sites are 
DNaseI hypersensitive and marked by H3K4me1, which are features of 
enhancers  [246,  344,  346].  Similar  sites  are  seen  genome-wide  at 
locations distal to Th1-specific genes with T-bet binding being required for 
expression of these genes [246]. Figure 4.12 illustrates the position of T-
bet sites distal to the Ifng/IFNG locus in mouse and human showing their 
locations relative to the IFNG super-enhancer and RNA sequencing data in 
human.  In  other  literature  these  conserved  non-coding  sequences  have 
been referred to by their locations in mouse relative to Ifng: CNS-6 (Human 
-3.8kb in Figure 4.12), CNS-22 (-15.7kb and -16kb), CNS-34 (-30kb and -
30.4kb).     205 
 
Figure 4.12: T-bet sites distal to Ifng/IFNG in mouse and human 
T-bet binding sites distal to Th1-specific genes have been previously published and are 
exemplified by those at the Ifng/IFNG locus. These binding sites are conserved between 
mouse and human and are illustrated here in relation to the IFNG super-enhancer and 
RNA sequencing data. Dotted lines link up corresponding conserved sites. The murine 
locus is shown in its reverse orientation. +: positive strand; -: negative strand. 
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To test if this T-bet binding was necessary for eRNA transcription from the 
IFNG  super-enhancer,  naïve  CD4  T  cells  from  wild  type  and  T-bet 
knockout  (Tbx21
-/-)  mice  were  cultured  under  Th1  and  Th2  polarising 
conditions and the level of eRNA at these sites assess by qPCR (Figure 
4.13,  cultures  performed  by  Ian  Jackson).  Similar  to  the  trend  visible 
through RNA sequencing (Figure 4.8), eRNAs transcribed from the super-
enhancer (-40kb, -38.7kb, -29kb, -26kb and -10kb) were increased in Th1 
compared  to  Th2  cells  and  were  transcribed  at  a  greater  level  in 
restimulated compared to unstimulated cells. This pattern was reflected in 
the expression of Ifng itself. In contrast, most downstream transcripts were 
decreased  with  restimulation  and  naïve  Th1  progenitor  cells  showed  a 
higher level of -26kb transcript than Th1 cells (Figure 4.13), demonstrating 
the  complexity  of  non-coding  transcription  that  may  be  involved  in 
regulating  Ifng  expression.  With  loss  of  T-bet,  expression  of  all  these 
targets was reduced. This was also true of transcripts downstream of Ifng 
(+25kb, +35kb, +41kb, +60kb) while the housekeeping gene Gapdh did not 
show this trend Figure 4.13). This demonstrated that full transcription of 
eRNAs from the IFNG super-enhancer, and other enhancers at the Ifng 
locus, requires T-bet binding.  
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Figure 4.13: T-bet is required for Ifng super-enhancer transcription 
Naïve T cells from WT and T-bet knockout (Tbx21
-/-) mice were cultured under Th1 and 
Th2  polarising  conditions  and  harvested  at  48  hours  and  7  days  with  and  without 
restimulation. QPCR was performed for Ifng and several eRNA loci up and downstream. 
Targets are shown in order of their distance to Ifng and named with reference to this. Ifng 
and eRNAs upstream showed an increase upon stimulation, which was limited upon loss 
of  T-bet.  Downstream  eRNAs  however,  while  their  full  expression  requires  T-bet,  are 
decreased upon stimulation. The housekeeping gene Gapdh does not show these trends. 
Enrichment  is  normalised  to  Hprt.  Data  are  mean  and  standard  deviation.  US: 
unstimulated; RS: restimulated.   
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4.2.8  IFNG upstream eRNA transcription is dependent upon 
P-TEFb 
As  described,  our  lab  has  observed  that  transcriptional  regulation  of 
lineage-specific gene expression occurs at the point of elongation rather 
than initiation (Figure 4.2.A, Richard Jenner). ChIP-Seq of the elongation 
factor  P-TEFb  shows  that  lineage-specific  processivity  of  RNAPII  and 
recruitment  of  P-TEFb  is  enriched  at  genes  associated  with  super-
enhancers  compared  to  those  at  typical  enhancers,  implying  that  the 
greater  T-bet  binding  seen  at  super-enhancers  is  associated  with 
increased  transcriptional  elongation  through  P-TEFb  recruitment  (Figure 
4.2.B, Richard Jenner). Supporting this, the coincident localisation of T-bet 
and  P-TEFb  at  Th1  loci  can  be  seen  in  Figure  4.8.  As  greater  RNA 
production is also seen at super-enhancers compared to typical enhancers 
(Figure 4.10), I hypothesised that P-TEFb binding at super-enhancers is 
required for super-enhancer eRNA transcription. To test this, mouse naïve 
T cells were cultured under Th1 and Th2 polarising conditions with and 
without treatment with inhibitors of P-TEFb (Arnulf Hertweck). Two P-TEFb 
inhibitors were used: JQ1, which blocks the histone acetyl recognising BET 
domain  of  BRD4  that  functions  in  P-TEFb  recruitment    [381];  and 
Flavopiridol, which inhibits the kinase activity of the Cdk9 subunit of P-
TEFb that phosphorylates RNAPII  [380]. 
 
Figure 4.14 displays the effect of inhibition of P-TEFb recruitment with JQ1 
while  Figure  4.15  shows  the  effect  of  inhibition  of  P-TEFb  activity  with 
Flavopiridol. As expected Ifng expression and transcripts around the Ifng 
locus  were  increased  in  Th1  compared  to  Th2  cells.  Consistent  with 
experiments with human cells (Figure 4.7, Figure 4.12), restimulation of   209 
mouse Th1 cells also led to an increase in eRNA upstream of Ifng while 
transcripts further downstream (+60kb in particular) were decreased upon 
restimulation (Figure 4.12). The increase in transcription of Ifng and eRNAs 
is  reduced  in  the  presence  of  both  JQ1  (Figure  4.14)  and  Flavopiridol 
(Figure 4.15) with dosage dependent effect observed. Restimulation and 
treatment with inhibitors did not affect the expression of the housekeeping 
gene Gapdh the expression of which is not lineage specific. Therefore the 
T-bet associated upregulation of eRNAs at the super-enhancer upstream 
of Ifng requires P-TEFb function. 
 
In  addition,  JQ1  and  Flavopiridol  differed  in  their  effect  on  transcript 
production downstream. While JQ1 had the same dose dependent effect 
as  at  upstream  targets  and  high  concentration  of  Flavopiridol  (10µM, 
Figure  4.15  [++])  also  inhibited  transcription,  treatment  with  a  lower 
concentration of Flavopiridol (1µM, Figure 4.15 [+]) lead to a seemingly 
paradoxical increase in transcription. This occurred with restimulated but 
not unstimulated cells and only in Th1-polarised cells. This reinforces the 
concept that regulation of non-coding transcripts around the Ifng locus is 
complex  with  transcripts  upstream  and  downstream  showing  differential 
response.     210 
 
Figure 4.14: P-TEFb inhibition with JQ1 diminishes eRNA transcription 
Naïve T cells were cultured in vitro under Th1 and Th2 polarising conditions for 13 days 
before treatment with the P-TEFb inhibitor JQ1. P-TEFb inhibition was performed with and 
without restimulation, for either 6 or 24 hours, with low or high concentrations of JQ1 or 
none at all. QPCR was performed for Ifng and several eRNA loci up and downstream. 
Targets are shown in order of their distance to Ifng and named with reference to this. Ifng 
and  eRNAs  upstream  showed  an  increase  upon  stimulation,  which  was  limited  with 
addition of JQ1 in a dose dependent manner. Due to limited material, two downstream 
targets were prioritised for analysis and showed the expected expression given the trend 
observed in Figure 4.13. The housekeeping gene Gapdh does not show these trends. 
Enrichment  is  normalised  to  Hprt.  Data  are  mean  and  standard  deviation.  US: 
unstimulated; RS: restimulatedJQ1. -: DMSO only; +: 50nM JQ1; ++: 500nM JQ1.   
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Figure 4.15: P-TEFb inhibition with Flavopiridol diminishes eRNA transcription 
Naïve T cells were cultured in vitro under Th1 and Th2 polarising conditions for 13 days 
before treatment with the P-TEFb inhibitor Flavopiridol. P-TEFb inhibition was performed 
with and without restimulation with low or high concentrations of Flavopiridol or none at all. 
QPCR was performed for Ifng and several eRNA loci up and downstream. Targets are 
shown in order of their distance to Ifng and named with reference to this. Ifng and eRNAs 
upstream  showed  an  increase  upon  stimulation,  which  was  limited  with  addition  of 
Flavopiridol in a dose dependent manner. Downstream targets showed the same trend 
observed in Figure 4.13 regarding restimulation and exhibited an unexpected increase 
with  the  lower  concentration  of  Flavopiridol.  The  housekeeping  gene  Gapdh  does  not 
show  these  trends.  Enrichment  is  normalised  to  Hprt.  Data  are  mean  and  standard 
deviation.  US:  unstimulated;  RS:  restimulated.  -:  DMSO  only;  +:1µM  Flavopiridol; 
++:10µM Flavopiridol.   
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4.2.9  Characterisation  of  novel  T-bet  super-enhancer 
eRNAs 
In  order  to  identify  novel  specific  transcripts,  RNA-Seq  data  was 
assembled into transcript structures using Cufflinks (John Ambrose) and 
transcripts  at  T-bet  super-enhancers  identified  as  described  in  Section 
2.5.9. RNAs overlapping repeats (tRNA, rRNA and snRNA) and the coding 
regions of Gencode annotated transcripts were excluded. As eRNAs do 
not  exhibit  splicing,  multi-exonic  transcripts  were  also  excluded.  The 
identities of all eRNAs at T-bet super-enhancers are described in Table 
7.30. This table details the coordinates and strand of each transcript and 
the super-enhancer it is transcribed from, which have been designated IDs 
based on their nearest protein-coding gene. The level of each transcript 
(FPKM)  in  each  condition  for  donor  2  is  also  given.  As  expected, 
transcripts at T-bet super-enhancers are transcribed at a higher level in 
total  RNA  from  restimulated  Th1  cells  compared  to  polyadenylated 
fractions, Th2 cells and unstimulated cells, showing that the general trends 
observed  genome  wide  in  Figure  4.6,  Figure  4.7  and  Figure  4.9  are 
features  of  each  individual  transcript.  Twenty-one  transcripts  were 
identified at the IFNG super-enhancer. These are described in Table 7.30 
and illustrated in Figure 4.16.      213 
 
Figure 4.16: Novel eRNAs at the IFNG super-enhancer 
Locations of individual eRNA transcripts at the IFNG super-enhancer as detailed in Table 
7.30. Their positions are shown relative to T-bet, P-TEFb and RNAPII binding sites and 
trimethylated  H3K4.  +:  positive  strand;  -:negative  strand.  RS:  restimulated;  US: 
unstimulated.    
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4.3  Discussion 
Observations  in  our  lab  have  has  shown  that  lineage-specific  gene 
expression during Th1 versus Th2 differentiation is primarily regulated at 
the point of transcriptional elongation rather than initiation (Figure 4.2.A). In 
addition,  lineage-specific  genes  that  exhibit  increased  transcriptional 
elongation are preferentially associated with super-enhancers (Figure 4.2), 
which are defined by increased binding of the lineage-specific transcription 
factor T-bet compared to typical enhancers.  
 
As  the  function  of  enhancers  has  been  associated  with  transcription  of 
ncRNAs,  termed  eRNAs  [421,  425,  428,  431],  I  investigated  the 
transcriptional output of super-enhancers. I report here that in addition to 
super-enhancer associated genes the super-enhancers themselves exhibit 
lineage-specific  transcription  (Figure  4.6)  and  transcription  is  increased 
upon  restimulation  (Figure  4.7),  showing  that  transcription  from  super-
enhancers mirrors that of associated protein coding genes. In addition, this 
super-enhancer  transcription  shows  characteristics  of  eRNA  that  have 
been associated with functional effects, including lack of polyadenylation 
(Figure 4.9, [420, 421]) and bidirectional transcription (Figure 4.11 [420, 
421]). Therefore the T-bet super-enhancers eRNAs identified here appear 
to be regulated and processed in the same manner as previously identified 
functional eRNAs. I have identified individual eRNAs produced from the T-
bet super-enhancer upstream of Ifng (Table 7.30) and at other T-bet super-
enhancers throughout the human genome (Table 7.30). As expected these 
are  higher  in  Th1  restimulated  cells  compared  to  Th2  cells  and 
unstimulated  cells  (Table  7.30).  Furthermore,  super-enhancers  produce   215 
more RNA than typical enhancers (Figure 4.10), which is consistent with 
the production of ncRNA being a functional effect of the increased T-bet 
occupancy  that  defines  super-enhancers.  Supporting  this,  loss  of  T-bet 
leads to reduced transcription of eRNAs from the Ifng super-enhancer and 
of  other  potential  regulatory  transcripts  downstream  of  the  Ifng  locus 
(Figure 4.13), suggesting that this transcription is a direct result of T-bet 
binding. The ultimate proof of a functional effect for these eRNAs would be 
to  knock  them  down  or  delete  them  without  affecting  DNA-dependent 
enhancer effects and demonstrating they are necessary for full expression 
of their associated genes. 
 
Lineage-specific  gene  expression  is  controlled  at  the  point  of 
transcriptional  elongation  and  at  super-enhancers  T-bet  binding  is 
colocalised with the elongation factor P-TEFb (Figure 4.8). I hypothesised 
that the elongation factor P-TEFb may have functional effects at super-
enhancers through transcription of eRNAs. Treatment with two inhibitors of 
P-TEFb,  which  block  activity  at  different  points,  reduced  transcription  of 
eRNAs at the Ifng super-enhancer (Section 4.2.8, Figure 4.14 and Figure 
4.15) suggesting that P-TEFb binding at T-bet sites is functional. This is 
consistent  with  lineage-specific  control  of  gene  expression  by  super-
enhancers being mediated through recruitment of P-TEFb by T-bet. 
 
The presence of H3K4me3 at enhancers has been debated  [293, 344]. 
However the super-enhancer eRNA loci I report here are associated with 
H3K4me3 (Figure 4.8). eRNA loci have instead been reported to exhibit 
higher  levels  of  H3K4me1  than  H3K4me3    [293,  344,  356].  As  I  lack 
H3K4me1 data for human Th1 cells I cannot confirm this. However it is   216 
interesting  to  note  that  at  the  IFNG  locus  the  level  of  H3K4me3  is 
comparable between the gene itself and the eRNAs upstream (Figure 4.8). 
At  other  super-enhancers  presented  here  (Figure  4.8)  there  is  greater 
enrichment  of  H3K4me3  at  the  gene  compared  to  eRNAs.  This  might 
suggest differences in regulation or activity of eRNAs at different genes.  
 
Non-coding  transcripts  downstream  of  Ifng  (+25kb,  +35kb,  +41kb  and 
+60kb,Figure 4.13,Figure 4.14 and Figure 4.15) were regulated differently 
to  those  at  the  Ifng  super-enhancer  (-40kb,  -29kb,  -25kb,  -10kb,Figure 
4.13,Figure 4.14 and Figure 4.15) with restimulation leading to a decrease 
in the level of RNA as assessed by qPCR (Figure 4.13). This response to 
stimulation  in  this  region  can  also  be  seen  through  RNA  sequencing 
(Figure 4.12). Corroborating this, Tmevpg1, a long ncRNA, which promotes 
Ifng  expression  in  mice,  has  been  previously  observed  to  be 
downregulated  in  response  to  stimulation    [463].  This  may  reflect 
differences  in  transcriptional  regulation  during  polarisation  compared  to 
those  that  occur  upon  restimulation.  The  exception  to  this  trend  is  the 
+13kb transcript, which is downstream of Ifng but is also upregulated upon 
stimulation  (Figure  4.13,  Figure  4.14  and  Figure  4.15).  As  Figure  4.12 
shows, this transcript corresponds to +21kb location in humans, which is 
bound by T-bet in our ChIP-Seq data. In Figure 4.8 P-TEFb can be seen to 
colocalise with T-bet. This shows that at this location downstream of Ifng 
there is the same relationship between T-bet, P-TEFb and production of 
RNA as at the Ifng super-enhancer. This common regulation may result 
from  the  Ifng  super-enhancer  and  the  downstream  region  immediately 
flanking  the  Ifng  gene  being  in  close  physical  proximity,  which  is 
suggestive  of  DNA  looping.    Binding  of  CTCF,  a  chromatin  insulator   217 
involved in DNA looping, has been previously described around the IFNG 
locus at several sites  [230]. An interaction between the published human -
31kb  and  +22kb  CTCF  locations    [230]  would  explain  the  common 
regulatory  events  stretching  from  the  IFNG  super-enhancer  (starting 
around  -30kb  in  human)  to  the  immediate  downstream  site  (+21kb  in 
human).  The  insulating  effect  of  CTCF  explains  why  the  same  trend  in 
regulation with stimulation does not extend beyond this region downstream 
of Ifng and into the IFNG-AS1 (Tmevpg1) locus.  
 
A difference was also seen between eRNA regulation and all downstream 
transcripts in a paradoxical increase in transcription downstream of Ifng 
upon  treatment  of  Flavopiridol  upon  stimulation  (+13kb,  +25kb,  +35kb, 
+41kb, +60kb, Figure 4.15). This could be explained by an accumulation of 
these  pre-transcribed  RNA  at  a  post-transcriptional  level  or  off-target 
effects  of  Flavopiridol  that  increase  transcription.  This  upregulation  in 
transcript  level  at  particular  sites  with  Flavopiridol  treatment  has  been 
reported in human fibroblasts  [563] with increased RNAPII occupation at 
gene  bodies  also  noted  showing  that  this  effect  is  due  to  increased 
transcriptional  elongation.  This  suggests  a  P-TEFb  independent 
mechanism for elongation of RNAPII at some loci, which is supported by 
an  observation  that  inhibition  of  Cdk9  with  another  inhibitor,  DRB,  has 
limited effect on the level of some transcripts  [386]. In addition, as JQ1 did 
not have the same effect as Flavopiridol, this effect may be a response to 
Cdk9 inhibition, which is targeted by Flavopiridol but not JQ1. In addition to 
its  role  in  phosphorylating  RNAPII,  Cdk9  has  addition  roles  including  in 
guiding chromatin modifications  [564]. In this context of human fibroblasts, 
upregulation with Flavopiridol treatment was also seen at specific immune   218 
responsive loci and was suggested to be a stress induced response to P-
TEFb inhibition  [563]. This could suggest the region downstream of Ifng 
responds  differently  to  inflammatory  signals  than  the  upstream  region 
allowing  variable  response  to  the  locus  depending  on  environmental 
stimulus.  
The  observed  differences  in  regulation  between  super-enhancer  eRNAs 
and those downstream of Ifng, including Tmevpg1, illustrate the complexity 
of ncRNA transcription around the Ifng locus. 
     219 
5  Functional  roles  of  the  identified  lineage  specific  of 
ncRNAs 
5.1  Introduction 
I have identified ncRNAs that differ in expression between T cell lineages 
and  may  have  functional  implications  for  lineage  specification.  This 
includes  the  identification  of  long  intergenic  ncRNAs  preferentially 
expressed  in  primary  human  Treg  compared  to  Tresp  (Chapter  3)  and 
enhancer RNAs with Th1 specific expression (Chapter 4). A key question 
is whether or not these ncRNAs are functional, whether instead it is the act 
of transcription of the RNAs that is important rather than the RNA itself, or 
whether the RNAs are merely transcriptional “by-products” with no role in 
the cell.  
 
Examination  of  my  Treg  lincRNA  data  and  the  surrounding  literature 
suggested two RNAs were the best candidates for having a function in 
Treg biology.  CRNDE is upregulated in colorectal cancer [524] and other 
cancers  [524,  548]  and  the  high  expression  in  ESCs  [442]  and  the 
decrease in expression with specialisation [526] have led to an association 
of CRNDE with a cycling stem-cell state. An unspliced CRNDE transcript 
containing a highly-conserved intronic region has been shown to promote 
growth and suppresses apoptosis in fibroblasts [526]. Additional unspliced 
transcripts  are  downregulated  by  insulin  signalling  through  mTOR  and 
Raf/MAPK  [550]  and  knockdown  of  these  transcripts  impacts  upon 
processes  downstream  of  insulin  such  as  glucose  and  lipid  metabolism 
[550]. A physical association has been identified between CRNDE and the 
chromatin-modifying complexes PRC2 and CoREST using native RNA IP   220 
[441],  leading  to  the  suggestion  that  the  CRNDE  transcript  may  target 
recruitment of these complexes with effects on regulation of transcription. 
 
A second candidate is LOC286442. While there is no published data on 
the function of this uncharacterised lincRNA, LOC286442 had the highest 
fold-difference between Treg and Tresp of any identified lincRNA by array 
(13.9 fold, Figure 3.3). In addition, FOXP3 binding was apparent at the 
promoter  and  in  intronic  regions  (Figure  3.6),  supporting  Treg-specific 
regulation of the LOC286442 gene. 
 
Enhancer  RNAs  have  been  found  to  contribute  to  enhancer  function  in 
other  cell  types.  Transcription  from  T-bet  super-enhancers  is  increased 
compared to typical enhancers (Figure 4.10) and this transcription is Th1 
specific  (Figure  4.6).  RNAPII  binding  co-localises  with  the  Th1  lineage-
specifying  transcription  factor  T-bet  and  the  transcriptional  elongation 
factor P-TEFb, with loss of T-bet and inhibition of P-TEFb limiting super-
enhancer eRNA transcription (Figure 4.13 and Figure 4.14, respectively). 
This suggests T-bet may function at super-enhancers to recruit P-TEFb to 
lineage specific genes. I have identified the individual transcripts produced 
from the super-enhancer upstream of IFNG and hypothesised that super-
enhancer eRNAs also have a functional impact on gene expression.  
5.1.1  Knockdown strategies to interrogate ncRNA function 
One  method  to  interrogate  ncRNA  function  is  through  knockdown 
approaches,  using  RNA  interference  (RNAi).  Figure  5.1  illustrates  the 
mechanisms and cellular machinery involved in knockdown of coding and 
non-coding  transcripts  through  RNAi  in  order  to  assess  how  their  loss   221 
affects cellular function. These mechanisms include short interfering RNA 
(siRNA) and short hairpin RNA (shRNA), which require delivery into the 
cell  through  transfection  or  vector  (including  viral  vectors)  transduction, 
respectively.  Both  mechanisms  rely  upon  the  cellular  machinery  that 
processes  and  enacts  endogenous  post-transcriptional  gene  silencing 
(PTGS)  through  genomically  encoded  microRNAs  (miRNA).  The 
requirement  for  cytoplasmic  processing  machinery  potentially  limits  the 
effectiveness of shRNA for knockdown of non-coding transcripts that may 
be  localised  to  the  nucleus.  As  shown  in  Figure  5.1,  cell  intrinsic  RNA 
interference  is  mediated  by  genomically  encoded  microRNAs  (miRNA). 
miRNAs are transcribed as long primary transcripts called pri-miRNAs that 
are then processed by Drosha in the nucleus [565, 566] to the pre-miRNA 
form, which consists of a stem-loop structure formed by complementary 
base pairing. This pre-miRNA is a substrate for export to the cytoplasm by 
Exportin5 [567], where it is further processed by Dicer [568] to a mature 
miRNA  for  loading  into  the  Argonaut/RISC  (RNA  induced  silencing 
complex) complex [569, 570]. Argo/RISC catalyses the separation of the 
passenger  (sense)  guide  (anti-sense)  miRNA  strands  and  guides  the 
annealing of the passenger strand with its complementary seed region in 
the  3’  untranslated  region  (UTR)  of  the  target  mRNA.  With  full 
complementarity this annealing leads to transcript accumulation within P-
bodies where degradation occurs [571, 572], while partial complementarity 
leads  to  translational  repression  [571],  both  of  which  ultimately  lead  to 
reduced expression of the protein encoded by the target mRNA. Figure 5.1 
illustrates how shRNA, which resembles the pri-miRNA form, co-opts this 
process. siRNAs can be introduced into cells through transfection, either   222 
using electroporation/nucleofection or using liposomes, and already being 
in  a  mature,  pre-processed  form,  siRNAs  are  directly  loaded  into 
Argonaut/RISC  complex  in  either  the  cytoplasm  or  nucleus  [573].  A 
potential advantage of using siRNA is that it by-passes the requirement for 
Dicer, which is generally thought to be restricted to the cytoplasm [574]. 
5.1.1  Locked  nucleic  acids  as  an  alternative  strategy  to 
knockdown ncRNAs 
Several  publications  have  recently  described  the  use  of  locked  nucleic 
acids  (LNA)  for  the  knockdown  of  ncRNA  targets  ([421,  427]).  LNAs 
contain  a  ribose  moiety  with  a  covalent  bond  between  the  2’  and  4’ 
oxygens [575, 576]. This bridge locks the ribose conformation, enhancing 
the stability, specificity and sensitivity of base pairing with a target [577]. 
LNAs  can  also  contain  DNA  or  RNA  nucleotides,  as  either  mixmers,  in 
which the LNAs are interspersed with the regular nucleotides, or gapmers, 
in  which  the  LNAs  flank  a  stretch  of  DNA  or  RNA.  Annealing  of  an 
antisense  LNA-DNA  gapmer  with  a  target  complementary  RNA  can  be 
used  to  degrade  target  RNAs  through  enzymatic  cleavage  by  RNaseH, 
which recognises DNA:RNA hybrids [578]. In addition, LNA hybridisation 
may sterically block the activity of a transcript [579]. Due to the stability of 
LNA, entry into a cell can be mediated through gymnosis [580] i.e. entry 
into the cell in parallel with nutrients during normal cell growth.     223 
 
Figure 5.1: Knockdown mechanisms mediated by cellular RNAi machinery 
RNA  interference  mechanisms  include  endogenous  microRNA  (miRNA),  short  hairpin 
RNA  (shRNA)  and  short  interfering  RNA  (siRNA).  Pri-pre-miRNA  are  processed  by 
Drosha in the nucleus to their pre-miRNA form, which is exported to the cytoplasm by 
Exportin5. Here, further processing is performed by Dicer to form a mature miRNA for 
loading  into  the  Argonaut/RISC  complex.  Argo/RISC  catalyses  the  separation  of  the 
passenger (sense) guide (anti-sense) miRNA strands and guides the annealing of the 
passenger strand with its complementary seed region in the 3’ untranslated region (UTR) 
of the target mRNA. shRNA, which is transcribed in the nucleus after transduction of a 
viral vector co-opts this process. Short interfering RNA however, enters the cell through 
electrical or chemical induction of membrane pores through transfection, and being in a 
mature, pre-processed form, is directly loaded into Argonaut/RISC complex in either the 
cytoplasm or nucleus. RISC: RNA induced silencing complex.   
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5.1.2  Aims 
In the experiments below I have attempted to explore the functional roles 
of the Treg lincRNAs I identified in Chapter 3 and of the super-enhancer 
eRNAs I identified in Chapter 4. I first sought insights into the biological 
roles  of  the  Treg  lincRNAs  though  gene  ontology  of  co-regulated 
transcripts identified by hierarchical clustering. I then optimised knockdown 
approaches in order to investigate the effect of the loss of these lincRNAs 
on  Treg  phenotype  and  super-enhancer  eRNAs  on  downstream  gene 
expression using the IFNG locus as a model. 
 
1.  To use Gene Ontology to identify potential biological roles for Treg 
lincRNAs based on the co-regulated genes with which they cluster. 
2.  Optimise strategies to knock-down lincRNAs in Tregs using siRNAs. 
3.  Optimise  the  use  of  LNA  oligonucleotides  for  interrogating  eRNA 
function in Th1 cells. 
     225 
5.2  Results 
5.2.1  Genes  and  biological  processes  associated  with 
CRNDE 
In order to identify biological process that are relevant to CRNDE function, 
I examined genes with known functions that exhibited expression patterns 
similar  to  CRNDE.  This  “guilt-by-association”  approach  has  previously 
been  used  to  provide  insights  into  potential  functions  for  unannotated 
genes [441]. Genes were identified by hierarchical clustering of microarray 
data (Section 2.5.2). As Figure 5.2.A illustrates, the genes with the most 
similar expression, as shown by their proximity in the cluster, included TKK 
(TTK protein kinase [MSP1]), a spindle checkpoint kinase [581], DSCC1 
(Defective in sister chromatid cohesion 1), an S phase replication factor 
[582], ASPM (abnormal spindle homolog), KIF23 (kinase family member 
23)  and  GXYLT2  (glucoside  xylosytransferase  2).  This  small  cluster 
therefore  appeared  relevant  to  cell  cycling.  A  larger  cluster  of  genes 
allowed  identification  of  statistically  significantly  associated  biological 
processes through gene ontology (304 genes, P (adjusted) <0.05). These 
biological processes also included cell cycling thereby also reflecting the 
local  cluster  of  genes  Figure  5.2.B.  To  select  for  genes  with  the  most 
relevance to Treg biology, I identified genes in this cluster that were also 
differentially expressed between Treg and Tresp (Figure 3.2.A, Table 7.1 
and  Table  7.2).  From  this  list  of  genes  (Table  7.31)  those  of  particular 
relevance to Treg biology included TNFRSF8 (also known as CD30) and 
TNFRSF9 (known as CD137 and 4-1BB). CD30 is preferentially expressed 
on activated compared to resting lymphocytes, in agreement with the array 
data  (Figure  5.2)  and  is  relevant  to  Treg  function  in  the  context  of   226 
autoimmunity  through  limitation  of  autoreactive  CD8  T  cell  proliferation 
[583], while signalling via 4-1BB promotes Treg expansion [221, 584, 585]. 
MKI67 (ki67) was also of interest because, although its expression is not 
specific to Treg function, it is commonly used as a proliferation associated 
antigen in Treg assays. I hypothesised that CRNDE may have a role is 
these processes through regulating the expression, directly or indirectly of 
ki67, CD30 and/or 4-1BB.      227 
 
Figure 5.2: Genes and biological processes associated with CRNDE expression. 
Genes with similar expression patterns to CRNDE as identified by hierarchical clustering 
were used in a ‘guilt-by-association’ approach to identify biological processes other genes 
with possible relevance to CRNDE function. A: The genes with most similar expression to 
CRNDE. B: A larger cluster of genes were used in gene ontology to identify biological 
processes associated with CRNDE expression (304 genes, P (adjusted) <0.05). C: These 
genes were compared with those differentially expressed between Treg and Tresp (476 
genes, Figure 3.2.A, Table 7.1Table 7.2) to identify those with those most relevant to Treg 
biology. From this list (Table 7.31) MKI67, TNFRSF8 and TNFRSF9 were recognised as 
particularly interesting. TKK: TTK protein kinase; DSCC1: Defective in sister chromatid 
cohesion  1;  ASPM:  abnormal  spindle  homolog;  KIF23:  kinase  family  member  23; 
GXYLT2: glucoside xylosytransferase 2.   
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autoimmunity through limiting autoreactive CD8 T cell 
proliferation 
[583] 
TNFRSF9 (4-1BB, 
CD137) 
Downstream signalling leads to Treg expansion  [584]   228 
5.2.2  CRNDE expression in response to T cell activation 
To better understand the association between CRNDE expression and T 
cell activation and proliferation, I examined its expression during in vitro T 
cell polarisation cultures using the microarray and RNA-Seq data obtained 
in Chapter 4. Figure 5.3 shows the differential expression between naïve T 
cells and Th1 and Th2 cells. CRNDE had a notably higher expression in in 
vitro polarised cells compared to unactivated ex vivo naïve T cells. This is 
shown in relation to changes in expression of other Treg ncRNAs (Figure 
5.3.A). Most of these Treg ncRNAs did not show this trend. I confirmed this 
differential expression by qPCR (Figure 5.3.B) and RNA-Seq data (Figure 
5.3.C). This supports a role for CRNDE in general T cell activation rather 
than a specific involvement in Treg phenotype. Additionally, CRNDE also 
appeared to be upregulated in Th2 cells compared to Th1 cells.     229 
 
Figure 5.3: CRNDE is upregulated during T cell activation. 
Expression  of  CRNDE  was  examined  in  unactivated  naïve  T  cells  in  comparison  to 
activated  and  in  vitro  polarised  Th1  and  Th2  cells.  A:  Microarray  data  comparing 
expression of CRNDE and other Treg ncRNAs. ENST00000415387 is not shown as it was 
filtered  out  during  median  centering  of  array  data.  LOC100132741  was  not  qPCR 
validated as a Treg ncRNA in Section 3.2.2 due to its high repetitive sequence but is 
included here as its upregulation in unactivated naïve T cells was striking. B: Quantitative 
PCR confirming the differential expression of CRNDE between naïve cells and in vitro 
polarization cells. C: Examination of this trend using RNA-Seq data.     
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5.2.3  Isoforms of CRNDE present in primary human Treg 
There are 10 annotated isoforms of CRNDE (Figure 3.7) and biological 
associations  have  been  made  with  particular  isoforms.  For  example, 
gVCIn4 transcripts that contain a genomic region that is conserved among 
vertebrates are associated with promotion of growth and suppression of 
apoptosis  in  fibroblasts  [526].  Such  unspliced  transcripts  are 
downregulated  by  insulin  signalling  and  appear  to  be  antagonistic  to 
processes  downstream  of  insulin  signalling  such  as  glucose  and  lipid 
metabolism,  while  spliced  transcripts  are  not  [550].  Such  unspliced 
transcripts may represent nascent RNA which is still tethered to DNA and 
therefore  in  close  proximity  to  transcriptional  machinery  with  potential 
influence  on  transcriptional  regulation.  As  the  alternative  splicing  of 
CRNDE appears to have biological consequences, and as information on 
the  exons  included  would  inform  the  design  of  siRNA  for  knockdown,  I 
designed  isoform  specific  primers  to  determine  which  transcript  was 
expressed in primary human Treg. Figure 5.4 illustrates all 10 isoforms in 
relation to the regions detected by the microarray probe and qPCR primers 
and the relative enrichment of these amplicons in primary human Treg and 
Tresp. As this shows, the microarray probe and the original qPCR primers 
used for validation of microarray data (amplicon 1 [1F/R]) both detect exon 
6 of CRNDE and are therefore not informative of intron inclusion. qPCR 
primers to potential intronic unspliced transcripts, including exon 6 to intron 
6 (amplicon 2 [2F/R]) and gVCIn4 (amplicon 3 [3F/R]) show no detectable 
transcript  by  gel  electrophoresis  (Figure  5.4.B)  or  qPCR  (Figure  5.4.C), 
while a spliced isoform including exons 2 and 6 is present (Figure 5.4.B, 
amplicon  4  [4F/R])  and  is  more  abundant  in  Treg  compared  to  Tresp   231 
(Figure  5.4.C).  The  amplicon  representing  this  spliced  product  was 
expected  to  be  349bp  if  it  includes  the  longest  exon  5  annotation  but 
excludes exon 3. Gel electrophoresis confirmed an amplicon of this size in 
Treg  (Figure  5.4.B).  This  supports  the  presence  of  isoforms 
ENST00000559598  and  ENST00000502066  (Figure  5.4.A).  Products  at 
266bp  and  277bp,  which  reflect  ENST00000501177  and 
ENST00000559432, respectively, are not present (Figure 5.4.A, B). Could 
comment  on  whether  these  results  are  consistent  with  RNA-seq  data. 
Therefore CRNDE undergoes splicing in primary human Treg and spliced 
transcripts contribute to the differential expression seen between Treg and 
Tresp.     232 
 
Figure 5.4: Isoforms of CRNDE expressed in human primary Treg 
A: The 10 annotated isoforms of CRNDE. The approximate position of gVCIn4 described 
by Ellis et al. 2014 is shown by the red square. Locations of the regions detected by the 
microarray probe and qPCR primers are indicated. 1F and 1R correspond to the primers 
used for qPCR validation of CRNDE expression (Figure 3.4). B: The amplicons from the 
qPCR primers described in A in primary human Treg. C: The relative enrichment of each 
amplicon in Treg and Tresp. F: forward primer; R: reverse primer. E: exon.   
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5.2.4  Genes  and  biological  processes  associated  with 
LOC286442 
In order to gain insight into the role of LOC286442 in Treg, I took the same 
approach as described in Section 5.2.1 to identify biological processes with 
potential relevance to LOC286442 function. I identified genes with known 
functions  that  exhibited  expression  patterns  similar  to  LOC286442  by 
hierarchical clustering of microarray data (Section 2.5.2). As Figure 5.5.A 
illustrates,  the  majority  of  genes  with  the  most  similar  expression  were 
identifiable  by  accession  numbers  rather  than  HGNC  gene  symbols, 
implying their functions are not well understood. In accordance with this, 
literature  surrounding  these  genes  was  limited  and  so  their  expression 
does not inform LOC286552 function. A larger cluster of genes allowed 
identification  of  statistically  significantly  associated  biological  processes 
through gene ontology, as shown in Figure 5.5.B (200 genes, P (adjusted) 
<0.05). These biological processes included T cell specific processes such 
as  antigen  processing  and  presentation  and  regulation  of  lymphocyte 
development  and  T  cell  differentiation.  To  select  for  genes  with  most 
relevance to Treg biology, I identified genes in this cluster that were also 
differentially expressed between Treg and Tresp (Figure 3.2.A, Table 7.1 
and Table 7.2). From this list of genes (Table 7.32), several genes had 
notable  relevance  to  Treg  biology  not  least  FOXP3,  the  Treg  lineage-
specifying transcription factor [37-39]. Also present in this list was Helios 
(IKZF2) a transcription factor that shows Treg-specific expression within 
the  peripheral  lymphocyte  compartment.  Within  Treg,  the  expression  of 
Helios has been proposed to be exclusive to thymically derived, ‘naturally-
occurring’ nTreg, as opposed to peripherally induced Treg [89], however   234 
this  assertion  has  proved  controversial  [90,  91,  587]  and  the  exact 
influence that Helios has over Treg function is not understood. In addition, 
expression  of  TNFR2  (TNFRSF1B)  was  also  seen  in  association  with 
LOC286442.  TNFR2  is  a  TNF  receptor,  which  has  been  frequently 
associated with Treg function [217-219]. For example, in both humans and 
mice TNFR2 ligation leads to Treg expansion [217, 220] and expression of 
TNFR2 identifies Treg with increased function [220] and through a potential 
negative feedback loop for the control of inflammation, TNF signalling has 
been  shown  to  stabilise  Treg  phenotype  through  TNFR2  [217-219].  I 
therefore  hypothesised  that  LOC286442  may  have  a  role  is  these 
processes  through  regulating  the  expression,  directly  or  indirectly  of 
FOXP3, IKZF2 (Helios) and/or TNFRSF1B (TNFR2).     235 
 
 
Figure 5.5: Gene and biological processes associated with LOC286442 expression 
Genes  with  similar  expression  patterns  to  LOC286442  as  identified  by  hierarchical 
clustering were used in a ‘guilt-by-association’ approach to identify biological processes 
other  genes  with  possible  relevance  to  LOC286442  function.  A:  The  genes  with  most 
similar expression to LCO286442. B: A larger cluster of genes were used in gene ontology 
to identify biological processes associated with LOC286442  expression (200 genes, P 
(adjusted)  <0.05).  C:  These  genes  were  compared  with  those  differentially  expressed 
between Treg and Tresp (476 genes, Figure 3.2.A, Table 7.1Table 7.2) to identify those 
with  those  most  relevant  to  Treg  biology.  From  this  list  (Table  7.32)  FOXP3,  IKZF2 
(Helios) and TNFRSF1B (TNFR2) were recognised as particularly interesting. SLC9A7P1: 
solute carrier family, subfamily A member 7 pseudogene 1.    
Gene  Relevance  References 
TNFRSF1B (TNFR2)  Expression and downstream signalling is associated with 
enhanced Treg function 
[37-39] 
FOXP3  Treg lineage-specifying transcription factor  [89, 93, 217]  
IKZF2 (Helios)  Transcription factor associated with nTreg compared to 
iTreg 
[219, 220] 
Donor  1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 
Treg  Tresp 
Naive  Memory  Naive  Memory 
XM_003118559 
LOC100131234 
ENST00000390247 
SLC9A7P1 
ENST00000432978 
LOC286442 
A 
B 
Genes 
differentially 
expressed 
between Treg 
and Tresp 
Genes with 
similar 
expression 
patterns to 
LOC286442 
Genes of potential interest 
C 
200 genes, 292 probes 
(476)  (200) 
(78) 
B
i
o
l
o
g
i
c
a
l
 
p
r
o
c
e
s
s
e
s
 
0  10  20  30  40 
Fold enrichment 
DNA damage response, signal transduction 
Cell cycle checkpoint 
DNA integrity checkpoint 
Regulation of T cell differentiation 
Regulation of lymphocyte development 
DNA damage checkpoint 
Antigen processing and presentation 
Recombinational repair 
Double-strand break repair via homologous recombination 
Antien processing and presentation of exogenous antigen   236 
5.2.5  siRNA  transfection  results  in  prohibitively  low  cell 
viability 
To assess the functional effects of CRNDE and LOC286442 ncRNAs in 
Treg  biology,  I  sought  to  knock  these  transcripts  down  and  assess  the 
effect of their loss on phenotype and function. As described in Sections 
5.2.1  and  5.2.4,  CRNDE  expression  was  associated  with  expression  of 
TNFRSF8 (CD30), TNFRSF9 (4-1BB) and MKI67 (ki67) while LOC286442 
expression was associated with TNFRSF1B (TNFR2), FOXP3 and IKZF2 
(Helios),  genes  that  have  relevance  to  Treg  function.  Therefore,  I 
hypothesised  that  CRNDE  and  LOC286442  may  contribute  to  Treg 
function  through  direct  or  indirect  influence  on  expression  of  their 
respective  associated  genes.  In  order  to  test  this,  I  designed  siRNAs 
against CRNDE and LOC286442 transcripts to assess the effect of loss of 
these ncRNAs on expression of these genes.  
 
As described in Section 5.1.1 and Figure 5.1, several strategies exist for 
knockdown of transcripts. As ncRNAs may function within the nucleus to 
influence  gene  expression  through  regulation  of  transcription,  and  as 
shRNA mediated gene expression requires cellular components restricted 
to the cytoplasm, I attempted knockdown using siRNA. In support of this 
approach,  siRNA  is  commonly  used  for  knockdown  of  non-coding 
transcripts    [449,  456,  588],  while  publications  involving  shRNA  for  this 
purpose  are  limited.  I  therefore  used  a  nucleofection  procedure 
recommended for unstimulated human T cells (Section 2.2.10.1  [469]). 
Assuming  transfection  would  not  be  efficient  for  100%  of  cells,  a 
fluorescent indicator (siGLO) was co-transfected with target siRNA (in a   237 
1:1 ratio) to allow selection for transfection competent cells by FACS. In 
addition,  a  greater  number  of  cells  per  transfection  condition,  with  a 
minimum of 7x10
5 but an ideal range of 5-10x10
6, were recommended for 
increased viability. National Blood Service buffy coats were used to obtain 
these  numbers  of  Tregs,  which  contribute  1%  of  PBMCs,  and  yielded 
around  10x10
6  Treg  per  donor  allowing  for  3  conditions  (knockdown  of 
FOXP3 and a Treg ncRNA alongside a non-targeting control) with 2x10
6s 
per  condition.  siRNA  to  Treg  ncRNAs  were  designed  using  an  online 
algorithm recommended by the manufacturer (Section 2.2.10.1,  [467]) and 
this was compared with an off-the-shelf siRNA to FOXP3. Knockdown was 
assessed in comparison to a non-targeting control. As Figure 5.6.A shows, 
siRNA  transfection  resulted  in  low  cell  viability  compared  to  an 
untransfected control, with 13.7% live cells after transfection, as indicated 
by lack of DAPI staining. This is in comparison with the manufacturer’s 
suggestion  of  80%  viability  [469].  The  transfection  efficiency  of  DAPI-
negative cells was 79.7% (Figure 5.6.B), which is much higher than the 
manufacturer’s suggestion of 40% [469], possibly indicating that the use of 
the  siGLO  transfection  indicator  does  not  accurately  reflect  transfection 
competency. I sorted the live population into siGLO-positive and negative 
fractions and, as the yield of cells was too low to perform functional assays 
(Figure  5.6.C),  assessed  the  knockdown  efficiency  of  the  commercially 
available FOXP3 siRNA compared to the siRNA I had designed to Treg 
ncRNA LOC286442. As Figure 5.6.D shows, the siRNA against FOXP3 
resulted in a 31% decrease in FOXP3 RNA compared to the non-targeting 
control.  However,  the  high  standard  error,  comparative  enrichment  of 
FOXP3 RNA in siGLO- controls and low cell viability limited the reliability of   238 
this  observation.  No  knockdown  was  seen  using  the  siRNA  targeted  at 
LOC286442.     239 
 
Figure 5.6: siRNA transfection results in prohibitively low cell viability 
In  order  to  investigate  the  functional  role  of  Treg  ncRNAs,  knockdown  was  attempted 
through transfection of siRNA A: Cell viability measured by DAPI staining. B: Transfection 
efficiency as measured with the siGLO transfection indication. C: Comparison of numbers 
of  cells  before  and  after  transfection  and  sorting  for  the  live,  transfection  competent 
population.  D:  Knockdown  efficiency  of  siRNA  targeted  against  FOXP3  and  the  Treg 
ncRNA LOC286442. 5S ribosomal RNA is shown as a housekeeping control. siGLO- cells 
were also collected as a negative control..   
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5.2.6  Increased cell number through Treg expansion does 
not aid knockdown  
The low cell viability post-transfection as shown in Section 5.2.5 (Figure 
5.6)  may  have  related  to  the  low  number  of  cells  at  the  point  of 
transfection: Although 2x10
6 cells were used, which is above the minimum 
recommendation of 7x10
5, the ideal range is 5-10x10
6 cells [469]. The use 
of primary human Treg, which at 1% of PBMCs are infrequent in peripheral 
blood,  limited  the  number  of  cells  per  condition  and  so  I  attempted  to 
increase cell number through in vitro expansion of Treg before performing 
transfections, as described in Section 2.2.8 For the use of stimulated cells 
1-5x10
6  cells  per  transfection  was  recommended  alongside  the  use  of 
alternative electroporation programs (Section 2.2.10.1, [469]). I therefore 
compared  these  recommended  Amaxa  programs  and  using  various  cell 
numbers. As Table 5.1 demonstrates, increasing the number of cells and 
altering the transfection program used did not improve cell viability. 
 
Table 5.1: Changes in Treg number and transfection programs do not enhance the 
efficiency of siRNA transfection  
Transfection 
program 
Number of 
cells (10
6)  Proportion of live cells (% of total) 
Proportion of siGLO+ 
cells (% of live) 
U-014 
2.5  7.3  92.1 
5.0  8.0  82.6 
T-023 
2.5  11.6  25.3 
5.0  13.9  31.9 
T-020 
2.5  9.2  28.9 
5.0  9.8  22.7 
      241 
5.2.7  Electroporation with Agile Pulse shows improved cell 
viability but siRNA promotes death in T cells 
A  novel  electroporation  technology  recently  became  available  and  has 
been  successfully  applied  to  the  transfection  of  primary  human  T  cells 
(personal  correspondence  with  Laurie  Menger,  [589]).  The  Agile  Pulse 
(BTX® Harvard Apparatus) differs from conventional electroporation and 
Amaxa nucleofection through variation of the combination of pulse voltage, 
pulse  duration  and  interval  duration  during  the  sequences  of  pulses 
applied. This allows, for example, a combination of initial short but high 
voltage pulses followed by lower voltage pulses of a longer duration. This 
has been shown to increase transfection efficiency [589] and combinations 
of pulses have been optimised for successful transfection of T cells with 
mRNA for TALEN-mediated genome editing (Laurie Menger, Karl Peggs, 
personal  communication).  Using  a  GFP  mRNA  as  a  comparator  with 
known capability to transfect T cells, I examined the use of the Agile Pulse 
for transfection of siRNA into T cells. As Figure 5.7 shows, 87.3% of cells 
were viable 24hr post-transfection with GFP mRNA (x M). However, an 
equimolar concentration of siRNA resulted in only 13% live cells, a 6.7 fold 
decrease in viability compared to GFP mRNA. Titrating the concentration 
of  siRNA  showed  that  cell  viability  was  proportional  to  siRNA 
concentration, demonstrating that siRNA transfection is toxic to T cells. In 
addition, siRNA concentration was proportional to transfection efficiency, 
with the lowest molarity resulting in 23% of transfected cells, compared to 
88%  for  the  highest  molarity.  Therefore,  the  use  of  siRNA  requires  a 
compromise  between  cell  viability  and  transfection  efficiency.  The  toxic 
effect of siRNA compared to mRNA may relate to the similarity of double   242 
stranded siRNA to viral epitopes, which may be recognised by TLR3 on T 
cells leading to apoptosis [590].     243 
 
Figure 5.7: Transfection of siRNA leads to decrease in cell viability 
The viability and transfection efficiency of transfection using Agile Pulse electroporation 
was compared for transfection of mRNA (for GFP) and an equimolar concentration of 
siRNA. The concentration of siRNA was titrated to examine the direct effect of siRNA on 
viability. .      244 
5.2.8  Locked  nucleic  acid  treatment  achieves  effective 
knockdown in T cells 
Due to the lack of success using siRNA I attempted instead to knockdown 
ncRNAs using LNAs (Section 5.1.1) LNAs against CRNDE and GAPDH 
were designed in collaboration with RaNA Therapeutics and LNAs against 
LOC286442 were designed by Exiqon. I treated T cells with a fluorescently 
tagged  non-targeting  control  LNA  as  described  in  Section  2.2.11  and 
assessed cell viability, LNA uptake and knockdown efficiency. As Figure 
5.8.A shows, 90.7% of cells were viable after LNA treatment, which was 
comparable  with  cells  not  treated  with  LNA,  revealing  no  obvious  toxic 
effects of LNA unlike that seen with siRNA (Figure 5.7). Titration of LNA 
targeted  towards  GAPDH  (Figure  5.8.C),  demonstrated  a  dosage  effect 
with lower transcript level detected with increasing concentration of LNA. 
This effect was specific to GAPDH; although transcript levels were variable 
with other conditions, the same dose response was not seen for the non-
targeting control not for 5S ribosomal RNA.  
 
Surprisingly, 99.81% of cells exhibited fluorescence after incubation with 
non-targeting control LNA, suggesting that nearly all cells had taken it up 
(Figure  5.8.B).  To  confirm  such  surprisingly  highly  efficient  uptake,  I 
hypothesised  that  this  high  proportion  of  LNA-positive  cells  could 
potentially be explained by adherence of LNA to the cell surface rather 
than actual entry into the cell. In this circumstance, any decrease in target 
level could be due to changes in gene expression resulting from signalling 
downstream  of  cell  surface:LNA  interaction  rather  than  an  LNA-RNA 
interaction  leading  to  RNA  degradation.  For  this  reason,  internalisation   245 
analysis  was  performed  through  integration  of  flow  cytometry  and 
microscopy (Image Stream Technology, Section 2.2.4). Using markers for 
the cell surface (CD4) and nucleus (Hoerchst), I compared the similarity of 
fluorescent  LNA  to  these  locations  through  measurements  of 
internalisation  (comparison  of  LNA  with  CD4),  nuclear  localisation 
(comparison of LNA with Hoerchst) and co-localisation. As Figure 5.9.A 
shows, the median score for LNA internalisation was 1.821, which was not 
dissimilar to internalisation of the nucleus, a positive control, which scored 
1.969.  The  nuclear  localisation  score  for  CD4  was  1.641  while  nuclear 
localisation  of  LNA  was  greater  with  a  median  score  of  2.645.  As  a 
negative  control  for  co-localisation,  CD4  (cell  surface)  and  Hoerchst 
(nucleus)  were  compared,  giving  a  similarity  score  of  0.7874.  The  co-
localisation of LNA with both the cell surface and the nucleus gave greater 
similarity scores of 1.166 and 1.268, respectively. These measurements 
are therefore consistent with cellular uptake of LNA.  
 
It was possible that LNA uptake was heterogeneous in the cell population 
with some cells demonstrating increased uptake compared to others. Such 
a bimodal population distribution could allow analysis of phenotypic effects 
to  be  restricted  to  cells  with  optimum  uptake.  As  Figure  5.9.B  shows,  I 
examined the co-localisation of LNA with CD4 against the co-localisation of 
LNA with the nucleus. The cell population appeared unimodal, indicating 
that similar uptake of LNA occurs in all cells. Figure 5.9.C illustrates the co-
localisation of fluorescence for a representative cell.     246 
 
Figure 5.8: Knockdown using LNAs shows unexpected efficiency of LNA uptake by 
CD4 T cells. 
A:  Cell  viability  after  culture  with  and  without  LNA  treatment.  B:  Assessment  of  LNA 
uptake  by  CD4  T  cells  through  gymnosis.  C:  Targeting  of  LNAs  towards  the  GAPDH 
transcript. 5S ribosomal RNA is given as a control for non-specific effects of knockdown. 
Cultures treated with a non-targeting LNA and no LNA at all were also assessed.   
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Figure 5.9: Internalisation of LNA by CD4 T cells 
Internalisation  of  LNA  by  CD4  T  cells  was  assessed  by  Image  Stream  Technology 
(Amnis)  A:  Median  scores  for  fluorescence  similarity  comparing  cell  surface  (CD4), 
nucleus  (Hoechst)  and  LNA  gated  on  focussed,  single  cells.  Internalisation  is  the 
fluorescence similarity of a parameter with the cell surface (CD4). Nuclear localisation is 
the fluorescence similarity of a parameter with the nucleus (Hoechst) Co-localistion is the 
fluorescence similarity of two chosen parameters. Fluorescence similarity is measured as 
bright detail similarity and reflects the correlation coefficient between the pixel values of 
two image pairs. A lower score indicates less similarity in fluorescence and therefore a 
lower physical association. B: A unimodal population distribution of LNA localisation is 
seen. Co-localisation score is the ratio of bright detail similarity between two parameters. 
C:  An  example  representative  of  the  focussed,  single  cell  population  illustrating 
distribution of LNA through the cell and physical overlap of LNA with both the nucleus 
(Hoechst) and cell surface (CD4). Brightfield demonstrates cellular morphology with white 
light.     248 
5.2.9  Effect of CRNDE knockdown on Treg phenotype 
In  order  to  interrogate  the  role  of  CRNDE  upregulation  in  Treg  versus 
Tresp, I knocked CRNDE down using LNAs, as optimised in Section 5.2.8. 
Figure  5.10  demonstrates  that  knockdown  of  CRNDE  using  LNAs  was 
effective. Compared to no LNA-control, CRNDE LNA resulted in a  67% 
reduction in CRNDE transcript level and compared to non-targeting control 
LNA,  CRNDE  LNA  resulted  in  a  71%  reduction.  I  hypothesised  that 
knockdown of CRNDE may affect expression of the co-regulated genes I 
had identified by cluster analysis (Section 5.2.1), and therefore assessed 
changes  in  their  expression  that  correlated  with  CRNDE  knockdown. 
These  genes  of  interest  included  those  encoding  the  TNF  receptor 
superfamily members CD30 (TNFRSF8) and 4-1BB (TNFRSF9), signalling 
through which has been related to Treg function [217-219, 221, 583-585]. 
The gene for ki67 (MKI67), which is upregulated upon cell cycling, was 
also identified as being co-expressed with CRNDE. This association may 
suggest role for CRNDE in general T cell proliferation rather than a Treg 
specific role and with this in mind I assessed changes in ki67 in total T 
cells  as  well  as  Treg.  In  addition  I  assessed  the  impact  of  CRNDE 
knockdown  on  expression  of  the  Treg  lineage-specifying  transcription 
factor FOXP3.  
 
The phenotypic correlations of Treg and total T cells in respect to these 
genes of interest are presented in Figure 5.11. As shown, upon knockdown 
of CRNDE, changes for most proteins of interest were not significant when 
compared  to  the  non-targeting  control  and  cells  cultured  without  LNA 
treatment.  Expression  was  also  similar  in  cells  treated  with  an  LNA   249 
targeting  GAPDH.  CRNDE  knockdown  did  however  show  a  significant 
difference in the proportion of CD30 positive cells when compared to the 
non-targeting control (Figure 5.11.A middle, p=0.04). However, there was 
no difference to non-treated cells and so this could instead represent an 
increase in CD30 expression in the control LNA-treated population. 
 
While performing these experiments I confirmed that donors showed the 
expected upregulation of CRNDE in Treg compared to Tresp. In doing this 
I noticed that expression of CRNDE was reduced between ex vivo Treg 
and those activated in vitro during LNA knockdown experiments (Figure 
5.12).  This  was  unexpected  given  the  association  of  CRNDE  with 
activation  (Section  5.2.2).  Indeed,  consistent  with  the  array  data, 
expression in Tresp increased with in vitro activation (Figure 2.12). This 
suggested  that  CRNDE  expression  is  differentially  regulated  in  Treg 
compared to Tresp.      250 
 
Figure 5.10: Knockdown of CRNDE 
Knockdown of CRNDE using LNAs targeted against the transcript was assessed by qPCR 
in comparison to treatment without LNAs and treatment with a non-targeting control. Non-
specific decrease in transcript level was assessed by comparison with an LNA targeted at 
the GAPDH transcript. Fold enrichment is relative to HPRT1.   
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Figure 5.11: Effect of CRNDE knockdown on expression of CD30, 4-1BB, ki67 and 
FOXP3. 
Genes correlating with CRNDE expression were assessed by flow cytometry for changes 
that correlated with CRNDE knockdown. A: Changes in CD30 expression upon treatment 
with LNAs targeted against CRNDE and GAPDH as well as a non-targeting LNA and no 
LNA  at  all.  Representative  FACS  plots  gated  on  FOXP3+  cells  are  shown  along  with 
percentage of CD30-positive cells and MFI of these cells indicated in brackets (left). Data 
from four biological replicates for the proportion of CD30-positive cells (middle) and MFI 
(right). B: As for A, except for 4-1BB. C: as for A except ki67. D: As for A except for 
FOXP3 and for the whole population. E: As for D except for ki67. Plots show mean and 
SEM. Significance was estimated using two-tailed, paired t test.   
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Figure 5.12: Differential regulation of CRNDE in Treg and Tresp 
Comparison of the level of CRNDE expression in Treg and Tresp ex vivo and upon in vitro 
activation. Fold enrichment is relative to HPRT1. Plots show mean and SEM. Significance 
was estimated using two-tailed, paired t test.   
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5.2.10 Effect of LOC286442 knockdown on Treg phenotype 
I also performed knockdown experiments for the Treg ncRNA LOC286442 
in  order  to  gain  insight  into  its  functional  role  in  Treg  biology.  Again, 
knockdown was attempted using LNAs and Figure 5.13 demonstrates the 
efficiency of this approach for LOC286442. Compared to the non-targeting 
control LNA, there was a 40% reduction in transcript level in cells treated 
with an LNA to LOC286442 and compared to culture without LNA, there 
was a 34% reduction. As for CRNDE (Section 5.2.9), I assessed the effect 
of this knockdown on the expression of Treg genes with similar expression 
patterns to LOC286442; FOXP3, Helios and TNFR2. Figure 5.14 presents 
the  effect  of  LNA  treatment  on  the  expression  of  these  proteins 
demonstrating that no significant difference could be seen.     254 
 
Figure 5.13: Knockdown of LOC286442 
Knockdown of LOC286442 using LNAs targeted against the transcript was assessed by 
qPCR  in  comparison  to  treatment  without  LNAs  and  treatment  with  a  non-targeting 
control. Non-specific decrease in transcript level was assessed by comparison with an 
LNA targeted at the GAPDH transcript. Fold enrichment is relative to HPRT1   
5S ribosomal RNA 
N
o
 
L
N
A
 
L
N
A
-
n
o
n
-
t
a
r
g
e
t
i
n
g
 
L
N
A
-
G
A
P
D
H
 
L
N
A
-
L
O
C
2
8
6
4
4
2
 
LOC286442 
N
o
 
L
N
A
 
L
N
A
-
n
o
n
-
t
a
r
g
e
t
i
n
g
 
L
N
A
-
G
A
P
D
H
 
L
N
A
-
L
O
C
2
8
6
4
4
2
  0 
2 
4 
6 
8 
10 
12 
F
o
l
d
 
e
n
r
i
c
h
m
e
n
t
 
0 
0.0001 
0.0002 
0.0003 
0.0004 
0.0005 
0.0006 
F
o
l
d
 
e
n
r
i
c
h
m
e
n
t
   255 
 
Figure 5.14: Effect of LOC286442 knockdown on expression of FOXP3, Helios and 
TNFR2. 
Genes  correlating  with  LOC296442  expression  were  assessed  by  flow  cytometry  for 
changes that correlated with LOC286442 knockdown. A: Changes in FOXP3 expression 
upon treatment with LNAs targeted against LOC286442 and GAPDH as well as a non-
targeting LNA and no LNA at all. Representative FACS plots gated on total live cells are 
shown  (left)  along  with  percentage  of  FOXP3-positive  cells  and  MFI  of  these  cells 
indicated in brackets. Data from four biological replicates is given for the proportion of 
FOXP3-positive cells (middle) and MFI (right). B: As for A, except for Helios and gated on 
FOXP3+ cells. C: as for B except TNFR2. Plots show mean and SEM. Significance was 
estimated using two-tailed, paired t test 
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5.2.11 Effect of IFNG eRNA knockdown on IFNG expression 
As  described  in  Chapter  4,  I  have  identified  eRNAs  from  T-bet  super-
enhancers upstream of Th1 specific genes. To determine if these eRNAs 
could play a role in IFNG activation, I sought to knockdown eRNAs from 
the IFNG super-enhancer using LNAs. I therefore polarised Th1 cells in 
vitro (Section 2.2.9) in the presence of LNA to IFNG eRNAs, GAPDH or a 
fluorescent non-targeting control (Section 2.2.11). As Figure 5.15 shows, 
cells  were  successfully  polarised,  as  represented  by  IFNγ  expression 
(Figure 5.15.A) and LNA uptake-efficiency was similar to that seen in the 
optimisation experiments described in Section 5.2.8. Th1 polarised cells 
were treated with 8 different LNAs separately and also pooled together. 
These  LNAs  were  targeted  at  4  different  RNA-Seq  peaks  at  the  IFNG 
super-enhancer, with each peak being targeted by 2 different LNAs. Figure 
5.15.C  describes  the  proportion  of  IFNγ  positive  cells  for  each  LNA 
treatment and the median fluorescence intensity (MFI) of the IFNγ positive 
population. The fold difference for both the proportion and MFI are given 
relative  to  the  non-targeting  control.  For  donor  1,  both  LNAs  targeting 
eRNA4  resulted  in  a  change  in  IFNγ  expression  compared  to  the  non-
targeting control with a modest increase in the proportion of IFNγ positive 
cells  (1.2  fold  for  both  LNA-7  and  LNA-8)  but  around  half  the  MFI  (as 
shown  by  a  fold  difference  of  0.5  and  0.6  for  LNA-7  and  LNA-8, 
respectively). The same trend was also seen for the pool of LNAs, with an 
increase in the proportion of IFNγ cells by 1.3 fold and a 0.5 fold difference 
in MFI). For donor 2 this trend was not observed with treatment of LNAs 
targeted  at  eRNA4,  but  a  similar  observation  was  noted  for  both  LNAs 
targeted at eRNA3. In this circumstance the proportion of  IFNγ positive   257 
cells  was  similar  to  the  non-targeting  control  (as  indicated  by  a  fold 
difference of 1.0 and 1.1 for LNA-5 an LNA-6, respectively) but the MFI 
was again reduced by around a half (as shown by a fold difference of 0.4 
and 0.5 for LNA-5 and LNA-6, respectively). For both donors, LNA-2, which 
was targeted at eRNA1 showed a 1.2-fold increase in the proportion of 
IFNγ positive cells. In addition, LNA targeted to GAPDH, which does not 
have a direct effect on IFNG transcription, showed at similar increase in 
the proportion of IFNγ positive cells as LNAs for eRNA3 in donor 1 (1.2 
fold), along with a decrease in MFI (0.7 fold). In donor 2, an increase in 
MFI was seen under this condition.   258 
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Figure 5.15:Effect of IFNG eRNA knockdown on IFNG expression 
(From  previous  page)  Th1  polarised  cells  from  two  donors  were  treated  with  LNAs 
targeted to eRNAs transcribed from the IFNG super-enhancer and the effect on IFNγ 
level assessed by flow cytometry. A: Polarisation of Th1 cells as shown by expression 
of IFNγ in stimulated cells not treated with LNA relative (red) to an unstimulated control 
(grey). B: LNA efficiency demonstrated with a fluorescently tagged LNA (red) relative to 
an  untagged  LNA  (grey).  C:  Th1  polarised  cells  were  treated  with  8  different  LNAs 
separately  and  pooled  together.  These  LNAs  were  targeted  at  4  different  RNA-Seq 
peaks at the IFNG super-enhancer with each peak being targeted by 2 different LNAs. 
The proportion of IFNγ positive cells in LNA-eRNA treated cells are given, as well as the 
median  fluorescence  intensity  of  the  IFNγ p o s i t i v e  p o pulation.  The  fold  difference 
relative to a non-targeting control is also provided. MFI: median fluorescent intensity. 
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To  assess  if  these  differences  in  IFNγ  expression  by  flow  cytometry 
correlated with a specific decrease in the level of eRNA transcript targeted 
by each LNA, I performed qPCR (Figure 5.16.A). As eRNAs are expected 
to influence gene expression at the level of transcription I also examined 
the  effect  of  eRNA  knockdown  on  the  level  of  IFNG  mRNA  by  qPCR 
(Figure 5.16.B). As Figure 5.16 shows IFNG RNA increased in abundance 
upon stimulation in both donors and, in donor 1, eRNA3 and eRNA4 were 
both increased upon stimulation in parallel with this. Although both eRNAs 
were detectable in donor 2, the increase in abundance upon stimulation 
was not observed. For both donors, there was no appreciable difference in 
expression of IFNG or either eRNA when a non-targeting control or an LNA 
targeting GAPDH was introduced and so there is no evidence of off-target 
or non-specific effects through these controls. However, there was also no 
obvious  difference  in  IFNG,  eRNA3  or  eRNA4  RNA  abundance  in  cells 
treated with LNAs targeting these eRNAs versus the non-targeting control. 
Therefore, transcript level does not reflect the trend seen at the protein 
level by flow cytometry (Figure 5.15). 
   261 
 
 
Figure 5.16: Effect of LNA of the level of targeted eRNAs from the IFNG super-enhancer and the corresponding level of IFNG mRNA 
transcript. 
Knockdown of targeted eRNAs and IFNG transcript level was assessed by qPCR. 
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5.3  Discussion 
In the experiments described in this chapter I have explored the functional 
relevance  of  ncRNAs  identified  in  Chapters  0  and  4  for  T  cell  lineage 
differentiation. In doing this, I have focused on the Treg lincRNAs CRNDE 
and LOC286442 as well as eRNAs from T-bet super-enhancers using the 
IFNG super-enhancer as a model.  
 
Examining  genes  with  associated  expression  patterns  to  the  Treg 
lincRNAs,  I  observed  that  CRNDE  was  associated  with  biological 
processes such as cell cycling and proliferation (Figure 5.2). In vitro Th1 
and Th2 polarisation data supported a role for CRNDE in these processes 
in T cells in general, with upregulation being seen in in vitro activated cells 
compared to ex vivo unactivated naïve T cells (Figure 5.3). This is also 
consistent  with  published  work  that  has  demonstrated  an  association 
between CRNDE expression and several cancers [524, 548]. Surprisingly, 
I observed that Treg and Tresp differed in this respect, with CRNDE level 
decreasing  in  vitro  upon  Treg  activation  (Figure  5.12).  This  may  be 
explained by the reduced proliferation of Treg in vitro compared to Tresp 
[591, 592]. In addition, it has been suggested that CRNDE may have a role 
in  pluripotency  due  to  observations  that  CRNDE  is  highly  expressed  in 
ESCs [442]  and spermatozoa [526] with its expression decreasing with 
differentiation [526]. The observation that CRNDE increases in expression 
during T cell differentiation counters this suggestion. However, considering 
the high cycling state of ESCs [593] and low cycling state of naïve T cells, 
these observations are in fact consistent and suggest a general role for 
CRNDE in cell cycling, proliferation and activation.   263 
 
Despite the decrease in CRNDE expression in Treg upon activation and 
the requirement for cell activation for delivery of LNAs via gymnosis, I was 
able  to  achieve  knockdown  of  CRNDE  (Figure  5.10).  In  assessing  the 
impact of loss of CRNDE on Treg phenotype, I saw a significant decrease 
in expression of the TNF receptor superfamily member CD30 (TNFRSF8) 
on  Treg  compared  to  a  non-targeting  control  (Figure  5.11).  However  it 
should be noted that treatment with the non-targeting control lead to an 
increase  in  CD30  expression  compared  to  treatment  with  no  LNA 
suggesting  that  the  difference  in  CD30  expression  upon  CRNDE 
knockdown may relate to an artefactual increase in expression in the non-
targeting control. If CRNDE does truly contribute to CD30 expression on T 
cells, this may indicate a link between the role of CRNDE in proliferation 
and the role of CD30 in Treg expansion. The use of further control LNAs 
should help to resolve this issue. 
 
Encouragingly, LOC286442 expression was associated with several genes 
relevant to Treg biology, supporting a role for the lincRNA in Tregs. These 
genes  included  FOXP3,  Helios  and  TNFR2.  However,  I  did  not  see  a 
difference in expression of these proteins upon knockdown of LOC286442 
using  LNAs  (Section  5.2.10).  This  may  relate  to  the  relatively  low 
knockdown efficiency seen for LOC286442 compared to CRNDE (Figure 
5.13). Additional experiments to probe the role of LOC286442 in Treg are 
suggested in Section 6.5 (Future work). 
 
While knocking down IFNG super-enhancer eRNAs to assess their impact   264 
on IFNG expression, I observed a change in expression of IFNγ by flow 
cytometry that correlated with the eRNA targeted (Figure 5.15). However 
this  difference  in  IFNγ  protein  did  not  correlate  with  a  difference  at  the 
transcript  level  and  treatment  with  LNAs  did  not  produce  effective 
knockdown of the eRNA targets (Figure 5.16). This lack of knockdown is 
perhaps not unexpected for eRNA transcripts, which are unstable and low 
in abundance. In addition, as LNAs can sterically inhibit transcript activity 
as  well  as    induce  cleavage,  it  is  possible  that  while  a  decrease  in 
transcript level was not observed, eRNA function may nevertheless have 
been reduced. 
     265 
6  Discussion 
The lineage choice of a naïve CD4 T cell during differentiation supports the 
tailoring of the immune system towards different pathogens. Although the 
DNA sequence present in each T cell is nearly identical, the process of 
differentiation  allows  different  T  cell  identities  to  arise  through  the 
increased activity of lineage-specific genes and the repression of genes 
relevant to alternative cell fates. These lineage-specific gene expression 
programs  require  maintenance  at  the  level  of  transcriptional  regulation. 
Transcriptional  activity  is  governed  by  accessibility  of  DNA  regulatory 
regions, such as enhancers, to regulatory proteins including transcription 
factors  and  chromatin-modifying  complexes.  This  accessibility  is  in  part 
influenced  by  histone  modifications.  Recently,  the  pervasive  and  tissue-
specific  transcription  of  multiple  classes  of  ncRNAs  has  been 
demonstrated  to  play  a  role  in  cell  differentiation  and  function  and  has 
altered our perception of the central dogma of molecular biology. 
 
I have presented here the identification of several classes of ncRNAs with 
T  cell  lineage-specific  expression  and  that  have  the  potential  for 
influencing T cell function. These include lincRNAs that are upregulated in 
primary human Tregs compared to Tresp and eRNAs emanating from T-
bet  super-enhancers  that  show  Th1  specific  expression.  Through 
knockdown experiments, I have investigated the functional role of these 
ncRNAs. In addition, I have explored the dysregulation of Treg lincRNAs in 
the Treg relevant context of autoimmunity, specifically SLE. Differences in 
Treg gene expression between SLE patients and healthy individuals have 
also  been  explored,  focused  on  transcription  factors  and  changes  in   266 
histone modifications at genes dysregulated in SLE. 
6.1  The role of CRNDE in Treg 
The lincRNA CRNDE was identified as upregulated in Treg compared to 
Tresp (Section 3.2.2). Supporting a role for CRNDE in Treg, there is some 
enrichment of the Treg lineage-specifying transcription factor FOXP3 at the 
CRNDE gene suggesting its expression is regulated by this factor (Section 
3.2.4).  The  gene  TSS  exhibits  H3K4me3,  while  H3K4me1  is  minimal 
(Figure 3.5), and contains introns, patterns that are consistent with CRNDE 
encoding a lincRNA rather than an eRNA. The expression of lncRNAs has 
been  suggested  to  be  a  mechanism  for  the  genomic  targeting  of 
chromatin-modifying complexes to specific genes (Section 1.3.3.1.,  [441]). 
Consistent  with  this,  CRNDE  has  been  shown  to  associate  with  the 
chromatin-modifying complexes PRC2 and coREST  [441] and knockdown 
of PCR2 and CRNDE show overlap in the biological processes affected  
[441].  The  repeats  present  in  CRNDE  exonic  sequences  (Figure  3.7) 
support  the  possibility  of  secondary  structures  that  may  promote  an 
interaction  with  chromatin  modifiers  (Section  1.3.3).  If  CRNDE  acts  to 
regulate the expression of other genes, one might expect those genes to 
share  a  gene  expression  profile  with  CRNDE.  The  correlation  between 
CRNDE expression and that of its genomic neighbour IRX5 across several 
cell types  [526] could therefore be indicative of regulation of IRX5 in cis. 
While this correlation is not seen here in Treg (Section 3.2.6) and IRX5 
does not have a known function in T cell differentiation, other genes co-
regulated with CRNDE are potential candidate target. With this hypothesis 
in  mind,  I  examined  the  identities  of  genes  that  I  found  correlated  with 
CRNDE  expression  (Section  5.2.1)  and  found  several  that  had  been   267 
published to have roles in Treg function, including CD30 and 4-1BB. After 
optimising  techniques  to  achieve  knockdown  of  lncRNAs  in  T  cells,  I 
examined  changes  in  the  expression  of  these  genes  upon  depletion  of 
CRNDE (Section 5.2.9). I found a significant decrease in CD30 expression 
correlated  with  CRNDE  knockdown,  which  implicates  CRNDE  in  Treg 
expansion through supporting the expression of this TNF receptor that has 
a role in this process. However, due to the non-specific increase in CD30 
seen with a non-targeting control LNA, it is possible that this is artefactual. 
Consistent  with  this,  I  did  not  observe  any  effect  of  CRNDE  LNA  on 
expression  of  the  proliferation  marker  ki67.  Experiments  with  additional 
negative control LNAs and additional independent LNAs targeting CRNDE 
will help resolve this issue.  
 
Gene  ontology  analysis  showed  that  genes  with  similar  expression  to 
CRNDE  were  enriched  for  processes  relating  to  cell  cycling  and 
proliferation. This is consistent with the published association of CRNDE 
with several cancers  [524, 548]. The upregulation of CRNDE ex vivo could 
therefore reflect the proliferation of Treg in vivo in response to self antigens  
[591, 592]. In SLE patients, although the difference was not significant, 
CRNDE  showed  a  tendency  towards  decreased  expression  in  memory 
compared to naïve Treg (Section 3.2.9). This may reflect a lower activity of 
memory  Treg  in  SLE,  which  other  published  research  has  suggested 
(Section 1.1.3.6.1,  [96]). The decreased expression of CRNDE in Tresp 
compared to Treg could be due to the increased mTOR signalling that is 
seen  in  Tresp    [201,  594].  Ellis  et  al.  2014  observed  that  CRNDE 
expression decreased in fibroblasts upon insulin signalling through mTOR 
and  Raf/MAPK    [550].  In  addition,  CRNDE  expression  was  shown  to   268 
increase through treatment with rapamycin, an inhibitor of mTOR, even in 
the absence of insulin signalling  [550]. This is relevant to Treg biology 
because  rapamycin  promotes  the  expansion  of  Treg    [201,  595]  and 
therefore CRNDE may have a role in supporting Treg expansion. Ellis et 
al. 2014 showed this relationship between mTOR and CRNDE was unique 
to unspliced transcripts containing intronic sequences rather than spliced 
transcripts  [550]. With this in mind, I performed isoform specific qPCR, 
demonstrating the presence of spliced isoforms of CRNDE that contributed 
to the difference in expression between Treg and Tresp (Section 0). This 
suggests that CRNDE may not be regulated downstream of rapamycin in 
Tregs.  However,  as  control  of  the  CRNDE  gene  may  differ  between 
fibroblasts and T cells, it remains to be seen if CRNDE expression is Treg 
is responsive to rapamycin. 
 
6.2  The role of lincRNA LOC286442 in Treg 
The lincRNA LOC286442 was also upregulated in Treg compared to Tresp 
and showed the highest fold difference of any ncRNA by array (Section 
3.2.1).  Similar  to  the  CRNDE  gene,  FOXP3  bound  to  the  promoter  of 
LOC286442 suggesting it forms part of the Treg transcriptional program. In 
addition, LOC286442 exhibited lower (but not significantly so) expression 
in Treg relative to Tresp in SLE patients compared to healthy individuals 
(Section 3.2.9), indicating either decreased expression of LOC286442 in 
SLE  Treg  and/or  increased  expression  in  SLE  Tresp.  Hierarchical 
clustering identified genes with similar expression patterns to LOC286442 
as enriched for processes related to T cell differentiation and lymphocyte 
development. This included the Treg genes FOXP3, Helios and TNFR2. 
Treatment  with  LNAs  targeted  against  LOC286442  resulted  in  modest   269 
knockdown  of  the  lncRNA,  but  no  effect  on  the  expression  of  these 
proteins. 
6.3  The  functional  importance  of  super-enhancer 
transcription 
I have demonstrated here (Chapter 4) that T-bet super-enhancers exhibit 
lineage-specific  transcription  that  correlates  with  transcription  from 
associated  Th1-specific  genes.  These  super-enhancer  eRNAs  share 
characteristics  with  previously  annotated  functional  enhancer  transcripts 
such as lack of poly-adenylation [420, 421] and bidirectional transcription 
[420, 421]. In addition, I determined that eRNA transcription is increased at 
T-bet super-enhancers compared to normal enhancers and I detailed the 
chromosomal coordinates of eRNAs upregulated in Th1 cells from T-bet 
super-enhancers.  At  the  IFNG  super-enhancer,  I  demonstrated  using  a 
knockout mouse that loss of T-bet leads to reduced transcription of these 
eRNAs,  in  addition  to  suboptimal  transcription  of  the  IFNG  gene  itself. 
Additionally, observations from our lab have show that the transcriptional 
elongation factor P-TEFb is recruited to super-enhancers and this binding 
localises with that of T-bet. I have shown here through chemical inhibition 
that these eRNAs are a product of that P-TEFb activity. These data are 
consistent  with  lineage-specific  control  of  gene  expression  by  super-
enhancers being mediated through recruitment of P-TEFb by T-bet with 
the resultant transcription of eRNAs. 
 
Following these observations, I questioned whether the presence of the 
super-enhancer eRNA transcripts themselves are a functional requirement 
for  transcription  of  downstream  genes.  Using  the  super-enhancer 
upstream  of  IFNG  as  a  model  for  super-enhancer  eRNA  function,  I   270 
performed LNA knockdown experiments to assess the impact of the loss of 
these  eRNA  transcripts  upon  IFNG  transcription  (Section  5.2.11).  The 
technical  difficulties  involved  in  knocking  down  eRNAs  are  appreciated 
within  the  field,  as  demonstrated  by  the  low  frequency  of  reports 
demonstrating functional roles for eRNAs. These difficulties arise from the 
nuclear localisation of eRNAs, which makes them relatively impervious to 
classical  knockdown  techniques,  and  their  low  abundance  and  low 
stability, which decrease the likelihood that knockdown methods will have 
any effect. In Th1 polarising cultures from two separate donors treated with 
8 different LNAs against 4 eRNAs, I was unable to achieve knockdown that 
corresponded with a decrease in IFNG transcript or protein. Despite no 
detectable change in eRNA or IFNG transcript, the level of IFNγ protein did 
appear to differ in a manner that correlated with the targeting of LNAs, 
albeit with donor variation. As LNAs can limit transcript activity in addition 
to  inducing  RNaseH  mediated  cleavage,  it  is  conceivable  that  LNA 
treatment may have affected the activity of these eRNA transcripts leading 
to  changes  in  IFNG  expression.  It  is  also  theoretically  possible  that  a 
change in IFNG mRNA not detectable in the assays presented here may 
have resulted from alternative splicing of the IFNG gene. While regulation 
of alternative splicing has been functionally attributed to ncRNAs such as 
the Zeb2 natural antisense transcript [448], to my knowledge such as role 
has  not  been  previously  postulated  or  supported  for  eRNAs  or  even 
upstream enhancers, although looping of the IFNG locus may provide a 
platform  for  interactions  between  super-enhancer  eRNAs  and  splicing 
regulatory regions within the gene.  
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6.4  The transcriptional identity of SLE Treg 
Through investigating differential gene expression in naïve and memory 
Treg of SLE patients compared to healthy individuals, I identified several 
transcription factors that were differentially expressed (Section 3.2.8). This 
included  MAFB,  which  was  upregulated  in  SLE  Treg  and  has  been 
reported in T cells before [545] but does not have a well understood role, 
and  NR4A3,  which  has  recently  been  demonstrated  to  support  Treg 
development  [547].  Neither  of  these  transcription  factors  have  been 
associated  with  SLE  or  any  other  human  autoimmune  disease  before. 
From the work presented here it is not possible to determine whether the 
increase  in  the  expression  of  these  transcription  factors  could  be 
responsible  for  a  Treg  defect  that  may  contribute  to  pathogenesis  or 
whether their increased expression instead reflects the activity of Treg in 
responding to inflammation. 
 
I also found that H3K9me3 was significantly increased in Treg and Tresp 
at  genes  that  were  differentially  expressed  between  SLE  patients  and 
healthy  individuals  (Section  3.2.10).  This  was  unexpected  because  the 
majority of literature relates H3K9me3 to chromatin condensation for the 
repression of genomic instability at repetitive genomic regions [361, 362, 
364].  An  additional  role  for  H3K9me3  has  been  described  at  actively 
transcribed  genes  [363]  through  regulation  of  alternative  splicing  [371]. 
This may suggest the differential expression seen in SLE may be in part 
regulated at this level and supports further investigation of the control of 
H3K9me3  deposition  and  its  function  in  cell  lineage  specification  in 
response to environmental stimulus.     272 
6.5  Future work 
I  have  presented  here  several  knockdown  approaches  to  assess  the 
impact  of  loss  of  ncRNA  on  cell  function  (Chapter  5).  LNA  gapmer 
oligonucleotides,  which  exert  their  effect  through  RNaseH-mediated 
cleavage  of  DNA-RNA  hybrids,  were  successful  in  knocking  down 
lincRNAs that were identified as preferentially expressed in Treg (Chapter 
0). However, LNAs did not successfully knockdown eRNAs upstream of 
IFNG  (Chapter  4).  As  LNAs  can  also  interfere  with  target  activity  and 
function without cleavage of the transcript, it remains possible that LNAs 
could  be  used  to  inhibit  eRNAs.  Observing  this  effect  is  challenging 
compared to detecting changes in transcript level by qPCR but I did not 
detect an effect of LNAs on IFNG expression suggesting the LNAs did not 
affect  eRNA  function.  However  this  does  not  rule  out  a  functional 
relationship  between  IFNG  super-enhancer  eRNA  transcripts  and 
expression  of  IFNG  and  this  could  be  explored  further  through  tiling  of 
LNAs  along  the  length  of  all  IFNG  super-enhancer  eRNAs  in  order  to 
target all potentially functional transcript regions. In addition, these eRNAs 
may  be  dynamically  regulated  throughout  Th1  differentiation  and  so 
characterisation of their transcription over a time may aid in defining the 
point  in  differentiation  when  functional  effects  are  likely  to  be  seen.  In 
addition, recent evidence has demonstrated the presence of Dicer in the 
nucleus  [596,  597],  at  least  in  some  mammalian  cellular  contexts, 
suggesting  an  shRNA  approach  may  be  more  effective  than  previously 
thought.  However,  attempts  have  been  made  in  our  lab  to  knockdown 
these eRNAs using shRNAs without success (Arnulf Hertweck). Genome 
editing  using  CRISPR/Cas  (clustered  regularly  interspaced  short   273 
palindromic  repeats/CRISPR  associated)  or  TALEN  (transcription 
activator-like effector nucleases) systems may provide an alternative, more 
robust  strategy.  CRISPR/Cas  is  based  on  the  disruption  of  genomic 
sequence through the induction of double strand breaks catalysed by the 
Cas9 endonuclease, with CRISPR RNA sequence guiding the site of this 
cleavage [598, 599]. TALEN are similar in principle, with nuclease activity 
being guided by the specific binding of a fused TAL effector DNA binding 
domain  [600].  Applied  to  protein-coding  genes,  genome  editing  allows 
targeted disruption of open reading frames and substitution of codons to 
render  a  protein  dysfunctional.  This  technique  can  also  be  aimed  at 
disruption  of  transcriptional  start  sites  in  order  to  ablate  transcription 
entirely, which is relevant for non-coding regions that produce transcripts in 
which functional domains are unknown. 
 
It is possible that the identity and sequence of transcripts produced from 
the IFNG super-enhancer has less consequence on expression of IFNG 
than the act of transcription itself. For example, eRNA transcription may 
allow binding of other factors to enhancers or allow histone modifications 
important for enhancer activity. A potential mechanism would be through 
the  formation  of  RNA:DNA  hybrids  termed  R-loops  [601].  R-loops  are 
triplex structures involving two strands of single stranded DNA unwound as 
a result of RNAP activity with a single strand of complementary nascent 
RNA annealed to one strand [601]. Among other transcriptional processes, 
these  have  been  implicated  in  the  recruitment  of  histone  methyl 
transferases leading to tri-methylation of H3K4 upstream of transcription 
start sites [602, 603]. Detection of R-loops at transcribed super-enhancer   274 
sites  could  be  performed  by  nucleic  acid  isolation  coupled  to  RNaseH 
mediated cleavage and sequencing or using the R-loop-specific antibody 
S9.6 [602]. 
 
I  have  demonstrated  here  that  production  of  eRNA  from  T-bet  super-
enhancers co-localises with T-bet and P-TEFb binding (Chapter 4, Figure 
4.8). In addition, increased transcription is a function of the increased T-bet 
binding at super-enhancers compared to typical enhancers (Figure 4.10) 
and this transcription is reliant upon both T-bet (Figure 4.13) and P-TEFb 
(Figure 4.14Figure 4.15). In addition to potential functional roles for the 
transcripts  produced  from  super-enhancers,  this  transcription  may  be  a 
non-functional biochemical by-product of the binding of the transcriptional 
elongation factor P-TEFb. We have suggested that P-TEFb recruitment by 
T-bet  is  a  mechanism  for  how  T-bet  and  other  lineage-specifying 
transcription factors promote differentiation (publication is currently in peer 
review process). Further support for this could come from demonstrating 
loss  of  P-TEFb  binding  at  super-enhancers  leads  to  reduced  P-TEFb 
binding at downstream genes. This would require site specific inhibition of 
P-TEFb  binding  at  super-enhancers  but  not  at  genes.  This  could  be 
achieved  through  site  specific  disruption  of  P-TEFb  bound  regions  at 
super-enhancers  through  genome  editing  techniques.  In  addition,  RNA-
Seq from cells treated with P-TEFb inhibitors (JQ1 and flavopiridol, Section 
4.2.8)  would  indicate  if  P-TEFb  regulated  transcription  is  specifically 
disrupted at lineage specific genes. As JQ1 and flavopiridol are already in 
clinical use to inhibit transcription in the context of several cancers  [604, 
605] their application to inflammatory diseases could also be realised. As   275 
super-enhancers are enriched for disease associated SNPs  [326], it would 
also be interesting to determine if Th1 eRNAs are associated with SNPs 
linked to autoimmune and allergic conditions. 
 
I  have  identified  several  long  ncRNAs  that  are  upregulated  in  primary 
human  Treg  compared  to  Tresp  (Chapter  3).  CRNDE  and  LOC286442 
were  investigated  in  functional  assays  through  knockdown  with  LNA 
gapmer  oligonucleotides  (Chapter  5).  While  this  approach  achieved 
successful knockdown, phenotypic effects, specifically the expression of 
biologically  relevant  genes  with  similar  expression  patterns,  were  not 
observed. Additional approaches could focus on identifying perturbations 
in expression of cytokine and chemokine receptors and the secretion of 
cytokines  and  chemokines,  particularly  those  with  similar  expression  to 
CRNDE (such as IL7, CCRL2, IL12RB2, IL1R1, CCR10, CCR3, CCR4, 
CCR5 Table 7.31) and LOC286442 (such as IL21, IL1RAP Table 7.32). In 
addition,  examination  of  the  effect  of  knockdown  on  global  gene 
expression, rather than the identification of genes with similar expression 
to  the  target  of  interest  ex  vivo,  could  be  achieved  using  microarrays. 
Ultimately,  the  effect  of  CRNDE  expression  of  Treg  function  could  be 
demonstrated  through  in  vitro  Treg  suppression  assays,  measuring  the 
effect of Treg on Tresp proliferation and cytokine production. The effect of 
knockdown on differentiation rather than maintenance of Treg could also 
be explored, for example through in vitro polarisation or expansion of Treg. 
The latter is particularly relevant as this is often performed with rapamycin  
[201,  595],  which  has  been  shown  to  increase  the  level  of  CRNDE 
transcripts in fibroblasts  [550]. In this context, rapamycin was used as an 
inhibitor of insulin signalling through blockade of mTOR, which decreased   276 
expression  of  unspliced  transcripts  of  CRNDE.  While  I  have  seen 
preferential  expression  of  spliced  rather  than  unspliced  transcripts  in 
Treg(Section  0),  the  influence  of  rapamycin  on  CRNDE  may  still  have 
significance  in  this  alternative  cellular  context.  It  would  therefore  be 
informative to explore the effect that rapamycin has on CRNDE expression 
and the effect of CRNDE knockdown in Treg or overexpression in Tresp 
during expansion conditions. 
 
CRNDE  expression  ex  vivo  was  shown  to  correlate  with  biological 
processes  of  cell  cycling  and  proliferation  (Section  5.2.1).  However, 
expression of CRNDE decreased rather than increased in Treg with in vitro 
activation,  which  may  be  related  to  the  decreased  proliferation  of  Treg 
observed  in  vitro  [591,  592].  This  complicates  interpretation  of  LNA-
mediated knockdown experiments, which require cell activation for uptake 
of LNA. To circumvent this issue, the use of a recently published Crnde 
knockout  mouse    [410]  could  be  used  to  assess  loss  of  Crnde in  vivo. 
Induction of systemic inflammation, for example with Complete Freund’s 
Adjuvant (CFA), could allow investigation of the role of Crnde in immune 
activation. In addition, the effect of CRNDE overexpression in Tresp could 
be explored but this has limitations if the function of CRNDE is dependent 
upon the genomic site of its transcription. 
 
The cellular localisation of ncRNAs is directly related to their mechanisms 
of  action.  For  example,  those  with  roles  in  transcriptional  regulation  of 
gene  expression  are  located  in  the  nucleus  (such  as  Xist    [398])  while 
cytoplasmic ncRNAs may have roles in structure and protein localisation 
(such as NRON  [462]). Therefore, confirming the nuclear localisation of 
CRNDE  and  LOC286442,  through  subcellular  fractionation  and  qPCR,   277 
would  support  a  role  for  the  impact  of  these  ncRNAs  on  transcriptional 
regulation of gene expression in Treg. Structural predictions would also be 
informative  of  ncRNA  mechanism,  as  would  experiments  identifying 
proteins with which the RNAs associate. 
 
By comparison of expression between naïve and memory Treg and Tresp 
of  SLE  patients  and  healthy  controls,  the  role  of  the  identified  Treg 
ncRNAs in the context of autoimmunity was also explored (Section 3.2.9). 
Although none were significantly up or down regulated in SLE patients, 
CRNDE  showed  the  greatest  median  log2  fold  difference  in  naïve 
compared to memory Treg between SLE patients and healthy individuals 
(median log2 ratios of 0.6 and -1.6 respectively, Figure 3.13.B) suggesting 
it is either upregulated in naïve Treg and/or downregulated in memory Treg 
in SLE. Given the association of CRNDE with cell cycling and proliferation 
(Section 5.2.1) and observations that memory Treg (FOXP3
highCD45RA-, 
‘activated Treg’  [96]), which are more suppressive  [96], are present at a 
lower  frequency  in  SLE  patients  (Section,  1.1.3.6,    [96]),  it  may  be 
informative to correlate the expression of CRNDE in memory Treg with 
disease activity SLE patients. This may be achievable in a larger cohort of 
SLE patients through in situ hybridisation coupled to flow cytometry.  
 
Several differentially expressed transcription factors in Treg between SLE 
patients  and  healthy  controls  were  identified  (Figure  3.12).  Of  these, 
NR4A3 (nuclear receptor subfamily 4, group A, member 3, also known as 
NOR1) has been functionally associated with Treg, with the NR4A family 
essential to Treg development  [547]. Investigation of the role of NR4A3 
upregulation in SLE would require determination of whether this differential 
expression precedes autoimmune inflammation or is a consequence of it.   278 
This could be achieved through comparison of NR4A3 expression in Treg 
of SLE patients and healthy controls in response to in vitro culture with 
inflammatory cytokines.  
 
While  identification  of  differential  histone  modification  patterns  between 
SLE patients and healthy individuals was precluded by the low frequency 
of Treg in peripheral blood and the relatively high cell numbers required for 
ChIP-Seq, differential histone modifications were identified at genes that 
differed  in  expression  between  SLE  patients  and  healthy  individuals 
(Section 3.2.10). Enrichment of H3K9me3 was seen at genes upregulated 
in healthy individuals compared to SLE patients (Figure 3.15 and Figure 
3.16). As H3K9me3 has been associated with regulation of splicing during 
transcriptional elongation  [363, 371], it would be informative to see if these 
genes  are  alternatively  spliced  between  SLE  patients  and  healthy 
individuals.  This  may  also  suggest  that  regulation  of  splicing  through 
H3K9me3  deposition  is  influential  in  determining  a  response  to  an 
inflammatory environment. This could be further investigated by observing 
enrichment of H3K9me3 genome wide in response to in vitro culture with 
inflammatory cytokines. Recent developments allowing ChIP-Seq with tens 
of thousands of cells  [606] also now allow for histone modifications to be 
measured in Tregs from healthy versus SLE patients. 
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7  Appendix 
7.1  Differentially expressed transcripts between Treg 
and Tresp identified by microarray 
7.1.1  Differential gene expression between T cell subsets in 
healthy donors 
Table 7.1: Transcripts upregulated in total Treg compared to total Tresp  
Gene symbol 
A_33_P3298398  E2F7  IL2RB  PLAU 
A_33_P3332616  ENST00000354689  IL7  PLCG2 
ABHD5  ENST00000390247  INPP5F  PLEKHG1 
ACTA2  ENST00000390252  INTS6  PMAIP1 
ADAMTS4  ENST00000390559  IRAK3  POU2AF1 
ADRBK2  ENST00000390606  KALRN  PTPLA 
AHR  ENST00000432978  KCNK1  PTTG1 
AIM2  ENST00000444919  KIAA0101  PTTG2 
AP3M1  ENST00000477036  KIF20B  PTTG3P 
AR  ENST00000492167  KIF5B  RANBP9 
ARG1  ENST00000502284  KLK1  RBBP8 
ARHGAP11B  ENST00000517927  LAIR2  RBMS3 
ARHGAP31  ENTPD1  LAT2  REL 
ASPM  F5  LAYN  RPS16P5 
ATP2B1  FAM102B  lincRNA:chr10:118574085-118608460_R  RRM2B 
ATP2B4  FAM129C  lincRNA:chr10:97639610-97667003_F  RTKN2 
ATXN7L1  FAM160B1  lincRNA:chr12:12884108-12894958_F  SELP 
BARD1  FAM19A2  lincRNA:chr12:32571608-32576908_R  SEMA7A 
BASP1  FAM46C  lincRNA:chr13:50614546-50615364_R  SESTD1 
BCAS1  FANCA  lincRNA:chr18:68297754-68318093_R  SETD7 
BIRC3  FANCL  lincRNA:chr2:179914333-179915343_R  SGPP1 
BIRC5  FANK1  lincRNA:chr2:213437296-213768199_R  SHMT2 
BRCA2  FBXL20  lincRNA:chr2:213703255-213723530_F  SKAP2 
BRIP1  FCRL1  lincRNA:chr2:64455559-64478475_F  SLC14A1 
BUB1  FCRL2  lincRNA:chr21:30749379-30901454_F  SLC2A8 
C18orf1  FCRL3  lincRNA:chr3:106526585-106630535_R  SLC39A10 
C18orf54  FHL3  lincRNA:chr3:106619835-106630535_R  SLC9A7 
C9orf167  FLJ45482  lincRNA:chr3:114031960-114042235_F  SLC9A7P1 
CASC5  FOXP3  lincRNA:chr3:13093175-13147525_R  SMC4 
CASK  GADD45A  lincRNA:chr7:22611226-22701411_R  SMC6 
CCDC50  GCC2  lincRNA:chr7:7928975-7996750_R  SMPD3 
CCNA2  GCNT4  lincRNA:chr8:95917724-95933974_F  SNORA16B 
CCNB2  GEN1  lincRNA:chrX:115401722-115413847_R  SPATS2L 
CCNG2  GJB6  LMCD1  STAM 
CCR3  GK  LOC100131234  SUOX 
CD200  GLCCI1  LOC100132741  SWAP70   280 
Gene symbol 
CD22  GNB4  LOC286442  TBC1D4 
CD24  GPD2  LRRC32  TBC1D9 
CD38  GPR174  LRRC37A3  TFRC 
CD40  GPR55  LUZP6  TIGIT 
CD74  GSTA4  MAP3K5  TK1 
CDCA5  HECW2  MCM4  TMEM38A 
CDCA7  HELLS  MELK  TNFRSF13C 
CDCA8  HIST1H1B  METTL7A  TNFRSF1B 
CDHR3  HIST1H2AI  MGST2  TNFRSF8 
CDK1  HIST2H3A  MINK1  TNFRSF9 
CDK14  HJURP  MKI67  TOX 
CEACAM4  HLA-DMA  MREG  TP53INP1 
CENPE  HLA-DMB  MXD3  TPR 
CENPI  HLA-DOA  MYB  TRIB1 
CENPM  HLA-DPA1  MYO1E  TRIM32 
CEP128  HLA-DPB1  MYO5C  TRIO 
CEP55  HLA-DQA1  NAMPT  TTN 
CHDH  HLA-DQA2  ND4L  TUFT1 
CHST7  HLA-DQB1  NEDD4L  TXNDC11 
CIITA  HLA-DQB2  NF1  TYMS 
CIT  HLA-DRA  NHLRC2  UBE2C 
CLNK  HLA-DRB1  NP113779  UHRF1 
CNGA1  HLA-DRB4  NUSAP1  USP15 
CNKSR2  HLA-DRB5  OAS1  UTS2 
CRNDE  HMGB3  OBFC2A  VAV3 
CTLA4  HMMR  OGN  VDR 
CTNNAL1  HS3ST1  OIP5  WNT10A 
CTPS2  HVCN1  P2RY1  XM_003118559 
CTSC  ICA1  PARVB  ZBTB32 
CXXC5  IDE  PBK  ZC3H12D 
DNAH8  IKZF2  PDE4D  ZNF193 
DOK3  IKZF3  PELI1  ZNF532 
DTL  IKZF4  PER2  ZNRF2 
DUSP10  IL1R2  PICALM  ZNRF2P1 
DUSP4  IL2RA  PIP5K1B    
 
Table 7.2: Genes downregulated in total Treg compared to total Tresp 
Gene symbol 
A_33_P3253902  CTSW  lincRNA:chr3:184997356-185017181_F  RSAD2 
A_33_P3271187  CYB561  lincRNA:chr3:184997356-185033531_F  RTN4R 
A_33_P3343605  CYP2J2  lincRNA:chr3:18507452-18568034_F  SBF2 
ABCB1  D4S234E  lincRNA:chr6:11118364-11146189_R  SCARNA6 
ABLIM2  DENND5A  lincRNA:chr7:130793407-130794935_R  SCML4 
ACR  DHRS3  LMF1  SDC3 
ACSL6  DOCK9  LOC100130000  SEMA4C   281 
Gene symbol 
ACVR1C  DPP4  LOC100130298  SFMBT2 
ADAM23  DUSP14  LOC100506342  SH3BGR 
ADC  EDA  LOC100507199  SLC40A1 
ADCY9  EFHC2  LOC440297  SMAGP 
ALPK1  EMR4P  LOC441461  SNAPC1 
ANK3  ENST00000390341  LPIN2  SOAT2 
ANKRD55  ENST00000414198  LRRC6  SOCS3 
APBA2  ENST00000449914  LRRN3  SOX8 
ARHGEF4  ENST00000512129  MATK  SPEF2 
ATP10A  EOMES  MDGA1  SPEG 
AXIN2  FAM19A1  ME3  SPEM1 
B3GNT3  FCGBP  MORC2-AS1  ST6GALNAC1 
BAG3  FGF9  MSRA  SUN3 
BC036215  FRY  NAP1L3  SVIL 
BEX5  GCET2  NELL2  SYTL2 
C12orf53  GPRC5B  NFIA  TAF4B 
C14orf132  GRASP  NLRP3  TC2N 
C14orf45  GRB10  NMUR2  TCEAL2 
C17orf67  ID2  NOSIP  THC2564554 
C1orf151-NBL1  IL4R  OTUD7A  THC2704282 
C1orf172  KCTD13  PCSK5  THEMIS 
C2orf40  KCTD3  PDE4D  TLR1 
CACNA1B  KRT2  PDE6B  TLR2 
CAND2  KRTAP4-11  PIM1  TMEM63C 
CASP10  lincRNA:chr1:173831852-173837202_F  PION  TMEM71 
CCDC112  lincRNA:chr1:59049237-59065662_R  PITPNC1  TRPV5 
CCL27  lincRNA:chr10:4944575-4977950_F  PLAG1  TTC16 
CD200R1  lincRNA:chr10:89908970-89919320_F  PLCB1  UGT3A1 
CDK6  lincRNA:chr11:8697549-8703349_F  PLEK2  VIPR1 
CEBPE  lincRNA:chr12:102593870-102602595_F  PLXDC1  WDR86 
CELA1  lincRNA:chr12:127160147-127258072_F  PRKCE  WNT1 
CFH  lincRNA:chr14:71020897-71044497_F  PRRT2  WNT10B 
CFHR3  lincRNA:chr14:92220122-92237072_F  PTGDR  WNT7A 
CHD7  lincRNA:chr14:92223102-92223962_R  PTPRO  WNT7B 
CHN2  lincRNA:chr14:96507172-96661947_F  RAD54B  XYLT1 
CHRNB3  lincRNA:chr14:96548697-96561747_F  RBMS1  ZACN 
CNIH4  lincRNA:chr14:96555696-96556712_F  RECK  ZBTB47 
CNTD1  lincRNA:chr15:40828033-40834483_F  RIPK2  ZNF462 
COPS7B  lincRNA:chr16:90043749-90053849_R  RLN2  ZNF541 
CR1  lincRNA:chr2:105424027-105429249_F  ROBO3 
  
  
  
CR2  lincRNA:chr20:56156369-56171644_F  RORB 
CRB3  lincRNA:chr22:25588075-25594350_F  RRAGD 
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Table 7.3: Gene upregulated in healthy Treg naive compared to Treg memory, Tresp 
naïve and Tresp memory 
Gene symbol 
AF194718  ENST00000390237  FCRL2  MS4A1 
AFF3  ENST00000390243  FCRL5  NCF1 
BANK1  ENST00000390294  FCRLA  NP113779 
BCL11A  ENST00000390551  FXYD2  OSBPL10 
BF175071  ENST00000390556  HHEX  PLCG2 
BLNK  ENST00000390603  HS3ST1  PNOC 
CD19  ENST00000390615  HVCN1  SETBP1 
CD22  ENST00000390632  KIAA0125  SNX22 
CD24  ENST00000424969  KIAA0226L  SPIB 
CDCP1  ENST00000426099  LILRB1  SYK 
CNR2  ENST00000468879  lincRNA:chr11:117668490-117680359_R  TBC1D9 
COBLL1  ENST00000471857  lincRNA:chr2:165531204-165538379_R  TCL1A 
CPNE5  ENST00000479981  LOC283663  TLR10 
CXXC5  ENST00000492167  LOC96610  TNFRSF13C 
EBF1  FAM129C  LYN  VPREB3 
ENST00000354689  FCRL1  MEF2C  WDFY4 
 
Table 7.4: Genes downregulated in healthy Treg naive compared to Treg memory, 
Tresp naïve and Tresp memory 
Gene symbol 
Zero transcripts identified 
 
Table 7.5: Genes upregulated in healthy Treg memory compared to Treg naïve, 
Tresp naïve and Tresp memory 
Gene symbol 
ACTA2  E2F2  lincRNA:chr2:111965352-112252622_F  RHOXF1 
ADPRH  ENTPD1  lincRNA:chr2:111965652-112101793_R  RTKN2 
ANKS1B  EZH2  lincRNA:chr2:111992304-111994467_R  SCG5 
BARD1  F5  lincRNA:chr2:112005726-112123291_R  SEMA3G 
BC021693  FAM110C  lincRNA:chr3:171506056-171528740_R  SGMS1 
BFSP2  FAM124B  lincRNA:chr3:8615882-8616354_F  SLC1A1 
BIRC5  FAM160B1  lincRNA:chr7:105551484-105564551_F  ST7 
C15orf53  FAM164A  lincRNA:chr7:105551628-105553084_F  STAM 
CCR10  FAM46C  lincRNA:chrX:115401722-115413847_R  TFRC 
CCR3  FANK1  LMCD1  THC2477815 
CCR4  FAS  LMNA  TK1 
CCR8  GINS2  LOC541471  TNFRSF8 
CD70  GPR19  LRRC32  TNFRSF9 
CDHR3  HPGD  MEOX1  TOX 
CEP128  IL1R1  MYO5C  TRIB1 
CHEK1  IL7  NEDD4L  TRIM16L 
CHST7  INPP1  NINJ2  TTN 
CLNK  JAKMIP1  OAS1  UTS2   283 
Gene symbol 
CPNE2  JSRP1  OBFC2A  VANGL1 
CTNNAL1  KIAA1841  PHTF1  VDR 
CXCR6  LAYN  PMAIP1  WEE1 
DGKH  LINC00152  PMCH  ZBTB32 
DUSP10  LINC00312  PMCHL1  ZC3H12C 
DUSP4  lincRNA:chr2:111954496-112125102_R  PTPLA    
 
Table 7.6: Gene downregulated in healthy Treg memory compared to Treg naïve, 
Tresp naïve and Tresp memory 
Gene symbol 
ACVR1C  DACT1  lincRNA:chr8:32785489-32902343_F  PLAG1 
ALPK1  DCHS1  LMF1  PLXDC1 
APBA2  DENND5A  ME3  RASGRF2 
AXIN2  FAM26F  NAP1L3  SATB1 
C2orf40  FBP1  NELL2  SLC40A1 
CERS6  IGF1R  NRIP1  SPG20 
CRTAM  KCTD3  PCSK5  TCF7 
CYP2J2  lincRNA:chr10:4944575-4977950_F  PELI2  THC2564554 
 
Table 7.7: Genes upregulated in healthy Tresp naive compared to Treg naïve, Treg 
memory and Tresp memory 
Gene symbol 
DACT1  KRT2 
 
Table 7.8: Genes downregulated in healthy Tresp naive compared to Treg naïve, 
Treg memory and Tresp memory 
Gene symbol 
ACTA2  FANCL  lincRNA:chr10:118574085-118608460_R  PYHIN1 
ADAM19  FAS  lincRNA:chr21:26934779-26952204_F  SETD7 
AHNAK  FCRL3  lincRNA:chrX:115401722-115413847_R  SGPP2 
AIM2  ICA1  LOC338620  ST8SIA1 
ATXN1  IL18R1  MAP3K5  TIGIT 
BACE1  IL2RA  NCF4  TNFRSF1B 
CHST7  IL2RB  PERP  TP53INP1 
FAM46C  ITGB1  PREX1  WNT10A 
FANCA  LAIR2  PTPN22  ZNF193 
 
Table 7.9: Genes upregulated in healthy Tresp memory compared to Treg naïve, 
Treg memory and Tresp naïve 
Gene symbol 
ABCB1  CFH  IL15  PLCB1 
ADAM23  CFHR3  IL18RAP  PRR5L 
ADRB2  CR1  IL4I1  PTGDR 
AUTS2  D4S234E  LATS2  SOAT2   284 
Gene symbol 
BFSP1  F2R  LYAR  SPON1 
BHLHE40  HOPX  MCOLN2  STOM 
CCL5  IFNG  MYBL1  TMEM200A 
 
Table 7.10: Genes downregulated in healthy Tresp memory compared to Treg naïve, 
Treg memory and Tresp naïve 
Gene symbol 
CD38  lincRNA:chr2:179914333-179915343_R  PTGIR 
GNG8  MYB  TTN 
 
7.1.2  Differential  gene  expression  between  SLE  patients 
and healthy controls 
Table 7.11: Genes upregulated in SLE total CD4  
Gene symbol 
A_24_P49597  FAM22G 
lincRNA:chr9:37579075-
37586275_R  RBM38 
A_24_P67552  FAM46A 
lincRNA:chrX:71132475-
71339425_R  RBM44 
A_33_P3229527  FANCC 
lincRNA:chrX:73164162-
73291277_F  RCL1 
A_33_P3309643  FBXO32 
lincRNA:chrX:73794800-
73800175_R  REC8 
A_33_P3402783  FBXO33  LOC100131726  REL 
ABCA1  FCGR1B  LOC100506036  RELL1 
ABCD3  FEM1B  LOC100509175  RIPK2 
ACSS1  FLJ22447  LOC254057  RNF103 
ADNP2  FLJ45684  LOC283575  RNMT 
AHNAK  FOSL2  LOC374890  RPS26 
AK074144  FTSJD2  LOC388796  RSAD2 
AKR7L  FUT10  LOC401022  S100A12 
ANK3  G0S2  LOC643770  S100A9 
APOBEC3A  GADD45A  LOC649294  SCARF2 
APOBEC3B  GFRA1  LOC650293  SEC14L3 
APOM  GHRL  LOC729867  SECISBP2L 
AQP9  GMFB  LOC79015  SEPSECS 
AREG  GRASP  LPP  SETD7 
ARID5A  GRM2  LRRC24  SH3YL1 
ARL8B  GTF3C4  LRRC25  SIK1 
ARRDC4  H1FX  LRRC8B  SLC16A6 
ARTN  H3F3B  LY6E  SLC25A13 
AVPI1  HCG4B  LYN  SLC25A30 
B3GNT2  HERC5  MAFB  SLC2A3 
B7H6  HERC6  MAFF  SLC3A1 
BAALC  HIF1A  MAP3K8  SMAD1 
BACH1  HIVEP3  MAX  SMURF1 
BCL2  HMGB2  MBIP  SOD2   285 
Gene symbol 
BCL2L11  HSH2D  MBP  SPATA24 
BCL3  IDS  MCM9  SPATS2L 
BCL6  IFI27  MED23  SPPL3 
BE613848  IFI44  METRNL  STAT3 
BGN  IFI44L  MGP  SUB1 
BZW1  IFI6  MMD  SUGP1 
C10orf68  IFIT3  MMP9  SUPV3L1 
C10orf76  IFIT5  MRPL19  SYCE2 
C1S  IFITM3  MRPL42P5  SYF2 
C20orf111  IGFALS  MTFP1  SYNM 
C20orf7  IKZF5  MTRR  TAB3 
C5AR1  IL17C  MX1  TAF8 
C7orf40  IL1RN  MX2  TAS2R20 
C8G  IL20RB  MXI1  TBC1D15 
CBX3P2  ILKAP  NAMPT  TEPP 
CCDC157  IRS2  NAP1L5  TET2 
CCDC19  ISG15  NCAPH  THC2489251 
CCL2  ITCH  NEDD9  THC2499144 
CCR1  ITGA7  NFIL3  THC2524986 
CCT6B  ITGB2  NFKBIA  THC2566834 
CD83  KCNK7  NFKBIB  THC2596076 
CDC23  KLF10  NFKBIE  THNSL2 
CDKN2D  KLF11  NFU1  THUMPD2 
CDYL2  KLHDC7B  NPDC1  TMEM105 
CEP95  KLHL12  NR4A3  TMEM119 
CFD  KLHL15  NR6A1  TMEM2 
CFL2  KLHL5  NRCAM  TMEM87A 
CIR1  LAMP3  NUDCD3  TNFAIP3 
CLEC7A  LAP3  NUDT4  TNNC2 
CLP1  LATS1  OAS1  TOX 
CMPK2  LINC00487  OAS3  TREM1 
CNP  lincRNA:chr1:207534352-207540427_F  OCLN  TRIM22 
COQ10B 
lincRNA:chr10:119344760-
119356235_R  ODC1  TSTD2 
CPLX3 
lincRNA:chr10:128586385-
128592960_F  ODF3B  TXNDC11 
CR605633  lincRNA:chr10:3521025-3527500_R  OR52N4  UBAP2L 
CSDA  lincRNA:chr12:92366844-92524394_R  OXR1  UPB1 
CTBS  lincRNA:chr12:92378756-92535489_R  PCGF5  USP18 
CXCL2  lincRNA:chr13:48450924-48481320_R  PDE4D  USP41 
CYB5RL 
lincRNA:chr14:103209147-
103227872_R  PELI1  UTP23 
DCTN6  lincRNA:chr16:10479917-10481598_F  PER1  UTRN 
DDIT4  lincRNA:chr17:78301614-78306077_F  PFKFB3  VAV3 
DDX60  lincRNA:chr19:57769688-57777413_F  PGAP1  WASH3P 
DEF8  lincRNA:chr19:57773281-57774106_F  PGGT1B  WHAMM 
DENND3  lincRNA:chr2:216583792-216584130_R  PHLDB3  WIPF1 
DENR  lincRNA:chr2:238021286-238040461_F  PIAS2  WTAP   286 
Gene symbol 
DHX40  lincRNA:chr2:54284416-54307601_R  PIGA  XAF1 
DUSP5  lincRNA:chr2:61157504-61158747_F  PIM3  XLOC_001688 
DYNLT1  lincRNA:chr2:91693289-91693947_R  PLA2G4C  XLOC_006925 
EDN1  lincRNA:chr3:128154578-128156195_F  PLBD1  XM_003118559 
EFCAB10  lincRNA:chr3:188598106-188603231_F  PLK3  XM_003118785 
EIF2AK2  lincRNA:chr3:194190336-194206786_R  PLSCR1  XM_003119830 
ENST00000369381  lincRNA:chr3:47207196-47217796_F  POLR1C  YAF2 
ENST00000370708  lincRNA:chr4:5529699-5536524_R  PPM1A  YOD1 
ENST00000418620  lincRNA:chr5:131804581-131808735_F  PPM1B  ZBP1 
ENST00000422603  lincRNA:chr5:139117291-139127116_R  PPT1  ZBTB43 
ENST00000433105  lincRNA:chr5:179091169-179097344_R  PRB1  ZBTB44 
EPSTI1  lincRNA:chr6:30001621-30013571_R  PRB4  ZC3H12A 
ERC1  lincRNA:chr6:56749266-56765891_F  PRH2  ZFP36L2 
ERMN  lincRNA:chr6:64472483-64499031_F  PRPH  ZNF292 
ETNK1  lincRNA:chr7:12762625-12862575_R  PSMD5  ZNF295 
ETV3  lincRNA:chr7:36771855-36772721_R  PTP4A1  ZNF326 
EXOSC7  lincRNA:chr8:118761334-118761831_R  RAB11FIP1  ZNF507 
EXT1  lincRNA:chr8:118762879-118763140_R  RAB30  ZNF584 
FAM132A  lincRNA:chr8:126718218-126979293_F  RAD1  ZNFX1 
FAM133B  lincRNA:chr8:6554042-6564617_R  RAD23B  ZRSR2 
FAM13A  lincRNA:chr9:34666200-34672975_R  RAMP1 
  
   FAM183B  lincRNA:chr9:36456325-36463750_R  RBBP6 
 
Table 7.12: Genes downregulated in SLE total CD4 
Gene symbol 
A_33_P3357626  EPHB4  LOC100129186  SLC23A3 
A_33_P3363305  ERAP1  LOC100131094  SLC24A1 
A_33_P3382887  ETNK1  LOC100131138  SLC25A19 
A_33_P3398196  F2RL1  LOC100132057  SLC35A1 
A_33_P3399755  FAM118B  LOC100506676  SLC35B3 
A_33_P3422712  FAM173B  LOC100506713  SLC35C1 
AA489744  FAM203A  LOC151174  SLC35F3 
ABHD6  FAM43A  LOC157562  SLC46A1 
ACADM  FAM63A  LOC253039  SLC8A3 
ACCS  FANCE  LOC283856  SPATA21 
ACN9  FASLG  LOC389834  SPIN4 
ACOT13  FASTKD1  LOC401397  SPTBN1 
ADORA2A  FBLN5  LOC401431  ST6GAL1 
AHSA1  FBXL18  LOC642852  STT3A 
AK123308  FBXO44  LOC643837  SUCLA2 
AK123945  FCRLB  LOC645431  TAF1A 
AK124695  FGF9  LOC654433  TBC1D20 
AKTIP  FIGNL1  LOC727916  TCEAL1 
ANKH  FIGNL2  LOC728705  TDP1 
ANKRD13C  FLCN  LOC728875  TDRD10   287 
Gene symbol 
ANKRD5  FLJ33630  LOC729678  TEKT4 
ANKRD58  FLJ39639  LPAR6  TERF1 
AP1AR  FPGT  LRIF1  TES 
ARFIP1  FSD1  LRR1  TFCP2 
ARHGAP18  FTSJD1  LRRC27  THAP2 
ARHGAP42  GBE1  LRRD1  THAP3 
ARSK  GDF10  LY9  THAP7-AS1 
ASPHD2  GDPD3  M6PR  THAP8 
ATG4C  GEMIN6  MAB21L2  THC2537043 
ATG9B  GFOD2  MAGOHB  THC2550350 
ATP6V1C1  GGCT  MAT2A  THC2672097 
ATP6V1D  GGPS1  MBOAT7  THC2724742 
ATP9A  GIN1  MCMBP  THNSL1 
ATXN10  GINS3  MED11  TIA1 
BBS10  GKAP1  METTL12  TIMD4 
BBS12  GLRX  METTL20  TKTL1 
BC039426  GOLPH3L  MGAT2  TMEM14E 
BPNT1  GOSR2  MGC2752  TMEM185A 
BPTF  GTF2H1  MKKS  TMEM187 
BREA2  GTF2H5  MKS1  TMEM218 
BRK1  GVINP1  MMACHC  TMEM60 
BTN2A1  HCG4  MMRN1  TMEM63A 
BUD13  HIST2H2BE  MOB3A  TMEM79 
C10orf57  HIST2H2BF  MON1A  TMEM8C 
C12orf76  HKDC1  MRM1  TMEM99 
C14orf109  HLTF  MRPS14  TNFRSF1A 
C16orf5  HMGCR  MRS2  TOB2 
C17orf69  HN1L  MSH2  TOR1A 
C17orf80  HOMEZ  MSRB2  TOR1B 
C18orf18  HOXB2  MTHFSD  TP53RK 
C19orf25  HSCB  MTMR10  TPM1 
C19orf73  HSD17B4  MYCBP  TRAF5 
C1orf201  HSD17B7  MYOM2  TRIM13 
C1orf31  HSPH1  N6AMT1  TRIM4 
C1orf56  HYLS1  N6AMT2  TRIM68 
C20orf134  ICMT  NAA30  TRMT1L 
C2CD2L  IDI2-AS1  NAB2  TRNAU1AP 
C2orf42  IFFO2  NAPEPLD  TTC36 
C2orf43  IFNAR1  NDUFAF1  TTC9C 
C2orf44  IHH  NEFM  TUBBP5 
C5orf39  IKBIP  NEK4  TUBD1 
C5orf62  ILK  NEURL  TUBE1 
C6orf115  IPO5  NF1  TUBGCP4 
C6orf211  IRAK2  NFYA  TXLNA 
C8orf55  ITGA10  NMT1  TXNDC17   288 
Gene symbol 
C9orf64  ITGB1BP1  NOC3L  TXNDC9 
C9orf69  ITPR2  NPSR1  UBE2T 
CASP10  JRKL  NS3BP  UBTD2 
CASP8AP2  KBTBD6  NT5E  UFSP1 
CBX1  KCNK6  NUP43  UGDH 
CCDC121  KIAA1009  OPA3  UNG 
CCDC126  KLHL25  OR7E5P  UTP14C 
CCDC142  KLHL6  ORAI3  VEZT 
CCDC34  KLHL9  ORC2  VPS35 
CCDC75  KRCC1  ORMDL2  VSIG1 
CCDC76  KRTAP1-3  OSBPL11  WDR41 
CD200R1  KRTAP19-2  PAQR8  WDR62 
CDK20  LACTB2  PARS2  WDR92 
CDK2AP2  LAIR1  PAX8  WRB 
CEACAM21  LBH  PCGF6  XCL1 
CEBPE  LCE1E  PCYOX1  XLOC_000787 
CENPBD1  LIMA1  PDE4DIP  XLOC_007052 
CENPJ  LINC00324  PDE7A  XLOC_011219 
CENPK  lincRNA:chr1:113540052-113551227_F  PDGFB  XLOC_013282 
CENPQ  lincRNA:chr1:147706526-147727651_R  PGBD2  XLOC_013283 
CEP19  lincRNA:chr1:201482952-201545677_F  PHF13  XLOC_013837 
CEP250  lincRNA:chr1:246948452-246962677_F  PHF23  XPO5 
CEP76  lincRNA:chr10:29699919-29733919_F  PIGV  YIPF5 
CETN3  lincRNA:chr10:88688970-88694220_F  PIN4  ZCCHC6 
CGN  lincRNA:chr10:89908970-89919320_R  PIP5K1B  ZFP64 
CHCHD7  lincRNA:chr11:6764642-6767690_R  PLEKHO2  ZGLP1 
CIRBP  lincRNA:chr11:82783427-82803502_F  PNP  ZKSCAN3 
CISD1  lincRNA:chr13:31179400-31191300_R  PNPLA7  ZMYM6NB 
CISH  lincRNA:chr15:69373209-69387524_F  POLH  ZNF137P 
CLCN3  lincRNA:chr17:44271698-44279998_F  PPM1D  ZNF148 
CLN5  lincRNA:chr17:44271698-44280036_F  PPP1R10  ZNF167 
CMKLR1  lincRNA:chr17:45149116-45150265_R  PRDX3  ZNF17 
CNIH4  lincRNA:chr18:10552875-10561225_R  PREPL  ZNF175 
COLEC11  lincRNA:chr19:28266143-28266711_R  PRIM1  ZNF189 
COPS5  lincRNA:chr19:28266664-28268543_R  PRPSAP1  ZNF2 
CPNE1  lincRNA:chr19:28269395-28283939_R  PRSS16  ZNF202 
CRAT  lincRNA:chr19:28269547-28283939_R  PRSS36  ZNF223 
CREBL2  lincRNA:chr19:28293532-28294380_F  PSMA8  ZNF226 
CRK  lincRNA:chr19:28296773-28297062_F  PSTPIP2  ZNF232 
CROCCP3  lincRNA:chr19:37493217-37493673_F  PURA  ZNF234 
CRYZ  lincRNA:chr19:56807196-56809238_F  RAB10  ZNF235 
CTH  lincRNA:chr2:121054680-121065605_F  RAB22A  ZNF248 
CTU1  lincRNA:chr2:168402979-168414804_F  RAD50  ZNF257 
CU677518  lincRNA:chr2:32237771-32245946_F  RAD51D  ZNF260 
CXCR7  lincRNA:chr2:70275822-70282955_R  RAD54B  ZNF283   289 
Gene symbol 
CYB5B  lincRNA:chr22:25408700-25464025_R  RALA  ZNF284 
CYHR1  lincRNA:chr3:114043485-114052926_F  RALBP1  ZNF285 
DARS2  lincRNA:chr4:103337452-103350952_R  RAP2B  ZNF30 
DB462629  lincRNA:chr4:15657202-15695627_F  RAVER2  ZNF322 
DCAF7  lincRNA:chr4:28383262-28404481_R  RBM14  ZNF347 
DCLRE1A  lincRNA:chr5:141839041-141871766_R  RBM4B  ZNF397 
DDX58  lincRNA:chr5:44826637-44828692_F  RFESD  ZNF404 
DENND2D  lincRNA:chr5:44828220-44828690_F  RGL1  ZNF420 
DET1  lincRNA:chr5:86109465-86540020_F  RGS14  ZNF470 
DGCR14  lincRNA:chr6:30260107-30262700_F  RGS19  ZNF48 
DGKQ  lincRNA:chr6:30271847-30274737_R  RIMBP3  ZNF485 
DHFRL1  lincRNA:chr6:30271849-30272880_R  RINT1  ZNF530 
DIRC1  lincRNA:chr6:32862495-32869036_F  RLN1  ZNF557 
DNAJC19  lincRNA:chr6:32862560-32869332_F  RLN2  ZNF567 
DNAJC24  lincRNA:chr6:43988722-43993947_F  RMI1  ZNF571 
DNM1P46  lincRNA:chr6:5013951-5056876_R  RNASEL  ZNF594 
DNMT3B  lincRNA:chr6:86386083-86388435_F  RNF2  ZNF613 
DOK1  lincRNA:chr6:86386801-86387887_F  RNF5  ZNF641 
DOK4  lincRNA:chr7:105564174-105564567_R  RNF8  ZNF667 
DOLPP1  lincRNA:chr7:112756783-112757127_R  RPA2  ZNF681 
DPF2  lincRNA:chr7:17719170-17720283_R  RSG1  ZNF691 
DYNLL1  lincRNA:chr7:77313167-77314643_R  RTN3  ZNF70 
ECE2  lincRNA:chr8:102185399-102185979_R  RTN4R  ZNF71 
EFNA4  lincRNA:chr8:102193085-102195404_R  SAC3D1  ZNF773 
EGLN2  lincRNA:chr8:38616218-38630243_R  SAP18  ZNF775 
EGR1  lincRNA:chr8:90623517-90627537_R  SAR1B  ZNF785 
EIF5B  lincRNA:chr8:92071874-92082224_R  SARDH  ZNF786 
ENST00000390450  lincRNA:chr9:123606154-123611279_F  SCG3  ZNF793 
ENST00000390463  lincRNA:chr9:5610300-5622250_R  SENP8  ZNF816 
ENST00000399269  lincRNA:chrX:102024544-102185719_R  SETX  ZNF84 
ENST00000411846  lincRNA:chrX:130864569-130871024_R  SGK223  ZNF862 
ENST00000416673  lincRNA:chrX:15690954-15744304_R  SH3BP5L  ZNF879 
ENST00000427872  lincRNA:chrX:64628047-64628361_R  SH3PXD2A  ZNF880 
ENST00000434336  lincRNA:chrX:6745350-6897125_F  SIRT4  ZNRD1-AS1 
ENST00000444043  lincRNA:chrX:68406650-68432200_F  SKIV2L2  ZSCAN20 
ENST00000450721  lincRNA:chrX:73164675-73232924_F  SKP2  ZSWIM3 
ENST00000485364  LMAN2L  SLAIN1  ZW10 
EPG5  LOC100128737  SLC16A10 
  
   EPHA1  LOC100129138  SLC22A5 
 
Table 7.13: Genes upregulated in SLE total Treg 
Gene symbol 
A_24_P49597  EPSTI1  IFI44L  OAS3 
AHNAK  ERMN  IFI6  ODF3B 
APOBEC3A  FAM183B  IL1RN  OR52N4   290 
Gene symbol 
APOBEC3B  FLJ22447  LAMP3  PER1 
BCL3  FLJ45684  LINC00487  PLBD1 
CCDC157  FOSL2  lincRNA:chr2:54284416-54307601_R  PLSCR1 
CCDC19  G0S2  LOC100509175  RPS26 
CCR1  GRASP  LOC254057  RSAD2 
CMPK2  GRM2  MAFB  SETD7 
CR605633  HERC5  MAP3K8  SLC3A1 
EDN1  IFI27  METRNL  USP18 
EIF2AK2  IFI44  NR4A3  VAV3 
 
Table 7.14: Genes downregulated in SLE total Treg 
Gene symbol 
A_33_P3398196  FAM43A  lincRNA:chr10:88688970-88694220_F  SLC35F3 
ARHGAP42  GOLPH3L  lincRNA:chr18:10552875-10561225_R  YIPF5 
ATG4C  HKDC1  lincRNA:chr19:28293532-28294380_F  ZFP14 
CCDC126  HOMEZ  lincRNA:chr2:121054680-121065605_F  ZMYM6NB 
CD200R1  IDI2-AS1  lincRNA:chr2:32237771-32245946_F  ZNF175 
CENPQ  ITGA10  lincRNA:chr6:108346507-108355057_R  ZNF232 
CXCR7  LCE1E  LOC100131138  ZNF322 
ENST00000485364  LIMA1  RIMBP3  ZNF404 
 
Table 7.15: Genes upregulated in SLE total Tresp 
Gene symbol 
A_24_P49597  ERMN  LOC100509175  RAMP1 
ANK3  EXT1  LOC254057  RPS26 
APOBEC3A  GADD45A  LOC643770  SLC16A6 
C10orf68  GHRL  MAX  SLC3A1 
CCDC19  HERC5  MED23  TMEM2 
CCT6B  IFI27  NFKBIE  TOX 
CD83  IFI44L  ODF3B  UPB1 
CFL2  IL20RB  PCGF5  USP41 
CPLX3  KLF11  PDE4DIP  VAV3 
DST  KLHL15  PELI1  XM_003118559 
EIF2AK2  LAMP3  PER1  ZC3H12A 
EPSTI1  lincRNA:chr2:54284416-54307601_R  PIM3  ZRSR2 
 
Table 7.16: Genes downregulated in SLE total Tresp 
Gene symbol 
A_33_P3282213  FANCE  lincRNA:chr8:92071874-92082224_R  THAP3 
A_33_P3398196  FBLN5  lincRNA:chrX:64628047-64628361_R  THAP8 
AK124695  FCRLB  LOC100131131  THNSL1 
ANKRD58  FIGNL1  LOC100131138  TMEM187 
ARFIP1  FLJ39639  LOC100132057  TMEM60   291 
Gene symbol 
ARHGAP42  FSD1  LOC100507199  TMEM8C 
ATG4C  GOLPH3L  LOC728705  TRMT1L 
BC039426  HKDC1  LRRC27  UBE2T 
BPTF  HN1L  MAB21L2  UBTD2 
C9orf69  ITGA10  METTL13  XLOC_013282 
CENPBD1  JRKL  MRPS14  ZNF175 
CENPQ  KLHL9  MYOM2  ZNF2 
CEP19  LAIR1  NAPEPLD  ZNF226 
CISH  LCE1E  NUP43  ZNF232 
COLEC11  LIMA1  OSBPL11  ZNF260 
CXCR7  lincRNA:chr1:113540052-113551227_F  PDGFB  ZNF322 
CYHR1  lincRNA:chr10:89908970-89919320_R  RAD54B  ZNF404 
DB462629  lincRNA:chr2:121054680-121065605_F  RIMBP3  ZNF470 
DGCR14  lincRNA:chr2:168402979-168414804_F  RLN1  ZNF530 
DHFRL1  lincRNA:chr22:25408700-25464025_R  RLN2  ZNF594 
ENST00000390463  lincRNA:chr7:112756783-112757127_R  SLC35F3  ZNF613 
ENST00000399269  lincRNA:chr8:38616218-38630243_R  SPATA21  ZNF793 
ENST00000485364  lincRNA:chr8:90623517-90627537_R  STT3A    
 
Table 7.17: Genes upregulated in SLE Treg naive 
Gene symbol 
Zero transcripts identified 
 
Table 7.18: Genes downregulated in SLE Treg naive 
Gene symbol 
CD200R1 
 
Table 7.19: Genes upregulated in SLE Treg memory 
Gene symbol 
APOBEC3A  CD163  LINC00487  MAFB 
CCR1  IFI27  LOC100509175    
 
Table 7.20: Genes downregulated in SLE Treg memory 
Gene symbol 
Zero transcripts identified 
 
Table 7.21: Genes upregulated in SLE Tresp naïve 
Gene symbol 
EPSTI1  OAS3  CPLX3 
 
   292 
Table 7.22: Genes downregulated in SLE Tresp naïve 
Gene symbol 
Zero transcripts identified 
 
 
Table 7.23: Genes upregulated in SLE Tresp memory 
Gene symbol 
IGFL2 
 
Table 7.24: Genes downregulated in SLE Tresp memory 
Gene symbol 
DGCR14  EOMES  FASLG  ZNF175   293 
Table 7.25: Non-coding transcripts upregulated in Treg 
 
Treg subset of upregulation 
Probe ID  Accession  Gene name 
Naïve 
Treg 
Memory 
Treg 
Total 
Treg 
A_32_P8813  LOC283663  uncharacterised LOC283663  ✓       
A_19_P00316450  lincRNA:chr3:8615882-8616354_F  lincRNA:chr3:8615882-8616354_F     ✓    
A_23_P170378  PMCHL1  pro-melanin-concentrating hormone-like 1, pseudogene     ✓    
A_23_P166779  LINC00312  long intergenic non-protein coding RNA 312     ✓    
A_32_P42725  ENST00000432978  ENST00000432978        ✓ 
A_33_P3846114  LOC286442  uncharacterised LOC286442        ✓ 
A_33_P3718269  ENST00000517927  ENST00000517927        ✓ 
A_19_P00317691 
lincRNA:chr13:50614546-
50615364_R  lincRNA:chr13:50614546-50615364_R        ✓ 
A_33_P3332616  A_33_P3332616  A_33_P3332616        ✓ 
A_33_P3348519  ENST00000502284  ENST00000502284        ✓ 
A_19_P00802201  lincRNA:chr7:7928975-7996750_R  lincRNA:chr7:7928975-7996750_R        ✓ 
A_23_P60016  PTTG3P  pituitary tumor-transforming 3, pseudogene        ✓ 
A_33_P3221613  ENST00000444919  ENST00000444919        ✓ 
A_24_P145009  ZNRF2P1  zinc and ring finger 2 pseudogene 1        ✓ 
A_33_P3357097  LOC100132741  uncharacterised LOC100132741        ✓ 
A_33_P3254380  SLC9A7P1 
solute carrier family 9 (sodium/hydrogen exchanger), member 7 pseudogene 
1        ✓ 
A_32_P104063  CRNDE  colorectal neoplasia differentially expressed (non-protein coding)        ✓ 
A_19_P00331075 
lincRNA:chr3:106619835-
106630535_R  lincRNA:chr3:106619835-106630535_R        ✓ 
A_19_P00316108  lincRNA:chr2:64455559-64478475_F  lincRNA:chr2:64455559-64478475_F        ✓ 
A_33_P3416142  LOC100131234  familial acute myelogenous leukemia related factor        ✓ 
A_33_P3337609  ENST00000411475  ENST00000411475        ✓ 
A_19_P00321651 
lincRNA:chr2:213437296-
213768199_R  lincRNA:chr2:213437296-213768199_R        ✓ 
   294 
 
7.2  Donor information 
Table 7.26: Details of healthy donors 
Healthy donor age range is from 23 to 54 years with a median of 30 and standard deviation of 12 years  
Donor ID  Gender  Age (years)  Ethnicity 
HC1  Female  31  Caucasian 
HC2  Female  23  Caucasian 
HC3  Female  30  Caucasian 
HC4  Female  30  Caucasian 
HC5  Female  54  Caucasian 
 
Table 7.27: Details of SLE donors 
            Clinical details at time of sampling  
Donor ID  Gender  Age  Ethnicity  Disease 
severity 
C3 (g/L)  Anti-dsDNA 
antibody titre 
Features  Treatment 
SLE1  Female  36  Caucasian  Mild  Normal  Normal 
Athritis, dermatological 
and neurological 
involvement 
DMARDs (hydroxychloroquine), NSAIDs 
(aspirin), corticosteroids (prednisolone), 
gastroprotective agents (lansoprazole), calcium 
supplementation 
SLE2  Female  21  Caucasian  Mild  Normal  Normal  Arthritis, neurological 
involvement 
DMARDs (mycophenolate mofetil, 
hydroxychloroquine), NSAIDs (aspirin, 
piroxicam), calcium supplementation 
SLE3  Female  37  Caucasian  Mild  Normal  Normal  General  No medication 
SLE4  Female  32  Caucasian  Moderately 
active  0.82  97  Arthritis, fatigue 
DMARDs (hydroxychloroquine), NSAIDs 
(aspirin, piroxicam), corticosteroids 
(prednisolone)  
SLE5  Female  34  Caucasian  Moderately 
active  0.58  Normal  Renal disease  DMARDs (hydroxychloroquine, azathioprine), 
corticosteroids (prednisolone)    295 
7.3  Th1 and Th2 specific genes identified by microarray 
Table 7.28: Genes upregulated in Th1 cells 
Gene symbol 
lincRNA:chr12:68421607-
68422081_F 
IL15  KCNA2  KLHDC7B  OAS3  FAM172BP 
CCR1  DOK5  lincRNA:chr2:111992304-
111994467_R 
SH3RF1  PELI2  C15orf53 
G0S2  ENPP6  EIF2AK2  A_33_P3278684  C10orf10  GBP3 
IFNG  ENST00000400702  CPLX1  GLUL  NP113779  LOC79015 
ANXA3  BCL2L14  SH3BP5  lincRNA:chr1:205404014-
205407007_R 
IL23R  IFI30 
C15orf48  EPHA4  IFI6  MX2  PRDM8  PLAC8 
ITGA6  TLR1  NPDC1  EBF4  DDX60L  BC029255 
IFI44L  CLIC2  RSAD2  ADCY4  ANTXR2  lincRNA:chr2:112005726-
112123291_R 
TMEM213  MTMR11  NAPSA  TM6SF1  PARP9  GCNT1 
EPAS1  TSHZ3  LAG3  DPY19L4  FES  SYNM 
ETV7  STX3  ENST00000426099  BICD1  SGPP2  XM_003118976 
S100A9  CYB561  KAT2B  RASA3  lincRNA:chr1:89874262-
89947412_F 
CRISPLD1 
PRR5L  IL18RAP  TSPAN15  P2RX5  SPTBN5  IL31RA 
ALPK1  TMEM30B  BTBD11  FAM3C  EPSTI1  IFIH1 
HSD11B1  DNAJC6  LILRB3  FAAH2  RORC  LAMP3 
STEAP1  C4orf26  EBI3  RAMP1  GIMAP8  NR3C2 
LOC100507421  ENST00000378350  lincRNA:chr11:36494424-
36500099_F 
MANEAL  DDX60  CXCL10 
ABCA1  CCNA1  PARP12  lincRNA:chr22:25588075-
25594350_F 
ANK3  MYH6 
CD38  CPLX3  MAMLD1  CEACAM1  CCNI2  PLEKHG3 
ENST00000360485  EGFL6  CD8B  RARRES3  GBP4  UNQ6494 
MYH7  CHST15  DNAJC12  PREX1  DTX3L  ATP9A 
IL2  IL12RB2  EIF4E3  ATP2B4  PDGFRB  AF363068   296 
Gene symbol 
PLEK  NPTX1  PRF1  lincRNA:chr4:8359032-
8359781_R 
PRG4  TNFSF13B 
IL21  MX1  TNFRSF18  SSBP3  JUN  LOC100289580 
ENPP2  LOC100128019  TMEM200A  LPGAT1  GPR174  MAP6 
TIMD4  PNMA2  LAMB3  SMAD3  IL26  PARP14 
TXK  RASGRF2  PITPNC1  MGC70870  SNCA  NELL2 
CCR5  IRAK2  CDC42EP1  MICA  C4BPB  GPR155 
ATP8B4  ELOVL7  A_24_P143653  CPNE8  PLSCR1  IL18R1 
TRPS1  IFIT5  TRIM22  TNFSF10  CD274  LOC541471 
XAF1  IRAK3  ITGA3  CXCL16  HOXB6  lincRNA:chr2:111965652-
112101793_R 
RIPK2  USP18  SAMD9  IRF1  AIRE  SOD2 
ATP6V0A4  MBL1P  HBEGF  lincRNA:chr4:8357036-
8359103_R 
TPST2  C12orf35 
GPR34  TSHZ2  NUAK2  EDA  OSBP2  ASPHD2 
MATN4  DGKG  GALNT10  CD59  RAPGEF2  BBS12 
TBX21  GADD45B  PPARG  ARNTL  HOXB3  STAT2 
MAP3K5  LOC100506342  MAP3K8  PPP2R2B  OR52N4  PRIC285 
CDO1  ZG16B  HES1  IL13RA1  BC026731  LOC100131733 
IFI44  PCSK5  KBTBD11  ISG15  F2RL1  ISG20 
FAM26F  SAMD9L  lincRNA:chr4:8357101-
8357609_R 
CAST  TRANK1  ARRDC3 
SLAMF7  lincRNA:chr1:89874262-
89947412_R 
CLIC5  TG  HERC6  ITGAX 
ALOX5  HS6ST2  CDYL2  PALLD  TCF7  TNFAIP2 
HPGD  UBD  TIFA  GAS8  GBP1  CA6 
IFIT1  RCAN2  FMOD  LOC100505719  BCL2L11  TTC39C 
LYN  USP41  KIRREL2  TGFBR1  HOXB4  lincRNA:chr14:101297417-
101297818_F 
SHISA2  lincRNA:chr21:29817053-
30047175_R 
ELOVL6  RNF157  PVRL3  HLA-C   297 
Gene symbol 
lincRNA:chr21:29818746-
30047176_R 
INSC  lincRNA:chr13:44760050-
44767325_R 
CARD16  ELOVL4  lincRNA:chr8:107055124-
107072278_F 
DMD  MLLT4  D4S234E  KRT33A  PYGM  GCH1 
ENST00000390252  GADD45G  lincRNA:chr2:111954496-
112125102_R 
CARD17  PAG1  SYNE2 
GREM2  CFH  CCL25  A_33_P3314091  STOM  RNF213 
DAPK2  PACSIN1  CYFIP1  ZBTB47  HERC5  VOPP1 
IFIT3  lincRNA:chr2:111994580-
111996624_R 
HIC1  DPF3  OTUD1  MUC1 
PDE4B  lincRNA:chr2:111960680-
111962218_R 
EMR1  XLOC_003385  lincRNA:chr2:37325696-
37331035_R 
FCHSD2 
LMO4  DOCK5  GHRL  RIMS3  MDM1  OAS2 
NLRP7  CFHR3  CD40  HOXB2  PDE1B  DAZAP1 
GNLY  MAST4  lincRNA:chr2:111964707-
111965184_R 
KIAA1671  lincRNA:chr17:78306364-
78308071_R 
HLA-B 
ENST00000492167  LACC1  SLC41A2  DGCR14  A_33_P3410019  DYRK2 
lincRNA:chr10:5156300-
5171275_R 
STYK1  KIAA1217  RHOBTB2  LOC729603  FAS 
lincRNA:chr12:68383224-
68415107_F 
RORA  FEZ1  ENST00000390398  AHNAK   
HAVCR1  RHOU  ZDHHC19  CLEC2B  KCNA3 
SIPA1L2  ENST00000390247  RASGEF1A  LY6E  STT3B 
XLOC_013923  IFI35  CASP1  TDRD7  lincRNA:chr16:80631802-
80632239_R 
 
     298 
Table 7.29: Genes upregulated in Th2 cells 
Gene symbol 
CRH  SEMA5A  CCR8  CACNB2  NEK6  MYH10 
KRT1  KCNK1  IGFBP2  RAC3  GPR125  GALNT3 
LOC728218  LOC729970  CLDND2  MFSD4  lincRNA:chr6:22191803-
22194614_F 
LOC730091 
MAOA  PECAM1  ZNF239  RGS9  HECW2  AK096239 
PTGIS  LOC643650  TCEA3  C18orf56  PI16  HIP1 
CALD1  FAM174B  C9orf47  lincRNA:chr7:129401614-
129418239_R 
CD244  GNB4 
FLJ45983  RBM47  ENST00000513415  ENST00000399967  AW002507  MRAP2 
HOMER2  LOR  ACTN3  ABCG2  GPR183  PSMA8 
IL17RB  GJB2  lincRNA:chr18:45332602-
45354102_F 
RNF215  DACT1  lincRNA:chr14:96507172-
96661947_F 
TRIM49L2  VSIG10L  UCHL1  NEK10  SIGLEC12  ENST00000338857 
KIAA1462  FNBP1L  ZP1  lincRNA:chr8:32785498-
32902078_F 
TMEM98  C14orf132 
HTR2B  PCDH8  ANKRD57  EEF2K  lincRNA:chr3:171506056-
171528740_R 
LOC100134285 
TRIM43  lincRNA:chr3:171506370-
171528740_R 
ENST00000460965  lincRNA:chr8:104254399-
104295074_R 
OGDHL  NMUR1 
CR604707  SIGLECP3  FRRS1  METTL9  LOC100506220  ACCN2 
RNF43  C8orf46  CTDSPL  lincRNA:chr14:71276672-
71284022_F 
lincRNA:chr12:4958789-
4970589_F 
OSBPL1A 
LRRC32  lincRNA:chr8:37258592-
37350868_R 
TPTE2P6  WFDC1  BCAR3  MBOAT1 
lincRNA:chr1:214512902-
214523621_R 
lincRNA:chr6:138961057-
139020207_R 
PACSIN3  C1orf162  CA2  MTL5 
C15orf27  SPINK2  CPNE5  CFD  lincRNA:chr7:105517604-
105553086_F 
DYNC2LI1 
MAOB  LPCAT2  PDE9A  C6orf99  LOC286442  TLE2 
PTPN20B  SCPEP1  FRG2  GPER  PLEKHH2  NSMCE1 
LIMA1  LOC728084  AUH  GJC1  ITM2C  LOC400684 
S1PR3  AF074986  ARHGEF26  MRPS26  SIGLEC10  ZNF488 
PDE7B  XLOC_013837  GATM  ST7  IFNGR2  LOC730101   299 
Gene symbol 
LOC100129034  LOC728819  TERT  SEC11C  HPGDS  COMP 
ANXA8L2  SOX4  ENST00000378416  CD33  A_33_P3250273  lincRNA:chr2:232366756-
232372381_R 
ENST00000549427  ZBTB8A  A_33_P3333985  TMPRSS13  ZNF697  HILPDA 
RXRA  PLD1  MLC1  IQCJ-SCHIP1  PIWIL2  SCHIP1 
PLA2G4A  NRP1  lincRNA:chr6:22146709-
22147336_R 
LMCD1  RRS1  FAM171A1 
CLIC6  PPP1R14A  lincRNA:chr8:58106178-
58152853_R 
lincRNA:chr2:217380530-
217421230_F 
lincRNA:chr7:105525814-
105538089_F 
AKAP12 
THC2685600  ABHD6  NPAS2  TGFBR3  SPINT2  SLC40A1 
PTPN20A  PNMAL1  ABCC4  CEP70  DUSP6  CCR4 
THC2675356  FAM124B  PLAU  RUNX2  ADORA2B  SLC45A3 
TPRG1  REEP2  B3GAT1  GALNTL4  C9orf135  OXER1 
C8orf85  SLC39A14  SLC17A3  ARG2  SVOPL  C10orf55 
LOC100505806  SGIP1  lincRNA:chr6:5013951-
5056876_F 
MARCKS  UTS2  TRAM2 
AK075182  ERRFI1  PTPRN2  lincRNA:chr16:54944999-
54959642_R 
SMAD1  ACTN1 
CAPSL  NM_144710  XDH  TTN  RYR1  LOC728671 
FBLN5  SLC47A1  XLOC_006828  SCAI  ADHFE1  LINC00263 
MYO3B  LINC00340  OXCT2  AGBL2  lincRNA:chr2:224501706-
224587681_R 
SGSH 
IGF2BP3  CYP19A1  IL12A  HIST1H1A  SMAD2  lincRNA:chr8:32785489-
32902343_F 
CLDN1  ENST00000536986  RNF125  lincRNA:chr10:97639610-
97667003_F 
CDON  LOC727916 
A_33_P3295623  lincRNA:chr7:105551484-
105564551_F 
PTPRVP  LOC100506105  SLMO1  CTTN 
PTGDR2  ECSCR  LOC100505933  ENPP3  NFIL3  lincRNA:chr2:39745746-
39826668_F 
CHDH  ZYG11A  INPP4B  LOC442132  ZMAT1  GAMT 
ARMCX1  lincRNA:chr1:101518537-
101561912_F 
BFSP2  TLR5  CYSLTR2  HSBP1L1 
MRC2  SPATA3  GSTA4  ETS2  AGPAT9  DFNB59   300 
Gene symbol 
AOAH  CTNNAL1  C21orf96  LINC00239  NUDT9P1  TRPC1 
lincRNA:chr8:67304071-
67319246_R 
DNAJC5B  TRIM2  PTER  TRIO  TMEM45B 
MEOX1  IL9  FLJ21408  HS3ST1  THC2680609  SPRYD7 
ENPP1  FAM150B  PIP5K1B  CNR2  GLT1D1  PEX2 
TNFSF11  THY1  XLOC_005143  SNTA1  XM_942053  A_33_P3390939 
BHLHE22  A_24_P229726  SLC9A7P1  P2RX1  AHRR  MIR600HG 
ENST00000442072  MGST3  SH3BGR  B9D1  DEPDC4  LIMS2 
FZD3  AXIN2  CR591103  PNPLA3  LOC100132774  ALDH5A1 
CABLES1  A_33_P3416196  NME4  ENST00000309775  EPN2  BC039426 
DDC  THBS4  ACSM3  SCARB1  BC039440  TEX14 
lincRNA:chr5:9547425-
9554550_F 
CERCAM  GATA3  ETFB  RGS12  PCSK4 
GJB6  IL31  AGAP7  HSPA4L  ZNF532  SLC15A3 
CDCP1  CACNA1D  LOC388780  GNRH2  AR  lincRNA:chrX:57003000-
57010915_R 
MYL9  BMS1P1  TMEM44  lincRNA:chr1:101548009-
101552817_F 
SORD  MAP2K6 
PMCH  GDF10  RNASE4  NT5DC2  lincRNA:chr14:96555696-
96556712_F 
BARX1 
GAD1  ENST00000423719  GML  ST7-AS1  ISYNA1  SH3RF2 
IKZF2  LOC400768  SLC17A9  LRRC20  NKD2  PON2 
ICAM4  STON1  BEX1  lincRNA:chr3:37864071-
37876621_R 
GAB2  S100P 
PTPN14  CTHRC1  FV367791  SOX12  C10orf128  ANG 
HRH4  RCBTB2  LOC642826  DIRC3  LOC100505683  SLIT3 
GPR55  lincRNA:chr2:74193717-
74210392_R 
lincRNA:chr19:53702413-
53709013_F 
SYPL1  SLC4A7  FAM8A1 
ENST00000431083  RUNX1  XAGE3  lincRNA:chr2:65103471-
65188448_R 
ACOXL  ZAR1 
PMCHL1  C5  lincRNA:chr6:5047814-
5048418_F 
CLEC11A  lincRNA:chr4:128758375-
128769050_F 
C6orf81 
ENST00000543306  lincRNA:chr14:96548697-
96561747_F 
lincRNA:chr2:208360030-
208378555_R 
AEBP1  ZFR2  FOXP1   301 
Gene symbol 
NMT2  FLJ37798  PTPLA  CCDC151  GNAI1  PRKCA 
NCS1  TBC1D4  lincRNA:chr10:97639610-
97666960_R 
ZNF827  KLHDC9  BEND5 
TOX  RAB27B  C6orf52  NUDT11  ALDH7A1  LOC286063 
MYBL1  LOC728558  PNOC  FLJ35946  NUDT7   
lincRNA:chr17:67547498-
67549996_F 
LOC348761  CAMK1  ENST00000445310  NDFIP2 
ATP12A  lincRNA:chr7:105551628-
105553084_F 
NUDT8  lincRNA:chr8:32853730-
32902348_F 
ACCS 
F12  ARMCX4  CEP55  GNAS-AS1  C1orf228   302 
7.4  T-bet super-enhancer eRNAs upregulated in Th1 cells 
Table 7.30: T-bet super-enhancer eRNAs upregulated in Th1 cells 
Comparison of super-enhancer eRNA FPKM values in Th1 and Th2 cells. RS and US conditions are also given. Super-enhancer IDs correspond 
to the nearest annotated genic TSS. Note that some super-enhancers correspond to more than one gene and some genes have more than one 
super-enhancer (named A, B). Transcripts within each super-enhancer are numbered individuallyAll are donor 2. FPKM: Fragments per kilbase 
per million mapped reads; RS: restimulated; US: unstimulated. 
Super-enhancer  eRNA  FPKM 
Nearest 
gene  Coordinates  ID  Coordinates  Strand 
Th1 RS 
Total 
RNA 
Naïve 
NA 
polyA 
Th1 
US 
polyA 
Th1 
RS 
polyA 
Th2 
US 
polyA 
Th2 
RS 
polyA 
Th1 
US 
Total 
RNA 
Th2 
US 
Total 
RNA 
Th2 
RS 
Total 
RNA 
ACSL6  chr5:1313555
65-131362793 
ACSL6-
eRNA 
chr5:131356657
-131357166  +  2.3055  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA1 
chr5:157023417
-157023721  -  2.7278  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA2 
chr5:157023979
-157024554  +  2.4523  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA3 
chr5:157023706
-157023927  +  3.7953  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19 
chr5:1570216
83-157035243 
ADAM19-
eRNA4 
chr5:157026788
-157027098  -  3.3749  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19 
chr5:1570216
83-157035243 
ADAM19-
eRNA5 
chr5:157027429
-157028493  +  4.7502  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA6 
chr5:157029978
-157030311 
+  3.0170  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA7 
chr5:157029992
-157030455  -  1.8950  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA8 
chr5:157028565
-157029066  +  2.0414  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA9 
chr5:157028654
-157029833  -  2.2948  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA10 
chr5:157030661
-157031333  +  3.6196  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA11 
chr5:157035113
-157035593  +  1.4985  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ADAM19  chr5:1570216
83-157035243 
ADAM19-
eRNA12 
chr5:157033477
-157034749  -  5.6473  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ARL4C  chr2:2351870
10-235201525 
ARL4C-
eRNA1 
chr2:235198404
-235198555  -  5.5206  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ARL4C  chr2:2351870
10-235201525 
ARL4C-
eRNA2 
chr2:235198636
-235199094  +  4.6265  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ARL4C 
chr2:2351870
10-235201525 
ARL4C-
eRNA3 
chr2:235199199
-235200084  +  1.9239  0.0000  0.0000  0.0000  0.0000  0.0000  1.6774  0.0000  0.5581   303 
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BCL2 
chr18:608670
75-60888556 
BCL2-
eRNA2 
chr18:60874451
-60875137  +  1.8059  0.0000  2.5765  0.0000  4.9736  2.7211  1.1531  2.4339  1.7132 
BHLHE40  chr3:5018681-
5028927 
BHLHE40-
eRNA1 
chr3:5018251-
5018805 
-  2.1900  0.0000  0.0000  0.0000  1.5204  1.6852  1.5601  0.0000  0.0000 
BHLHE40  chr3:5018681-
5028927 
BHLHE40-
eRNA2 
chr3:5018911-
5020038 
-  3.7477  0.0000  0.0000  1.1805  1.3014  1.2163  1.5601  1.3390  0.9337 
BZRAP1-
BZRAP1-
AS1-
MIR142-
MIR4736 
chr17:564048
68-56422171 
BZRAP1-
BZRAP1-
AS1-
MIR142-
MIR4736-
eRNA2 
chr17:56421372
-56421856  -  2.0149  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
C14orf182 
chr14:504659
40-50469622 
C14orf182-
eRNA1 
chr14:50466125
-50466481  +  3.0147  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
C14orf182  chr14:504659
40-50469622 
C14orf182-
eRNA2 
chr14:50468239
-50468594 
+  2.7222  0.0000  1.4524  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CCND2_A  chr12:425189
9-4263091 
CCND2_A-
eRNA 
chr12:4255795-
4256015 
+  2.9997  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CCND2_B  chr12:437837
6-4382287 
CCND2_B-
eRNA1 
chr12:4379265-
4379590  +  2.5179  0.0000  0.0000  1.9808  2.2714  1.8225  0.0000  0.0000  0.0000 
CCND2_B  chr12:437837
6-4382287 
CCND2_B-
eRNA2 
chr12:4381542-
4381780  +  2.4636  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CDC7  chr1:9201443
9-92022120  CDC7-eRNA  chr1:92014156-
92014687  -  3.7775  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.9815 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA1 
chr5:131435172
-131435732  -  1.3526  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA2 
chr5:131434302
-131434947  -  2.3171  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA3 
chr5:131439647
-131440231  +  0.8610  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA4 
chr5:131439735
-131440156  -  1.4900  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2 
chr5:1314347
67-131447219 
CSF2-
eRNA5 
chr5:131441469
-131442119  +  1.6084  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2 
chr5:1314347
67-131447219 
CSF2-
eRNA6 
chr5:131437391
-131439434  -  2.5725  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA7 
chr5:131440368
-131441404 
+  2.2799  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA8 
chr5:131438074
-131438922 
+  7.0811  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
CSF2  chr5:1314347
67-131447219 
CSF2-
eRNA9 
chr5:131445138
-131446685  -  6.6748  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000   304 
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DAD1 
chr14:230189
61-23031423 
DAD1-
eRNA1 
chr14:23029112
-23029481  -  1.5900  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
DAD1  chr14:230189
61-23031423 
DAD1-
eRNA2 
chr14:23029566
-23030690 
-  2.5197  0.0000  0.0000  0.0000  0.0000  0.0000  1.4594  0.0000  1.6159 
DAD1  chr14:230189
61-23031423 
DAD1-
eRNA3 
chr14:23030947
-23031474 
+  1.1573  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
DDIT4  chr10:740568
69-74057959 
DDIT4-
eRNA 
chr10:74056798
-74057020  -  5.1205  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  1.0450 
DNAJC5B  chr8:6684393
4-66868440 
DNAJC5B-
eRNA1 
chr8:66860843-
66861343  +  1.4316  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
DNAJC5B  chr8:6684393
4-66868440 
DNAJC5B-
eRNA2 
chr8:66864987-
66865346  +  1.6419  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
DNAJC5B  chr8:6684393
4-66868440 
DNAJC5B-
eRNA3 
chr8:66868189-
66868713  +  1.3587  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
DPP4  chr2:1628091
95-162810979 
DPP4-
eRNA2 
chr2:162807513
-162809532  -  5.2821  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
DPP4  chr2:1628091
95-162810979 
DPP4-
eRNA3 
chr2:162810486
-162810797  -  2.3002  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ETS1_A 
chr11:128188
606-
128195137 
ETS1_A-
eRNA1 
chr11:12819376
7-128194277  -  1.5003  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.9050 
ETS1_A 
chr11:128188
606-
128195137 
ETS1_A-
eRNA2 
chr11:12819490
8-128195243  +  2.9147  1.5624  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
ETS1_B 
chr11:128159
970-
128175956 
ETS1_B-
eRNA1 
chr11:12816089
0-128161198 
+  2.3272  1.7242  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  1.0655 
ETS1_B 
chr11:128159
970-
128175956 
ETS1_B-
eRNA2 
chr11:12816130
1-128161787  +  1.6889  4.0460  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.6368 
ETS1_B 
chr11:128159
970-
128175956 
ETS1_B-
eRNA3 
chr11:12817206
7-128172569  -  4.6829  1.1694  0.0000  0.0000  0.0000  0.9912  2.9895  2.5651  2.4060 
FAM3C  chr7:1211702
65-121171217 
FAM3C-
eRNA 
chr7:121171080
-121172242  +  3.8357  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
FASLG_A  chr1:1726682
45-172677990 
FASLG_A-
eRNA1 
chr1:172667787
-172669169  -  1.9274  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
FASLG_A  chr1:1726682
45-172677990 
FASLG_A-
eRNA2 
chr1:172667799
-172669328  +  1.8440  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
FASLG_A  chr1:1726682
45-172677990 
FASLG_A-
eRNA3 
chr1:172673366
-172673879  +  1.4906  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
FASLG_A 
chr1:1726682
45-172677990 
FASLG_A-
eRNA4 
chr1:172672704
-172673047  -  2.2046  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000   305 
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FASLG_A 
chr1:1726682
45-172677990 
FASLG_A-
eRNA5 
chr1:172677906
-172678241  +  1.7812  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
FASLG_B  chr1:1726314
75-172644841 
FASLG_B-
eRNA1 
chr1:172641155
-172642259 
+  1.7263  0.0000  0.0000  2.8497  0.0000  0.9179  0.0000  0.0000  0.0000 
FASLG_B  chr1:1726314
75-172644841 
FASLG_B-
eRNA2 
chr1:172638368
-172640852 
+  3.4000  0.0000  0.0000  1.2570  0.0000  4.2255  0.0000  0.0000  1.3290 
FURIN  chr15:913951
96-91400410 
FURIN-
eRNA1 
chr15:91395070
-91395587  +  1.5762  0.0000  2.8526  2.1995  0.0000  0.0000  1.5772  0.0000  0.0000 
FURIN  chr15:913951
96-91400410 
FURIN-
eRNA2 
chr15:91395777
-91395913  +  5.9337  0.0000  2.9839  0.0000  0.0000  0.0000  1.5772  0.0000  0.0000 
FURIN  chr15:913951
96-91400410 
FURIN-
eRNA3 
chr15:91395099
-91395937  -  2.5633  0.0000  0.0000  0.0000  0.0000  0.0000  1.3259  0.0000  0.0000 
FURIN  chr15:913951
96-91400410 
FURIN-
eRNA4 
chr15:91398235
-91398700  +  2.4404  0.0000  1.7486  1.4920  0.0000  0.0000  1.2746  0.0000  0.0000 
FURIN  chr15:913951
96-91400410 
FURIN-
eRNA5 
chr15:91399760
-91399908  -  7.1107  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GIMAP2  chr7:1503608
53-150374281 
GIMAP2-
eRNA 
chr7:150365291
-150365691  -  1.9091  0.0000  0.0000  0.0000  0.0000  0.0000  1.9046  0.0000  0.0000 
GZMB  chr14:251345
09-25143870 
GZMB-
eRNA1 
chr14:25134585
-25134900  -  4.8789  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GZMB  chr14:251345
09-25143870 
GZMB-
eRNA2 
chr14:25135162
-25135595  +  2.5253  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GZMB 
chr14:251345
09-25143870 
GZMB-
eRNA3 
chr14:25139478
-25139867  -  2.5833  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GZMB  chr14:251345
09-25143870 
GZMB-
eRNA4 
chr14:25140444
-25141198 
+  1.9570  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GZMB  chr14:251345
09-25143870 
GZMB-
eRNA5 
chr14:25141916
-25142135 
-  11.7962  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GZMB  chr14:251345
09-25143870 
GZMB-
eRNA6 
chr14:25142187
-25142738  -  4.0391  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
GZMB  chr14:251345
09-25143870 
GZMB-
eRNA7 
chr14:25143615
-25145250  +  6.1301  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
HAVCR1  chr5:1564520
61-156458115 
HAVCR1-
eRNA1 
chr5:156452040
-156452349  -  2.3181  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
HAVCR1  chr5:1564520
61-156458115 
HAVCR1-
eRNA2 
chr5:156455530
-156455718  -  4.8793  2.0498  1.7704  1.6278  0.0000  0.0000  0.0000  0.0000  0.0000 
HAVCR1  chr5:1564520
61-156458115 
HAVCR1-
eRNA3 
chr5:156453808
-156454390  -  1.1235  3.1777  3.2988  2.3066  0.0000  0.0000  0.9958  0.0000  0.0000 
HAVCR1  chr5:1564520
61-156458115 
HAVCR1-
eRNA4 
chr5:156457466
-156457504  +  107.426
1  0.0000  0.0000  0.0000  0.0000  0.0000  77.786
2 
97.700
4 
81.829
1 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA1 
chr12:68555552
-68557747  -  6.5995  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000   306 
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IFNG 
chr12:685571
78-68584152 
IFNG-
eRNA2 
chr12:68557941
-68558204  +  2.6064  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA3 
chr12:68558346
-68559126 
+  3.0193  0.0000  0.0000  0.0000  0.0000  0.0000  1.6371  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA4 
chr12:68560053
-68560736 
-  2.7581  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA5 
chr12:68560996
-68561819  +  1.0097  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA6 
chr12:68563166
-68564061  +  2.0912  0.0000  0.9318  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA7 
chr12:68564507
-68566330  -  1.0585  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA8 
chr12:68565959
-68566925  +  4.1601  0.0000  0.0000  0.0000  0.0000  0.0000  1.0490  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA9 
chr12:68567631
-68567788  -  4.7777  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA10 
chr12:68567943
-68570462  -  2.4613  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA11 
chr12:68570568
-68572497  -  2.0250  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA12 
chr12:68573107
-68574069  -  7.3884  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG 
chr12:685571
78-68584152 
IFNG-
eRNA13 
chr12:68569397
-68573651  +  4.7151  0.0000  1.0905  0.0000  0.0000  0.0000  1.3463  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA14 
chr12:68574321
-68575293 
-  6.7932  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA15 
chr12:68574930
-68575825 
+  3.5305  0.0000  0.0000  0.0000  0.0000  0.0000  0.8119  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA16 
chr12:68575974
-68576496  +  2.1930  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA17 
chr12:68579518
-68579839  +  4.2589  0.0000  0.0000  0.0000  0.0000  0.0000  1.1004  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA18 
chr12:68582527
-68582731  +  7.3817  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA19 
chr12:68582792
-68582974  +  4.2228  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA20 
chr12:68583093
-68583432  +  2.5547  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IFNG  chr12:685571
78-68584152 
IFNG-
eRNA21 
chr12:68583731
-68584878  +  6.4636  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IKZF1  chr7:5041532
9-50428541 
IKZF1-
eRNA3 
chr7:50427621-
50428323  -  1.1978  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000   307 
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Th2 
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RNA 
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IL1RL1 
chr2:1028696
42-102879068 
IL1RL1-
eRNA1 
chr2:102876118
-102876419  +  2.2086  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IL1RL1  chr2:1028696
42-102879068 
IL1RL1-
eRNA2 
chr2:102874335
-102875233 
-  1.1366  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
IL1RL1  chr2:1028696
42-102879068 
IL1RL1-
eRNA3 
chr2:102878148
-102878499 
+  1.6858  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
KLF6  chr10:384740
8-3852963 
KLF6-
eRNA1 
chr10:3847347-
3848142  +  1.3559  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
KLF6  chr10:384740
8-3852963 
KLF6-
eRNA2 
chr10:3851566-
3851830  -  2.3779  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
KLF6  chr10:384740
8-3852963 
KLF6-
eRNA3 
chr10:3852219-
3852637  -  1.8777  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00501  chr3:1770764
01-177078107 
LINC00501-
eRNA 
chr3:177077927
-177078367  +  1.2989  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00861  chr8:1269425
86-126963824 
LINC00861-
eRNA2 
chr8:126960301
-126960620  +  2.4919  0.0000  0.0000  0.0000  0.0000  0.0000  2.5605  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA1 
chrX:135710066
-135710736  +  1.2599  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA2 
chrX:135710197
-135710695  -  1.0272  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA3 
chrX:135709744
-135709971  +  2.8800  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892 
chrX:1357094
55-135717895 
LINC00892-
eRNA4 
chrX:135711408
-135712084  +  2.2753  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA5 
chrX:135707035
-135709677 
-  3.7462  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA6 
chrX:135708509
-135709692 
+  4.0882  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA7 
chrX:135716883
-135717234  -  3.0651  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC00892  chrX:1357094
55-135717895 
LINC00892-
eRNA8 
chrX:135717454
-135717772  +  2.4119  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC01136  chr1:2032561
22-203259100 
LINC01136-
eRNA1 
chr1:203258872
-203259654  +  2.6347  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC01136  chr1:2032561
22-203259100 
LINC01136-
eRNA2 
chr1:203258938
-203259627  -  3.8105  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
LINC01136  chr1:2032561
22-203259100 
LINC01136-
eRNA3 
chr1:203258166
-203258725  -  3.7824  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
MIR1206  chr8:1289898
35-129005802 
MIR1206-
eRNA2 
chr8:128992174
-128992591  -  2.0335  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
MIR1206  chr8:1289898
35-129005802 
MIR1206-
eRNA5 
chr8:128994061
-128994636  -  1.7931  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000   308 
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MIR1206 
chr8:1289898
35-129005802 
MIR1206-
eRNA6 
chr8:129002678
-129003394  -  1.4484  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
MIR1206  chr8:1289898
35-129005802 
MIR1206-
eRNA9 
chr8:128999402
-129000026 
-  1.2775  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
MIR1206  chr8:1289898
35-129005802 
MIR1206-
eRNA10 
chr8:129003534
-129005286 
-  15.2530  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
MIR6855  chr9:1326479
39-132651721 
MIR6855-
eRNA 
chr9:132647694
-132648130  -  3.6987  2.0606  0.0000  2.2898  1.3187  2.6857  0.0000  1.8109  1.8140 
P2RX5  chr17:359713
7-3616557 
P2RX5-
eRNA 
chr17:3608728-
3608935  -  3.5459  0.0000  0.0000  2.0603  0.0000  0.8903  0.0000  0.0000  0.0000 
PDE4B  chr1:6674070
7-66754118 
PDE4B-
eRNA2 
chr1:66748774-
66749233  -  2.0262  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
PMF1  chr1:1561861
28-156188127 
PMF1-
eRNA3 
chr1:156187492
-156187857  -  3.2207  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
PRDM1  chr6:1062569
56-106263358 
PRDM1-
eRNA1 
chr6:106259426
-106260049  +  0.8824  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
PRDM1  chr6:1062569
56-106263358 
PRDM1-
eRNA2 
chr6:106262299
-106262651  -  1.6802  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
PRSS2  chr7:1425055
41-142507253 
PRSS2-
eRNA1 
chr7:142506816
-142507034  -  2.7598  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
PRSS2  chr7:1425055
41-142507253 
PRSS2-
eRNA2 
chr7:142504344
-142506747  -  4.8010  0.0000  0.0000  0.0000  0.0000  0.0000  1.0954  0.0000  0.0000 
PRSS2 
chr7:1425055
41-142507253 
PRSS2-
eRNA3 
chr7:142507150
-142508606  +  7.5967  0.0000  1.9048  0.0000  0.0000  0.0000  6.6907  0.0000  1.4580 
PRSS2  chr7:1425055
41-142507253 
PRSS2-
eRNA4 
chr7:142505671
-142506729 
+  2.1565  0.0000  1.9757  0.0000  0.0000  0.6960  1.4467  0.9551  0.0000 
PTGER4  chr5:4042825
2-40442140 
PTGER4-
eRNA1 
chr5:40436922-
40437396 
-  1.8455  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
PTGER4  chr5:4042825
2-40442140 
PTGER4-
eRNA2 
chr5:40439610-
40440051  +  2.0022  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
RASA3 
chr13:114907
886-
114914450 
RASA3-
eRNA 
chr13:11491346
3-114914439 
-  1.6847  1.2028  4.4353  0.0000  0.0000  0.0000  2.2126  0.0000  0.0000 
RASGRP1  chr15:389030
99-38903891 
RASGRP1-
eRNA 
chr15:38903557
-38903845 
+  2.5245  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
RP11-
162J8.2 
chr6:1494496
10-149469908 
RP11-
162J8.2-
eRNA 
chr6:149460824
-149461379  -  1.6392  0.0000  0.0000  1.2020  0.0000  0.0000  2.8108  1.2477  0.0000 
RP11-
402G3.3 
chr9:1174531
86-117459756 
RP11-
402G3.3-
eRNA1 
chr9:117454418
-117454876  +  2.1440  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
RP11- chr9:1174531 RP11- chr9:117455055 +  2.4969  0.0000  0.0000  1.1046  0.0000  0.0000  0.0000  0.0000  0.0000   309 
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402G3.3  86-117459756  402G3.3-
eRNA2 
-117455529 
RP11-
402G3.3 
chr9:1174531
86-117459756 
RP11-
402G3.3-
eRNA3 
chr9:117453593
-117454351  +  2.7243  0.0000  0.0000  0.0000  0.0000  0.0000  1.4632  0.0000  0.0000 
RP11-
402G3.3 
chr9:1174531
86-117459756 
RP11-
402G3.3-
eRNA4 
chr9:117457340
-117457613  +  3.7327  0.0000  0.0000  1.0779  0.0000  0.0000  0.0000  0.0000  0.0000 
RP11-
402G3.3 
chr9:1174531
86-117459756 
RP11-
402G3.3-
eRNA5 
chr9:117459195
-117459402  +  2.9549  0.0000  0.0000  1.6345  0.0000  0.0000  0.0000  0.0000  0.0000 
RP11-
402G3.3 
chr9:1174531
86-117459756 
RP11-
402G3.3-
eRNA6 
chr9:117459048
-117459360 
-  1.7626  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
RUNX3  chr1:2527880
7-25293528 
RUNX3-
eRNA2 
chr1:25292287-
25293209 
-  1.3745  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
RUNX3  chr1:2527880
7-25293528 
RUNX3-
eRNA3 
chr1:25292400-
25292992 
+  0.9231  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
SATB1  chr3:1875426
1-18767707 
SATB1-
eRNA1 
chr3:18754020-
18754599  -  0.9561  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
SATB1  chr3:1875426
1-18767707 
SATB1-
eRNA6 
chr3:18766081-
18767084  -  1.9257  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
SLAMF7  chr1:1607257
55-160727039 
SLAMF7-
eRNA1 
chr1:160726697
-160727291  +  1.6480  0.0000  0.0000  1.2674  0.0000  0.0000  0.0000  0.0000  0.0000 
SLAMF7  chr1:1607257
55-160727039 
SLAMF7-
eRNA2 
chr1:160726014
-160726627  +  2.4494  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
SLC39A10  chr2:1963970
23-196408137 
SLC39A10-
eRNA 
chr2:196398283
-196398880  -  1.5969  0.0000  0.0000  0.0000  0.0000  0.0000  1.3776  0.9374  0.8830 
SNORA14B  chr1:2351472
61-235148139 
SNORA14B-
eRNA1 
chr1:235147882
-235148623  +  5.4502  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
STAT1  chr2:1918848
59-191915035 
STAT1-
eRNA1 
chr2:191887037
-191887457  -  1.3695  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
STAT1 
chr2:1918848
59-191915035 
STAT1-
eRNA2 
chr2:191893432
-191893944  -  1.2448  1.3357  0.0000  0.0000  0.0000  0.0000  0.0000  1.5157  0.6829 
TBKBP1 
chr17:457803
92-45798949 
TBKBP1-
eRNA1 
chr17:45797233
-45797694  +  1.3442  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
TBKBP1  chr17:457803
92-45798949 
TBKBP1-
eRNA2 
chr17:45795790
-45796638 
+  4.0843  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
TBKBP1  chr17:457803
92-45798949 
TBKBP1-
eRNA3 
chr17:45798812
-45800365 
+  5.8705  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
TNFAIP8_B  chr5:1186645
08-118679814 
TNFAIP8_B-
eRNA3 
chr5:118675331
-118676206  -  1.1445  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000   310 
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TNFAIP8_B 
chr5:1186645
08-118679814 
TNFAIP8_B-
eRNA6 
chr5:118678516
-118679446  -  0.9485  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000  0.0000 
   311 
7.5  Genes  with  similar  expression  patterns  to  Treg 
ncRNAs 
Table 7.31: Treg relevant genes associated with CRNDE expression 
Gene name 
A_33_P324104
3  CDCA2  FAM164A  KIAA1841  NPC1  SMC4 
A_33_P333398
5  CDCA5  FAM58BP  KIF11  NUSAP1  SMC6 
ABHD5  CDCA7  FAM72A  KIF14  OAS1  SNED1 
ACTA2  CDCA8  FAM72D  KIF15  OAS2  SNORD3B-1 
ADAM19  CDHR3  FAM83D  KIF18A  OBFC2A  SNX10 
ALCAM  CDK1  FANCA  KIF23  OGN  SPATS2L 
ANLN  CDKN3  FANCI  KLF11  OOEP  SPC25 
ANXA2  CEBPA  FANCL  LAYN  OR5T3  SPSB1 
ARHGAP11A  CENPA  FANK1  LINC00467  PARP12  SRGAP2 
ASPM  CENPE  FHL2 
lincRNA:chr1:211556096-
211605878_F  PARVB  ST7-AS1 
ATP1B1  CENPF  FLJ45482  lincRNA:chr10:97639610-97667003_F  PBK  ST8SIA4 
ATP2B4  CENPN  FLJ45983  lincRNA:chr11:74358152-74366327_R  PCK2  STAM 
ATXN7L1  CENPW  FLNA  lincRNA:chr12:4958789-4970589_F  PCNA  STIL 
B3GNT5  CEP128  GAB2  lincRNA:chr16:80631802-80632239_R  PCTP  TBC1D2 
BARD1  CEP55  GADD45A 
lincRNA:chr2:111954496-
112125102_R  PDE1B  TFRC 
BATF  CHDH  GCC2  lincRNA:chr2:111960179-
112010479_R 
PHTF1  THC2477815 
BATF3  CHEK1  GINS1  lincRNA:chr2:111965652-
112101793_R  PLEKHH3  TJP2 
BCAS1  CHRNA6  GINS2  lincRNA:chr2:111992304-
111994467_R  PMAIP1  TK1 
BFSP2  CHST11  GMNN 
lincRNA:chr2:111997376-
112123246_R  PMCH  TMEM38A 
BIRC5  CIT  GNA15  lincRNA:chr2:112005726-
112123291_R 
PMCHL1  TNFRSF8 
BLM  CKS2  GPR19  lincRNA:chr2:213703255-
213723530_F  POLE2  TNFRSF9 
BRCA1  CLSPN  GRAMD4  lincRNA:chr3:130569543-
130575125_F  POLQ  TOP2A 
BRCA2 
CNTNAP
1  GTF2IRD1 
lincRNA:chr3:171506056-
171528740_R  PPP1R26  TOX 
BRIP1  CORO2A  GXYLT2  lincRNA:chr7:7928975-7996750_R  PPP1R2P9  TPM4 
BTG3  CPNE2  HECW2  lincRNA:chrX:45897556-45923781_R  PTTG1  TPX2 
BUB1  CREG2  HERPUD1  LMCD1  PTTG2  TRIB1 
BUB1B  CRNDE  HIST1H1B  LMNA  PTTG3P  TRIM16L 
BZRAP1  CTNNA1  HIST1H2AI  LMNB1 
RAB11FIP
1  TRIM32 
C11orf80  CTNNAL
1 
HIST1H2A
L 
LOC115110  RAB11FIP
5 
TRIP13 
C12orf48  CTSA  HIST2H3A  LOC541471  RACGAP1  TTC7B 
C12orf75  CTSC  HJURP  LOXL1  RAD51  TTK 
C15orf53  DAB2IP  HMGB3  LRP8  RAD54L  TTN 
C18orf1  DCP1B  HMGB3P1  LRRC32  RAP1GDS
1  TUFT1 
C8orf85  DIAPH3  HMMR  MCM4  RBBP8  TXN 
C9orf167  DLGAP5  HN1  MCM5  RGPD1  TXNRD2 
CARD6  DPYSL2  HPGD  MELK  RGS1  TYMS 
CASC5  DSCC1  HS3ST3B1  MEOX1  RHOXF1  UBE2C 
CASP8  DTL  HSPA1A  METRNL  RPL39L  UHRF1 
CCDC50  DUSP10  HTATIP2  MGST2  RTKN2  UTS2   312 
Gene name 
CCNA2  DUSP4  HTR2B  MKI67  SAT1  VAV3 
CCNB2  E2F2  ICA1  MLF1IP  SCG5  WBSCR27 
CCNE2  E2F7  IL12RB2  MND1  SEMA3G  WDHD1 
CCNG2  ELK3  IL1R1  MSC  SGMS1  WEE1 
CCR10  ENTPD1  IL7  MSMO1  SKA3  WNT10A 
CCR3  EXO1  INPP1  MTHFD2  SKAP2  XLOC_011950 
CCR4  EZH2  IRF5  MYO5C  SLC16A1 
XM_00113073
4 
CCR8  EZR  JAZF1  NBEAL2  SLC1A1  XM_00311967
4 
CCRL2  F5  JSRP1  NDC80  SLC2A8  ZNF193 
CD59  FAM110A  KCNN4  NEK10  SLC35F2  ZWINT 
CD70  FAM110C  KEAP1  NFE2L3  SLC7A5 
  CDC45  FAM124B  KIAA0101  NINJ2  SMAD1 
 
Table 7.32: Treg relevant genes associated with LOC286442 expression 
 
Gene symbol 
A_33_P3324409  CR600327  GSTA4 
lincRNA:chr13:40669725
-40795050_F  PDE4D  TDRD9 
A_33_P3339701  CTLA4  GTSE1 
lincRNA:chr13:50613143
-50613550_R  PER2  THC2495962 
A_33_P3414022  CTNNAL1  HELLS 
lincRNA:chr2:179914333
-179915343_R  PML  TIRAP 
ABCC4  CXorf21  HLA-DMA 
lincRNA:chr2:200834655
-200839730_F  POU2AF1  TMEM236 
ACACB  CXorf64  HLA-DMB 
lincRNA:chr2:27788931-
27790011_R  PRLH  TMEM38A 
ACSBG1  CYP3A4  HLA-DOA 
lincRNA:chr3:114031960
-114042235_F  PSMD9  TMEM44 
AMZ1  DCHS2  HLA-DPA1 
lincRNA:chr5:3612325-
3623500_F  PTPLA  TMPPE 
ANKRD54  DGCR11  HLA-DPB1 
lincRNA:chr7:45019225-
45026725_F  RAPH1  TNFRSF1B 
APAF1  DISP2  HLA-DQB1 
lincRNA:chr8:101925424
-101930749_F  RBMS3  TP53RK 
ARFIP1  DNAH8  HLA-DRA 
lincRNA:chr8:103953859
-103990104_F  REL  TPR 
ARHGAP21  DPY19L3  HLA-DRB1 
lincRNA:chr8:16113839-
16424929_R  RTKN2  TRIO 
BASP1  E2F1  HLA-DRB3 
lincRNA:chr8:95917724-
95933974_F  S100A7  TTN 
BMF  ELK1  HLA-DRB4 
lincRNA:chr8:96743021-
96861105_R  SASS6  TTYH2 
BMP1  ENST00000390247  HLA-DRB5 
lincRNA:chrX:55936225-
56241400_F  SEBOX  TWIST1 
BMPR2  ENST00000432978  HUS1  LMBRD2  SELP  UAP1L1 
BRCA1  ENST00000433110  HVCN1  LOC100130894  SEMA7A  UNC5C 
BRCA2  ENST00000517927  ICA1  LOC100131234 
SH3PXD2
A  VDR 
BRIP1  ENTPD1  IDI2-AS1  LOC100132741  SHMT2  VSIG10L 
BTC  FAIM2  IKZF2  LOC143188  SLA2 
XLOC_00261
3 
C19orf71  FAM124B  IKZF4  LOC286442  SLC14A1 
XLOC_00720
6 
C22orf34  FAM19A2  IL1RAP  LOC392364  SLC15A1 
XLOC_01037
6 
C5orf30  FANCA  IL21  LOC651337  SLC15A4 
XM_0031185
59 
C6orf211  FANCB  INPP5F  MCU  SLC16A1 
XM_0031192
19 
CD200  FCRL1  IRF4  METTL7A  SLC43A2  YWHAE   313 
Gene symbol 
CD302  FCRL2  KBTBD8  MLC1  SLC9A7  ZBTB32 
CD40  FCRL3  KDM1B  MS4A6A 
SLC9A7P
1  ZNF100 
CD74  FHL2  KLHL12  MXD3  SMPD3  ZNF185 
CDK14  FOXP3  KLK1  MYO1E  SNAP29  ZNF684 
CENPL  GEN1  KRTAP11-1  NEDD4L  SSC5D  ZNF80 
CGB2  GFRA2  LAT2  OR5H6  STAM  ZWINT 
CHRM5  GK  LINC00167  OR7E91P  STARD4 
  
CIITA  GLCCI1 
lincRNA:chr10:726
89994-
72706119_R  OTUD4  STRADA 
CORO1C  GLCE 
lincRNA:chr12:732
63758-
73528783_F  P2RX5  SWAP70 
CPPED1  GPM6A 
lincRNA:chr12:760
15433-
76261508_R  P2RY1  TBX2 
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